<SEC-DOCUMENT>0001824293-25-000073.txt : 20250515
<SEC-HEADER>0001824293-25-000073.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250515083834
ACCESSION NUMBER:		0001824293-25-000073
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GRI Bio, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		25948967

	BUSINESS ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(619) 400-1171

	MAIL ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRI BIO, Inc.
		DATE OF NAME CHANGE:	20230424

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vallon Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20200910
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ck0001824293-20250331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:68c973fd-86f9-4003-b2e2-53898e349275,g:1fe3509e-ff4f-4a4a-9eb6-8112f8d4de8c,d:beb529ed7e2d4f5fb095c3c93743cecb-->
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ck0001824293="http://www.vallon-pharma.com/20250331" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ck0001824293-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-28">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-30">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-28" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-173">0.1429</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-29" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-174">0.0769</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-30" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-175">0.0588</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ck0001824293-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ck0001824293:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-29</xbrli:startDate><xbrli:endDate>2024-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-21</xbrli:startDate><xbrli:endDate>2025-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-20</xbrli:startDate><xbrli:endDate>2024-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-21</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-20</xbrli:startDate><xbrli:endDate>2024-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-26</xbrli:startDate><xbrli:endDate>2024-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesBCommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-21</xbrli:startDate><xbrli:endDate>2024-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-05</xbrli:startDate><xbrli:endDate>2025-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedAndSeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesBCommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD2WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-21</xbrli:startDate><xbrli:endDate>2024-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:October2024PAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInAugust2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInSeptember2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029OneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE1CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE3CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:April2025PAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-15</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_1"></div><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2025</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from_________to_________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40034</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="ck0001824293-20250331_g1.jpg" alt="GRI_ LOGO SELECT_ColorJPG.jpg" style="height:101px;margin-bottom:5pt;vertical-align:text-bottom;width:201px" id="i-1"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">GRI BIO, INC.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">82-4369909</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Identification No.)&#160;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">2223 Avenida de la Playa</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">#208</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">La Jolla</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CA</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92037</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">619</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">400-1170</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.0001<br/>per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">GRI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-23">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-25">x</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of May&#160;14, 2025, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-26">2,141,473</ix:nonFraction> shares of the Registrant&#8217;s common stock were outstanding.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_7"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:8pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_13">PART&#160;I. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_19">Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_22">Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_25">Consolidated Statements of Changes in Stockholders&#8217; Equity (unaudited) for the three months ended  March 31, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_28">Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_31">Notes to Unaudited Interim Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_85">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_85">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_85">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_109">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_109">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_112">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_112">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_115">PART&#160;II. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_115">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_115">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_118">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_118">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_121">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_121">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_124">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_124">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_127">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_127">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_127">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_130">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_130">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_130">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_133">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_133">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_136">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_136">25</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_139">26</a></span></div></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_13"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_16"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"/><td style="width:70.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">3,281</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">5,028</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-34">649</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-35">587</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">3,930</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">5,615</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-38">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-39">4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-40">109</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-41">120</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-42">4,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-43">5,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-45">897</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">1,368</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-47">691</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-48">50</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-49">48</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">2,779</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">1,636</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-52">58</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-53">71</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-54">2,837</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">1,707</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-56"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-57"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, <ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-58"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-59">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-60"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-61">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-62"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-63">525,358</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-64"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-65">525,485</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-66">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-67">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-68">43,991</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-69">43,772</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-70">42,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-71">39,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-72">1,205</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-73">4,032</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-74">4,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-75">5,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_22"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.429%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-76">1,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-77">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-78">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="f-79">962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-80">3,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-81">1,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-82">3,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-83">1,895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" format="ixt:fixed-zero" scale="3" id="f-84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-85">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-86">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-87">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-88">3,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-89">1,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-90"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-91">5.80</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-92"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-93">101.05</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-94"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-95">525,447</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-97">18,665</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_25"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:45.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.891%"/><td style="width:0.1%"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paid-in Capital</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-98">525,485</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-99">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-100">43,772</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-101">39,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-102">4,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-103">220</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-104">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fractional share adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment" scale="0" id="f-105">127</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment" scale="3" id="f-106">1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment" scale="3" id="f-107">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">3,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-109">3,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2025 (unaudited)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-110">525,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">43,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-113">42,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-114">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.876%"/><td style="width:0.1%"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Paid-in Capital</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-115">2,909</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-116">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-117">31,792</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-118">31,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-119">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-120">37</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-121">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fractional share adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment" scale="0" id="f-122">1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and prefunded warrants in financing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-123">1,495</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-124">4,389</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-125">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prefunded warrant exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise" format="ixt:num-dot-decimal" scale="0" id="f-126">10,047</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">1,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-128">1,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2024 (unaudited)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-129">14,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-131">36,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-132">33,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-133">2,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_28"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-134">3,046</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-135">1,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-136">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-137">1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-138">220</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-139">37</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-140">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-141">2</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-142">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-143">14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-144">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-145">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-146">331</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-147">744</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-148">562</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-149">172</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-150">11</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-151">14</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-152">1,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-153">2,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in financing transactions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-154">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-155">5,500</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment for fractional shares in connection with reverse stock split</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:PaymentForFractionalSharesReverseStockSplit" scale="3" id="f-156">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:PaymentForFractionalSharesReverseStockSplit" format="ixt:fixed-zero" scale="0" id="f-157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of deferred stock issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-158">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-159">1,014</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-160">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-161">4,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-162">1,747</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-163">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-164">5,028</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-165">1,808</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-166">3,281</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-167">4,091</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Recognition of right-of-use assets and lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:RecognitionOfRightOfUseAssetsAndLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-168">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:RecognitionOfRightOfUseAssetsAndLeaseLiabilities" scale="3" id="f-169">152</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Deferred stock issuance costs in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" scale="3" id="f-170">247</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" scale="3" id="f-171">97</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_31"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_34"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-172" continuedAt="f-172-1" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="f-172-1" continuedAt="f-172-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recapitalization</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-172-2">On January 29, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split). On February 21, 2025, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen (the February 2025 Reverse Stock Split and together with the January 2024 Reverse Stock Split and the June 2024 Reverse Stock Split, the Reverse Stock Splits). Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits.</ix:continuation> </span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_40"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="f-176" continuedAt="f-176-1" escape="true">LIQUIDITY</ix:nonNumeric></span></div><ix:continuation id="f-176-1" continuedAt="f-176-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-177">42,786</ix:nonFraction> in accumulated deficit through March&#160;31, 2025. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of March&#160;31, 2025, the Company had cash of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-178">3,281</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, Common Stock, pre-funded warrants and common warrants in a public offering (the February 2024 Offering) for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-179">4,389</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-180">1,110</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="6" id="f-181">10.0</ix:nonFraction>&#160;million shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of <ix:nonFraction unitRef="number" contextRef="c-32" decimals="3" name="ck0001824293:SaleOfStockAgentCompensationPercentage" scale="-2" id="f-182">3.0</ix:nonFraction>% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement. As of March&#160;31, 2025, the Company has sold <ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-183">325,618</ix:nonFraction> shares of Common Stock in the ATM Offering at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-34" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-184">11.07</ix:nonFraction> per share, raising $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-185">3,605</ix:nonFraction> of gross proceeds and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-186">3,467</ix:nonFraction>, after deducting commissions to the sales agent and other ATM Offering related expenses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell Common Stock, pre-funded warrants and common warrants, in a public offering (the June 2024 Offering), for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-187">3,172</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-188">1,057</ix:nonFraction>.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-176-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2024, the Company entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of certain of its issued and outstanding common warrants to purchase shares of its Common Stock, offering these Holders the opportunity to exercise all of their common warrants for cash at a reduced exercise price. In addition, these Holders received new unregistered common warrants. The net proceeds to the Company from the exercise of the common warrants were $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-189">609</ix:nonFraction> after deducting placement agent fees and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="ck0001824293:ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" scale="3" id="f-190">154</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through the third quarter of 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#8217;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements. These unaudited interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div></ix:continuation><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_43"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-191" continuedAt="f-191-1" escape="true">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-191-1" continuedAt="f-191-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-192" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the U.S. Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2024 balance sheet was derived from the Company&#8217;s audited consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim consolidated financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2025, and the consolidated results of operations and consolidated stockholders&#8217; deficit for the three months ended March&#160;31, 2025 and 2024 and consolidated cash flows for the three months ended March&#160;31, 2025 and 2024. Consolidated results of operations for the three months ended March&#160;31, 2025, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2024, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March&#160;14, 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-193" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-194" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-191-2" continuedAt="f-191-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-195" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the consolidated balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At March&#160;31, 2025, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the consolidated balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its consolidated statements of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the consolidated statement of operations for the three months ended March&#160;31, 2025. As of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the warrant liability was immaterial.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredChargesPolicyTextBlock" id="f-196" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-197" continuedAt="f-197-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div></ix:nonNumeric><div style="margin-bottom:8pt"><ix:continuation id="f-197-1" continuedAt="f-197-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. For the three-month period ended March&#160;31, 2024, basic net loss per common share includes the weighted average of the February 2024 Pre-Funded Warrants (as defined below). Diluted net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period, plus the dilutive effect of common stock equivalents outstanding during each period, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-197-2">. As the Company had a net loss in each of the three months ended March&#160;31, 2025 and 2024, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive</ix:continuation>.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-191-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-198" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-199">21,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-200">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-201">359,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-202">46,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-203">380,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-204">46,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-205" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended March&#160;31, 2025. ASUs not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on these unaudited interim consolidated financial statements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-07). This amended guidance applies to all public entities and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the provisions of ASU 2023-07 and has included the required disclosures in this Quarterly Report on Form 10-Q. See Note 8 for additional disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_55"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-206" continuedAt="f-206-1" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="f-206-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-207" escape="true"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-208">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-209">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-210">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-211">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-212">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-213">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-214">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-215">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-216">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-217">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-218"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-219">1</ix:nonFraction></ix:nonFraction> in each of the three-month periods ended March&#160;31, 2025 and 2024.</span></div></ix:continuation><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_58"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-220" continuedAt="f-220-1" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-221" escape="true"><ix:continuation id="f-220-1"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="f-222">630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="f-223">342</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="f-224">233</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="f-225">12</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-226">505</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-227">337</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-228">1,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-229">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_64"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-230" continuedAt="f-230-1" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="f-230-1" continuedAt="f-230-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the February 2024 Offering, (i) <ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-231">1,495</ix:nonFraction> shares (the February 2024 Shares) of Common Stock, (ii) <ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-232">21,131</ix:nonFraction> pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-233">21,131</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-234">22,631</ix:nonFraction> Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-235">22,631</ix:nonFraction> shares of Common Stock and (iv) <ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-236">22,631</ix:nonFraction> Series B-2 common warrants (the Series B-2 Common Warrants and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-237">22,631</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-238">4,389</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-239">1,110</ix:nonFraction>. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q (the Quarterly Report) as the &#8220;February 2024 Warrants.&#8221; The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-240">one</ix:nonFraction> February 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-241">one</ix:nonFraction> February 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-242">one</ix:nonFraction> Series B-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-243">one</ix:nonFraction> Series B-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-49" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-244">243.10</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-50" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-245">0.0221</ix:nonFraction> for each February 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain ownership limitations, the February 2024 Warrants were exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for <ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-246">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-50" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-247">0.0221</ix:nonFraction> and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-248">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-51" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-249">243.10</ix:nonFraction> for a <ix:nonNumeric contextRef="c-51" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-250">five-year</ix:nonNumeric> period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-251">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-52" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-252">243.10</ix:nonFraction> for an <ix:nonNumeric contextRef="c-52" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-253">18</ix:nonNumeric>-month period after February 6, 2024, the date of issuance. The February 2024 Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-254">4,279</ix:nonFraction> is included in additional paid-in capital. As of March&#160;31, 2025, all of the February 2024 Pre-Funded Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Company&#8217;s previously outstanding Series A-1 Warrants was reduced to par, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-255">0.0001</ix:nonFraction>, per share pursuant to the terms of the Series A-1 Warrants. As of March&#160;31, 2025, all of the Series A-1 Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="6" id="f-256">10.0</ix:nonFraction>&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of <ix:nonFraction unitRef="number" contextRef="c-32" decimals="3" name="ck0001824293:SaleOfStockAgentCompensationPercentage" scale="-2" id="f-257">3.0</ix:nonFraction>% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company has sold <ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-258">325,618</ix:nonFraction> shares of Common Stock in the ATM Offering at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-34" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-259">11.07</ix:nonFraction> per share, raising $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-260">3,605</ix:nonFraction> of gross proceeds and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-261">3,467</ix:nonFraction>, after deducting commissions to the sales agent and other ATM Offering related expenses. On May 5, 2025, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="3" id="f-262">1,671</ix:nonFraction>, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-263">3,605</ix:nonFraction> that were sold under the ATM Offering through March&#160;31, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company issued and sold, in the June 2024 Offering, (i) <ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-264">3,529</ix:nonFraction> shares (the June 2024 Shares) of Common Stock, (ii) <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-265">125,047</ix:nonFraction> pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-266">125,047</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-267">128,577</ix:nonFraction> Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-268">128,577</ix:nonFraction> shares of Common Stock, and (iv) <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-269">128,577</ix:nonFraction> Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants), exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-270">128,577</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-271">3,172</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-272">1,057</ix:nonFraction>. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Quarterly Report as the &#8220;June 2024 Warrants.&#8221; The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-273">one</ix:nonFraction> June 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-274">one</ix:nonFraction> June 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-275">one</ix:nonFraction> Series C-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-276">one</ix:nonFraction> Series C-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-59" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-277">31.11</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-278">0.0017</ix:nonFraction> for each June 2024 Pre-Funded Warrant).</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span><br/></span></div><ix:continuation id="f-230-2" continuedAt="f-230-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants were exercisable for <ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-279">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-280">0.0017</ix:nonFraction>, were exercisable immediately and have been exercised in full as of March&#160;31, 2025. Each Series C-1 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-61" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-281">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-282">31.11</ix:nonFraction> for a <ix:nonNumeric contextRef="c-61" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-283">five-year</ix:nonNumeric> period beginning after September 6, 2024. Each Series C-2 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-62" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-284">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-285">31.11</ix:nonFraction> for an <ix:nonNumeric contextRef="c-62" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-286">18</ix:nonNumeric>-month period beginning after September 6, 2024. The June 2024 Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-287">2,908</ix:nonFraction> is included in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an engagement agreement with Wainwright, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-288">9,001</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Common Stock (the June 2024 PA Warrants). The June 2024 PA Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-64" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-289">38.89</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, will expire on June 26, 2029 and are exercisable beginning after September 6, 2024. The June 2024 PA Warrants were classified as equity and the fair value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="f-290">229</ix:nonFraction> is included in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2024 Repricing Letter Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2024, the Company entered into the Repricing Letter Agreements with certain Holders of its issued and outstanding Series B Common Warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-291">44,842</ix:nonFraction> shares of its Common Stock, offering these Holders the opportunity to exercise all of their Series B Common Warrants for cash at a reduced exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-65" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-292">17.00</ix:nonFraction> per share. In addition, these Holders received new unregistered Series D-1 common warrants (the Series D-1 Common Warrants) exercisable for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-293">44,839</ix:nonFraction> shares of Common Stock and new unregistered Series D-2 common warrants (the Series D-2 Common Warrants and, together with the Series D-1 Common Warrants, the Series D Common Warrants) exercisable for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-67" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-294">44,839</ix:nonFraction> shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-68" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-295">17.00</ix:nonFraction> per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. This transaction is referred to as the &#8220;Warrant Repricing Transaction.&#8221;</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rsuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to <ix:nonFraction unitRef="number" contextRef="c-69" decimals="INF" name="ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds" scale="-2" id="f-296">7.0</ix:nonFraction>% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to <ix:nonFraction unitRef="number" contextRef="c-69" decimals="INF" name="ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds" scale="-2" id="f-297">1.0</ix:nonFraction>% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="ck0001824293:SaleOfStockReimbursementOfAccountableExpenses" format="ixt:num-dot-decimal" scale="0" id="f-298">25,000</ix:nonFraction> and non-accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses" format="ixt:num-dot-decimal" scale="0" id="f-299">10,000</ix:nonFraction>. The Company has also issued to Wainwright or its designees the October 2024 PA Warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-300">3,140</ix:nonFraction> shares of Common Stock (the October 2024 PA Warrant). The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-70" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-301">21.25</ix:nonFraction> per share.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to the Company from the exercise of the Series B Common Warrants were $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="ck0001824293:ProceedsFromWarrantExercisesNetOfOfferingExpense" scale="3" id="f-302">202</ix:nonFraction> after deducting placement agent fees and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="ck0001824293:ClassOfWarrantOrRightOfferingCost" scale="3" id="f-303">560</ix:nonFraction>. The issuance under the Repricing Letter Agreements represented $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-304">1,526</ix:nonFraction> in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-230-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-305" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company had the following warrants outstanding to purchase Common Stock: </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-306">210</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-71" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-307">243.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-308">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-72" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-309">464,100.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-310">128,577</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-311">31.11</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-312">44,839</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-74" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-313">17.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-314">16</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-315">43,548.05</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-316">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-76" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-317">0.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-77" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-318">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-77" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-319">94,970.33</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-320">210</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-321">243.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-322">9,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-79" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-323">38.8875</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-80" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-324">128,577</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-325">31.11</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-326">44,839</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-327">17.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-328">3,140</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-82" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-329">21.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_70"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-330" continuedAt="f-330-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-330-1" continuedAt="f-330-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;R 2018 Plan generally have a contractual life of up to <ix:nonNumeric contextRef="c-83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-331">10</ix:nonNumeric> years. As of March&#160;31, 2025, awards granted under the A&amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-332">21,270</ix:nonFraction> shares of the Company's Common Stock were outstanding and <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-333">21,275</ix:nonFraction> shares of the Company&#8217;s Common Stock were reserved for issuance under the A&amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;R 2018 Plan may be increased pursuant to the A&amp;R 2018 Plan&#8217;s &#8220;evergreen&#8221; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed <ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" scale="-2" id="f-334">4</ix:nonFraction>% of the aggregate number of shares of the Company&#8217;s Common Stock outstanding on the final day of the immediately preceding calendar year.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-335" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three months ended March&#160;31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.262%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-336">25</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-338">195</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-339">37</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-340">220</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-341">37</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-330-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-342" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the three months ended March&#160;31, 2025:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average remaining contractual term&#160;(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="f-343">142</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-344">4,376.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-89" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-345">9.63</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-346">21,128</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-347">11.66</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-348">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-349">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-350">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-351">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-352">21,270</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-353">40.80</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-354">9.81</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-355">21,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-356">28.71</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-357">9.81</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-358">21,270</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-359">40.80</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-360">9.81</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, all of the outstanding and exercisable stock options were out of the money and therefore had <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="0" id="f-361">no</ix:nonFraction> intrinsic value. As of March&#160;31, 2025, the unrecognized compensation cost related to unvested stock options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="f-362">214</ix:nonFraction>. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of <ix:nonNumeric contextRef="c-90" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-363">1.57</ix:nonNumeric> years. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-364">21,128</ix:nonFraction> stock options to its employees and non-employee directors during the three months ended March&#160;31, 2025. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-365" continuedAt="f-365-1" escape="true">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-365-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-366">110.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-90" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-367">5.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-368">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-369">4.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-370">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-371">No</ix:nonFraction> equity-based awards were granted during the three-month period ended March&#160;31, 2024.</span></div></ix:continuation><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_587"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-372" continuedAt="f-372-1" escape="true">SEGMENT REPORTING</ix:nonNumeric></span></div><ix:continuation id="f-372-1" continuedAt="f-372-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-373">one</ix:nonFraction> reportable segment: biotechnology research. The biotechnology research segment consists of the research and development of products for the treatment of inflammatory disease. The Company&#8217;s CODM is W. Marc Hertz, Ph.D., Chief Executive Officer and Director.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the biotechnology research segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the biotechnology research segment based on research and development expenses and general and administrative expenses as part of the overall review of the Company&#8217;s consolidated net loss and consolidated cash flows as compared to prior quarters and the Company&#8217;s operating budget.</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-372-2">The Company has incurred significant losses since its inception and anticipates incurring continued losses in the future. As such, the CODM uses cash forecast models in deciding how to allocate resources based on the Company&#8217;s available cash resources, as well as its forecasted expenditures.  This information, in conjunction with the assessment of the probability of the success of the Company&#8217;s research and development activities, is used to plan the timing and size of future capital raises.</ix:continuation> </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_76"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-374" continuedAt="f-374-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-374-1" continuedAt="f-374-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation and Release Agreement</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-374-2">In connection with the resignation of David Baker, the Company&#8217;s Former Chief Executive Officer, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker received continuation of his then current salary and certain COBRA benefits for <ix:nonNumeric contextRef="c-92" name="ck0001824293:COBRABenefitsPaymentPeriod" format="ixt-sec:durmonth" id="f-375">18</ix:nonNumeric> months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to <ix:nonFraction unitRef="number" contextRef="c-92" decimals="INF" name="ck0001824293:PercentageOfTargetBonus" scale="-2" id="f-376">150</ix:nonFraction>% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</ix:continuation> </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_79"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-377" continuedAt="f-377-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="f-377-1" continuedAt="f-377-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, the Company entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which the Company agreed to sell, in a public offering (the April 2025 Offering), (i) <ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-378">202,000</ix:nonFraction> shares (the April 2025 Shares) of Common Stock, (ii) <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-379">1,186,888</ix:nonFraction> pre-funded warrants (the April 2025 Pre-Funded Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-380">1,186,888</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-381">1,388,888</ix:nonFraction> Series E-1 common stock warrants (the Series E-1 Common Warrants) to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-382">1,388,888</ix:nonFraction> shares of Common Stock, (iv) <ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-383">1,388,888</ix:nonFraction> Series E-2 common stock warrants (the Series E-2 Common Warrants) to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-384">1,388,888</ix:nonFraction> shares of Common Stock, and (v) <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-385">1,388,888</ix:nonFraction> Series E-3 common stock warrants (the Series E-3 Common Warrants, and collectively with the Series E-1 Warrants and the Series E-2 Warrants, the Series E Common Warrants) to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-386">1,388,888</ix:nonFraction> shares of Common Stock, for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-387">5,000</ix:nonFraction>, before deducting offering expenses. The April 2025 Offering closed on April 2, 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-388">one</ix:nonFraction> April 2025 Share or <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-389">one</ix:nonFraction> April 2025 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-390">one</ix:nonFraction> Series E-1 Common Warrant, <ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-391">one</ix:nonFraction> Series E-2 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-392">one</ix:nonFraction> Series E-3 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-98" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-393">3.60</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-394">0.0001</ix:nonFraction> for each April 2025 Pre-Funded Warrant). The April 2025 Pre-Funded Warrants have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-395">0.0001</ix:nonFraction> per share, become exercisable immediately upon issuance and expire when exercised in full. Each Series E Common Warrant has an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-396">3.20</ix:nonFraction> per share and became exercisable immediately upon issuance. The Series E-1 Common Warrants expire April 2, 2030. The Series E-2 Common Warrants expire on October 2, 2026. The Series E-3 Common Warrants expire on January 2, 2026. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the April 2025 Offering pursuant to an engagement agreement between the Company and Wainwright dated as of March 7, 2025. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to <ix:nonFraction unitRef="number" contextRef="c-101" decimals="INF" name="ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds" scale="-2" id="f-397">7.0</ix:nonFraction>% of the gross proceeds received by the Company from the offering, plus a management fee equal to <ix:nonFraction unitRef="number" contextRef="c-101" decimals="INF" name="ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds" scale="-2" id="f-398">1.0</ix:nonFraction>% of the gross proceeds received by the Company from the offering,  reimbursement for accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="ck0001824293:SaleOfStockReimbursementOfAccountableExpenses" format="ixt:num-dot-decimal" scale="0" id="f-399">25,000</ix:nonFraction>,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reimbursement of up to $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="ck0001824293:SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" format="ixt:num-dot-decimal" scale="0" id="f-400">100,000</ix:nonFraction> for legal fees and expenses and other out-of-pocket expenses and up to $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="ck0001824293:SaleOfStockClearingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-401">15,950</ix:nonFraction> for the clearing expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company also issued to Wainwright, or its designees, warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-402">97,222</ix:nonFraction> shares of Common Stock (the April 2025 PA Warrants). The April 2025 PA Warrants became exercisable immediately upon issuance, expire on April 1, 2030, and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-103" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-403">4.50</ix:nonFraction> per share.</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-377-2">As discussed in Note 6, &#8220;Stockholders&#8217; Equity&#8221; to these unaudited interim consolidated financial statements, on May 5, 2025, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="3" id="f-404">1,671</ix:nonFraction>, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-405">3,605</ix:nonFraction> that were sold under the ATM Offering through March 31, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3. Since March 31, 2025, the Company has sold shares of Common Stock with an aggregate gross sales price of $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-406">399</ix:nonFraction>. As of the date of the filing of this Quarterly Report considering the net proceeds from the April 2025 Offering and the net proceeds from the Sales Agreement for sales occurring since March 31, 2025, the Company&#8217;s stockholders&#8217; equity is greater than $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-407">2.5</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_85"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q (the Quarterly Report), the audited financial statements and notes thereto, as well as management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 filed with the Securities and Exchange Commission (the SEC) on March&#160;14, 2025 (the Annual Report). Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 12E of the Securities Exchange Act of 1934, as amended (the Exchange Act), that involve risks and uncertainties. As a result of many factors, including those factors set out under the section entitled &#8220;Risk Factors&#8221; included in the Annual Report, our actual results could differ materially from the results described in or implied by these forward-looking statements.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_88"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells. GRI-0621 is also an oral formulation of tazarotene, a synthetic retinoid acid receptor-beta and gamma selective agonist, that is approved in the United States for topical treatment of psoriasis and acne. As of March 31, 2025, it has been evaluated in over 1,700 patients as an oral product for up to 52-weeks. We are developing GRI-0621 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung that affects approximately 140,000 people in the United States, with up to 40,000 new cases per year in the United States. Some estimate that IPF affects 3 million globally. While there are currently two approved therapies for the treatment of lung fibrosis, neither has been associated with improvements in overall survival, and both therapies have been associated with significant side effects leading to poor therapeutic adherence. In preliminary data from our trials to date with GRI-0621, and earlier trials with oral tazarotene, we have observed GRI-0621 to be well-tolerated and to inhibit iNKT cell activity in subjects. We and others have shown that activated iNKT are upregulated in IPF, primary sclerosing cholangitis, metabolic dysfunction-associated steatohepatitis, alcoholic liver disease, systemic lupus erythematosus (SLE), multiple sclerosis (MS), ulcerative colitis patients as well as other indications. In these patients activated iNKT cells are correlated with more severe disease. The U.S. Food and Drug Administration has cleared our Investigative New Drug (IND) application, and we have received authorization of our clinical trial application from both the United Kingdom Medicines and Healthcare Products Regulatory Agency and the Australian Therapeutic Goods Administration to initiate the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the, U.S., United Kingdom and Australia, respectively. We are evaluating GRI-0621 in a randomized, double-blind, multi-center Phase 2a biomarker study, for which we commenced enrollment in December 2023. Based on our current enrollment projections, we expect interim data from this trial to be available in the second quarter of 2025 and topline results to be available in the third quarter of 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and would be developed for the treatment of autoimmune disorders, with much of our preclinical work in SLE or lupus and MS. In lupus, the immune system mistakenly attacks its own healthy tissues, especially joints and skin, but can affect almost every organ and tissue of the body. The condition can be fatal and often causes debilitating bouts of fatigue and pain that prevent nearly half of adult patients from working. Lupus affects between 160,000 - 200,000 patients in the United States, with around 80,000 &#8211; 100,000 patients in the United States suffering from kidney nephritis, one of the most serious manifestations of SLE, typically within five years of diagnosis. There is no cure for lupus, but medical interventions and lifestyle changes can help control it. SLE treatment consists primarily of immunosuppressive drugs that inhibit the activity of the immune system. Only two drugs have been approved for lupus in the past 50 years, and new treatment options are sorely needed. In order to focus our resources on our GRI-0621 program, we have limited our development of GRI-0803 pending additional funding. Subject to obtaining the requisite additional funding and IND clearance, we intend to evaluate GRI-0803 in a Phase 1a and 1b trial initially targeting SLE. We expect to file an IND application with respect to this Phase 1a and 1b trial in 2025. We expect to continue to evaluate indications to select the best fit for further development of the program, but our initial focus would be on lupus.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Splits</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2025, our stockholders approved a reverse stock split of our common stock, par value $0.0001 per share (Common Stock), within the range of not less than one-for-2 and not more than one-for-23, and our board of directors subsequently approved the February 2025 Reverse Stock Split at the ratio of one-for-17. Following these approvals, we filed an amendment to our amended and restated certificate of incorporation, as amended with the Secretary of State of the State of Delaware to effect the February 2025 Reverse Stock Split as of 4:01 p.m. Eastern Time on February 21, 2025. Shares of our Common Stock began trading on a post-split basis on February 24, 2025. The February 2025 Reverse Stock Split had the effect of reducing the aggregate number of outstanding shares of Common Stock from 8,933,366 shares on a pre-reverse split basis to a total of 525,358 shares outstanding on a post-reverse split basis. On February 21, 2025, our stockholders approved the February 2025 Reverse Stock Split. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2025 Securities Purchase Agreement </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, we entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which we issued and sold, in a public offering (the April 2025 Offering), (i) 202,000 shares (the April 2025 Shares) of Common Stock, (ii) 1,186,888 pre-funded warrants (the April 2025 Pre-Funded Warrants) exercisable for an aggregate of 1,186,888 shares of Common Stock, (iii) 1,388,888 Series E-1 common stock warrants (the Series E-1 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, (iv) 1,388,888 Series E-2 common stock warrants (the Series E-2 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, and (v) 1,388,888 Series E-3 common stock warrants (the Series E-3 Common Warrants, and collectively with the Series E-1 Warrants and the Series E-2 Warrants, the Series E Common Warrants) to purchase up to 1,388,888 shares of Common Stock, for gross proceeds of $5,000, before deducting offering expenses. The securities were offered in combinations of (a) one April 2025 Share or one April 2025 Pre-Funded Warrant, together with (b) one Series E-1 Common Warrant, one Series E-2 Common Warrant and one Series E-3 Common Warrant, for a combined purchase price of $3.60 (less $0.0001 for each April 2025 Pre-Funded Warrant). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The April 2025 Pre-Funded Warrants are exercisable for one share of Common Stock at a price of $0.0001 per share, are exercisable immediately and will expire when exercised in full. Each Series E Common Warrant is exercisable into one share of Common Stock at a price per share of $3.20 and is immediately exercisable. The Series E-1 Common Warrants will expire on the five-year anniversary of the date of issuance. The Series E-2 Common Warrants will expire on the 18-month anniversary of the date of issuance. The Series E-3 Common Warrants will expire on the nine-month anniversary of the date of issuance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, we entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which we may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0 million of our Common Stock from time to time through Wainwright as our sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we have sold 325,618 shares of our Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3.6 million of gross proceeds and net proceeds of $3.5 million, after deducting commissions to the sales agent and other ATM Offering related expenses. On May 5, 2025, we filed a prospectus supplement to our registration statement on Form S-1 (File No. 333-279348) to increase the amount of shares of Common Stock that we may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1.7 million, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3.6 million that were sold under the ATM Offering through March&#160;31, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasdaq Compliance - Bid Price Deficiency</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules of The Nasdaq Capital Market also require that we maintain a closing price for shares of our Common Stock of at least $1.00 per share (the Minimum Bid Price Rule). On September 10, 2024, we received a letter from the Listings Qualification Department (the Staff) of The Nasdaq Stock Market LLC, indicating that we no longer met the Minimum Bid Price Rule because the closing bid price for our Common Stock was less than $1.00 for the previous 30 consecutive business days prior thereto. We subsequently effected the February 2025 Reverse Stock Split. On March 10, 2025, we received a letter from the Staff indicating that we were once again in compliance with the Minimum Bid Price Rule. </span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_91"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses have consisted primarily of costs related to our development program for our lead product candidate GRI-0621. These expenses include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead-related expenses and travel-related expenses for our research and development personnel; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expenses incurred under agreements with contract research organizations, contract manufacturing organizations and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities as well as consultants that support the implementation of our clinical and non-clinical studies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our direct research and development expenses are tracked by product candidate, we do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates as these costs are deployed across multiple programs. We expect our research and development expenses to increase over the next several years as we conduct our planned clinical and preclinical activities for our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to corporate matters.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our general and administrative expenses will continue to increase as we incur costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors&#8217; and officers&#8217; insurance, legal and accounting costs and investor relations costs, as well as an increase in personnel expenses as we hire additional personnel.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with Accounting Standards Codification (ASC) 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precludes the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were measured at fair value upon issuance using a Black-Scholes valuation model and are recorded as a liability on the consolidated balance sheet. The fair value of the May 2022 Warrants is measured at each reporting date and changes in fair value are recognized in the consolidated statements of operations in the period of change. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash and cash equivalents held with institutional banks.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_94"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2025 and 2024 </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,051</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,051)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,895)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,046)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,887)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $1.6 million and $0.9 million for the three months ended March&#160;31, 2025 and 2024, respectively. The $0.7 million increase in research and development expenses was primarily due to an increase of $0.7 million in expenses related to the registration development program of GRI-0621. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $1.4 million and $1.0 million for the three months ended March&#160;31, 2025 and 2024, respectively. The $0.4 million increase was primarily related to a $0.3 million increase in personnel expense including stock based compensation expense and a $0.2 million increase in professional fees.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $5,000 and $6,000 for the three months ended March&#160;31, 2025 and 2024, respectively. </span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_97"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $3.0 million and $1.9 million for the three months ended March&#160;31, 2025 and 2024, respectively. As of March&#160;31, 2025, we had an accumulated deficit of $42.8 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our working capital requirements to date through the issuance of Common Stock, warrants, convertible notes and promissory notes. As of March&#160;31, 2025, we had $3.3 million in cash. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,203)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,747)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025 and 2024, $1.7 million and $2.2 million were used in operating activities, respectively. The $0.5 million decrease was primarily due to an increase in non-cash adjustments of $0.2&#160;million related to stock-based compensation expenses, as well as a $1.1&#160;million increase in accounts payable and a $0.7&#160;million increase in accrued expenses, offset by a $1.2 million increase in net loss and a $0.4 million decrease in prepaid and other assets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $11,000 for the three months ended March&#160;31, 2025 and was primarily related to stock issuance costs related to the April 2025 Purchase Agreement. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $4.5 million for the three months ended March&#160;31, 2024 and was primarily related to $5.5 million of proceeds from the February 2024 Offering (defined below). The increase was offset by $1.0 million of stock issuance costs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2025 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, we entered the April 2025 Purchase Agreement, pursuant to which we issued and sold, in the April 2025 Offering, (i)  202,000 April 2025 Shares, (ii) 1,186,888 April 2025 Pre-Funded Warrants exercisable for an aggregate of 1,186,888 shares of Common Stock, (iii) 1,388,888  Series E-1 Common Warrants to purchase up to 1,388,888 shares of Common Stock, (iv) 1,388,888  Series E-2 Common Warrants to purchase up to 1,388,888 shares of Common Stock, and (v) 1,388,888 Series E-3 Common Warrants, to purchase up to 1,388,888 shares of Common Stock, for gross proceeds of $5,000, before deducting offering expenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we have sold 325,618 shares of our Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3.6 million of gross proceeds and net proceeds of $3.5 million, after deducting commissions to the sales agent and other ATM Offering related expenses. On May 5, 2025, we filed a prospectus supplement to our registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that we may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1.7 million, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3.6 million that were sold under the ATM Offering through March&#160;31, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, we entered into  securities purchase agreement , pursuant to which we issued and sold, in a public offering (the February 2024 Offering), (i) 1,495 shares of Common Stock, (ii) 21,131 pre-funded warrants exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 common warrants exercisable for an aggregate of 22,631 shares of Common Stock, and (iv) 22,631 Series B-2 common warrants exercisable for an aggregate of 22,631 shares of Common Stock for net proceeds of $4.4&#160;million, after deducting offering expenses of $1.1&#160;million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses were $3.0 million and $1.9 million for the three months ended March&#160;31, 2025 and 2024, respectively. As of March&#160;31, 2025, we had $3.3 million in cash and an accumulated deficit of $42.8 million. We expect to devote substantial financial resources to our planned activities, particularly as we prepare for, initiate, and conduct our planned clinical trials of GRI-0621 and GRI-0803, advance our discovery programs and continue our product development efforts. In addition, we expect to incur additional costs associated with operating as a public company. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements through the third quarter of 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We intend to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if our research and development efforts are successful. If we are </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable to secure adequate additional funding, we will need to reevaluate our operating plans and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our technology on less favorable terms than we would otherwise choose or cease operations entirely. These actions could materially impact our business, results of operations and future prospects and the value of shares of our Common Stock. In addition, attempting to secure additional financing may divert the time and attention of management from day-to-day activities and distract from our discovery and product development efforts. As a result, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue unless and until we successfully complete development, obtain regulatory approval for and successfully commercialize our current, or any future, product candidates.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_100"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any off-balance sheet transactions. We have no guarantees or obligations other than those which arise out of normal business operations.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_103"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of its financial condition and results of operations is based on its unaudited interim consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of these unaudited interim consolidated financial statements requires us to make estimates and assumptions that affect the amounts reported in the unaudited interim consolidated financial statements and accompanying notes. Management evaluates these estimates and judgments on an ongoing basis. Management bases its estimates on historical experience and on various other factors that it believes are reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in more detail in Note 3, &#8220;Summary of Significant Accounting Policies&#8221;, in our Annual Report.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_106"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not applicable to emerging growth companies. These exemptions include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about our executive compensation arrangements;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more, (b) December 31, 2026, the last day of the fiscal year following the fifth anniversary of the completion of Vallon&#8217;s initial public offering, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. </span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_109"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable to a smaller reporting company.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_112"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e)) of the Exchange Act as of March&#160;31, 2025. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon their evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures were not effective for the year ended December 31, 2024 due to the material weakness described in our Annual Report.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the course of preparing the Company&#8217;s financial statements for the Annual Report, management identified a material weakness related to the inaccurate computation of the non-cash deemed dividend associated with the re-pricing of the Series B Common Warrants in the Warrant Repricing Transaction in accordance with applicable GAAP guidance.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has implemented a plan to remediate this material weakness which includes the continued engagement of third-party professionals with appropriate expertise in accounting and reporting under GAAP and SEC regulations who have adequate experience related to non-recurring debt and equity transactions and the enhanced documentation related to the accounting treatment for such transactions and who will assist in reviewing the attendant calculations. Management has also refined our processes for communicating with our auditor as to when our financial statements and related materials have passed through the Company&#8217;s internal control processes.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding this material weakness, we believe that our financial statements contained in this Quarterly Report on Form 10-Q fairly present our financial position, results of operations and cash flows for the periods covered by this report in all material respects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we have implemented certain measures to remediate the material weakness identified in the design and operation of our internal controls over financial reporting. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) other than those noted above that occurred during the fiscal quarter covered by this report that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations of Effectiveness of Control</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. The design of any control system is based, in part, upon the benefits of the control system relative to its costs. Control systems can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. In addition, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_115"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_118"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition. </span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_121"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors previously disclosed in the Annual Report.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_124"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_127"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_130"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_133"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rule 10b5-1 Trading Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025, none of our directors or officers <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-408"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-409">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-410"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-411">terminated</ix:nonNumeric></ix:nonNumeric> &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408 of Regulation S-K.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_136"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference File No. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Filed</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/gri-202410k_ex31.htm">Amended and Restated Certificate of Incorporation, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/14/2025</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429323000129/val-20230421.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/26/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit41-8xk.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit41-8xk.htm">Pre-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit41-8xk.htm">Funded Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/2/2025</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit42-8xk.htm">Form of Series </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit42-8xk.htm">E</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit42-8xk.htm"> Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/2/2025</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit43-8xk1.htm">Form of Placement Agent Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/2/2025</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#9651;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit101-8xk.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit101-8xk.htm">Sec</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit101-8xk.htm">urities Purchase Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4/2/2025</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex311_ceo302cert33125.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312_cfo302cert33125.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312_cfo302cert33125.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321_ceosection906cert331.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321_ceosection906cert331.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322_cfosection906cert331.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322_cfosection906cert331.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless otherwise indicated, exhibits are filed herewith.</span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:0.1%"/><td style="width:2.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9651;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.  The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC. </span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_139"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.815%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRI BIO, INC.</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 15, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex311_ceo302cert33125.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ieb9a44de00fb40b9851abc9e6775ff66_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, W. Marc Hertz, Ph.D., certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2025 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:31.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May&#160;15, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz, Ph.D.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">W. Marc Hertz, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex312_cfo302cert33125.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i356a1506d6c844ac83f56e2dc43b1df9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2025 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.299%"><tr><td style="width:1.0%"></td><td style="width:29.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May&#160;15, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex321_ceosection906cert331.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7fcb9312d1374f0eaf645195c834f0cb_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, W. Marc Hertz, Ph.D., President and Chief Executive Officer of GRI Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended March&#160;31, 2025 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May&#160;15, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz, Ph.D.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">W. Marc Hertz, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex322_cfosection906cert331.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8ec5740cd0dd434c84e7709570bf28d9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly,  Chief Financial Officer of GRI Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended March&#160;31, 2025 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May&#160;15, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ck0001824293-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:68c973fd-86f9-4003-b2e2-53898e349275,g:1fe3509e-ff4f-4a4a-9eb6-8112f8d4de8c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ck0001824293="http://www.vallon-pharma.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vallon-pharma.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vallon-pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITY" roleURI="http://www.vallon-pharma.com/role/LIQUIDITY">
        <link:definition>9952157 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952158 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>9952159 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES">
        <link:definition>9952160 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952161 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>9952162 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTING" roleURI="http://www.vallon-pharma.com/role/SEGMENTREPORTING">
        <link:definition>9952163 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS">
        <link:definition>9952165 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9955512 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>9955513 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables">
        <link:definition>9955514 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9955515 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9955516 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
        <link:definition>9955517 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITYDetails" roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails">
        <link:definition>9955518 - Disclosure - LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails">
        <link:definition>9955519 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
        <link:definition>9955520 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails">
        <link:definition>9955521 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>9955522 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9955523 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails">
        <link:definition>9955524 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9955525 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9955526 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails">
        <link:definition>9955527 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails">
        <link:definition>9955528 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGDetails" roleURI="http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails">
        <link:definition>9955529 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9955530 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9955531 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ck0001824293_ChangeInFairValueOfWarrantLiability" abstract="false" name="ChangeInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" abstract="false" name="StockIssuedDuringPeriodSharesFractionalShareAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" abstract="false" name="StockIssuedDuringPeriodValueFractionalShareAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" abstract="false" name="StockIssuedDuringPeriodSharesWarrantExercise" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_ThroughFinancingMember" abstract="true" name="ThroughFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PaymentForFractionalSharesReverseStockSplit" abstract="false" name="PaymentForFractionalSharesReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities" abstract="false" name="RecognitionOfRightOfUseAssetsAndLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" abstract="false" name="DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesBCommonWarrantsMember" abstract="true" name="SeriesBCommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsOfferingExpenses" abstract="false" name="StockIssuanceCostsOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockMaximumValueOfSharesOffered" abstract="false" name="SaleOfStockMaximumValueOfSharesOffered" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockAgentCompensationPercentage" abstract="false" name="SaleOfStockAgentCompensationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" abstract="false" name="ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesB1CommonWarrantsMember" abstract="true" name="SeriesB1CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesB2CommonWarrantsMember" abstract="true" name="SeriesB2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesA1WarrantsMember" abstract="true" name="SeriesA1WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_SeriesC1CommonWarrantsMember" abstract="true" name="SeriesC1CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesC2CommonWarrantsMember" abstract="true" name="SeriesC2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PreFundedAndSeriesCWarrantsMember" abstract="true" name="PreFundedAndSeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_June2024PAWarrantsMember" abstract="true" name="June2024PAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesDWarrantsMember" abstract="true" name="SeriesDWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesD1WarrantsMember" abstract="true" name="SeriesD1WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesD2WarrantsMember" abstract="true" name="SeriesD2WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_October2024PAWarrantsMember" abstract="true" name="October2024PAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" abstract="false" name="SaleOfStockNumberOfSecuritiesIssuedPerTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockAggregateCashFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockManagementFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" abstract="false" name="SaleOfStockReimbursementOfAccountableExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" abstract="false" name="SaleOfStockReimbursementOfNonAccountableExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" abstract="false" name="ProceedsFromWarrantExercisesNetOfOfferingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ClassOfWarrantOrRightOfferingCost" abstract="false" name="ClassOfWarrantOrRightOfferingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInAugust2025Member" abstract="true" name="WarrantsExpiringInAugust2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInFebruary2026Member" abstract="true" name="WarrantsExpiringInFebruary2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInMarch2026Member" abstract="true" name="WarrantsExpiringInMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2026Member" abstract="true" name="WarrantsExpiringInApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInMay2027Member" abstract="true" name="WarrantsExpiringInMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJuly2027Member" abstract="true" name="WarrantsExpiringInJuly2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2028Member" abstract="true" name="WarrantsExpiringInApril2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInFebruary2029Member" abstract="true" name="WarrantsExpiringInFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJune2029Member" abstract="true" name="WarrantsExpiringInJune2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInSeptember2029Member" abstract="true" name="WarrantsExpiringInSeptember2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInOctober2029OneMember" abstract="true" name="WarrantsExpiringInOctober2029OneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInOctober2029TwoMember" abstract="true" name="WarrantsExpiringInOctober2029TwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" abstract="true" name="AmendedAndRestated2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_FormerChiefExecutiveOfficerMember" abstract="true" name="FormerChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_COBRABenefitsPaymentPeriod" abstract="false" name="COBRABenefitsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_PercentageOfTargetBonus" abstract="false" name="PercentageOfTargetBonus" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_SeriesECommonWarrantMember" abstract="true" name="SeriesECommonWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesE1CommonWarrantsMember" abstract="true" name="SeriesE1CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesE2CommonWarrantsMember" abstract="true" name="SeriesE2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesE3CommonWarrantsMember" abstract="true" name="SeriesE3CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_April2025PAWarrantsMember" abstract="true" name="April2025PAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" abstract="false" name="SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockClearingExpenses" abstract="false" name="SaleOfStockClearingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ck0001824293-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:68c973fd-86f9-4003-b2e2-53898e349275,g:1fe3509e-ff4f-4a4a-9eb6-8112f8d4de8c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_56d68d54-cb0d-4874-a294-15ec1e61227b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1fc54732-2c04-4365-9e77-d786700331cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_56d68d54-cb0d-4874-a294-15ec1e61227b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1fc54732-2c04-4365-9e77-d786700331cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0333b68f-815f-4a21-ba48-d0c5338cc93b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_56d68d54-cb0d-4874-a294-15ec1e61227b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0333b68f-815f-4a21-ba48-d0c5338cc93b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce987e37-01e8-4a7e-8625-f72a11ec4a46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d05cb8f4-8b13-4496-a44e-e1877f893a15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce987e37-01e8-4a7e-8625-f72a11ec4a46" xlink:to="loc_us-gaap_Liabilities_d05cb8f4-8b13-4496-a44e-e1877f893a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f2aa0ff-312e-4c4a-a51d-edc797ffb7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce987e37-01e8-4a7e-8625-f72a11ec4a46" xlink:to="loc_us-gaap_StockholdersEquity_2f2aa0ff-312e-4c4a-a51d-edc797ffb7fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_aa69e0b2-487e-430e-932e-566db523eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce987e37-01e8-4a7e-8625-f72a11ec4a46" xlink:to="loc_us-gaap_CommitmentsAndContingencies_aa69e0b2-487e-430e-932e-566db523eeb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_4464cc49-67ef-44ac-aa82-dca014407a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2a36fd11-6f2b-45fe-a822-dfeb19967ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4464cc49-67ef-44ac-aa82-dca014407a75" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2a36fd11-6f2b-45fe-a822-dfeb19967ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_83e1d447-a43d-4c0d-ae10-d19c68f8a174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4464cc49-67ef-44ac-aa82-dca014407a75" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_83e1d447-a43d-4c0d-ae10-d19c68f8a174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_55e76553-e357-47fc-b1a1-b112a238449a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_4464cc49-67ef-44ac-aa82-dca014407a75" xlink:to="loc_us-gaap_AssetsCurrent_55e76553-e357-47fc-b1a1-b112a238449a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7487d62e-dcc8-474d-a1d7-e5caf7ea7025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a6be1b71-18a6-4930-8d27-808199a7dec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7487d62e-dcc8-474d-a1d7-e5caf7ea7025" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a6be1b71-18a6-4930-8d27-808199a7dec5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_23bbc447-ab6a-4841-9ce8-712f97c20cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7487d62e-dcc8-474d-a1d7-e5caf7ea7025" xlink:to="loc_us-gaap_CommonStockValueOutstanding_23bbc447-ab6a-4841-9ce8-712f97c20cf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56a50ae5-d0f9-4959-ad2b-05a9d4da5af7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7487d62e-dcc8-474d-a1d7-e5caf7ea7025" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56a50ae5-d0f9-4959-ad2b-05a9d4da5af7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_86fd8714-a4b7-4a99-bce1-bb4ded632439" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_980009d2-8f0a-4c67-8c6b-e76838dd145a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_86fd8714-a4b7-4a99-bce1-bb4ded632439" xlink:to="loc_us-gaap_AccountsPayableCurrent_980009d2-8f0a-4c67-8c6b-e76838dd145a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7299992c-288e-4864-ae3c-4f82df3b360d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_86fd8714-a4b7-4a99-bce1-bb4ded632439" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7299992c-288e-4864-ae3c-4f82df3b360d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57f86187-380b-4288-bd8b-27e743ca0b36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_86fd8714-a4b7-4a99-bce1-bb4ded632439" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57f86187-380b-4288-bd8b-27e743ca0b36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a061f9fb-c11d-4f77-9890-62d83927f278" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b23e00a-fb08-407d-a3f7-9e00d6403c95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a061f9fb-c11d-4f77-9890-62d83927f278" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b23e00a-fb08-407d-a3f7-9e00d6403c95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4fdf4200-5bc8-4a0b-a4b9-fa4153e43807" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a061f9fb-c11d-4f77-9890-62d83927f278" xlink:to="loc_us-gaap_LiabilitiesCurrent_4fdf4200-5bc8-4a0b-a4b9-fa4153e43807" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_66cf29a1-3927-4fc4-879c-26a5bdcb7230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d0ff8e5e-476b-4e0c-b7df-490d751ba014" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_66cf29a1-3927-4fc4-879c-26a5bdcb7230" xlink:to="loc_us-gaap_OperatingExpenses_d0ff8e5e-476b-4e0c-b7df-490d751ba014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_53bde618-5215-4890-93b5-5d426d024c78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_070d1f95-004e-4c43-b6f3-ef9427d83d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_53bde618-5215-4890-93b5-5d426d024c78" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_070d1f95-004e-4c43-b6f3-ef9427d83d92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_49f223f5-cbae-4c17-80c4-3ff149347489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_53bde618-5215-4890-93b5-5d426d024c78" xlink:to="loc_us-gaap_OperatingIncomeLoss_49f223f5-cbae-4c17-80c4-3ff149347489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_0567271f-cc1e-43cb-94da-b2fe92b92cc5" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_53bde618-5215-4890-93b5-5d426d024c78" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_0567271f-cc1e-43cb-94da-b2fe92b92cc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c3a2fd27-804b-4239-a707-ebc38c3ef48a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_40a6fd7c-d262-4d0d-9a87-3a68f739e674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c3a2fd27-804b-4239-a707-ebc38c3ef48a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_40a6fd7c-d262-4d0d-9a87-3a68f739e674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6506200b-d5b0-4708-8636-33e55e75aaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c3a2fd27-804b-4239-a707-ebc38c3ef48a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6506200b-d5b0-4708-8636-33e55e75aaa4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43627039-8d81-484d-970c-e9571d6b473e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c246a042-89e1-4e01-ad34-c8e8896e6969" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43627039-8d81-484d-970c-e9571d6b473e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c246a042-89e1-4e01-ad34-c8e8896e6969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_223341e3-3bf2-4a39-b562-10e1ae8a149f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43627039-8d81-484d-970c-e9571d6b473e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_223341e3-3bf2-4a39-b562-10e1ae8a149f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_19dcbc78-7156-4d3e-be22-679a73b8d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43627039-8d81-484d-970c-e9571d6b473e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_19dcbc78-7156-4d3e-be22-679a73b8d76a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_efd4debe-c71a-4b85-9b3d-ac6add9b2761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43627039-8d81-484d-970c-e9571d6b473e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_efd4debe-c71a-4b85-9b3d-ac6add9b2761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_605c338d-edf6-465f-b151-3f801bc316bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43627039-8d81-484d-970c-e9571d6b473e" xlink:to="loc_us-gaap_ShareBasedCompensation_605c338d-edf6-465f-b151-3f801bc316bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dbb71a7e-7838-4735-b50d-3e437c5a4f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43627039-8d81-484d-970c-e9571d6b473e" xlink:to="loc_us-gaap_NetIncomeLoss_dbb71a7e-7838-4735-b50d-3e437c5a4f5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_7324f4e4-1ecf-4d80-af86-a4a42fafe6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43627039-8d81-484d-970c-e9571d6b473e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_7324f4e4-1ecf-4d80-af86-a4a42fafe6c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_da75ca3d-c8a3-479f-973c-277ee2dd9f04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43627039-8d81-484d-970c-e9571d6b473e" xlink:to="loc_us-gaap_Depreciation_da75ca3d-c8a3-479f-973c-277ee2dd9f04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9673840d-cb70-4736-bbe0-cf600481ddae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43627039-8d81-484d-970c-e9571d6b473e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9673840d-cb70-4736-bbe0-cf600481ddae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c4aafc0-a00f-45f2-a600-1fa435f04b06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_65696dab-915c-4550-a2b1-ec178482bd65" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c4aafc0-a00f-45f2-a600-1fa435f04b06" xlink:to="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_65696dab-915c-4550-a2b1-ec178482bd65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8278358f-113d-4f81-96c0-bcbc4a74cd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c4aafc0-a00f-45f2-a600-1fa435f04b06" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_8278358f-113d-4f81-96c0-bcbc4a74cd9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2b4ccfde-9980-4e27-940e-db61f1c5d60e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c4aafc0-a00f-45f2-a600-1fa435f04b06" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_2b4ccfde-9980-4e27-940e-db61f1c5d60e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c3f52849-0fa6-4d2c-9371-10722643ddc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9a4934-b5ed-4677-859a-bb2e11b3a24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c3f52849-0fa6-4d2c-9371-10722643ddc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ad9a4934-b5ed-4677-859a-bb2e11b3a24c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_569404b8-c767-43e7-8086-8004ddaf8262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c3f52849-0fa6-4d2c-9371-10722643ddc6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_569404b8-c767-43e7-8086-8004ddaf8262" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_465c990d-f236-4418-bfaa-96d53ba3e667" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f32766fe-682b-4c6e-9168-734c9881acf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_465c990d-f236-4418-bfaa-96d53ba3e667" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f32766fe-682b-4c6e-9168-734c9881acf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_73fa1c95-b442-49be-bb3e-b0770bc2e5db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_465c990d-f236-4418-bfaa-96d53ba3e667" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_73fa1c95-b442-49be-bb3e-b0770bc2e5db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_148cc6a0-f65e-4eb4-85b7-62e38932053f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_b950b797-226f-4092-96cc-d84de454478b" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_148cc6a0-f65e-4eb4-85b7-62e38932053f" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_b950b797-226f-4092-96cc-d84de454478b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_f1b434af-9e7d-49cc-9e58-eb1654b7a290" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_148cc6a0-f65e-4eb4-85b7-62e38932053f" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_f1b434af-9e7d-49cc-9e58-eb1654b7a290" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a9ad0681-02ab-4e02-91ee-59921ef07dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_148cc6a0-f65e-4eb4-85b7-62e38932053f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a9ad0681-02ab-4e02-91ee-59921ef07dbb" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ck0001824293-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:68c973fd-86f9-4003-b2e2-53898e349275,g:1fe3509e-ff4f-4a4a-9eb6-8112f8d4de8c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_06c4412c-1837-4980-9bb6-b467cf392354" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2f63dbca-23e3-4ec8-b5f1-54fc7c4e6881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_06c4412c-1837-4980-9bb6-b467cf392354" xlink:to="loc_us-gaap_StatementTable_2f63dbca-23e3-4ec8-b5f1-54fc7c4e6881" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b626deb8-b2df-4778-98ce-6ac10e05072c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2f63dbca-23e3-4ec8-b5f1-54fc7c4e6881" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b626deb8-b2df-4778-98ce-6ac10e05072c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b626deb8-b2df-4778-98ce-6ac10e05072c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b626deb8-b2df-4778-98ce-6ac10e05072c" xlink:to="loc_us-gaap_EquityComponentDomain_b626deb8-b2df-4778-98ce-6ac10e05072c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0902dc6d-91e1-4851-b1cf-a268da64c71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b626deb8-b2df-4778-98ce-6ac10e05072c" xlink:to="loc_us-gaap_EquityComponentDomain_0902dc6d-91e1-4851-b1cf-a268da64c71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_84a4caaa-f631-420c-9d01-b8924828721c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0902dc6d-91e1-4851-b1cf-a268da64c71a" xlink:to="loc_us-gaap_CommonStockMember_84a4caaa-f631-420c-9d01-b8924828721c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d69ccfe0-5479-4c2f-a088-3de31dbbb618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0902dc6d-91e1-4851-b1cf-a268da64c71a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d69ccfe0-5479-4c2f-a088-3de31dbbb618" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_02460e1f-0178-496b-8aeb-4330226a41bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0902dc6d-91e1-4851-b1cf-a268da64c71a" xlink:to="loc_us-gaap_RetainedEarningsMember_02460e1f-0178-496b-8aeb-4330226a41bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06c4412c-1837-4980-9bb6-b467cf392354" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5688e9f9-f349-482a-8091-1a6c10cc173f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5688e9f9-f349-482a-8091-1a6c10cc173f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d402c988-cb1b-4ec0-8f2d-67626ba4dc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_StockholdersEquity_d402c988-cb1b-4ec0-8f2d-67626ba4dc6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a100e532-dda5-4d6c-b933-180ab635c767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a100e532-dda5-4d6c-b933-180ab635c767" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_432ecba2-a535-41a3-b3d0-d7f6dc4cccee" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_432ecba2-a535-41a3-b3d0-d7f6dc4cccee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_c38a472f-8938-4ace-b257-f9e5eb403666" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_c38a472f-8938-4ace-b257-f9e5eb403666" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_96795ab8-566f-4e43-bc7f-f7ee26e17a42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_96795ab8-566f-4e43-bc7f-f7ee26e17a42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb88f73b-76ca-42ad-b871-d43e3588f913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb88f73b-76ca-42ad-b871-d43e3588f913" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_b5181aa1-136e-41e9-b630-160a65255367" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_b5181aa1-136e-41e9-b630-160a65255367" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88eaf750-b8df-48c5-9a9f-f67a76096592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_NetIncomeLoss_88eaf750-b8df-48c5-9a9f-f67a76096592" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b12ea235-4b84-4465-9b22-bdb2225b7a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0e5f2cc-4a8d-4dc3-8151-57ec72ff771b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7873a74e-5da4-4ab3-b4e2-26b0090ea70e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_StatementTable_7873a74e-5da4-4ab3-b4e2-26b0090ea70e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c2576d95-f790-45e9-b4dd-6affb6503db7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7873a74e-5da4-4ab3-b4e2-26b0090ea70e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c2576d95-f790-45e9-b4dd-6affb6503db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2576d95-f790-45e9-b4dd-6affb6503db7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c2576d95-f790-45e9-b4dd-6affb6503db7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2576d95-f790-45e9-b4dd-6affb6503db7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58f6966c-dd5a-4a1c-ba70-5708d039c8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c2576d95-f790-45e9-b4dd-6affb6503db7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58f6966c-dd5a-4a1c-ba70-5708d039c8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember_fa652aa7-55b3-4b75-9564-05386aed3a1c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58f6966c-dd5a-4a1c-ba70-5708d039c8c1" xlink:to="loc_ck0001824293_ThroughFinancingMember_fa652aa7-55b3-4b75-9564-05386aed3a1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67d66974-b79f-4979-85cd-61aeee6f55b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67d66974-b79f-4979-85cd-61aeee6f55b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_39fc5fa0-fee7-4fce-a8c4-4759fb9ebf18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67d66974-b79f-4979-85cd-61aeee6f55b5" xlink:to="loc_us-gaap_NetIncomeLoss_39fc5fa0-fee7-4fce-a8c4-4759fb9ebf18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67d66974-b79f-4979-85cd-61aeee6f55b5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b213e47a-f275-4756-9a76-40800ebc5b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:to="loc_us-gaap_Depreciation_b213e47a-f275-4756-9a76-40800ebc5b1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_146e9c4b-1ae1-4cef-8cb0-57e5c2433072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:to="loc_us-gaap_ShareBasedCompensation_146e9c4b-1ae1-4cef-8cb0-57e5c2433072" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_47b373db-9c5e-41b7-800b-d8dc26caa2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_47b373db-9c5e-41b7-800b-d8dc26caa2d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6995e326-95c9-4a5b-b1ed-4e67713187dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6995e326-95c9-4a5b-b1ed-4e67713187dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06bba2a4-a17a-4a40-90db-9923b33e0c63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06bba2a4-a17a-4a40-90db-9923b33e0c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ed5228b9-998a-4e48-8e8f-c812e3b35f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ed5228b9-998a-4e48-8e8f-c812e3b35f8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d971b335-ace3-40de-aba2-4061e798bec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d971b335-ace3-40de-aba2-4061e798bec5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bd9affd2-f071-4753-b9d1-81acc2fcf6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bd9affd2-f071-4753-b9d1-81acc2fcf6a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa314cee-80b7-41a7-aa8c-3310b0577d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67d66974-b79f-4979-85cd-61aeee6f55b5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa314cee-80b7-41a7-aa8c-3310b0577d5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e681f824-2b2e-486c-a004-168830c3b484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e681f824-2b2e-486c-a004-168830c3b484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_6632fc01-e498-4c27-bf14-8657578ba18d" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:to="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_6632fc01-e498-4c27-bf14-8657578ba18d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b1166b30-e3e4-4217-9d69-b84505ffc34a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b1166b30-e3e4-4217-9d69-b84505ffc34a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_937c2052-b106-4511-b275-c7ba5cbaf567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_937c2052-b106-4511-b275-c7ba5cbaf567" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_861f120c-9894-400e-88c3-37c04a267015" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_861f120c-9894-400e-88c3-37c04a267015" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d3eff85-c366-4662-9c9e-531bb30f395d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d3eff85-c366-4662-9c9e-531bb30f395d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18c0b6bf-52b6-41ab-94db-123845f44db4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ee69e99d-5a72-4622-9edb-f0c0cc1762ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ee69e99d-5a72-4622-9edb-f0c0cc1762ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities_2ab3bf07-7ea3-4fd3-b5d7-4ad2df91ca38" xlink:href="ck0001824293-20250331.xsd#ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ee69e99d-5a72-4622-9edb-f0c0cc1762ad" xlink:to="loc_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities_2ab3bf07-7ea3-4fd3-b5d7-4ad2df91ca38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_c75c4324-7239-475f-a649-44d928bf0f6c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ee69e99d-5a72-4622-9edb-f0c0cc1762ad" xlink:to="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_c75c4324-7239-475f-a649-44d928bf0f6c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#LIQUIDITYDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1d19ed74-d7f1-49bc-b054-a7294b700654" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1d19ed74-d7f1-49bc-b054-a7294b700654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1d19ed74-d7f1-49bc-b054-a7294b700654_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1d19ed74-d7f1-49bc-b054-a7294b700654" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1d19ed74-d7f1-49bc-b054-a7294b700654_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187661e2-2eb9-4465-875f-ed79b6d55e32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1d19ed74-d7f1-49bc-b054-a7294b700654" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187661e2-2eb9-4465-875f-ed79b6d55e32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_6821df6d-42e5-4aee-bfc1-f033d23b8aab" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187661e2-2eb9-4465-875f-ed79b6d55e32" xlink:to="loc_ck0001824293_PublicOfferingMember_6821df6d-42e5-4aee-bfc1-f033d23b8aab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_3cbb125c-27a1-40ad-98f7-46f507c10b48" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187661e2-2eb9-4465-875f-ed79b6d55e32" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_3cbb125c-27a1-40ad-98f7-46f507c10b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a1a60a13-ad62-4bd0-a4ab-46a70fafc47a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:to="loc_srt_RangeAxis_a1a60a13-ad62-4bd0-a4ab-46a70fafc47a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a1a60a13-ad62-4bd0-a4ab-46a70fafc47a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a1a60a13-ad62-4bd0-a4ab-46a70fafc47a" xlink:to="loc_srt_RangeMember_a1a60a13-ad62-4bd0-a4ab-46a70fafc47a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1db3e5b9-dfd9-432b-981e-4a73c9b86f32" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a1a60a13-ad62-4bd0-a4ab-46a70fafc47a" xlink:to="loc_srt_RangeMember_1db3e5b9-dfd9-432b-981e-4a73c9b86f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_94a6dadc-dd17-4fe1-9873-ab3d62c762c6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1db3e5b9-dfd9-432b-981e-4a73c9b86f32" xlink:to="loc_srt_WeightedAverageMember_94a6dadc-dd17-4fe1-9873-ab3d62c762c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4692aa33-fe85-4287-b8ab-86fe5edd5710" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4692aa33-fe85-4287-b8ab-86fe5edd5710" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4692aa33-fe85-4287-b8ab-86fe5edd5710_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4692aa33-fe85-4287-b8ab-86fe5edd5710" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4692aa33-fe85-4287-b8ab-86fe5edd5710_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f096c09e-0ee8-43e8-a26e-92f39d7d825d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4692aa33-fe85-4287-b8ab-86fe5edd5710" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f096c09e-0ee8-43e8-a26e-92f39d7d825d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember_45c67e39-c321-45a0-acdf-d286c8957aca" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f096c09e-0ee8-43e8-a26e-92f39d7d825d" xlink:to="loc_ck0001824293_SeriesBCommonWarrantsMember_45c67e39-c321-45a0-acdf-d286c8957aca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7829ff1b-8a83-46df-9b8c-a39b883766b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7829ff1b-8a83-46df-9b8c-a39b883766b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_904758bc-dd47-4f93-ab8a-f390fbff4c70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_904758bc-dd47-4f93-ab8a-f390fbff4c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_959494b0-fa75-41e4-b779-549800f7476d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_959494b0-fa75-41e4-b779-549800f7476d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_b435758f-23d6-473a-9bb1-cf66ac9778b6" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_b435758f-23d6-473a-9bb1-cf66ac9778b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_5ddf386e-7cc4-4567-8921-096a0b445bc5" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_5ddf386e-7cc4-4567-8921-096a0b445bc5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_c9cfa701-439c-451b-a0ca-773b1d0c30ca" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_c9cfa701-439c-451b-a0ca-773b1d0c30ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_54e67115-54d2-40e0-a747-0eb04e27bdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_54e67115-54d2-40e0-a747-0eb04e27bdc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b30468c0-2555-4c6e-8647-d1cb166bb85f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b30468c0-2555-4c6e-8647-d1cb166bb85f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c0dccb2-5cc9-4c09-af25-89841258e405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c0dccb2-5cc9-4c09-af25-89841258e405" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ff446240-0e17-4734-8b6c-5a5b8249bec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ff446240-0e17-4734-8b6c-5a5b8249bec8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_e87877f1-3b79-47ee-b772-ea104ec33253" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_e87877f1-3b79-47ee-b772-ea104ec33253" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b52b9d1-9202-41ca-90d0-2e86ad116952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b5d33a6-5038-4a69-b848-b0343b44df93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b52b9d1-9202-41ca-90d0-2e86ad116952" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b5d33a6-5038-4a69-b848-b0343b44df93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_451fe521-fac4-40cb-8ab9-f374145079c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b5d33a6-5038-4a69-b848-b0343b44df93" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_451fe521-fac4-40cb-8ab9-f374145079c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_451fe521-fac4-40cb-8ab9-f374145079c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_451fe521-fac4-40cb-8ab9-f374145079c1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_451fe521-fac4-40cb-8ab9-f374145079c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba31e177-6051-4ff8-a706-136f8bf69638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_451fe521-fac4-40cb-8ab9-f374145079c1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba31e177-6051-4ff8-a706-136f8bf69638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_80f8d5c7-f3ce-4058-a3b1-781e1e66d43a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba31e177-6051-4ff8-a706-136f8bf69638" xlink:to="loc_us-gaap_EmployeeStockOptionMember_80f8d5c7-f3ce-4058-a3b1-781e1e66d43a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_9f4b01df-6f0a-44bb-b78e-097e17bb3cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba31e177-6051-4ff8-a706-136f8bf69638" xlink:to="loc_us-gaap_WarrantMember_9f4b01df-6f0a-44bb-b78e-097e17bb3cdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b234cd64-b617-4e03-b3c0-c5630d694f15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b52b9d1-9202-41ca-90d0-2e86ad116952" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b234cd64-b617-4e03-b3c0-c5630d694f15" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9a261f8a-6de6-468c-8fb4-e57225bed585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a38225e-572d-4ff5-a59a-e5cd71489528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9a261f8a-6de6-468c-8fb4-e57225bed585" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a38225e-572d-4ff5-a59a-e5cd71489528" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d835cd8c-ae7d-48f0-b35c-cf2c4a3efa89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a38225e-572d-4ff5-a59a-e5cd71489528" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d835cd8c-ae7d-48f0-b35c-cf2c4a3efa89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d835cd8c-ae7d-48f0-b35c-cf2c4a3efa89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d835cd8c-ae7d-48f0-b35c-cf2c4a3efa89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d835cd8c-ae7d-48f0-b35c-cf2c4a3efa89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87673a69-6cc2-4c87-a343-653948758650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d835cd8c-ae7d-48f0-b35c-cf2c4a3efa89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87673a69-6cc2-4c87-a343-653948758650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_450f6a3c-2840-4d63-a1e6-ef1bc7ac8290" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87673a69-6cc2-4c87-a343-653948758650" xlink:to="loc_us-gaap_ComputerEquipmentMember_450f6a3c-2840-4d63-a1e6-ef1bc7ac8290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_55d40574-5b79-4088-bafc-315c6aaac52e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87673a69-6cc2-4c87-a343-653948758650" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_55d40574-5b79-4088-bafc-315c6aaac52e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_12ad488a-bc16-4ae8-83ae-1b1774c9a9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9a261f8a-6de6-468c-8fb4-e57225bed585" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_12ad488a-bc16-4ae8-83ae-1b1774c9a9ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b4e2418-27d8-4432-9e4e-cf9c6a228115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9a261f8a-6de6-468c-8fb4-e57225bed585" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b4e2418-27d8-4432-9e4e-cf9c6a228115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_00dde795-2b00-4b9a-9afa-51ecdfdf17cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9a261f8a-6de6-468c-8fb4-e57225bed585" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_00dde795-2b00-4b9a-9afa-51ecdfdf17cf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_48fcc9df-6760-4245-a693-800f3a702f89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_48fcc9df-6760-4245-a693-800f3a702f89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_48fcc9df-6760-4245-a693-800f3a702f89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_48fcc9df-6760-4245-a693-800f3a702f89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_48fcc9df-6760-4245-a693-800f3a702f89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_48fcc9df-6760-4245-a693-800f3a702f89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_bb83be2a-355e-45ab-bdf0-b0c13e740761" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_bb83be2a-355e-45ab-bdf0-b0c13e740761" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember_55828663-5e16-4038-b1f5-53c6069330d4" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_SeriesBCommonWarrantsMember_55828663-5e16-4038-b1f5-53c6069330d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_d5571545-06fc-4ce1-a37e-2276e2503a6d" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember_55828663-5e16-4038-b1f5-53c6069330d4" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_d5571545-06fc-4ce1-a37e-2276e2503a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_58ebbff8-3261-4622-b091-a93cbb4188c8" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember_55828663-5e16-4038-b1f5-53c6069330d4" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_58ebbff8-3261-4622-b091-a93cbb4188c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_4ec062ff-5fb0-45a8-9b0c-538297319a45" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_4ec062ff-5fb0-45a8-9b0c-538297319a45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_d227dad5-320b-4127-bcb0-1976c1337640" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_d227dad5-320b-4127-bcb0-1976c1337640" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_42ba5a55-dbcb-43ac-9f3a-317a7711f7ab" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_42ba5a55-dbcb-43ac-9f3a-317a7711f7ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_d24115cb-3867-4027-91af-a0279205dd24" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_d24115cb-3867-4027-91af-a0279205dd24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember_3eb7d1f7-3d07-4707-bdb5-0f1488e05b05" xlink:href="ck0001824293-20250331.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_June2024PAWarrantsMember_3eb7d1f7-3d07-4707-bdb5-0f1488e05b05" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember_66b4ebad-ef0e-4bf0-b22b-2aa8696068da" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_SeriesDWarrantsMember_66b4ebad-ef0e-4bf0-b22b-2aa8696068da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember_de7a277a-7651-40f0-9d23-08918c0dddd5" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesDWarrantsMember_66b4ebad-ef0e-4bf0-b22b-2aa8696068da" xlink:to="loc_ck0001824293_SeriesD1WarrantsMember_de7a277a-7651-40f0-9d23-08918c0dddd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember_ded41748-7923-479f-a22c-407a13a9ed8a" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesDWarrantsMember_66b4ebad-ef0e-4bf0-b22b-2aa8696068da" xlink:to="loc_ck0001824293_SeriesD2WarrantsMember_ded41748-7923-479f-a22c-407a13a9ed8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_October2024PAWarrantsMember_1e8ef61f-0232-4a67-98d5-fc8139f60f45" xlink:href="ck0001824293-20250331.xsd#ck0001824293_October2024PAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_October2024PAWarrantsMember_1e8ef61f-0232-4a67-98d5-fc8139f60f45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_75c53c4b-01ab-47ab-845d-43fe5cf0c9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_75c53c4b-01ab-47ab-845d-43fe5cf0c9b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_75c53c4b-01ab-47ab-845d-43fe5cf0c9b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_75c53c4b-01ab-47ab-845d-43fe5cf0c9b6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_75c53c4b-01ab-47ab-845d-43fe5cf0c9b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8153b065-321a-42ba-bd75-819d47b22a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_75c53c4b-01ab-47ab-845d-43fe5cf0c9b6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8153b065-321a-42ba-bd75-819d47b22a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_01c36859-4deb-45f1-836b-2f915f723e7e" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8153b065-321a-42ba-bd75-819d47b22a28" xlink:to="loc_ck0001824293_PublicOfferingMember_01c36859-4deb-45f1-836b-2f915f723e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_9c3bdc5a-2699-4a6e-b51d-2772a904e94c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8153b065-321a-42ba-bd75-819d47b22a28" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_9c3bdc5a-2699-4a6e-b51d-2772a904e94c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a61aa82-8168-4547-89d2-10600f856c44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:to="loc_srt_RangeAxis_0a61aa82-8168-4547-89d2-10600f856c44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0a61aa82-8168-4547-89d2-10600f856c44_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0a61aa82-8168-4547-89d2-10600f856c44" xlink:to="loc_srt_RangeMember_0a61aa82-8168-4547-89d2-10600f856c44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da45b47b-0f4b-442b-a9db-dcab0ce43dd1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0a61aa82-8168-4547-89d2-10600f856c44" xlink:to="loc_srt_RangeMember_da45b47b-0f4b-442b-a9db-dcab0ce43dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_d2e19be2-554a-4feb-9e7c-d0347bce699a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_da45b47b-0f4b-442b-a9db-dcab0ce43dd1" xlink:to="loc_srt_WeightedAverageMember_d2e19be2-554a-4feb-9e7c-d0347bce699a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_72fa9748-b2aa-496c-bc8f-b77ba4be587d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_72fa9748-b2aa-496c-bc8f-b77ba4be587d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_72fa9748-b2aa-496c-bc8f-b77ba4be587d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_72fa9748-b2aa-496c-bc8f-b77ba4be587d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_72fa9748-b2aa-496c-bc8f-b77ba4be587d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b500347b-3e67-45f0-8296-cee81427e885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_72fa9748-b2aa-496c-bc8f-b77ba4be587d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b500347b-3e67-45f0-8296-cee81427e885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2209b8d0-6f4e-48a4-9e33-6c9ffc2fb004" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b500347b-3e67-45f0-8296-cee81427e885" xlink:to="loc_us-gaap_SubsequentEventMember_2209b8d0-6f4e-48a4-9e33-6c9ffc2fb004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97623e51-ba5d-406d-b223-b9daf50e0a98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97623e51-ba5d-406d-b223-b9daf50e0a98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8f7d3621-8efb-4389-aab7-d13efd89d143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8f7d3621-8efb-4389-aab7-d13efd89d143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b9f0f88c-fae9-41eb-b0a9-bfa6366db1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b9f0f88c-fae9-41eb-b0a9-bfa6366db1a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e7ed1dc3-d037-4edb-b91c-eec5829a5184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e7ed1dc3-d037-4edb-b91c-eec5829a5184" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0ab0171c-6d29-4b76-b481-ef020922634b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0ab0171c-6d29-4b76-b481-ef020922634b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_cf505a98-fbae-4d42-89f0-c16d5560064a" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_cf505a98-fbae-4d42-89f0-c16d5560064a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_83f19055-6356-4f53-894d-40c64dd94768" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_83f19055-6356-4f53-894d-40c64dd94768" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_9e6592bb-226b-4b55-966d-d83ad48d3eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_9e6592bb-226b-4b55-966d-d83ad48d3eae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7ed36d02-fb8f-4ec9-98da-042a65e1292a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7ed36d02-fb8f-4ec9-98da-042a65e1292a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7d65c9fa-4eca-4bf7-9424-079f850a11dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7d65c9fa-4eca-4bf7-9424-079f850a11dc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e542e076-3c98-4f12-800c-1c3fd61de06f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e542e076-3c98-4f12-800c-1c3fd61de06f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_0f99f97f-a6ef-4323-b0cc-a3fe8e26d9e9" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_0f99f97f-a6ef-4323-b0cc-a3fe8e26d9e9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_69cce361-41de-4391-acd1-4c3e902c5bde" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_69cce361-41de-4391-acd1-4c3e902c5bde" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1017f5dd-8d4f-4a48-9390-26a6ecc8b445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1017f5dd-8d4f-4a48-9390-26a6ecc8b445" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_0c5c519a-f5de-4c53-8a6c-e49ace26fa6f" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_0c5c519a-f5de-4c53-8a6c-e49ace26fa6f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_6ed764c5-047a-4c8a-9fee-700d8d242c22" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_6ed764c5-047a-4c8a-9fee-700d8d242c22" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_7d2ab6be-389e-4de6-a4fd-9fd887b7f829" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_7d2ab6be-389e-4de6-a4fd-9fd887b7f829" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_7dc3fcf1-381c-42bf-accd-b1f95bf67b4c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_7dc3fcf1-381c-42bf-accd-b1f95bf67b4c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_9ae85d77-5f17-46b9-80ae-e0dd349a157d" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_9ae85d77-5f17-46b9-80ae-e0dd349a157d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_941a0b58-440c-4b9b-b3f1-cd7d3d21c336" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_941a0b58-440c-4b9b-b3f1-cd7d3d21c336" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7bbf2a7c-67b0-4ae9-9a71-f8a0dc4d4f21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7bbf2a7c-67b0-4ae9-9a71-f8a0dc4d4f21" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8001e74c-0355-4802-9d62-790c3f9c0101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c47a21f1-86f9-470b-b4a3-ea63fbfcdd66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8001e74c-0355-4802-9d62-790c3f9c0101" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c47a21f1-86f9-470b-b4a3-ea63fbfcdd66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_19aefa56-6609-4903-a359-6bd11a4f2f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c47a21f1-86f9-470b-b4a3-ea63fbfcdd66" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_19aefa56-6609-4903-a359-6bd11a4f2f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_19aefa56-6609-4903-a359-6bd11a4f2f1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_19aefa56-6609-4903-a359-6bd11a4f2f1d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_19aefa56-6609-4903-a359-6bd11a4f2f1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_19aefa56-6609-4903-a359-6bd11a4f2f1d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member_8c37ccbd-4295-411a-8f8b-b29ed5af9cd3" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInAugust2025Member_8c37ccbd-4295-411a-8f8b-b29ed5af9cd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_4365a331-8377-43d6-9a40-37c2814c762c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_4365a331-8377-43d6-9a40-37c2814c762c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMarch2026Member_b44c841b-f4ad-4a5b-8c31-07693455655f" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInMarch2026Member_b44c841b-f4ad-4a5b-8c31-07693455655f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2026Member_bb0fd691-9d20-4e9c-a5c7-60b3e1ddffaa" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2026Member_bb0fd691-9d20-4e9c-a5c7-60b3e1ddffaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_a0a59be9-5b96-4b16-aa87-eda231de017d" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_a0a59be9-5b96-4b16-aa87-eda231de017d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_147d7f4a-9d30-4bab-aba2-4bf414f512bc" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_147d7f4a-9d30-4bab-aba2-4bf414f512bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_6b84ccd6-383a-4130-b0c8-97ae834ce349" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_6b84ccd6-383a-4130-b0c8-97ae834ce349" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_004df3a7-8358-447e-9fb2-ce7f766c2280" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_004df3a7-8358-447e-9fb2-ce7f766c2280" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member_c40e8439-c142-4327-b7ae-03936a06028a" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2029Member_c40e8439-c142-4327-b7ae-03936a06028a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_152b5766-a030-4c3f-8845-d8c495defdd5" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInSeptember2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_152b5766-a030-4c3f-8845-d8c495defdd5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_76cc0325-fecf-418c-b17a-601a84934fd7" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInOctober2029OneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_76cc0325-fecf-418c-b17a-601a84934fd7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_d00d7694-10b3-4cbe-9436-0d513c6af24f" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInOctober2029TwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_d00d7694-10b3-4cbe-9436-0d513c6af24f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0a5e98af-759c-49c0-a162-cda438e7f91d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8001e74c-0355-4802-9d62-790c3f9c0101" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0a5e98af-759c-49c0-a162-cda438e7f91d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0ea308a3-2a51-4f1a-a900-b491585bb229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8001e74c-0355-4802-9d62-790c3f9c0101" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0ea308a3-2a51-4f1a-a900-b491585bb229" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1a1837ba-d7b5-465b-b90f-59e1a9c8a705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:to="loc_us-gaap_PlanNameAxis_1a1837ba-d7b5-465b-b90f-59e1a9c8a705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1a1837ba-d7b5-465b-b90f-59e1a9c8a705_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1a1837ba-d7b5-465b-b90f-59e1a9c8a705" xlink:to="loc_us-gaap_PlanNameDomain_1a1837ba-d7b5-465b-b90f-59e1a9c8a705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f4dbb0f0-963e-4400-8937-87b86c7b74d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1a1837ba-d7b5-465b-b90f-59e1a9c8a705" xlink:to="loc_us-gaap_PlanNameDomain_f4dbb0f0-963e-4400-8937-87b86c7b74d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_872e1c3a-1abb-4b75-accc-0b7737b55b8d" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f4dbb0f0-963e-4400-8937-87b86c7b74d9" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_872e1c3a-1abb-4b75-accc-0b7737b55b8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e9b55a65-de5d-4959-a0cc-5fb6c2f61e28" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:to="loc_srt_RangeAxis_e9b55a65-de5d-4959-a0cc-5fb6c2f61e28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9b55a65-de5d-4959-a0cc-5fb6c2f61e28_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e9b55a65-de5d-4959-a0cc-5fb6c2f61e28" xlink:to="loc_srt_RangeMember_e9b55a65-de5d-4959-a0cc-5fb6c2f61e28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_950ddfce-2991-4228-b721-99ace1867448" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e9b55a65-de5d-4959-a0cc-5fb6c2f61e28" xlink:to="loc_srt_RangeMember_950ddfce-2991-4228-b721-99ace1867448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8692d1b5-1f93-475c-8cbc-498a71662e37" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_950ddfce-2991-4228-b721-99ace1867448" xlink:to="loc_srt_MaximumMember_8692d1b5-1f93-475c-8cbc-498a71662e37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da6a93fd-bde5-47cd-9972-b94f61df1572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:to="loc_us-gaap_AwardTypeAxis_da6a93fd-bde5-47cd-9972-b94f61df1572" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da6a93fd-bde5-47cd-9972-b94f61df1572_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_da6a93fd-bde5-47cd-9972-b94f61df1572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da6a93fd-bde5-47cd-9972-b94f61df1572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d1b14eb-2274-4f52-8880-91c520bb7af8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_da6a93fd-bde5-47cd-9972-b94f61df1572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d1b14eb-2274-4f52-8880-91c520bb7af8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_922a3127-9446-4138-8bfd-3d5babd3e1de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d1b14eb-2274-4f52-8880-91c520bb7af8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_922a3127-9446-4138-8bfd-3d5babd3e1de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_68741aea-7a79-42c9-85a8-3f7c7bd5c52b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_68741aea-7a79-42c9-85a8-3f7c7bd5c52b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_93dfdae3-88e1-425f-b4a5-2206d248a64e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_93dfdae3-88e1-425f-b4a5-2206d248a64e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_42badf92-4c0c-4d33-89ae-b64253b1d21b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_42badf92-4c0c-4d33-89ae-b64253b1d21b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_ad71839e-7e7a-42cf-a7c2-a6045872234c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_ad71839e-7e7a-42cf-a7c2-a6045872234c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e9b110bd-2b55-4fa6-af64-88f5a0936abd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e9b110bd-2b55-4fa6-af64-88f5a0936abd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a8c7b157-662f-4a81-b3f0-2b9084e5dfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a8c7b157-662f-4a81-b3f0-2b9084e5dfcb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7017eace-88cb-445f-a98c-c17fcb787584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7017eace-88cb-445f-a98c-c17fcb787584" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_46474367-306a-44f9-8ca2-f5fe4b843cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_46474367-306a-44f9-8ca2-f5fe4b843cb9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7faad7c-56b9-48ce-93d6-62d718052515" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7faad7c-56b9-48ce-93d6-62d718052515" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e463ae63-0aed-4abe-ad25-7deb5e88f505" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e2057bad-e9b5-4ad5-ae05-ef20827f1aef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e463ae63-0aed-4abe-ad25-7deb5e88f505" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e2057bad-e9b5-4ad5-ae05-ef20827f1aef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9d26cca3-c059-4a8d-ae74-bfc3b4a51489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e2057bad-e9b5-4ad5-ae05-ef20827f1aef" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9d26cca3-c059-4a8d-ae74-bfc3b4a51489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9d26cca3-c059-4a8d-ae74-bfc3b4a51489_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d26cca3-c059-4a8d-ae74-bfc3b4a51489" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9d26cca3-c059-4a8d-ae74-bfc3b4a51489_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bfca0647-d0dc-4339-b789-29b8ee2cb8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d26cca3-c059-4a8d-ae74-bfc3b4a51489" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bfca0647-d0dc-4339-b789-29b8ee2cb8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2399b6f0-94f5-47e3-9e35-695ca2878ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bfca0647-d0dc-4339-b789-29b8ee2cb8d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2399b6f0-94f5-47e3-9e35-695ca2878ee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_92c28b10-a8c0-4684-a82b-b36711b7db94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bfca0647-d0dc-4339-b789-29b8ee2cb8d0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_92c28b10-a8c0-4684-a82b-b36711b7db94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a7ae2de5-10a7-4392-b25b-2af84d4170fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e463ae63-0aed-4abe-ad25-7deb5e88f505" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a7ae2de5-10a7-4392-b25b-2af84d4170fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c744ddc3-f63b-4764-a7d9-14b18e33e3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c744ddc3-f63b-4764-a7d9-14b18e33e3a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df34882b-0542-4601-b455-c61232798be1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c744ddc3-f63b-4764-a7d9-14b18e33e3a6" xlink:to="loc_us-gaap_AwardTypeAxis_df34882b-0542-4601-b455-c61232798be1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df34882b-0542-4601-b455-c61232798be1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_df34882b-0542-4601-b455-c61232798be1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_df34882b-0542-4601-b455-c61232798be1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95b6c70a-9c24-4041-aa79-e5f490f16b16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_df34882b-0542-4601-b455-c61232798be1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95b6c70a-9c24-4041-aa79-e5f490f16b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8ebefe07-1303-4909-9e11-1795064aa423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95b6c70a-9c24-4041-aa79-e5f490f16b16" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8ebefe07-1303-4909-9e11-1795064aa423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0bfd0480-b6cc-4c15-bc74-93971fc96f74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0bfd0480-b6cc-4c15-bc74-93971fc96f74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4895112d-029c-475a-a562-8e124cc2a63e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4895112d-029c-475a-a562-8e124cc2a63e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b948c278-7070-46c8-833d-bfc820020aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b948c278-7070-46c8-833d-bfc820020aca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d21f0864-0ca7-4551-8d5a-e80276a3e2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d21f0864-0ca7-4551-8d5a-e80276a3e2cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_4b0c37b4-2bb1-4ede-8102-23d98451489a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_SharePrice_4b0c37b4-2bb1-4ede-8102-23d98451489a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_842e6c03-d093-4775-a2cc-0f1f9ce904c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b71d7f1e-353b-4aad-a65d-1b763a60ab44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_842e6c03-d093-4775-a2cc-0f1f9ce904c7" xlink:to="loc_us-gaap_LossContingenciesTable_b71d7f1e-353b-4aad-a65d-1b763a60ab44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6775c8eb-fc01-448f-a179-e26884dd574f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b71d7f1e-353b-4aad-a65d-1b763a60ab44" xlink:to="loc_srt_TitleOfIndividualAxis_6775c8eb-fc01-448f-a179-e26884dd574f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6775c8eb-fc01-448f-a179-e26884dd574f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_6775c8eb-fc01-448f-a179-e26884dd574f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6775c8eb-fc01-448f-a179-e26884dd574f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_227e954e-abe9-4bfa-b03a-22898b83cc77" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_6775c8eb-fc01-448f-a179-e26884dd574f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_227e954e-abe9-4bfa-b03a-22898b83cc77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_28ef9639-9646-477e-9cd4-74c537e584b6" xlink:href="ck0001824293-20250331.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_227e954e-abe9-4bfa-b03a-22898b83cc77" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_28ef9639-9646-477e-9cd4-74c537e584b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_6897392a-af3e-4964-8403-3759b8f50528" xlink:href="ck0001824293-20250331.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_842e6c03-d093-4775-a2cc-0f1f9ce904c7" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_6897392a-af3e-4964-8403-3759b8f50528" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_b1ec989b-1f9f-4a56-9eea-122f257747dd" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_842e6c03-d093-4775-a2cc-0f1f9ce904c7" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_b1ec989b-1f9f-4a56-9eea-122f257747dd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_32b19de5-08ed-4223-84de-2d9a8290ed7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_32b19de5-08ed-4223-84de-2d9a8290ed7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_32b19de5-08ed-4223-84de-2d9a8290ed7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_32b19de5-08ed-4223-84de-2d9a8290ed7d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_32b19de5-08ed-4223-84de-2d9a8290ed7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fe3bb526-918c-45aa-b29c-2040fd18fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_32b19de5-08ed-4223-84de-2d9a8290ed7d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fe3bb526-918c-45aa-b29c-2040fd18fc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ae448e45-5014-48fb-b6df-1c26ad48d4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fe3bb526-918c-45aa-b29c-2040fd18fc74" xlink:to="loc_us-gaap_SubsequentEventMember_ae448e45-5014-48fb-b6df-1c26ad48d4ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4c3378c3-7bb7-4813-9405-630a75d8000f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4c3378c3-7bb7-4813-9405-630a75d8000f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c3378c3-7bb7-4813-9405-630a75d8000f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4c3378c3-7bb7-4813-9405-630a75d8000f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c3378c3-7bb7-4813-9405-630a75d8000f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94612759-fd91-4b82-940d-58a9ec9feadb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4c3378c3-7bb7-4813-9405-630a75d8000f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94612759-fd91-4b82-940d-58a9ec9feadb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_8e16626a-a493-4699-b603-2d50f7142353" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94612759-fd91-4b82-940d-58a9ec9feadb" xlink:to="loc_ck0001824293_PublicOfferingMember_8e16626a-a493-4699-b603-2d50f7142353" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_090751b8-58b7-41ff-ac70-d42f6cdf485b" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94612759-fd91-4b82-940d-58a9ec9feadb" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_090751b8-58b7-41ff-ac70-d42f6cdf485b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_06219eae-2a02-45ab-8010-6aeba5c88dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_06219eae-2a02-45ab-8010-6aeba5c88dd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_06219eae-2a02-45ab-8010-6aeba5c88dd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_06219eae-2a02-45ab-8010-6aeba5c88dd5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_06219eae-2a02-45ab-8010-6aeba5c88dd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7f4fd651-81fd-49bf-8e69-7cb40023e952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_06219eae-2a02-45ab-8010-6aeba5c88dd5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7f4fd651-81fd-49bf-8e69-7cb40023e952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_d2592b8b-b3fc-4220-801e-1433553b4dc9" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7f4fd651-81fd-49bf-8e69-7cb40023e952" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_d2592b8b-b3fc-4220-801e-1433553b4dc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesECommonWarrantMember_4e70d822-177d-4dfd-aa0e-4f3a7591a602" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesECommonWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7f4fd651-81fd-49bf-8e69-7cb40023e952" xlink:to="loc_ck0001824293_SeriesECommonWarrantMember_4e70d822-177d-4dfd-aa0e-4f3a7591a602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE1CommonWarrantsMember_4d14bd04-341a-4569-827f-2225cc81f5fc" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesE1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesECommonWarrantMember_4e70d822-177d-4dfd-aa0e-4f3a7591a602" xlink:to="loc_ck0001824293_SeriesE1CommonWarrantsMember_4d14bd04-341a-4569-827f-2225cc81f5fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE2CommonWarrantsMember_144e5b94-566d-436a-901a-d2729bad84b4" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesE2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesECommonWarrantMember_4e70d822-177d-4dfd-aa0e-4f3a7591a602" xlink:to="loc_ck0001824293_SeriesE2CommonWarrantsMember_144e5b94-566d-436a-901a-d2729bad84b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE3CommonWarrantsMember_b0604921-0547-4162-b316-c776db7349e9" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesE3CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesECommonWarrantMember_4e70d822-177d-4dfd-aa0e-4f3a7591a602" xlink:to="loc_ck0001824293_SeriesE3CommonWarrantsMember_b0604921-0547-4162-b316-c776db7349e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_April2025PAWarrantsMember_86c7b3e3-9a1c-488f-babf-0b0b27b591ab" xlink:href="ck0001824293-20250331.xsd#ck0001824293_April2025PAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7f4fd651-81fd-49bf-8e69-7cb40023e952" xlink:to="loc_ck0001824293_April2025PAWarrantsMember_86c7b3e3-9a1c-488f-babf-0b0b27b591ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39fafe32-0a1d-43be-afcd-12f21598b9ee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:to="loc_srt_RangeAxis_39fafe32-0a1d-43be-afcd-12f21598b9ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39fafe32-0a1d-43be-afcd-12f21598b9ee_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_39fafe32-0a1d-43be-afcd-12f21598b9ee" xlink:to="loc_srt_RangeMember_39fafe32-0a1d-43be-afcd-12f21598b9ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7fe0b93-be08-4e9c-8fdd-7b043e0cdc6a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_39fafe32-0a1d-43be-afcd-12f21598b9ee" xlink:to="loc_srt_RangeMember_c7fe0b93-be08-4e9c-8fdd-7b043e0cdc6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_92aeeac0-4e2c-48dc-953d-b62e968132a2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c7fe0b93-be08-4e9c-8fdd-7b043e0cdc6a" xlink:to="loc_srt_MaximumMember_92aeeac0-4e2c-48dc-953d-b62e968132a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_78ec5c84-bca1-41f6-8b6c-ead37ddbd5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_78ec5c84-bca1-41f6-8b6c-ead37ddbd5d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0aa8f512-cc9d-4db5-ae22-a20523ee4576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0aa8f512-cc9d-4db5-ae22-a20523ee4576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_997eb5f7-2e08-4dcc-90ef-dd0c72e9704e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_997eb5f7-2e08-4dcc-90ef-dd0c72e9704e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a626a1ed-f2cb-46a5-a7df-fa8bca525db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a626a1ed-f2cb-46a5-a7df-fa8bca525db9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_185a32bc-ad3c-450d-b615-ead0709415f3" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_185a32bc-ad3c-450d-b615-ead0709415f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1b44eee3-ed03-4f9a-9aaa-f50ad679176f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1b44eee3-ed03-4f9a-9aaa-f50ad679176f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_da2caddc-4660-4d8e-aeb1-4431ba32460d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_da2caddc-4660-4d8e-aeb1-4431ba32460d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_fc31f195-8bf3-49fc-a6c5-1766cb10d73f" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_fc31f195-8bf3-49fc-a6c5-1766cb10d73f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_5dee7415-0a48-453c-a9a3-15fc6f4fb623" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_5dee7415-0a48-453c-a9a3-15fc6f4fb623" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_538df720-f1f0-47eb-bd16-0c4423598cfa" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_538df720-f1f0-47eb-bd16-0c4423598cfa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_d67082f3-2692-4ea4-b093-b34830f51b61" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_d67082f3-2692-4ea4-b093-b34830f51b61" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockClearingExpenses_91d152be-2840-4fa4-99fe-2ed675f4f099" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockClearingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockClearingExpenses_91d152be-2840-4fa4-99fe-2ed675f4f099" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_0f9efea5-439a-49df-9c86-0bffa6995c0c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_0f9efea5-439a-49df-9c86-0bffa6995c0c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ca69344a-f64a-4b4e-bfc9-46cd08df7f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ca69344a-f64a-4b4e-bfc9-46cd08df7f28" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f15267b-e1d9-4d13-87ce-932351f302a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f15267b-e1d9-4d13-87ce-932351f302a2" xlink:type="arc" order="14"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ck0001824293-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:68c973fd-86f9-4003-b2e2-53898e349275,g:1fe3509e-ff4f-4a4a-9eb6-8112f8d4de8c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5e696206-89cb-4cea-9512-1555a9756df3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b4ec3de-9187-4ed7-b2f6-4d11e675aa03_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_578a9085-b08a-4c3c-9d73-5aa90140760d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ac557419-5119-4f54-b9b0-41150b5b7d7a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesD1WarrantsMember_eae8be94-b5de-4e01-828e-e141da32d07a_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesD1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D-1 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesD1WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesD1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D-1 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesD1WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesD1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D-1 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesD1WarrantsMember" xlink:to="lab_ck0001824293_SeriesD1WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c4fc9666-7908-4622-b221-ef4cb3381a83_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost_660b916f-352b-4327-aba6-76898cdc6488_terseLabel_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, offering cost</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost_label_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Offering Cost</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost_documentation_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Offering Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:to="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_3fb55e31-ac1d-4070-bf2f-5aeed2b01b78_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesB2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_56c672a9-0962-47ef-b052-e0e2adb3f4b6_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fractional share adjustment</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Fractional Share Adjustment</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Fractional Share Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_de6514ca-aa2f-41d8-8975-2de2b928ac07_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2fff0faf-6714-43e8-85a6-39d8f502c3a3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5224e6b5-a936-49f0-b71c-d23574d5ff69_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6c77da17-d692-4e44-b34f-b2cc5631b4de_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d61401a0-c4dd-4d19-939b-0aee5f4c2a1a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInSeptember2029Member_0509951c-859e-476a-8b82-ff477f66b085_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In September 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInSeptember2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In September 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInSeptember2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In September 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInSeptember2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_7d2b8a39-cdb5-445d-bad5-4e1d1fa5012f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9d6cb714-8d67-4c33-ae35-19913d7af2f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_d608e02c-6972-4235-ba44-7e197971beab_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, outstanding term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_16e65d3a-fc4c-4243-9746-5853655a4ffb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_1d5e3fb4-edb3-4a1e-8772-062ab48787cf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_18ebf563-5ffd-4756-b7a7-beb5d0d50415_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_11f8f612-96fa-43a9-845b-d59d95942950_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3dfff210-4bd6-4466-b1ef-3410dd0deffe_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6d572d0e-567b-4eec-b489-1f7f1a29d015_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ebdf3e29-cafe-4ee9-8aff-7c4cb9aafe4c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_19e84979-755b-4d51-aacf-0e93ffe6e63d_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_2d7e7406-6045-45a5-abc1-88136464420e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4912f570-47d8-47ec-beb4-21b2dea2e836_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_02f2ad72-bbb7-4a9c-a887-6cb3b3394106_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b26e7bb2-0317-42f6-867b-b7b0c3210279_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fa5f0b01-f942-4abf-8755-c2e33e5071ac_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6ea1dc93-a9f9-4300-a552-0aab5996bb6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_81bcf4b8-5a59-4797-a79f-a4f3aca1e528_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e3c97b00-95a0-4381-b6f0-8334093dc0c2_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_08986866-4c44-4e6b-ae5c-5aff0bdfb324_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ff8b951d-6d00-4017-8248-cadcf9b8479c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_78dec4ac-770c-4075-8669-ca73ec524f7b_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d3b8130a-09d4-46cd-9d51-99676cf3a626_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_5bce76f1-50e1-4236-9533-528707e7c2e8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a330045d-94a6-46a3-9c92-a34e782a6491_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_487dc4f0-5def-4b00-b147-3c066225eb13_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edb450f3-bcd0-4f0c-84cb-35c65c5b1f1f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a34bb86-f2e5-4004-b7c2-5adc269f0ff0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2026Member_ab7d04b9-aa80-4a22-9e8e-8b6d10358f83_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2026Member" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_75d75782-0779-4f0c-ad2c-83c04e7ff425_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4c1e8968-8c99-45e4-a28f-ea7c41ed9efe_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_0f016043-24a9-47d4-b258-850278c410d8_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dee74e7a-67a7-498b-896e-d9118d280aa7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_80a3463d-cc01-4c20-8d1f-b7e5705013a5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d7adf82d-0ed3-46a2-894b-7518ce8a596a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_25d8b2e7-73b8-4e83-9428-684da661f92a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_fc404cbf-a77c-4aa6-8c90-25af77a836f0_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9ae67c91-e865-427d-9dc7-4c7f0bbff346_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_c97f1657-afec-4373-a121-b6be056e3398_negatedLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fractional share adjustment (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Fractional Share Adjustment</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Fractional Share Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cec9eedf-e6b7-443c-9253-76ea8af17379_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f7df2024-54cf-4e47-9ced-b9c8d9d8e105_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a4f7ce0a-013b-4758-87c7-c36e83c9fe5e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8040ee69-9eff-40b5-b7d8-3c04d445ce3c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_d05131b5-265d-4972-89ca-b02b1102b659_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock issuance costs in accounts payable and accrued expenses</link:label>
    <link:label id="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs And Financing Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs And Financing Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:href="ck0001824293-20250331.xsd#ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:to="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0abc9c25-e27a-44f6-96a9-aa1c196720e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_adb73257-d3c0-4fff-aa62-4025ef70c8e6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_905a8200-1f04-43b1-8416-185e6d2e2fff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3cb977a9-aa02-4a68-b1a7-53f8f9ab2cfe_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_c2b2ba21-ad59-4e29-8070-5e81f52d366d_terseLabel_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of target bonus</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_label_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_documentation_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PercentageOfTargetBonus" xlink:to="lab_ck0001824293_PercentageOfTargetBonus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_66f5ee87-ee18-423c-8be0-0fb3f2b8ba22_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e00b6fb5-bf69-4d21-9be3-9dd8631b9268_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_a1f60a6b-586a-4c35-92e8-50abe17696a7_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesD2WarrantsMember_4ca8d32c-3896-4940-8881-4d9abd38e34e_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesD2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D-2 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesD2WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesD2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D-2 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesD2WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesD2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D-2 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesD2WarrantsMember" xlink:to="lab_ck0001824293_SeriesD2WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f7e427af-b674-4415-9bb2-f70c2cadf92b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_79ad8d4e-fe8f-49cc-9472-fcbe5a7ff7be_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_59cd7d46-b3f8-4a7a-b7e6-19d2dc1a9313_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_142f212e-019a-4b10-8bad-815631ae55bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5146e2b5-cff8-4ff9-ac3d-fcdcdd66f38b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d39e2ef1-9924-489f-94f0-dcf69e9243b1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ecfc67ee-b9e3-4e43-9d1a-58ca0524923c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7da93375-31da-4528-9d76-1723ca5685a9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8a79ea8b-c8d9-4355-a00f-e3c5c3c5113a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_815b864d-9006-48d3-951f-a54ca93369e3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_dc484f6a-d92a-4f46-a38e-2b67d952d5ff_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_abaf060c-d3e5-4eb7-9dc8-6ddff002d2c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_0fe89866-3546-4790-8b53-d8a559107fdb_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued General And Administrative Expenses, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued General And Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_d04d8f5b-76c9-44fc-bd5b-2bb042da8ff8_terseLabel_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PreFundedWarrantsMember" xlink:to="lab_ck0001824293_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_22f411b3-9fad-44f5-91bd-f331e9be15a6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90a0c02b-73f7-4e26-9545-4234695fb052_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cdb2c353-ed54-418d-b044-da12f232df14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a6d5ccc1-0395-4104-972e-6e81f3056e50_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f0395b35-34c5-4964-b037-cad4d308a40d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a7a40d42-a51d-4e90-ade2-76267e4f780f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesDWarrantsMember_06fa6efa-2801-426d-9c12-1bd6501057b8_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesDWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesDWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesDWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesDWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesDWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesDWarrantsMember" xlink:to="lab_ck0001824293_SeriesDWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_99848910-71eb-4af3-a9f8-b55cafe5edb0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6c290736-aea0-4450-807e-dfebd5f30993_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_bb4c8b98-9658-4254-bfa1-bbb21e97c274_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercise</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_405f66a7-b396-4136-abde-4e561685e727_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_79a0a15d-f12d-4692-b791-740f4d5a6abb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b4996640-7ec9-40ac-83d2-57eb48b4e74c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_8654eebe-d76f-471b-aa29-e7398d7ee410_terseLabel_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding</link:label>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_label_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</link:label>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_documentation_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:to="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_981e98d8-2d69-4752-a415-699bc5f0e136_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_506b9170-f0b1-48cb-b3c8-37b0dcdf3530_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_27f44725-bbdd-43fe-a1f6-9e1087c1e557_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_af8ead8c-be0a-45ef-8a25-ca1ba485615c_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prefunded warrant exercise (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_b800c14b-d36f-4943-a4c9-144c0ec691d1_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8bdac9c9-1c08-420b-a535-aa0843476408_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_83b5dae1-1f47-42a6-9ced-29e898b87b0e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_October2024PAWarrantsMember_e0086a04-3352-4c12-b2f5-27830bef9794_terseLabel_en-US" xlink:label="lab_ck0001824293_October2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">October 2024 PA Warrants</link:label>
    <link:label id="lab_ck0001824293_October2024PAWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_October2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">October 2024 PA Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_October2024PAWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_October2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">October 2024 PA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_October2024PAWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_October2024PAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_October2024PAWarrantsMember" xlink:to="lab_ck0001824293_October2024PAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b7cb9b26-671f-43b7-a450-5f0eb04a3b1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c919fd17-5d19-4bd6-980a-6fbfba646768_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_066f1f8f-1585-4f6f-9ae2-225b3d2d49d4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesBCommonWarrantsMember_a113e473-271d-448d-b187-44670def73a7_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesBCommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesBCommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_72b4811e-1267-4b2b-8099-9c10c1d56742_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_4a0c83ae-8865-4f74-a1c0-4fba2e1595c6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_d9ac3558-49a2-4259-a2f2-f8fcf60c5a6d_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_02d44d70-3a5f-4f40-a4ed-ac170b417392_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, maximum value of shares offered</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Value Of Shares Offered</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Value Of Shares Offered</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:to="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d5e0af0-5e5d-43a3-9f76-1026f18e561a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_April2025PAWarrantsMember_bf297bbd-5a24-48cc-99ed-be374c6ef015_terseLabel_en-US" xlink:label="lab_ck0001824293_April2025PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2025 PA Warrants</link:label>
    <link:label id="lab_ck0001824293_April2025PAWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_April2025PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2025 PA Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_April2025PAWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_April2025PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April 2025 PA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_April2025PAWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_April2025PAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_April2025PAWarrantsMember" xlink:to="lab_ck0001824293_April2025PAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_df687011-05ad-4324-8d4e-5ace3f796e7b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_5daab8b3-c12b-4810-8d3e-fbc3a83c87f7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_06ce9814-ec07-46fc-8af6-26a6726f1097_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional&#160; Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8d70ba2c-8b86-4768-b38c-c7385866fabd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_c3828242-fa2b-47dc-aabe-07e993760f42_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1ed3eac5-6ef4-4b09-98b1-de2e8c41ebe8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_66578ca2-a974-40ad-b719-00a8a86d8a78_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_5d139321-647a-49df-9ad5-71810ff8d56b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4a4d4da3-49ff-4126-b55b-31d0f6fdab79_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_June2024PAWarrantsMember_8789a980-2851-4da7-80a4-09354dbf85c0_terseLabel_en-US" xlink:label="lab_ck0001824293_June2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">June 2024 PA Warrants</link:label>
    <link:label id="lab_ck0001824293_June2024PAWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_June2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June 2024 PA Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_June2024PAWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_June2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">June 2024 PA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_June2024PAWarrantsMember" xlink:to="lab_ck0001824293_June2024PAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1fe1e8a2-852f-49a8-ae74-dbfff39e79a3_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_6492da0d-f133-4082-bb61-236df5113d4c_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_194d8631-0b28-4c41-aadf-1281489c0d99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrants Outstanding to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_5715cb79-2a0f-48da-a71b-7ee870b16ec0_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a91a0cc1-a3f6-40cf-9210-8427a46d8ed9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_a6b47a15-70d2-4e7c-ba67-7742449d186d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant issuance</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_cfb3eb7c-1d77-4275-aef1-622abfce98be_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5545303a-1d34-44ab-a343-cc6601c53f5e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation, weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesE2CommonWarrantsMember_a251aaee-3cc9-40db-8ddf-9c748aeff026_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesE2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesE2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesE2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesE2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesE2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE2CommonWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesE2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesE2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesE2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e2371db6-5879-4291-8bcf-e36622cccae4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_dc2ad6b9-f463-4188-983b-f76751173c6e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a3d4030e-8903-4ca9-97cf-28e1ceb925db_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_02edb0fb-d659-407f-96d6-bb951af88191_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_28fa3b9b-0828-4043-83d0-3e8a7fdff742_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6de2601c-67ae-4649-a67f-c9f4f9b0abfd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_a83f91b7-fbaf-4eba-8a93-c737efedf160_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_f54fd69a-7c84-46ef-8cdc-e9fa1a127ae4_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesC1CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_5225363d-6807-4b7f-8fcd-ab619c3072b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, 0.0001 par value; 250,000,000 shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; 525,358 and 525,485 shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c67fedfe-933d-45c3-8fee-44001cd74b02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_475db79f-69b5-4c17-8ebc-7cd3cfbd0c73_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6b21be6f-dc95-4b8c-865a-8bcf61b14659_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_96f2a98c-42e6-4ba8-b533-614c7a50bb67_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_749d1cb4-6751-4557-8594-fcd3b8834add_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember_63ce49b5-3bce-4d65-8faf-9745b5d4a68d_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, One</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, One [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInOctober2029OneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:to="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_31dd7548-938c-41ee-a6a0-d96e954b40d4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_06e4c8d0-0947-4851-937e-eb50ad1cff64_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_eb6794f0-c4d0-4ea8-b7c4-3d3a75af9947_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Stock Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b32f023e-ced7-45f0-8bbf-c1ab0ecb2f2d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ceae8129-9773-4924-b8e8-43b508630e59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_36c1851b-0657-40da-81d1-8720d15dac89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c01d315c-a748-488a-aeb0-7a52849eff42_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_33af7b01-184b-47e4-9ab1-a7aa3c7a80d9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ca132503-ef28-4ddc-80b7-f525eceef9ec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_557ce1fc-2c01-419e-8e32-7733d66762dc_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5fc4a6d2-30f5-4ff5-824c-48ff605c25b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_394b47e3-cd0c-4ebf-9c81-faa128382b1e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_3008fb79-36af-4ed0-b316-0f3b04d0d4dc_terseLabel_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_label_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_documentation_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:to="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_5d4c7c60-fc20-49bb-895e-078ad008cb44_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activity of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_1164c039-736a-450b-9ab4-9b3f99d1c64b_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:to="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_345f4eb6-ab36-42da-93fb-0fb9cfdbfe0d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_93573569-d7c4-4e8c-b0e4-385fa361c0b9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_46edb5c5-98ba-4607-a763-2038882de5b3_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIQUIDITY</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_d517bd6f-9784-4279-a258-e8c4ad74d500_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_11085daa-5675-45ac-8f2c-ab3d397eecd0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember_ce91862f-df0c-4716-b7d9-a5dbe018c74d_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, Two</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, Two [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInOctober2029TwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:to="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_809d91a8-6f32-4491-8bd8-1e836236398e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_462245d4-8a7e-404d-9759-dbb7b9b7d3e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_eb9c5aa8-df02-45d5-bb67-41c97bdc7e55_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_e07aa724-c673-42b6-ab13-b387cfc7b0bb_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of accountable expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Accountable Expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Accountable Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:to="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d1a33272-9010-4990-8883-93e734b777ba_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c0a3429e-e060-449d-95bd-3ef404164439_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3da44556-5240-498c-a16e-4129b76dcedf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term&#160;(years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae86bdb8-8020-4897-9475-adf86e1ce622_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_09bea07a-8235-4541-b2bf-db8b5e002e4b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_40b394f3-1ce9-4dcf-914f-6a371f9277e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_f49753e6-0464-402a-972e-c592d3b81a8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_535ae70f-f066-4a54-8c66-a9bed1c9a51f_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1300b8a9-4f05-4ca1-9580-dbd5db6ebc03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_eda100df-e4e7-49dd-b790-c25925132b56_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of deferred stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6837b735-f9fe-422b-8873-6bbb9028ac73_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_46520fc2-88dc-4dcf-b685-e75851b67137_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_54a2b9be-d2eb-476e-bf6a-7ecad7f78e19_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of option on grant date (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_fcb005f5-4feb-49e2-8f6e-3e6b7e253fc7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6c85c5db-e436-4252-b3b6-55faf6c525c0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and prefunded warrants in financing (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b2b0231a-0961-444b-84eb-a059024cfbae_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockClearingExpenses_bf9aaa0c-aa30-4cd4-bcfc-a2c8f210c509_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockClearingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clearing expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockClearingExpenses_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockClearingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Clearing Expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockClearingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockClearingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Clearing Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockClearingExpenses" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockClearingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockClearingExpenses" xlink:to="lab_ck0001824293_SaleOfStockClearingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3101410a-458f-414f-9868-524588651fc0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_f717578b-f147-473d-9ca6-ba1d798b3639_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_d366c77d-7f90-4a77-8312-b8eb5c94f550_terseLabel_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COBRA benefits, payment period</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_label_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_documentation_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:href="ck0001824293-20250331.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:to="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMarch2026Member_9b0bdd01-1b4c-4d50-a416-f462257d5176_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In March 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMarch2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In March 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMarch2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_d2edb1cb-25b1-45c4-8dc1-5c123343bb1f_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of non-accountable expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Non-Accountable Expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Non-Accountable Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:to="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f8d4170c-966d-4078-884e-25ee6bb63036_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_76407815-5aaa-44f4-861c-dd024d239764_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2232b2bc-e0c0-4f1e-ac0f-05fd2774e3bb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_6a965580-0876-4f33-9785-163fd3f78e92_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_3f793a75-4d95-41f4-9c70-3686f985086b_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3aee7b6d-4c61-431f-9245-eeac212550b3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a06edd09-e325-42b1-a1ba-ea0b60a162ab_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9c06ad96-75e6-4648-8c83-9c5ce54e9ff8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_98c8f92d-b6d0-428f-af2a-4b2b187f6075_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bf18819b-7b63-48d3-a388-ed3cdaab9145_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8dca26c2-9b2f-4229-babe-8260fc6a583f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b414ae0f-adc0-443d-8878-fb8a75f64022_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_10c0c6f5-3808-40a2-b9d8-3c61d16f38d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fe1ee669-84dd-4dc8-ac62-8359c8540635_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_279eb148-25ec-4095-a6d3-9bb88a1ffee5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1bf4cb48-2e47-4bf9-983d-4afeece509aa_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_de6d1d1a-ceee-4854-9506-c30bb57dd400_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:to="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_1954758c-68d3-4b44-aa5d-b5d01c59a641_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities_6f3a579a-8686-453e-987f-ade4acb54450_terseLabel_en-US" xlink:label="lab_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition of right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities_label_en-US" xlink:label="lab_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recognition Of Right Of Use Assets And Lease Liabilities</link:label>
    <link:label id="lab_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities_documentation_en-US" xlink:label="lab_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recognition Of Right Of Use Assets And Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities" xlink:href="ck0001824293-20250331.xsd#ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities" xlink:to="lab_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_cef68f6a-4359-43e7-ad31-1befa0369973_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_c8bff03b-a7a3-45ef-b818-4e90f8f3fc57_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesA1WarrantsMember" xlink:to="lab_ck0001824293_SeriesA1WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_5607f71f-5141-4950-be7d-4ae1f8dd4649_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash fee</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:to="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7e0cbd6a-3431-40e7-96aa-cb9f020ecf14_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_bdff1a35-049c-4cc2-a99e-10a06440764b_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, agent compensation, percentage</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Compensation, Percentage</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Compensation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:to="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_1fecd2b3-3181-4241-832b-d2b10b78d431_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees and expenses and other out of pocket expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Legal Fees And expenses And Other Out Of Pocket Expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Legal Fees And expenses And Other Out Of Pocket Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:to="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_54a0406c-737d-4906-afce-2cefb01e5efc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d7162fe2-f269-4b81-baf7-a3a0c0489c18_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_a6ab9bad-289d-48cf-a35d-fec39ba2ac7c_terseLabel_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement agent fees and offering expenses</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_label_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Right, Agent Fees and Offering Expense</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_documentation_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Right, Agent Fees and Offering Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:to="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_44b364fd-2dc2-46d2-8aa2-9b616b1b3f52_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management fee</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:to="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eba9f75d-cbc1-468a-b1fa-4c9505da97df_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4d33fe0f-d15d-4164-8145-ebb9125218e6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and prefunded warrants in financing</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_22dd35e7-faec-4ee9-9590-47283272632c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a8064f3b-2c10-444e-b89e-bbb2ca18a6bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_99e52c37-ba94-440d-ada0-a7aea040e660_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fca0e1ca-9dac-46c8-99e9-05f4c17278ab_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_2f14923e-da4f-42e3-9e9e-382d98c75a4a_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesB1CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_ef317e60-ba0e-4a63-9669-0fc98e065f76_terseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercise, net of offering cost</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Warrant Exercises, Net Of Offering Expense</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Warrant Exercises, Net Of Offering Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:to="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b8052129-f594-4a2f-8059-fd06fdedc4a4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_d4b6b894-2996-4993-b853-7a38c83bfa07_terseLabel_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer [Member]</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:to="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PublicOfferingMember_ab48dd1c-de02-42a1-bcf5-b31b04d4b8ee_terseLabel_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_ck0001824293_PublicOfferingMember_label_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_ck0001824293_PublicOfferingMember_documentation_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PublicOfferingMember" xlink:to="lab_ck0001824293_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_6660dd39-1b6d-4ff3-a986-c567aade99c7_terseLabel_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">A&amp;R 2918 Plan</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:to="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit_ce411f15-c16a-452f-9b72-4a7b70b5b429_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment for fractional shares in connection with reverse stock split</link:label>
    <link:label id="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit_label_en-US" xlink:label="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Fractional Shares, Reverse Stock Split</link:label>
    <link:label id="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit_documentation_en-US" xlink:label="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Fractional Shares, Reverse Stock Split</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:to="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0fa68e74-9e52-4043-b5c8-0b058c4c7863_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3b7a2fe9-a6d7-4482-9b75-e5691bb34623_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2956caef-fc42-410f-a762-bae7bead8ab0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9071cf7b-56c1-4a62-ac7a-f90d6005cd54_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesE3CommonWarrantsMember_8bbc5866-2b93-4cef-bf99-85de8fd5ec60_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesE3CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E-3 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesE3CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesE3CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E-3 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesE3CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesE3CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E-3 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE3CommonWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesE3CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesE3CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesE3CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0c6fb2b0-dc00-4356-9dd1-ba8cd724d84a_netLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock in financing transactions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4530f5a9-d6f2-4420-959f-ea6ecf868de5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_efa0c2de-c629-4b4f-ad16-af91b996772e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock awards, contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e2a8fe2f-0da2-461e-ba53-0f41d7d7567a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3c2b4f9b-2f24-4a66-95a0-602e80a040f5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b6ff43b0-b957-46fa-896f-84bee2793893_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_ac369165-f3dc-47ca-82e4-cf4d37523680_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_011b8c24-f2f4-4be5-9331-b8dd032ac73e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity based award granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8c40a019-b351-4e3c-a106-5455a44acc2f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_129bdaf4-c1b3-4b7d-af3b-09e676c809a6_terseLabel_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Through Financing</link:label>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_label_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Through Financing [Member]</link:label>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_documentation_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Through Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ThroughFinancingMember" xlink:to="lab_ck0001824293_ThroughFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_a0c64126-8eab-4f23-a2e8-21b41ca0e500_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_6f534ce5-a63a-40ab-8b32-34545f1a7eef_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c0126d9d-a69b-437a-bec2-74bba59ad3ed_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18ee84a8-020b-4890-9edf-2576a83d792e_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price per Share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d7d88db-51f6-4e82-b01c-7b407d4bcea6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesE1CommonWarrantsMember_07cfa8f6-0a18-4a43-9153-53740a477263_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesE1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E-1 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesE1CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesE1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E-1 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesE1CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesE1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E-1 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE1CommonWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesE1CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesE1CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesE1CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e0deacd1-122b-4a66-b8e3-fab39e9a88f4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_e959614a-c094-4ea9-b6da-02018823ab21_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities issued (in shares)</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Securities Issued Per Transaction</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Securities Issued Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:to="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1b1e06f6-9b4c-4da1-8296-5544f6010e5e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants not settleable in cash, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b089fb6e-8987-4dbb-9d53-ab6f4ae6f03e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_62fddfbf-d93f-4b12-bf26-f9e499159e31_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ae27a876-4139-4688-8684-7ff520921f58_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f552c870-f3bb-4a13-b557-ae694b0eb42d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_45caf920-c44b-408c-ae3f-9deff13ff16e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f29302ed-e857-4f54-94b2-d9f7a91b580f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_87d7ccdd-b464-4366-b752-75d328ad8a4c_terseLabel_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants</link:label>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:to="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6cf0b908-c20a-4109-beb5-1debeed5dbff_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9c1c0b00-4126-4270-9b16-3424d6e8f0e4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_36591845-c0b6-42f6-8a3e-32e98cdef2bc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ee69d3a6-0903-4899-ae9d-f1671900c1a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_08e42e34-0a0c-43d8-982e-44e2a3a1da38_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_b86f513a-43b3-4dd2-b043-3bd028ce0e09_terseLabel_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM</link:label>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AtTheMarketOfferingMember" xlink:to="lab_ck0001824293_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e000f3c9-b336-4d1b-8fd2-600cf858f23b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_99c778b5-f8bb-4f75-85b7-dd866f0dcb40_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_430a3a08-882f-4f6e-a0ed-3e7de66e4f4d_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesC2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be1a5897-9348-4f05-bc1c-573aa6bf3ae9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_72386602-ce12-408e-a196-0db13898720a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b77b4248-62ae-427e-b8b4-9aa31fae773c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_34cc173a-82a9-4d4a-ace1-fa34c3e3695f_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJune2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3f2117a7-0629-42c2-95bb-ade88932cdc4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fbecf7e2-992a-4b3a-a754-1f1896c91b08_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18b31d08-e127-486a-8c89-4c7871278a89_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesECommonWarrantMember_0f38eca5-a706-427f-a30f-88cc2c73073f_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesECommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E Common Warrant</link:label>
    <link:label id="lab_ck0001824293_SeriesECommonWarrantMember_label_en-US" xlink:label="lab_ck0001824293_SeriesECommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Common Warrant [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesECommonWarrantMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesECommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E Common Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesECommonWarrantMember" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesECommonWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesECommonWarrantMember" xlink:to="lab_ck0001824293_SeriesECommonWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cfd5b48b-ea1e-41b9-bd02-3b05ba18e596_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity (greater than)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9d541437-15e1-4be5-baf2-e9b462e1aff5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_47e99d59-384d-4443-8efd-e5c62ffaefe6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_78cf6a32-0da6-4b40-bc03-88559db07622_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c0bd6805-4555-4da0-88c1-e4849f8c20c3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_92e84ca9-7a39-447f-b2a1-53ee0a9091fa_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ck0001824293-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:68c973fd-86f9-4003-b2e2-53898e349275,g:1fe3509e-ff4f-4a4a-9eb6-8112f8d4de8c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/Cover" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c6cf2464-4bf4-47a9-9bc2-e8b716eb100f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_DocumentType_c6cf2464-4bf4-47a9-9bc2-e8b716eb100f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d61a1f0e-3e49-428f-bc8f-a81bbd8c1726" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_DocumentQuarterlyReport_d61a1f0e-3e49-428f-bc8f-a81bbd8c1726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b1ff413f-8810-4b82-9f7b-b5a3a91bdf81" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_DocumentPeriodEndDate_b1ff413f-8810-4b82-9f7b-b5a3a91bdf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0abbe705-ec68-486f-946a-adedad5a9c25" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_DocumentTransitionReport_0abbe705-ec68-486f-946a-adedad5a9c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_233ae07f-5dcc-4185-9a9a-7bd0d2181a0d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityFileNumber_233ae07f-5dcc-4185-9a9a-7bd0d2181a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a97eb21d-0b65-4970-85e7-19e3d98f18dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityRegistrantName_a97eb21d-0b65-4970-85e7-19e3d98f18dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_eb509ff4-ed27-4d42-8f41-bd9891a28301" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityIncorporationStateCountryCode_eb509ff4-ed27-4d42-8f41-bd9891a28301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fe639345-4684-4ad7-85ee-335bf00f8d9f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityTaxIdentificationNumber_fe639345-4684-4ad7-85ee-335bf00f8d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2a81a2ba-921b-4d03-9481-b61442e6c719" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityAddressAddressLine1_2a81a2ba-921b-4d03-9481-b61442e6c719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_17315138-565e-400d-b0dc-445dff901cdf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityAddressAddressLine2_17315138-565e-400d-b0dc-445dff901cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e778ff9e-354f-4fa1-9666-d0913794edfd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityAddressCityOrTown_e778ff9e-354f-4fa1-9666-d0913794edfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_22b1a87b-8eb5-46e0-bd36-14a3fbb4b2a7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityAddressStateOrProvince_22b1a87b-8eb5-46e0-bd36-14a3fbb4b2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c4508146-22f3-4924-be61-a6fcfd4811b1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityAddressPostalZipCode_c4508146-22f3-4924-be61-a6fcfd4811b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_46b6388c-d7b6-41c2-b751-ca8ce37a7c14" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_CityAreaCode_46b6388c-d7b6-41c2-b751-ca8ce37a7c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ef1fe899-093e-40ff-ac6d-255424b47bf2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_LocalPhoneNumber_ef1fe899-093e-40ff-ac6d-255424b47bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b4db3f37-794a-4a49-890d-e66d364dfdd1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_Security12bTitle_b4db3f37-794a-4a49-890d-e66d364dfdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_13ef0d11-170d-4423-8a55-520100077dc8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_TradingSymbol_13ef0d11-170d-4423-8a55-520100077dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_43745e7b-f244-4308-824f-694a6a601efe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_SecurityExchangeName_43745e7b-f244-4308-824f-694a6a601efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_65f6b9ba-2839-4761-bf76-0022015d75f8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityCurrentReportingStatus_65f6b9ba-2839-4761-bf76-0022015d75f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1405cd81-cb5c-48ad-88d8-731567508e59" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityInteractiveDataCurrent_1405cd81-cb5c-48ad-88d8-731567508e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5a07729e-0cbe-43ec-9fbf-0ca4e97caa78" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityFilerCategory_5a07729e-0cbe-43ec-9fbf-0ca4e97caa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2a6a6d17-a593-4f70-a459-beb613314781" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntitySmallBusiness_2a6a6d17-a593-4f70-a459-beb613314781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5fdc97db-b1fd-47c0-b7e0-042a4db81346" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityEmergingGrowthCompany_5fdc97db-b1fd-47c0-b7e0-042a4db81346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_4b030841-8901-4f3d-9ad4-292d2542161d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityExTransitionPeriod_4b030841-8901-4f3d-9ad4-292d2542161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d57a9ede-28ec-40f0-894c-51c11f47750d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityShellCompany_d57a9ede-28ec-40f0-894c-51c11f47750d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c2cf0f58-9fb0-4c5f-8af3-b684d5a41186" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c2cf0f58-9fb0-4c5f-8af3-b684d5a41186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f71b7ffc-90a5-4d3e-9947-f0e2988ba84e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_EntityCentralIndexKey_f71b7ffc-90a5-4d3e-9947-f0e2988ba84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2ac39879-0708-4df2-84a1-2b9ddb740f5d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_CurrentFiscalYearEndDate_2ac39879-0708-4df2-84a1-2b9ddb740f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0fd58528-d5bc-4c35-99d8-0d5ab9f5d304" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_DocumentFiscalYearFocus_0fd58528-d5bc-4c35-99d8-0d5ab9f5d304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c995a834-b805-4bf0-adc7-95cac9d9f2b8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c995a834-b805-4bf0-adc7-95cac9d9f2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ae6a3b7b-2c2a-4b48-a933-31d3aa0e9169" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8205dc50-2292-4fd7-95eb-89a201055d75" xlink:to="loc_dei_AmendmentFlag_ae6a3b7b-2c2a-4b48-a933-31d3aa0e9169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0e6f8298-8f3a-41cb-aaa2-ad098b3a4fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_66e497ae-6e0e-44cb-984c-dd8424065ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e6f8298-8f3a-41cb-aaa2-ad098b3a4fa0" xlink:to="loc_us-gaap_AssetsAbstract_66e497ae-6e0e-44cb-984c-dd8424065ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_600e9d06-8c6b-466b-a178-bc6d6e1a46d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66e497ae-6e0e-44cb-984c-dd8424065ac7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_600e9d06-8c6b-466b-a178-bc6d6e1a46d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5629f18-4f78-458e-babb-7af484a9a20e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_600e9d06-8c6b-466b-a178-bc6d6e1a46d4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5629f18-4f78-458e-babb-7af484a9a20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d26c1414-2b73-4634-baf3-4155b5f2f92f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_600e9d06-8c6b-466b-a178-bc6d6e1a46d4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d26c1414-2b73-4634-baf3-4155b5f2f92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a8cc9ea5-a20e-4758-a2b0-7527fe9ded29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_600e9d06-8c6b-466b-a178-bc6d6e1a46d4" xlink:to="loc_us-gaap_AssetsCurrent_a8cc9ea5-a20e-4758-a2b0-7527fe9ded29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e71f06a3-9b17-496f-9e8e-003506a7a070" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66e497ae-6e0e-44cb-984c-dd8424065ac7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e71f06a3-9b17-496f-9e8e-003506a7a070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8429a24a-9300-4ba7-94ef-29334fdfd0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66e497ae-6e0e-44cb-984c-dd8424065ac7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8429a24a-9300-4ba7-94ef-29334fdfd0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_22ff56f1-c28d-4f6d-97b7-f23bc9f24b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_66e497ae-6e0e-44cb-984c-dd8424065ac7" xlink:to="loc_us-gaap_Assets_22ff56f1-c28d-4f6d-97b7-f23bc9f24b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc96dbf3-983a-4efe-98aa-14a9e756595a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0e6f8298-8f3a-41cb-aaa2-ad098b3a4fa0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc96dbf3-983a-4efe-98aa-14a9e756595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_fc39bcb0-2d58-4411-98b9-b0c7391c0d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc96dbf3-983a-4efe-98aa-14a9e756595a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_fc39bcb0-2d58-4411-98b9-b0c7391c0d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b194da6d-db2f-4aaf-8b0b-b186c36b1044" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc39bcb0-2d58-4411-98b9-b0c7391c0d6d" xlink:to="loc_us-gaap_AccountsPayableCurrent_b194da6d-db2f-4aaf-8b0b-b186c36b1044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2d6a08e1-b296-47e1-b4a8-3094df56cb75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc39bcb0-2d58-4411-98b9-b0c7391c0d6d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2d6a08e1-b296-47e1-b4a8-3094df56cb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c573867-8eaf-4e09-b386-f425fd96456a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc39bcb0-2d58-4411-98b9-b0c7391c0d6d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c573867-8eaf-4e09-b386-f425fd96456a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e29fa92c-a773-42b4-b572-93324300b5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc39bcb0-2d58-4411-98b9-b0c7391c0d6d" xlink:to="loc_us-gaap_LiabilitiesCurrent_e29fa92c-a773-42b4-b572-93324300b5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9cc23a7-9d77-49e2-9000-1fa34c6a7530" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc96dbf3-983a-4efe-98aa-14a9e756595a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f9cc23a7-9d77-49e2-9000-1fa34c6a7530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_245133bb-3253-4860-8669-502e63e9d5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc96dbf3-983a-4efe-98aa-14a9e756595a" xlink:to="loc_us-gaap_Liabilities_245133bb-3253-4860-8669-502e63e9d5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e7e4bc1b-93ac-467c-b7ad-62777eb27d69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc96dbf3-983a-4efe-98aa-14a9e756595a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e7e4bc1b-93ac-467c-b7ad-62777eb27d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_73c7ee18-4ca6-42e6-8327-500948e2bbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc96dbf3-983a-4efe-98aa-14a9e756595a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_73c7ee18-4ca6-42e6-8327-500948e2bbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_5a5ebd6c-b030-44e0-b8cc-05ef14bc1054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73c7ee18-4ca6-42e6-8327-500948e2bbc1" xlink:to="loc_us-gaap_CommonStockValueOutstanding_5a5ebd6c-b030-44e0-b8cc-05ef14bc1054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5fd56942-5225-4658-8209-af97ea283755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73c7ee18-4ca6-42e6-8327-500948e2bbc1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5fd56942-5225-4658-8209-af97ea283755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1db771b-b107-437d-b266-36c71c5bbeff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73c7ee18-4ca6-42e6-8327-500948e2bbc1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e1db771b-b107-437d-b266-36c71c5bbeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dec6f6b5-0d03-4783-935d-e96dd2a8fa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_73c7ee18-4ca6-42e6-8327-500948e2bbc1" xlink:to="loc_us-gaap_StockholdersEquity_dec6f6b5-0d03-4783-935d-e96dd2a8fa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6fa278e-8ae1-45b8-a0c2-0485c4663c37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dc96dbf3-983a-4efe-98aa-14a9e756595a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c6fa278e-8ae1-45b8-a0c2-0485c4663c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_28fa7c6d-031a-484e-afc9-d031f1160e04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a9f22330-01e8-491d-8108-a3ee7f31c423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28fa7c6d-031a-484e-afc9-d031f1160e04" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a9f22330-01e8-491d-8108-a3ee7f31c423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f6170419-1b33-4140-b2fd-1f30bc43343f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28fa7c6d-031a-484e-afc9-d031f1160e04" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f6170419-1b33-4140-b2fd-1f30bc43343f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f9940787-a955-45d6-a2c5-8c5e9624161d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28fa7c6d-031a-484e-afc9-d031f1160e04" xlink:to="loc_us-gaap_CommonStockSharesIssued_f9940787-a955-45d6-a2c5-8c5e9624161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_68d35526-4ee1-4c87-a7f5-cf5790807ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_28fa7c6d-031a-484e-afc9-d031f1160e04" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_68d35526-4ee1-4c87-a7f5-cf5790807ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_18329a56-2e69-409a-a550-07e1e30555f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f1d61361-0a12-42ca-9a29-1ad77fd133a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18329a56-2e69-409a-a550-07e1e30555f9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f1d61361-0a12-42ca-9a29-1ad77fd133a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d9af87db-95e6-4887-9efb-e531d6721a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f1d61361-0a12-42ca-9a29-1ad77fd133a7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d9af87db-95e6-4887-9efb-e531d6721a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4786290e-a5a1-42d7-ab0a-06c9694f2d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f1d61361-0a12-42ca-9a29-1ad77fd133a7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4786290e-a5a1-42d7-ab0a-06c9694f2d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0d421c14-f571-4dbb-b317-2615cad9207d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f1d61361-0a12-42ca-9a29-1ad77fd133a7" xlink:to="loc_us-gaap_OperatingExpenses_0d421c14-f571-4dbb-b317-2615cad9207d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b2348efa-fa9b-41d5-ad1c-fe3d370fe084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18329a56-2e69-409a-a550-07e1e30555f9" xlink:to="loc_us-gaap_OperatingIncomeLoss_b2348efa-fa9b-41d5-ad1c-fe3d370fe084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_9b2ec7fc-806e-4d07-b9a7-5127af9f3b21" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18329a56-2e69-409a-a550-07e1e30555f9" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_9b2ec7fc-806e-4d07-b9a7-5127af9f3b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_55a12845-031d-4dc6-bf81-167e1c3f64f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18329a56-2e69-409a-a550-07e1e30555f9" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_55a12845-031d-4dc6-bf81-167e1c3f64f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71cedf6e-f484-4ac0-8c13-8e2a56f2750c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18329a56-2e69-409a-a550-07e1e30555f9" xlink:to="loc_us-gaap_NetIncomeLoss_71cedf6e-f484-4ac0-8c13-8e2a56f2750c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_45ef1224-6c38-4855-89b5-b7f1de9c43bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18329a56-2e69-409a-a550-07e1e30555f9" xlink:to="loc_us-gaap_EarningsPerShareBasic_45ef1224-6c38-4855-89b5-b7f1de9c43bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5b633393-bf18-4d69-99d4-5c8ea7bc7177" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18329a56-2e69-409a-a550-07e1e30555f9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5b633393-bf18-4d69-99d4-5c8ea7bc7177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81245b92-0fd6-4012-8f24-83602d36eab0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18329a56-2e69-409a-a550-07e1e30555f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_81245b92-0fd6-4012-8f24-83602d36eab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5eb58849-f056-408a-ae09-9faabd67b708" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_18329a56-2e69-409a-a550-07e1e30555f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5eb58849-f056-408a-ae09-9faabd67b708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_25b7d9ea-903d-4174-a20c-4ba6958d77b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2f63dbca-23e3-4ec8-b5f1-54fc7c4e6881" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_25b7d9ea-903d-4174-a20c-4ba6958d77b5" xlink:to="loc_us-gaap_StatementTable_2f63dbca-23e3-4ec8-b5f1-54fc7c4e6881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b626deb8-b2df-4778-98ce-6ac10e05072c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2f63dbca-23e3-4ec8-b5f1-54fc7c4e6881" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b626deb8-b2df-4778-98ce-6ac10e05072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0902dc6d-91e1-4851-b1cf-a268da64c71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b626deb8-b2df-4778-98ce-6ac10e05072c" xlink:to="loc_us-gaap_EquityComponentDomain_0902dc6d-91e1-4851-b1cf-a268da64c71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_84a4caaa-f631-420c-9d01-b8924828721c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0902dc6d-91e1-4851-b1cf-a268da64c71a" xlink:to="loc_us-gaap_CommonStockMember_84a4caaa-f631-420c-9d01-b8924828721c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d69ccfe0-5479-4c2f-a088-3de31dbbb618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0902dc6d-91e1-4851-b1cf-a268da64c71a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d69ccfe0-5479-4c2f-a088-3de31dbbb618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_02460e1f-0178-496b-8aeb-4330226a41bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0902dc6d-91e1-4851-b1cf-a268da64c71a" xlink:to="loc_us-gaap_RetainedEarningsMember_02460e1f-0178-496b-8aeb-4330226a41bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_06c4412c-1837-4980-9bb6-b467cf392354" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2f63dbca-23e3-4ec8-b5f1-54fc7c4e6881" xlink:to="loc_us-gaap_StatementLineItems_06c4412c-1837-4980-9bb6-b467cf392354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06c4412c-1837-4980-9bb6-b467cf392354" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5688e9f9-f349-482a-8091-1a6c10cc173f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5688e9f9-f349-482a-8091-1a6c10cc173f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d402c988-cb1b-4ec0-8f2d-67626ba4dc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_StockholdersEquity_d402c988-cb1b-4ec0-8f2d-67626ba4dc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a100e532-dda5-4d6c-b933-180ab635c767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a100e532-dda5-4d6c-b933-180ab635c767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_432ecba2-a535-41a3-b3d0-d7f6dc4cccee" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_432ecba2-a535-41a3-b3d0-d7f6dc4cccee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_c38a472f-8938-4ace-b257-f9e5eb403666" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_c38a472f-8938-4ace-b257-f9e5eb403666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_96795ab8-566f-4e43-bc7f-f7ee26e17a42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_96795ab8-566f-4e43-bc7f-f7ee26e17a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb88f73b-76ca-42ad-b871-d43e3588f913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb88f73b-76ca-42ad-b871-d43e3588f913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_b5181aa1-136e-41e9-b630-160a65255367" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_b5181aa1-136e-41e9-b630-160a65255367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88eaf750-b8df-48c5-9a9f-f67a76096592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_NetIncomeLoss_88eaf750-b8df-48c5-9a9f-f67a76096592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b12ea235-4b84-4465-9b22-bdb2225b7a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b12ea235-4b84-4465-9b22-bdb2225b7a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0e5f2cc-4a8d-4dc3-8151-57ec72ff771b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0f3a9e64-4976-459f-a04e-fec30fe53ab6" xlink:to="loc_us-gaap_StockholdersEquity_c0e5f2cc-4a8d-4dc3-8151-57ec72ff771b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_dba2f9c3-fd76-4ed2-a893-80910f0eed41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7873a74e-5da4-4ab3-b4e2-26b0090ea70e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dba2f9c3-fd76-4ed2-a893-80910f0eed41" xlink:to="loc_us-gaap_StatementTable_7873a74e-5da4-4ab3-b4e2-26b0090ea70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c2576d95-f790-45e9-b4dd-6affb6503db7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7873a74e-5da4-4ab3-b4e2-26b0090ea70e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c2576d95-f790-45e9-b4dd-6affb6503db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58f6966c-dd5a-4a1c-ba70-5708d039c8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c2576d95-f790-45e9-b4dd-6affb6503db7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58f6966c-dd5a-4a1c-ba70-5708d039c8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember_fa652aa7-55b3-4b75-9564-05386aed3a1c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58f6966c-dd5a-4a1c-ba70-5708d039c8c1" xlink:to="loc_ck0001824293_ThroughFinancingMember_fa652aa7-55b3-4b75-9564-05386aed3a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7873a74e-5da4-4ab3-b4e2-26b0090ea70e" xlink:to="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67d66974-b79f-4979-85cd-61aeee6f55b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67d66974-b79f-4979-85cd-61aeee6f55b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_39fc5fa0-fee7-4fce-a8c4-4759fb9ebf18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67d66974-b79f-4979-85cd-61aeee6f55b5" xlink:to="loc_us-gaap_NetIncomeLoss_39fc5fa0-fee7-4fce-a8c4-4759fb9ebf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67d66974-b79f-4979-85cd-61aeee6f55b5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b213e47a-f275-4756-9a76-40800ebc5b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:to="loc_us-gaap_Depreciation_b213e47a-f275-4756-9a76-40800ebc5b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_146e9c4b-1ae1-4cef-8cb0-57e5c2433072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:to="loc_us-gaap_ShareBasedCompensation_146e9c4b-1ae1-4cef-8cb0-57e5c2433072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_47b373db-9c5e-41b7-800b-d8dc26caa2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_47b373db-9c5e-41b7-800b-d8dc26caa2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6995e326-95c9-4a5b-b1ed-4e67713187dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6995e326-95c9-4a5b-b1ed-4e67713187dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a8a9ceca-e0fd-492d-ac59-3964ec044234" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06bba2a4-a17a-4a40-90db-9923b33e0c63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06bba2a4-a17a-4a40-90db-9923b33e0c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ed5228b9-998a-4e48-8e8f-c812e3b35f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ed5228b9-998a-4e48-8e8f-c812e3b35f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d971b335-ace3-40de-aba2-4061e798bec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d971b335-ace3-40de-aba2-4061e798bec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bd9affd2-f071-4753-b9d1-81acc2fcf6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adc6eee2-d113-43fc-a20c-97b0151a0a44" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bd9affd2-f071-4753-b9d1-81acc2fcf6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa314cee-80b7-41a7-aa8c-3310b0577d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67d66974-b79f-4979-85cd-61aeee6f55b5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa314cee-80b7-41a7-aa8c-3310b0577d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e681f824-2b2e-486c-a004-168830c3b484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e681f824-2b2e-486c-a004-168830c3b484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_6632fc01-e498-4c27-bf14-8657578ba18d" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:to="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_6632fc01-e498-4c27-bf14-8657578ba18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b1166b30-e3e4-4217-9d69-b84505ffc34a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b1166b30-e3e4-4217-9d69-b84505ffc34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_937c2052-b106-4511-b275-c7ba5cbaf567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e670f902-349c-44e9-a60c-f2a73fd5f88d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_937c2052-b106-4511-b275-c7ba5cbaf567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_861f120c-9894-400e-88c3-37c04a267015" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_861f120c-9894-400e-88c3-37c04a267015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d3eff85-c366-4662-9c9e-531bb30f395d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d3eff85-c366-4662-9c9e-531bb30f395d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18c0b6bf-52b6-41ab-94db-123845f44db4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18c0b6bf-52b6-41ab-94db-123845f44db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ee69e99d-5a72-4622-9edb-f0c0cc1762ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a05b16c3-2a98-4761-9175-97d54db210c5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ee69e99d-5a72-4622-9edb-f0c0cc1762ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities_2ab3bf07-7ea3-4fd3-b5d7-4ad2df91ca38" xlink:href="ck0001824293-20250331.xsd#ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ee69e99d-5a72-4622-9edb-f0c0cc1762ad" xlink:to="loc_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities_2ab3bf07-7ea3-4fd3-b5d7-4ad2df91ca38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_c75c4324-7239-475f-a649-44d928bf0f6c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ee69e99d-5a72-4622-9edb-f0c0cc1762ad" xlink:to="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_c75c4324-7239-475f-a649-44d928bf0f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8787f7e2-5847-4cfb-942d-0a1ac6f05780" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_b530c0f9-cf18-4b7b-9350-4fc3ca885819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8787f7e2-5847-4cfb-942d-0a1ac6f05780" xlink:to="loc_us-gaap_NatureOfOperations_b530c0f9-cf18-4b7b-9350-4fc3ca885819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#LIQUIDITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_966d008e-011f-4308-ba4d-d9ec250368c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_b6a9e243-7843-4bd8-b9de-15f6b5824416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_966d008e-011f-4308-ba4d-d9ec250368c8" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_b6a9e243-7843-4bd8-b9de-15f6b5824416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6c166e3d-6c29-4bf2-9f54-b438241657c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_a48b56ad-42ed-4247-901b-9c1ada06b6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c166e3d-6c29-4bf2-9f54-b438241657c8" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_a48b56ad-42ed-4247-901b-9c1ada06b6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5360cd41-ec02-4e70-a6e6-ed3bfb190b08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8449b146-1a4d-43f0-ad2a-dde8473fadb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5360cd41-ec02-4e70-a6e6-ed3bfb190b08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8449b146-1a4d-43f0-ad2a-dde8473fadb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d74b9f6f-a60f-4db1-bf23-2c2d096e90c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_aa744511-16da-42fe-94dc-e937fa2c928b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d74b9f6f-a60f-4db1-bf23-2c2d096e90c3" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_aa744511-16da-42fe-94dc-e937fa2c928b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_edcc70f3-f877-48a1-a3c0-8a7b0a537896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_53676ac6-e53f-400a-84e4-c6c06e5e75fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_edcc70f3-f877-48a1-a3c0-8a7b0a537896" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_53676ac6-e53f-400a-84e4-c6c06e5e75fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4757edc2-f56f-46c8-aa36-a2d1b54cf318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b910af63-d5b8-47d2-996a-b7bc8421e7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4757edc2-f56f-46c8-aa36-a2d1b54cf318" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b910af63-d5b8-47d2-996a-b7bc8421e7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SEGMENTREPORTING" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#SEGMENTREPORTING"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SEGMENTREPORTING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f9781010-30f0-4992-aadb-c5ade9c3073b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_3cbf8bae-ec1d-4d21-a739-2fd3479a357f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f9781010-30f0-4992-aadb-c5ade9c3073b" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_3cbf8bae-ec1d-4d21-a739-2fd3479a357f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22b8bc3d-f822-4e19-b9c6-63a891b252cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9ac7cba0-40a8-40ff-99b5-1f78d52f5d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22b8bc3d-f822-4e19-b9c6-63a891b252cf" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9ac7cba0-40a8-40ff-99b5-1f78d52f5d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_c37dd0c0-def6-4008-80a9-15ff4f8d3a26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_b6334f71-fc02-465e-919c-eb97bcf9d520" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_c37dd0c0-def6-4008-80a9-15ff4f8d3a26" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_b6334f71-fc02-465e-919c-eb97bcf9d520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9d26bcfa-3238-4672-847c-b7901b52eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3583fc9f-08e5-4164-81e3-7b834d9560be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d26bcfa-3238-4672-847c-b7901b52eb3c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3583fc9f-08e5-4164-81e3-7b834d9560be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9d8e3842-5d7d-4b90-a6cf-5d0dfd3f7d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d26bcfa-3238-4672-847c-b7901b52eb3c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_9d8e3842-5d7d-4b90-a6cf-5d0dfd3f7d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1d1f891f-782f-405f-bd86-8868f70630ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d26bcfa-3238-4672-847c-b7901b52eb3c" xlink:to="loc_us-gaap_UseOfEstimates_1d1f891f-782f-405f-bd86-8868f70630ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_80752995-5a9e-4557-b777-6f800c3524a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d26bcfa-3238-4672-847c-b7901b52eb3c" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_80752995-5a9e-4557-b777-6f800c3524a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_6de195b9-9a0c-4b53-89d1-e0de0885db42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d26bcfa-3238-4672-847c-b7901b52eb3c" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_6de195b9-9a0c-4b53-89d1-e0de0885db42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0c297e32-7150-4c48-a271-84a616a0a2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d26bcfa-3238-4672-847c-b7901b52eb3c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0c297e32-7150-4c48-a271-84a616a0a2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_237d94e7-9e5e-4c02-b0e1-b27a2dedf550" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9d26bcfa-3238-4672-847c-b7901b52eb3c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_237d94e7-9e5e-4c02-b0e1-b27a2dedf550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d698e16e-7f02-4434-8c46-83cbf4abd455" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_913e837e-a34d-4bba-aa7e-5a10a6801172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d698e16e-7f02-4434-8c46-83cbf4abd455" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_913e837e-a34d-4bba-aa7e-5a10a6801172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a21d9d3e-d63a-4087-83ce-5a4860119a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fd533105-2582-4e82-8930-fdf6e4efc712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a21d9d3e-d63a-4087-83ce-5a4860119a49" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_fd533105-2582-4e82-8930-fdf6e4efc712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dc9e48ca-0085-4b1a-b2bf-6c6156f5532c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0171556f-914c-4dd9-9f56-60fb660965a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dc9e48ca-0085-4b1a-b2bf-6c6156f5532c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0171556f-914c-4dd9-9f56-60fb660965a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_75e689c1-f54c-47a8-8aa6-fbe9e0c5f8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_f5e2e3a8-8077-466f-8915-e02d2b2b0b21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_75e689c1-f54c-47a8-8aa6-fbe9e0c5f8b6" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_f5e2e3a8-8077-466f-8915-e02d2b2b0b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c472b91c-d329-40a9-a4b3-0dc001a8fe87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_032a0380-4deb-4eaf-b9cd-a8fd9b352197" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c472b91c-d329-40a9-a4b3-0dc001a8fe87" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_032a0380-4deb-4eaf-b9cd-a8fd9b352197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_19249e4a-893c-43aa-a23a-c0ac1b429ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c472b91c-d329-40a9-a4b3-0dc001a8fe87" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_19249e4a-893c-43aa-a23a-c0ac1b429ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7b26a94f-2fc3-44ab-b18c-d80faa54ca5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c472b91c-d329-40a9-a4b3-0dc001a8fe87" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7b26a94f-2fc3-44ab-b18c-d80faa54ca5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8cc7d05c-0c43-45cb-81ff-02f9c04f21f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_96b3292b-da0c-4a57-9330-02138166b92a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8cc7d05c-0c43-45cb-81ff-02f9c04f21f8" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_96b3292b-da0c-4a57-9330-02138166b92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#LIQUIDITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41a105b6-df51-4439-b8c1-868850a48ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41a105b6-df51-4439-b8c1-868850a48ab4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1d19ed74-d7f1-49bc-b054-a7294b700654" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1d19ed74-d7f1-49bc-b054-a7294b700654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187661e2-2eb9-4465-875f-ed79b6d55e32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1d19ed74-d7f1-49bc-b054-a7294b700654" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187661e2-2eb9-4465-875f-ed79b6d55e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_6821df6d-42e5-4aee-bfc1-f033d23b8aab" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187661e2-2eb9-4465-875f-ed79b6d55e32" xlink:to="loc_ck0001824293_PublicOfferingMember_6821df6d-42e5-4aee-bfc1-f033d23b8aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_3cbb125c-27a1-40ad-98f7-46f507c10b48" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_187661e2-2eb9-4465-875f-ed79b6d55e32" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_3cbb125c-27a1-40ad-98f7-46f507c10b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a1a60a13-ad62-4bd0-a4ab-46a70fafc47a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:to="loc_srt_RangeAxis_a1a60a13-ad62-4bd0-a4ab-46a70fafc47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1db3e5b9-dfd9-432b-981e-4a73c9b86f32" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a1a60a13-ad62-4bd0-a4ab-46a70fafc47a" xlink:to="loc_srt_RangeMember_1db3e5b9-dfd9-432b-981e-4a73c9b86f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_94a6dadc-dd17-4fe1-9873-ab3d62c762c6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1db3e5b9-dfd9-432b-981e-4a73c9b86f32" xlink:to="loc_srt_WeightedAverageMember_94a6dadc-dd17-4fe1-9873-ab3d62c762c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4692aa33-fe85-4287-b8ab-86fe5edd5710" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4692aa33-fe85-4287-b8ab-86fe5edd5710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f096c09e-0ee8-43e8-a26e-92f39d7d825d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4692aa33-fe85-4287-b8ab-86fe5edd5710" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f096c09e-0ee8-43e8-a26e-92f39d7d825d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember_45c67e39-c321-45a0-acdf-d286c8957aca" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f096c09e-0ee8-43e8-a26e-92f39d7d825d" xlink:to="loc_ck0001824293_SeriesBCommonWarrantsMember_45c67e39-c321-45a0-acdf-d286c8957aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e53e7204-cf00-4bad-ac8f-eb5c0666aa2e" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7829ff1b-8a83-46df-9b8c-a39b883766b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7829ff1b-8a83-46df-9b8c-a39b883766b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_904758bc-dd47-4f93-ab8a-f390fbff4c70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_904758bc-dd47-4f93-ab8a-f390fbff4c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_959494b0-fa75-41e4-b779-549800f7476d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_959494b0-fa75-41e4-b779-549800f7476d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_b435758f-23d6-473a-9bb1-cf66ac9778b6" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_b435758f-23d6-473a-9bb1-cf66ac9778b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_5ddf386e-7cc4-4567-8921-096a0b445bc5" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_5ddf386e-7cc4-4567-8921-096a0b445bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_c9cfa701-439c-451b-a0ca-773b1d0c30ca" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_c9cfa701-439c-451b-a0ca-773b1d0c30ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_54e67115-54d2-40e0-a747-0eb04e27bdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_54e67115-54d2-40e0-a747-0eb04e27bdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_b30468c0-2555-4c6e-8647-d1cb166bb85f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_b30468c0-2555-4c6e-8647-d1cb166bb85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c0dccb2-5cc9-4c09-af25-89841258e405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c0dccb2-5cc9-4c09-af25-89841258e405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ff446240-0e17-4734-8b6c-5a5b8249bec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ff446240-0e17-4734-8b6c-5a5b8249bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_e87877f1-3b79-47ee-b772-ea104ec33253" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e79a0420-92dc-4ccb-9f66-78734a884c91" xlink:to="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_e87877f1-3b79-47ee-b772-ea104ec33253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d9c61cd7-380c-4b08-9f4d-d44fc9ef69a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b5d33a6-5038-4a69-b848-b0343b44df93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9c61cd7-380c-4b08-9f4d-d44fc9ef69a9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b5d33a6-5038-4a69-b848-b0343b44df93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_451fe521-fac4-40cb-8ab9-f374145079c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b5d33a6-5038-4a69-b848-b0343b44df93" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_451fe521-fac4-40cb-8ab9-f374145079c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba31e177-6051-4ff8-a706-136f8bf69638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_451fe521-fac4-40cb-8ab9-f374145079c1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba31e177-6051-4ff8-a706-136f8bf69638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_80f8d5c7-f3ce-4058-a3b1-781e1e66d43a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba31e177-6051-4ff8-a706-136f8bf69638" xlink:to="loc_us-gaap_EmployeeStockOptionMember_80f8d5c7-f3ce-4058-a3b1-781e1e66d43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_9f4b01df-6f0a-44bb-b78e-097e17bb3cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ba31e177-6051-4ff8-a706-136f8bf69638" xlink:to="loc_us-gaap_WarrantMember_9f4b01df-6f0a-44bb-b78e-097e17bb3cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b52b9d1-9202-41ca-90d0-2e86ad116952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b5d33a6-5038-4a69-b848-b0343b44df93" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b52b9d1-9202-41ca-90d0-2e86ad116952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b234cd64-b617-4e03-b3c0-c5630d694f15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b52b9d1-9202-41ca-90d0-2e86ad116952" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b234cd64-b617-4e03-b3c0-c5630d694f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5a27ad9e-d2c7-41f2-b593-706bb54ff511" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a38225e-572d-4ff5-a59a-e5cd71489528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5a27ad9e-d2c7-41f2-b593-706bb54ff511" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a38225e-572d-4ff5-a59a-e5cd71489528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d835cd8c-ae7d-48f0-b35c-cf2c4a3efa89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a38225e-572d-4ff5-a59a-e5cd71489528" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d835cd8c-ae7d-48f0-b35c-cf2c4a3efa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87673a69-6cc2-4c87-a343-653948758650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d835cd8c-ae7d-48f0-b35c-cf2c4a3efa89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87673a69-6cc2-4c87-a343-653948758650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_450f6a3c-2840-4d63-a1e6-ef1bc7ac8290" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87673a69-6cc2-4c87-a343-653948758650" xlink:to="loc_us-gaap_ComputerEquipmentMember_450f6a3c-2840-4d63-a1e6-ef1bc7ac8290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_55d40574-5b79-4088-bafc-315c6aaac52e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_87673a69-6cc2-4c87-a343-653948758650" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_55d40574-5b79-4088-bafc-315c6aaac52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9a261f8a-6de6-468c-8fb4-e57225bed585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2a38225e-572d-4ff5-a59a-e5cd71489528" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9a261f8a-6de6-468c-8fb4-e57225bed585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_12ad488a-bc16-4ae8-83ae-1b1774c9a9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9a261f8a-6de6-468c-8fb4-e57225bed585" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_12ad488a-bc16-4ae8-83ae-1b1774c9a9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b4e2418-27d8-4432-9e4e-cf9c6a228115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9a261f8a-6de6-468c-8fb4-e57225bed585" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b4e2418-27d8-4432-9e4e-cf9c6a228115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_00dde795-2b00-4b9a-9afa-51ecdfdf17cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9a261f8a-6de6-468c-8fb4-e57225bed585" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_00dde795-2b00-4b9a-9afa-51ecdfdf17cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#PROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c9343453-bc29-4916-8085-fa680ae0682c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0193e551-df65-4ac0-a1e9-52ed95f49a54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c9343453-bc29-4916-8085-fa680ae0682c" xlink:to="loc_us-gaap_Depreciation_0193e551-df65-4ac0-a1e9-52ed95f49a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f78d4e3b-fe3f-4a63-af77-86cf10f0e800" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_2fb6f3fd-4c82-4a6c-83e7-0af75685d5cf" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f78d4e3b-fe3f-4a63-af77-86cf10f0e800" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_2fb6f3fd-4c82-4a6c-83e7-0af75685d5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_5fe75a12-6e14-4b8b-9e50-5e64ebed5542" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f78d4e3b-fe3f-4a63-af77-86cf10f0e800" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_5fe75a12-6e14-4b8b-9e50-5e64ebed5542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_30b64c81-d0a5-47a2-92f6-e91146bc2984" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f78d4e3b-fe3f-4a63-af77-86cf10f0e800" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_30b64c81-d0a5-47a2-92f6-e91146bc2984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3a71148e-7ff4-43cd-8b83-8bdc4efae136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f78d4e3b-fe3f-4a63-af77-86cf10f0e800" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3a71148e-7ff4-43cd-8b83-8bdc4efae136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b4be60ad-568a-4fea-bf10-7c8a6ec5318f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b4be60ad-568a-4fea-bf10-7c8a6ec5318f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_48fcc9df-6760-4245-a693-800f3a702f89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_48fcc9df-6760-4245-a693-800f3a702f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_48fcc9df-6760-4245-a693-800f3a702f89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_bb83be2a-355e-45ab-bdf0-b0c13e740761" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_bb83be2a-355e-45ab-bdf0-b0c13e740761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember_55828663-5e16-4038-b1f5-53c6069330d4" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_SeriesBCommonWarrantsMember_55828663-5e16-4038-b1f5-53c6069330d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_d5571545-06fc-4ce1-a37e-2276e2503a6d" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember_55828663-5e16-4038-b1f5-53c6069330d4" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_d5571545-06fc-4ce1-a37e-2276e2503a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_58ebbff8-3261-4622-b091-a93cbb4188c8" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember_55828663-5e16-4038-b1f5-53c6069330d4" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_58ebbff8-3261-4622-b091-a93cbb4188c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_4ec062ff-5fb0-45a8-9b0c-538297319a45" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_4ec062ff-5fb0-45a8-9b0c-538297319a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_d227dad5-320b-4127-bcb0-1976c1337640" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_d227dad5-320b-4127-bcb0-1976c1337640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_42ba5a55-dbcb-43ac-9f3a-317a7711f7ab" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_42ba5a55-dbcb-43ac-9f3a-317a7711f7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_d24115cb-3867-4027-91af-a0279205dd24" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_d24115cb-3867-4027-91af-a0279205dd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember_3eb7d1f7-3d07-4707-bdb5-0f1488e05b05" xlink:href="ck0001824293-20250331.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_June2024PAWarrantsMember_3eb7d1f7-3d07-4707-bdb5-0f1488e05b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember_66b4ebad-ef0e-4bf0-b22b-2aa8696068da" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_SeriesDWarrantsMember_66b4ebad-ef0e-4bf0-b22b-2aa8696068da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember_de7a277a-7651-40f0-9d23-08918c0dddd5" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesDWarrantsMember_66b4ebad-ef0e-4bf0-b22b-2aa8696068da" xlink:to="loc_ck0001824293_SeriesD1WarrantsMember_de7a277a-7651-40f0-9d23-08918c0dddd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember_ded41748-7923-479f-a22c-407a13a9ed8a" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesDWarrantsMember_66b4ebad-ef0e-4bf0-b22b-2aa8696068da" xlink:to="loc_ck0001824293_SeriesD2WarrantsMember_ded41748-7923-479f-a22c-407a13a9ed8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_October2024PAWarrantsMember_1e8ef61f-0232-4a67-98d5-fc8139f60f45" xlink:href="ck0001824293-20250331.xsd#ck0001824293_October2024PAWarrantsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ae4d70b1-6f34-4d40-b693-e90f817e912e" xlink:to="loc_ck0001824293_October2024PAWarrantsMember_1e8ef61f-0232-4a67-98d5-fc8139f60f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_75c53c4b-01ab-47ab-845d-43fe5cf0c9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_75c53c4b-01ab-47ab-845d-43fe5cf0c9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8153b065-321a-42ba-bd75-819d47b22a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_75c53c4b-01ab-47ab-845d-43fe5cf0c9b6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8153b065-321a-42ba-bd75-819d47b22a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_01c36859-4deb-45f1-836b-2f915f723e7e" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8153b065-321a-42ba-bd75-819d47b22a28" xlink:to="loc_ck0001824293_PublicOfferingMember_01c36859-4deb-45f1-836b-2f915f723e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_9c3bdc5a-2699-4a6e-b51d-2772a904e94c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8153b065-321a-42ba-bd75-819d47b22a28" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_9c3bdc5a-2699-4a6e-b51d-2772a904e94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a61aa82-8168-4547-89d2-10600f856c44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:to="loc_srt_RangeAxis_0a61aa82-8168-4547-89d2-10600f856c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da45b47b-0f4b-442b-a9db-dcab0ce43dd1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0a61aa82-8168-4547-89d2-10600f856c44" xlink:to="loc_srt_RangeMember_da45b47b-0f4b-442b-a9db-dcab0ce43dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_d2e19be2-554a-4feb-9e7c-d0347bce699a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_da45b47b-0f4b-442b-a9db-dcab0ce43dd1" xlink:to="loc_srt_WeightedAverageMember_d2e19be2-554a-4feb-9e7c-d0347bce699a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_72fa9748-b2aa-496c-bc8f-b77ba4be587d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_72fa9748-b2aa-496c-bc8f-b77ba4be587d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b500347b-3e67-45f0-8296-cee81427e885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_72fa9748-b2aa-496c-bc8f-b77ba4be587d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b500347b-3e67-45f0-8296-cee81427e885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2209b8d0-6f4e-48a4-9e33-6c9ffc2fb004" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b500347b-3e67-45f0-8296-cee81427e885" xlink:to="loc_us-gaap_SubsequentEventMember_2209b8d0-6f4e-48a4-9e33-6c9ffc2fb004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7b2d6bc-89c2-4f03-a34e-51b63cf9197c" xlink:to="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97623e51-ba5d-406d-b223-b9daf50e0a98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97623e51-ba5d-406d-b223-b9daf50e0a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8f7d3621-8efb-4389-aab7-d13efd89d143" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8f7d3621-8efb-4389-aab7-d13efd89d143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b9f0f88c-fae9-41eb-b0a9-bfa6366db1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b9f0f88c-fae9-41eb-b0a9-bfa6366db1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e7ed1dc3-d037-4edb-b91c-eec5829a5184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e7ed1dc3-d037-4edb-b91c-eec5829a5184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0ab0171c-6d29-4b76-b481-ef020922634b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0ab0171c-6d29-4b76-b481-ef020922634b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_cf505a98-fbae-4d42-89f0-c16d5560064a" xlink:href="ck0001824293-20250331.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_cf505a98-fbae-4d42-89f0-c16d5560064a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_83f19055-6356-4f53-894d-40c64dd94768" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_83f19055-6356-4f53-894d-40c64dd94768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_9e6592bb-226b-4b55-966d-d83ad48d3eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_9e6592bb-226b-4b55-966d-d83ad48d3eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7ed36d02-fb8f-4ec9-98da-042a65e1292a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_7ed36d02-fb8f-4ec9-98da-042a65e1292a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7d65c9fa-4eca-4bf7-9424-079f850a11dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7d65c9fa-4eca-4bf7-9424-079f850a11dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e542e076-3c98-4f12-800c-1c3fd61de06f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e542e076-3c98-4f12-800c-1c3fd61de06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_0f99f97f-a6ef-4323-b0cc-a3fe8e26d9e9" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_0f99f97f-a6ef-4323-b0cc-a3fe8e26d9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_69cce361-41de-4391-acd1-4c3e902c5bde" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_69cce361-41de-4391-acd1-4c3e902c5bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1017f5dd-8d4f-4a48-9390-26a6ecc8b445" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1017f5dd-8d4f-4a48-9390-26a6ecc8b445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_0c5c519a-f5de-4c53-8a6c-e49ace26fa6f" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_0c5c519a-f5de-4c53-8a6c-e49ace26fa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_6ed764c5-047a-4c8a-9fee-700d8d242c22" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_6ed764c5-047a-4c8a-9fee-700d8d242c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_7d2ab6be-389e-4de6-a4fd-9fd887b7f829" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_7d2ab6be-389e-4de6-a4fd-9fd887b7f829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_7dc3fcf1-381c-42bf-accd-b1f95bf67b4c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_7dc3fcf1-381c-42bf-accd-b1f95bf67b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_9ae85d77-5f17-46b9-80ae-e0dd349a157d" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_9ae85d77-5f17-46b9-80ae-e0dd349a157d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_941a0b58-440c-4b9b-b3f1-cd7d3d21c336" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_941a0b58-440c-4b9b-b3f1-cd7d3d21c336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7bbf2a7c-67b0-4ae9-9a71-f8a0dc4d4f21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b0705e2f-a0e5-47a2-b1a4-74945745117e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_7bbf2a7c-67b0-4ae9-9a71-f8a0dc4d4f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cf2c52ab-2c44-47c2-8c0e-a588edebf655" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c47a21f1-86f9-470b-b4a3-ea63fbfcdd66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cf2c52ab-2c44-47c2-8c0e-a588edebf655" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c47a21f1-86f9-470b-b4a3-ea63fbfcdd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_19aefa56-6609-4903-a359-6bd11a4f2f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c47a21f1-86f9-470b-b4a3-ea63fbfcdd66" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_19aefa56-6609-4903-a359-6bd11a4f2f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_19aefa56-6609-4903-a359-6bd11a4f2f1d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member_8c37ccbd-4295-411a-8f8b-b29ed5af9cd3" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInAugust2025Member_8c37ccbd-4295-411a-8f8b-b29ed5af9cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_4365a331-8377-43d6-9a40-37c2814c762c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_4365a331-8377-43d6-9a40-37c2814c762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMarch2026Member_b44c841b-f4ad-4a5b-8c31-07693455655f" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInMarch2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInMarch2026Member_b44c841b-f4ad-4a5b-8c31-07693455655f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2026Member_bb0fd691-9d20-4e9c-a5c7-60b3e1ddffaa" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInApril2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2026Member_bb0fd691-9d20-4e9c-a5c7-60b3e1ddffaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_a0a59be9-5b96-4b16-aa87-eda231de017d" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_a0a59be9-5b96-4b16-aa87-eda231de017d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_147d7f4a-9d30-4bab-aba2-4bf414f512bc" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_147d7f4a-9d30-4bab-aba2-4bf414f512bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_6b84ccd6-383a-4130-b0c8-97ae834ce349" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_6b84ccd6-383a-4130-b0c8-97ae834ce349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_004df3a7-8358-447e-9fb2-ce7f766c2280" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_004df3a7-8358-447e-9fb2-ce7f766c2280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member_c40e8439-c142-4327-b7ae-03936a06028a" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2029Member_c40e8439-c142-4327-b7ae-03936a06028a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_152b5766-a030-4c3f-8845-d8c495defdd5" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInSeptember2029Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_152b5766-a030-4c3f-8845-d8c495defdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_76cc0325-fecf-418c-b17a-601a84934fd7" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInOctober2029OneMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_76cc0325-fecf-418c-b17a-601a84934fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_d00d7694-10b3-4cbe-9436-0d513c6af24f" xlink:href="ck0001824293-20250331.xsd#ck0001824293_WarrantsExpiringInOctober2029TwoMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0c01aedc-6961-4c2b-9633-f53b86c02fd5" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_d00d7694-10b3-4cbe-9436-0d513c6af24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8001e74c-0355-4802-9d62-790c3f9c0101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c47a21f1-86f9-470b-b4a3-ea63fbfcdd66" xlink:to="loc_us-gaap_ClassOfStockLineItems_8001e74c-0355-4802-9d62-790c3f9c0101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0a5e98af-759c-49c0-a162-cda438e7f91d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8001e74c-0355-4802-9d62-790c3f9c0101" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0a5e98af-759c-49c0-a162-cda438e7f91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0ea308a3-2a51-4f1a-a900-b491585bb229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8001e74c-0355-4802-9d62-790c3f9c0101" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0ea308a3-2a51-4f1a-a900-b491585bb229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd91465c-97a2-4f2b-9dc2-7b1c03736431" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd91465c-97a2-4f2b-9dc2-7b1c03736431" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1a1837ba-d7b5-465b-b90f-59e1a9c8a705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:to="loc_us-gaap_PlanNameAxis_1a1837ba-d7b5-465b-b90f-59e1a9c8a705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f4dbb0f0-963e-4400-8937-87b86c7b74d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1a1837ba-d7b5-465b-b90f-59e1a9c8a705" xlink:to="loc_us-gaap_PlanNameDomain_f4dbb0f0-963e-4400-8937-87b86c7b74d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_872e1c3a-1abb-4b75-accc-0b7737b55b8d" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f4dbb0f0-963e-4400-8937-87b86c7b74d9" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_872e1c3a-1abb-4b75-accc-0b7737b55b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e9b55a65-de5d-4959-a0cc-5fb6c2f61e28" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:to="loc_srt_RangeAxis_e9b55a65-de5d-4959-a0cc-5fb6c2f61e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_950ddfce-2991-4228-b721-99ace1867448" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e9b55a65-de5d-4959-a0cc-5fb6c2f61e28" xlink:to="loc_srt_RangeMember_950ddfce-2991-4228-b721-99ace1867448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8692d1b5-1f93-475c-8cbc-498a71662e37" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_950ddfce-2991-4228-b721-99ace1867448" xlink:to="loc_srt_MaximumMember_8692d1b5-1f93-475c-8cbc-498a71662e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da6a93fd-bde5-47cd-9972-b94f61df1572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:to="loc_us-gaap_AwardTypeAxis_da6a93fd-bde5-47cd-9972-b94f61df1572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d1b14eb-2274-4f52-8880-91c520bb7af8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_da6a93fd-bde5-47cd-9972-b94f61df1572" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d1b14eb-2274-4f52-8880-91c520bb7af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_922a3127-9446-4138-8bfd-3d5babd3e1de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4d1b14eb-2274-4f52-8880-91c520bb7af8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_922a3127-9446-4138-8bfd-3d5babd3e1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_58b7aa8c-be4f-4c73-9ffc-82b5c0cb0e1c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_68741aea-7a79-42c9-85a8-3f7c7bd5c52b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_68741aea-7a79-42c9-85a8-3f7c7bd5c52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_93dfdae3-88e1-425f-b4a5-2206d248a64e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_93dfdae3-88e1-425f-b4a5-2206d248a64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_42badf92-4c0c-4d33-89ae-b64253b1d21b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_42badf92-4c0c-4d33-89ae-b64253b1d21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_ad71839e-7e7a-42cf-a7c2-a6045872234c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_ad71839e-7e7a-42cf-a7c2-a6045872234c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e9b110bd-2b55-4fa6-af64-88f5a0936abd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e9b110bd-2b55-4fa6-af64-88f5a0936abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a8c7b157-662f-4a81-b3f0-2b9084e5dfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a8c7b157-662f-4a81-b3f0-2b9084e5dfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7017eace-88cb-445f-a98c-c17fcb787584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7017eace-88cb-445f-a98c-c17fcb787584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_46474367-306a-44f9-8ca2-f5fe4b843cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_46474367-306a-44f9-8ca2-f5fe4b843cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7faad7c-56b9-48ce-93d6-62d718052515" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7defc262-f991-4e94-8a50-8af32e70fbb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7faad7c-56b9-48ce-93d6-62d718052515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95dce18a-e1e6-47e7-8ccd-32bd43d4fa40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e2057bad-e9b5-4ad5-ae05-ef20827f1aef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_95dce18a-e1e6-47e7-8ccd-32bd43d4fa40" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e2057bad-e9b5-4ad5-ae05-ef20827f1aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9d26cca3-c059-4a8d-ae74-bfc3b4a51489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e2057bad-e9b5-4ad5-ae05-ef20827f1aef" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9d26cca3-c059-4a8d-ae74-bfc3b4a51489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bfca0647-d0dc-4339-b789-29b8ee2cb8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9d26cca3-c059-4a8d-ae74-bfc3b4a51489" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bfca0647-d0dc-4339-b789-29b8ee2cb8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2399b6f0-94f5-47e3-9e35-695ca2878ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bfca0647-d0dc-4339-b789-29b8ee2cb8d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2399b6f0-94f5-47e3-9e35-695ca2878ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_92c28b10-a8c0-4684-a82b-b36711b7db94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bfca0647-d0dc-4339-b789-29b8ee2cb8d0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_92c28b10-a8c0-4684-a82b-b36711b7db94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e463ae63-0aed-4abe-ad25-7deb5e88f505" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e2057bad-e9b5-4ad5-ae05-ef20827f1aef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e463ae63-0aed-4abe-ad25-7deb5e88f505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a7ae2de5-10a7-4392-b25b-2af84d4170fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e463ae63-0aed-4abe-ad25-7deb5e88f505" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a7ae2de5-10a7-4392-b25b-2af84d4170fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c4aafba-1322-460b-8a41-c6943284782d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31b9eeca-acf4-4e00-b623-fe69f898dcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c4aafba-1322-460b-8a41-c6943284782d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31b9eeca-acf4-4e00-b623-fe69f898dcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06a3e5a5-76c1-49c9-ba52-3f714c1275ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31b9eeca-acf4-4e00-b623-fe69f898dcb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06a3e5a5-76c1-49c9-ba52-3f714c1275ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_267b8e66-9db2-45c4-937a-1d10f9c41438" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31b9eeca-acf4-4e00-b623-fe69f898dcb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_267b8e66-9db2-45c4-937a-1d10f9c41438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_41ccc44d-fe20-449f-aee8-4bd8d0582d94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31b9eeca-acf4-4e00-b623-fe69f898dcb3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_41ccc44d-fe20-449f-aee8-4bd8d0582d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0fddbc6b-f41c-419d-994b-035ae13d706c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31b9eeca-acf4-4e00-b623-fe69f898dcb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0fddbc6b-f41c-419d-994b-035ae13d706c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e4e014ac-13a7-4b0a-b46c-12b638d91513" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_31b9eeca-acf4-4e00-b623-fe69f898dcb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e4e014ac-13a7-4b0a-b46c-12b638d91513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ba02084e-831c-4b24-8a9f-aa82eb673848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c4aafba-1322-460b-8a41-c6943284782d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ba02084e-831c-4b24-8a9f-aa82eb673848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f079b5b5-dc7d-490b-856c-7e9a9bad9125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c4aafba-1322-460b-8a41-c6943284782d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f079b5b5-dc7d-490b-856c-7e9a9bad9125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6bbf9196-49f3-4576-9c68-76672494df97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c4aafba-1322-460b-8a41-c6943284782d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6bbf9196-49f3-4576-9c68-76672494df97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_45157005-9436-48b1-859f-4a4eb9a44172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6bbf9196-49f3-4576-9c68-76672494df97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_45157005-9436-48b1-859f-4a4eb9a44172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_358f45ea-8f61-44ee-9609-58398e6fe333" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6bbf9196-49f3-4576-9c68-76672494df97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_358f45ea-8f61-44ee-9609-58398e6fe333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_37f2b64f-afbf-448e-92f3-2369e3d4a1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6bbf9196-49f3-4576-9c68-76672494df97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_37f2b64f-afbf-448e-92f3-2369e3d4a1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d06bcee2-e428-4938-96f6-b5a4f29d4af9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6bbf9196-49f3-4576-9c68-76672494df97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d06bcee2-e428-4938-96f6-b5a4f29d4af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0755fd0b-0eed-493d-be15-491c35a552d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6bbf9196-49f3-4576-9c68-76672494df97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0755fd0b-0eed-493d-be15-491c35a552d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fcf60a2d-043a-43a0-82f3-93a50bbf7218" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c4aafba-1322-460b-8a41-c6943284782d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_fcf60a2d-043a-43a0-82f3-93a50bbf7218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7d70e9ee-04e4-48c9-8e45-407042234388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c4aafba-1322-460b-8a41-c6943284782d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7d70e9ee-04e4-48c9-8e45-407042234388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b110e797-3414-40e1-bbc7-9fc7f3e29b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c4aafba-1322-460b-8a41-c6943284782d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b110e797-3414-40e1-bbc7-9fc7f3e29b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c65e4a9f-370f-4b00-9150-7e7d93385e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b110e797-3414-40e1-bbc7-9fc7f3e29b9c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c65e4a9f-370f-4b00-9150-7e7d93385e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d715e461-3ed5-4ebe-96d8-c9ecca82e83b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b110e797-3414-40e1-bbc7-9fc7f3e29b9c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d715e461-3ed5-4ebe-96d8-c9ecca82e83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d3d9c53c-253e-4c26-b0aa-d85b5c97d1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b110e797-3414-40e1-bbc7-9fc7f3e29b9c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d3d9c53c-253e-4c26-b0aa-d85b5c97d1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49d45628-f79b-4c78-a2c8-b1a369379908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c744ddc3-f63b-4764-a7d9-14b18e33e3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49d45628-f79b-4c78-a2c8-b1a369379908" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c744ddc3-f63b-4764-a7d9-14b18e33e3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_df34882b-0542-4601-b455-c61232798be1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c744ddc3-f63b-4764-a7d9-14b18e33e3a6" xlink:to="loc_us-gaap_AwardTypeAxis_df34882b-0542-4601-b455-c61232798be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95b6c70a-9c24-4041-aa79-e5f490f16b16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_df34882b-0542-4601-b455-c61232798be1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95b6c70a-9c24-4041-aa79-e5f490f16b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8ebefe07-1303-4909-9e11-1795064aa423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95b6c70a-9c24-4041-aa79-e5f490f16b16" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8ebefe07-1303-4909-9e11-1795064aa423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c744ddc3-f63b-4764-a7d9-14b18e33e3a6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0bfd0480-b6cc-4c15-bc74-93971fc96f74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0bfd0480-b6cc-4c15-bc74-93971fc96f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4895112d-029c-475a-a562-8e124cc2a63e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4895112d-029c-475a-a562-8e124cc2a63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b948c278-7070-46c8-833d-bfc820020aca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b948c278-7070-46c8-833d-bfc820020aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d21f0864-0ca7-4551-8d5a-e80276a3e2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d21f0864-0ca7-4551-8d5a-e80276a3e2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_4b0c37b4-2bb1-4ede-8102-23d98451489a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_32a213ea-f18e-4e59-8ff0-d473068a79fb" xlink:to="loc_us-gaap_SharePrice_4b0c37b4-2bb1-4ede-8102-23d98451489a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#SEGMENTREPORTINGDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b886c36d-bc25-4653-b590-6d14893e64ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_a4cca561-d419-4cf4-ac75-15d28b9634e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b886c36d-bc25-4653-b590-6d14893e64ff" xlink:to="loc_us-gaap_NumberOfReportableSegments_a4cca561-d419-4cf4-ac75-15d28b9634e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f301abce-71e0-47c4-bb7b-4ae4db4369c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b71d7f1e-353b-4aad-a65d-1b763a60ab44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f301abce-71e0-47c4-bb7b-4ae4db4369c9" xlink:to="loc_us-gaap_LossContingenciesTable_b71d7f1e-353b-4aad-a65d-1b763a60ab44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_6775c8eb-fc01-448f-a179-e26884dd574f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b71d7f1e-353b-4aad-a65d-1b763a60ab44" xlink:to="loc_srt_TitleOfIndividualAxis_6775c8eb-fc01-448f-a179-e26884dd574f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_227e954e-abe9-4bfa-b03a-22898b83cc77" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_6775c8eb-fc01-448f-a179-e26884dd574f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_227e954e-abe9-4bfa-b03a-22898b83cc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_28ef9639-9646-477e-9cd4-74c537e584b6" xlink:href="ck0001824293-20250331.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_227e954e-abe9-4bfa-b03a-22898b83cc77" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_28ef9639-9646-477e-9cd4-74c537e584b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_842e6c03-d093-4775-a2cc-0f1f9ce904c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b71d7f1e-353b-4aad-a65d-1b763a60ab44" xlink:to="loc_us-gaap_LossContingenciesLineItems_842e6c03-d093-4775-a2cc-0f1f9ce904c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_6897392a-af3e-4964-8403-3759b8f50528" xlink:href="ck0001824293-20250331.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_842e6c03-d093-4775-a2cc-0f1f9ce904c7" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_6897392a-af3e-4964-8403-3759b8f50528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_b1ec989b-1f9f-4a56-9eea-122f257747dd" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_842e6c03-d093-4775-a2cc-0f1f9ce904c7" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_b1ec989b-1f9f-4a56-9eea-122f257747dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="ck0001824293-20250331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ea2de3b1-802f-4250-b2a1-7033c7fa40c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ea2de3b1-802f-4250-b2a1-7033c7fa40c9" xlink:to="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_32b19de5-08ed-4223-84de-2d9a8290ed7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_32b19de5-08ed-4223-84de-2d9a8290ed7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fe3bb526-918c-45aa-b29c-2040fd18fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_32b19de5-08ed-4223-84de-2d9a8290ed7d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fe3bb526-918c-45aa-b29c-2040fd18fc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ae448e45-5014-48fb-b6df-1c26ad48d4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fe3bb526-918c-45aa-b29c-2040fd18fc74" xlink:to="loc_us-gaap_SubsequentEventMember_ae448e45-5014-48fb-b6df-1c26ad48d4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4c3378c3-7bb7-4813-9405-630a75d8000f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4c3378c3-7bb7-4813-9405-630a75d8000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94612759-fd91-4b82-940d-58a9ec9feadb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4c3378c3-7bb7-4813-9405-630a75d8000f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94612759-fd91-4b82-940d-58a9ec9feadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_8e16626a-a493-4699-b603-2d50f7142353" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94612759-fd91-4b82-940d-58a9ec9feadb" xlink:to="loc_ck0001824293_PublicOfferingMember_8e16626a-a493-4699-b603-2d50f7142353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_090751b8-58b7-41ff-ac70-d42f6cdf485b" xlink:href="ck0001824293-20250331.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_94612759-fd91-4b82-940d-58a9ec9feadb" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_090751b8-58b7-41ff-ac70-d42f6cdf485b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_06219eae-2a02-45ab-8010-6aeba5c88dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_06219eae-2a02-45ab-8010-6aeba5c88dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7f4fd651-81fd-49bf-8e69-7cb40023e952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_06219eae-2a02-45ab-8010-6aeba5c88dd5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7f4fd651-81fd-49bf-8e69-7cb40023e952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_d2592b8b-b3fc-4220-801e-1433553b4dc9" xlink:href="ck0001824293-20250331.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7f4fd651-81fd-49bf-8e69-7cb40023e952" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_d2592b8b-b3fc-4220-801e-1433553b4dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesECommonWarrantMember_4e70d822-177d-4dfd-aa0e-4f3a7591a602" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesECommonWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7f4fd651-81fd-49bf-8e69-7cb40023e952" xlink:to="loc_ck0001824293_SeriesECommonWarrantMember_4e70d822-177d-4dfd-aa0e-4f3a7591a602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE1CommonWarrantsMember_4d14bd04-341a-4569-827f-2225cc81f5fc" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesE1CommonWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesECommonWarrantMember_4e70d822-177d-4dfd-aa0e-4f3a7591a602" xlink:to="loc_ck0001824293_SeriesE1CommonWarrantsMember_4d14bd04-341a-4569-827f-2225cc81f5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE2CommonWarrantsMember_144e5b94-566d-436a-901a-d2729bad84b4" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesE2CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesECommonWarrantMember_4e70d822-177d-4dfd-aa0e-4f3a7591a602" xlink:to="loc_ck0001824293_SeriesE2CommonWarrantsMember_144e5b94-566d-436a-901a-d2729bad84b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE3CommonWarrantsMember_b0604921-0547-4162-b316-c776db7349e9" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SeriesE3CommonWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesECommonWarrantMember_4e70d822-177d-4dfd-aa0e-4f3a7591a602" xlink:to="loc_ck0001824293_SeriesE3CommonWarrantsMember_b0604921-0547-4162-b316-c776db7349e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_April2025PAWarrantsMember_86c7b3e3-9a1c-488f-babf-0b0b27b591ab" xlink:href="ck0001824293-20250331.xsd#ck0001824293_April2025PAWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7f4fd651-81fd-49bf-8e69-7cb40023e952" xlink:to="loc_ck0001824293_April2025PAWarrantsMember_86c7b3e3-9a1c-488f-babf-0b0b27b591ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_39fafe32-0a1d-43be-afcd-12f21598b9ee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:to="loc_srt_RangeAxis_39fafe32-0a1d-43be-afcd-12f21598b9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7fe0b93-be08-4e9c-8fdd-7b043e0cdc6a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_39fafe32-0a1d-43be-afcd-12f21598b9ee" xlink:to="loc_srt_RangeMember_c7fe0b93-be08-4e9c-8fdd-7b043e0cdc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_92aeeac0-4e2c-48dc-953d-b62e968132a2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c7fe0b93-be08-4e9c-8fdd-7b043e0cdc6a" xlink:to="loc_srt_MaximumMember_92aeeac0-4e2c-48dc-953d-b62e968132a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d0d948da-1ac6-4fa1-8bff-2e261aa16212" xlink:to="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_78ec5c84-bca1-41f6-8b6c-ead37ddbd5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_78ec5c84-bca1-41f6-8b6c-ead37ddbd5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0aa8f512-cc9d-4db5-ae22-a20523ee4576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0aa8f512-cc9d-4db5-ae22-a20523ee4576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_997eb5f7-2e08-4dcc-90ef-dd0c72e9704e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_997eb5f7-2e08-4dcc-90ef-dd0c72e9704e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a626a1ed-f2cb-46a5-a7df-fa8bca525db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a626a1ed-f2cb-46a5-a7df-fa8bca525db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_185a32bc-ad3c-450d-b615-ead0709415f3" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_185a32bc-ad3c-450d-b615-ead0709415f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1b44eee3-ed03-4f9a-9aaa-f50ad679176f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1b44eee3-ed03-4f9a-9aaa-f50ad679176f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_da2caddc-4660-4d8e-aeb1-4431ba32460d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_da2caddc-4660-4d8e-aeb1-4431ba32460d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_fc31f195-8bf3-49fc-a6c5-1766cb10d73f" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_fc31f195-8bf3-49fc-a6c5-1766cb10d73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_5dee7415-0a48-453c-a9a3-15fc6f4fb623" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_5dee7415-0a48-453c-a9a3-15fc6f4fb623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_538df720-f1f0-47eb-bd16-0c4423598cfa" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_538df720-f1f0-47eb-bd16-0c4423598cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_d67082f3-2692-4ea4-b093-b34830f51b61" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_d67082f3-2692-4ea4-b093-b34830f51b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockClearingExpenses_91d152be-2840-4fa4-99fe-2ed675f4f099" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockClearingExpenses"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockClearingExpenses_91d152be-2840-4fa4-99fe-2ed675f4f099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_0f9efea5-439a-49df-9c86-0bffa6995c0c" xlink:href="ck0001824293-20250331.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_0f9efea5-439a-49df-9c86-0bffa6995c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ca69344a-f64a-4b4e-bfc9-46cd08df7f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ca69344a-f64a-4b4e-bfc9-46cd08df7f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f15267b-e1d9-4d13-87ce-932351f302a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5f0a09ae-3f70-454d-9e5f-c3662b869fa2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f15267b-e1d9-4d13-87ce-932351f302a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ck0001824293-20250331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ck0001824293-20250331_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
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M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"-
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M)*75\.*CY6;"@T2D)?%D_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MF8X8IKIG#BJARY?5<Q=OT6ZJ:.355$<$3T?#7Q$8:X
M
M
M
M
M                      %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M
M8]J1Z./$EFGIB5L                 )'O!_P#K2>@+Y5G#7YY8UB'?]\R>
MU/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M     "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V
M               $CW@__6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>
M*V!T R\@
M
M
M
M                                               %8KTM'ZK;7OE6
M<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O
M!_\ K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M                              "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP
M'FO9<LI6L>U(]''B2S3TQ*V                 $CW@_P#UI/0%\JSAK\\L
M:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M
M
M
M
M             !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)
M9IZ8E;                 "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*I
MVLG[;M^CCQ6P.@&7D
M
M
M
M                                                         K%>
MEH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M      !(]X/_ -:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M
M
M
M
M                                        5BO2T?JMM>^59Q+^9O*K
M<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P                 D>\'_ZTGH"
M^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M
M
M
M
M                      K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K
M'M2/1QXDLT],2M@                !(]X/_P!:3T!?*LX:_/+&L0[_ +YD
M]J?@/-^Q5.UD_;=OT<>*V!T R\@
M
M
M
M
M      %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
M                )'O!_P#K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ
M./%; Z 9>0
M
M
M
M                                                 "L5Z6C]5MKW
MRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $
MCW@__6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M
M
M
M
M                               %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?
M@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G#7YY
M8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M              "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B
M2S3TQ*V                 $CW@_P#UI/0%\JSAK\\L:Q#O^^9/:GX#S?L5
M3M9/VW;]''BM@= ,O(
M
M
M
M                                                         !6*
M]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M       "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*IVLG[;M^CCQ6P.@&7
MD
M
M
M
M                                         K%>EH_5;:]\JSB7\S>5
M6YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_ -:3
MT!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M
M
M
M
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MHF>%H2HHUQ@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0]:TR)G4LGFLO$1$_7;5RWP3.$>;ICCG@CIRY(KHJ\S,3X;GJEOH
M
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M/%)\_P!ZK/?EW+V2/D!W)_%;0_>EKU)VYF_7*^O)],!XI/G^]5GOR[E[)'R
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MY[^,D].>2,81A&$81A'LB_:='TBFJ*J<KEHJB<8F+5&,3Z4Y573EPE4GR
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MF*J:HFFJF8XXJIG"8F.C$QB[<3$QC'$^@XGZ
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MQ,3$\3L92]>G-6XFNJ8FN.C/3:NR#5=P
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M:JIGJNC<OWKOV2NJKP9EY@7HX0
M
M &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P
M           I3>F6_P!FO03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*
M&:3Y;X
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M3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M                                  'Y+^_L<58WN4RE[:8W&XVTN+_(
MY&_N*-G8V%C9T9[B[O;V[N)Z=O:VEK;TYIZE2>:62226,TT80A&+DM6KM^[3
M9LTU5WJZHIIIIB9JJJF<(B(CAF9G@B(X9G@@XN&>)7KZWO28O#HZ3?POK'&6
MT7W5]RMC_75O)K/"%Y9U..[+(T.[Y&EL'-5]2N-/C87$W>EC6U^GLE:C-)&%
M2A+VP[=KMVW,WWM[==CSNLV:= T.O">R9R)[/-,\?8\G3,7>5'2OSEXF)X*I
M4V_JF6L\%$\NOJ<77\C%4<ZR/2;/$IZGY\M@.--PPW2-QO?>5M[? \&4[BAR
M!5L9X?R<<MS'F8W&XT,M1FFC_P")U^&N21E[L(T>V$9IM\MWW,TW/;%Q;S6L
MY>YKVL4X3->=PFQ%7]7*486IIGSM_MB>/RW0BCWM4S5W@IGD4]3CZ_'UL%?S
M:=LVK><]DMJW;9M@W#:,S7C=9?9-IS.1V#/96YFA"$;G)9C+7-WD+ZO&$(0C
M/5J33=D/NMJ,ED<CIF5HR.FV;67R5N,*+=NBFW13'2IHIB*:8ZD1"G3,U3C5
M.,N/NV_
M                                              &A]Z'E\1_J<^57
M7^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F
M6_V:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO@
M
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MR9>>+&:X[%RIBFB]7*OY;/V,SP4SR;G2GQNGXO43)->W=
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M7*O*]*."/_'@XHT68W5
M
M :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M          "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAF
MD^6^
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MPKHF,:;ENK#&BY1-5%<<--4QPKBMW+=VB*[<Q-$NZ%NOL
M      !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
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M'$<C&[R9FFN]7"W,UG[^:X)GDVNE'C]/Q.HAD;#NB
M
M                         T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF
M%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O/4!^(.*4C/>]?
MRQM1[FR/U>94/6_,V_!GQE#-)\M\
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M=FN>5&$U437;PKFZ,KG+6;HQHX*XXXZ,>3'52A,+.V
M   K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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MJJF9JGHRXH[SY
M                                                          :'
MWH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M       "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6
M^
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M +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M\51'+O1]-F)B)C'DVHIIY55RV<[J->8F;=O&FQ]&?!ZG4ZZMHW!4L
M
M                                       !H?>AY?$?ZG/E5U_@BXV1
M-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO03
M[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X
M
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M9NS$133F+43$5Q$1%=,TW*(B*IIHNW)9RC-V\>*Y'''CQU)2[L".X
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M.*/'GJ^(AK;".B
M
M  T/O0\OB/\ 4Y\JNO\ !%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M              4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?
M&4,TGRWP
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MSAK\\L:Q#O\ OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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M2
M                                                  :'WH>7Q'^I
MSY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K                 "
ME-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M
M                    FW\#3Q6,]X9G5+8QW')9*]Z6.:K[#ZKSUK-*->YI
M8"G"K5M=?Y=PEA3DKU(YW0*]]/4NZ=&G/5R.'GN;:$LU>-K/1UOYRVX[*[Y=
MB:HT^BBG;?3J:[N2N3A'+X(FYE:ZIP\I?BF(IF9B+=V**\8IY<5=_(9N<K=\
MM]BJX_)\+Q&JYALSB=BQ&*V# 9.QS6"SN-L<SA<QB[JC?8S+8G)VM*]QV3QU
M[;3U+>\L;^SKR5:-6G--)4ISPFEC&$810?9C+W\IF*\IFJ*K>9M5U45T51--
M5-5,S%5-43PQ53,3$Q/#$QA*[(F)C&.)])POT                !6*]+1^
MJVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M   "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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M7M;7*:
M                                                        T/O0
M\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M     %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\
M
M                          !H!^BM>*36Y3X]O_#FYIV.:YWWB/"76R=-
MN7RUUW[K9>)K*;RFP\9PN+NO&M=Y3C.M7A=8NC)WYHZ_6J4I):=#%0[T5_/>
MW)TZ)JU.]S9VSAI>?N1;U"FF."WFI^QYC"(PBG,1')N3.'U^(JF9JO\ !<6D
MYOET]K5SY:/,^!TO"\3P%R)'PK0                "L5Z6C]5MKWRK.)?S
M-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@_\
MUI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                         !1%])]\8N?/Y//>&CTU[7V8+"W<E'JXW; W
M<)OPQG;*XH75EP+C<A;S?R=CK]W0EN-K\E-&:M?0I8N>:G"VR5O7DXYE_-^C
M*V;6^/;"Q_S5RG'2[-<>8HF)B<[53/TUR)Y.6QXJ.5?B)Y=FNF@:KG<9[5M3
MP?33XWD];IJ2B1]0@
M
M       &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P
M                 I3>F6_V:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFW
MX,^,H9I/EO@
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M >;]BJ=K)^V[?HX\5L#H!EY
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M1$1$80M.9F9QGC?@<K\
M
M          :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H
M8K                 "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?
MF;?@SXRAFD^6^
M                                          NJ^B+==\VO[WR[X>^\
MYJ?\%;_0ON<."*-]=TH4;;<=>QUM9\JZABZ=:::YJU]BU*RM,W1MZ791H28+
M(UHR]^O/-&.?GZ;L8S>EY#>MIEN.SY6:<GG9IB<9M7*IG+7:L."(MW9JLS5/
M#,WK5..%,0KFCYC"JK+5<4\,>#T8ZW#X4KZ",!<                "L5Z6
MC]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V
M     $CW@_\ UI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MW3V3,WHC"<QFJXCLMV>CAC$46XGAIM46Z)F>3BLW-9BK,WINU<70CI1T(_\
M'1>#&4'7
M
M:'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M         "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9
MI/EO@
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M^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P
MD>\'_P"M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                              *.'I9GB33R2ZEX:G%6=[):TF Y6ZH+
MO'7$(]Z2%23*<4\3WLU.O&,.RI2I[3E+>I2A'U,)/3J?_P 1325<Q7<_$]GW
MQ:Y:X8FO+:=%4?Z.9S4<'5G+6ZHG\)B8\Q*@ZOFN+*T>#5XT>/UE&E):H(
M
M                                                  #0^]#R^(_U
M.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M
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MRLNY75=KFY7YJ9Q=3JZ^
M
M             &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A
M;G:&*P                 I3>F6_P!FO03[>>H#\0<4I&>]Z_EC:CW-D?J\
MRH>M^9M^#/C*&:3Y;X
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ME6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                 *(OI=/7E5RFT<0^'GH><J0QVL4+'G+GVC9S3227&PY6
MVN;+B33;ZK)4ISS?@C!5[W.75K/+/0J1R6+K0CY6AV22<<PO=A38R6?WL:I:
MCLUZ:LGD9GH6Z9B<U=IC^O7%%FFJ)BJ.QWJ>*KAH&L9C&:<M3Q1PSXT>/UE)
M1(^H0
M                                                          #0
M^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M        4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGR
MWP
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ME1_R.G92W9B<,)KJICZY<JC&<*KMR:KE7#YJJ<%E7KE5Z[5=JXZIQ>?%UN(
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MA>&I_EY=#7S2^ _< ?+1OB^-FTO^*9W[^=JY7UNWZ6/(/HPO#4_R\NAKYI?
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MH?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL
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M:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M !(]X/\ ]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MJY<KJZ=5=<S55/5F9E58B*8Y-,1$0Y ZC]
M                                            9&/CA_6T==O[<\M^
M)L*GGYMGS$[,?!E/U=:S\_[<N>B14,X.F                 T/O0\OB/\
M4Y\JNO\ !%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M  4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
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M%VC&.53C,3$TUT556ZJ*ZK6O6;F7N3;N1A5'T>K'4>7%ZN$
M     !KY^#/N,^]>%7T#YN>M+6FL>F?C;3H3RUJ%Q"63CO$2\?TZ/?MY*=.6
M:WIZQ"G&2,._3C+W)XS3RS1C 9SA=/C3-]^U.6B,.5K.8N\4Q]GJ[/CP]/LF
M./%/'&$3"\LE5RLI;G^K$=;@29,-NT              K%>EH_5;:]\JSB7\
MS>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/\
M]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MQT(=K*&^P
M                    &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/\
MMRYZ)%0S@Z8                #0^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?
MC687)HWV"OT?C0MSM#%8                 4IO3+?[->@GV\]0'X@XI2,]
M[U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $Y7HVOUTW1C_>
M)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
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M5%VU<HG&FNW<IBJBNF>C353,3$]*5HU1-,S35P51+C;N/D
M   !JZ^CI9FKG?!FZ*KVM1IT)Z&&YGPT)*<TTTLU+7>H_F'7Z%:,9O5\I<T<
M9+4GA]R$TT80]3L0;<[;+TY;G#;1VZ9F8FYE*_#N:?E+DQX4U81U(7=ILXY*
MCP_JI38-<7>              5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+E
ME*UCVI'HX\26:>F)6P                 D>\'_ .M)Z OE6<-?GEC6(=_W
MS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M  .C.ISG' ],W3ISEU"[/+3JX3A;BG>^2[VTJ3QIQR<VH:YD,U:8:C-+&$T;
MO-WMI3M*,L/OIZU:66'JQ@N;8S9K-;9;6Z9LGDL8S.HYZSEXGSO9;E-$USU*
M(F:IZ41,N.[<BU:JN3Q4Q,]9BX[CMN>W[;MJWK:K^IE=HW38\YMNR9.K"$*N
M1SVQY.ZS&8OZD(>I"I>9"\J5(]GJ=LST2Z?D,KI>0L:9D:8HR66LT6K=,<5-
M%NF***?"IB(635,U535/',N-NX^0                   %R/T>KP"\?SO;
M:QUT]<&D5+GAN-2VS73_ ,%[3CH0LN8)/)T[BPY2W_&77WUSQ9)/-";#XNM3
MA)LD\L+JO";$PI4\I'QSKN=)=V8KO;L]VV9B-H<)HSV=M5<.4Z%66L51Q9GH
M7;D3CEX\I3A?Y4V:WIVGQ<PS%^/*=".GU9ZG2Z?@<=_VA0H6M"C:VM&E;6UM
M2IT+>WH4Y*-"A0HR0IT:-&C3A+3I4J5.6$LLLL(0EA#LAZB+&JJJNJ:ZYF:Y
MG&9GAF9GCF9Z,RN%_5\@
M                                #(Q\</ZVCKM_;GEOQ-A4\_-L^8G9
MCX,I^KK6?G_;EST2*AG!TP                &A]Z'E\1_J<^577^"+C9$W
MWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F6_V:]!/M
MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO@                )R
MO1M?KINC'^\3_A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y=H
M                                          #/$]+-Z#L?PYU(<<=;
M?'^"DQVG]35I<:CRK+C[2%''V7.&D8ZA-99RX\C3I6MM=\CZ'3IU/)RPC4N+
MW W]W5FFJ5YXI8^8KO/N[0;(9S=OJMV:]0T:J+N6Y4XU3D[U4XT1CC,QE[^,
M8\5-%^U13$13"W-7R_(NQ?ICRM?'X,>3'B2J*M]%&                  :
MKGHVOU+/1C_>)_Q7\ZH/N>!_$5M%_8/T9DEVZ9[1H\/ZJ4Y+6EWP
M     %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
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MKU55=ZNJ:JJJIF:JJIG&9F9X9F9X9F>&9X973Q<$<3];C
M                                                           &
M1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M     -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M              !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9
M\90S2?+?                 3E>C:_73=&/]XG_  H<ZM:>>!_#KM%_8/TG
MDG?TSV]1X?U,M5M!\NT
M          !"]Z01TW6/4KX475'C?P?+>;)PUK5#J-TVYC#O5,5DN&YZNQ;3
M>4)/^W5N^,)L_8]GW>[>1C#MC"$&Q'-5VPN;';\M$O<ODY/4;TY"['GJ<WA;
MMQ/4C,]@K_T'1U&UV7*5QT:8Y4>%_1BR>TYZT0                 &JYZ-
MK]2ST8_WB?\ %?SJ@^YX'\16T7]@_1F27;IGM&CP_JI3DM:7?
M   5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P
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M;5%BW%JCS,1_XGPWH9:;D
M                                    9&/CA_6T==O[<\M^)L*GGYMG
MS$[,?!E/U=:S\_[<N>B14,X.F                 T/O0\OB/\ 4Y\JNO\
M!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?
M[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M    $Y7HVOUTW1C_ 'B?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M                                                  <&Y/T?'\G<
M:<A\;9:G0JXKD+1MMT?)TKJG"M;5,?MF R&!O:=Q2FEGEJT)[:_FA/+&6,)I
M>V'9%4]%U*[HNLY36+$S%_*9FU>IF.">5:KIKC">A.-/ ^:Z8KHFF>*8F&(W
M=6MS8W-Q97MO7L[RSKUK6[M+JC4M[FUN;>I-2KV]Q0JRR5:%>A5DC+/)-"$T
MLT(PC"$8/2#171<HBY;F*K=41,3$XQ,3PQ,3'!,3'%*QGYWV_
M      &JYZ-K]2ST8_WB?\5_.J#[G@?Q%;1?V#]&9)=NF>T:/#^JE.2UI=\
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MG'@PNW;U%48T1*Y-(RW(MSF*O-5<7@?TSXD+<C0U6
M                                                         &1C
MXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M   -#[T/+XC_ %.?*KK_  1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M               %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!
MGQE#-)\M\                !.5Z-K]=-T8_P!XG_"ASJUIYX'\.NT7]@_2
M>2=_3/;U'A_4RU6T'R[0
M            &(GR?_:5R'[>=M_'^0>D31?R/E/<UKZBE8M7FI\%P94WR
M              U7/1M?J6>C'^\3_BOYU0?<\#^(K:+^P?HS)+MTSVC1X?U4
MIR6M+O@             *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[
M4CT<>)+-/3$K8                 2/>#_]:3T!?*LX:_/+&L0[_OF3VI^
M\W[%4[63]MV_1QXK8'0#+R                                 <0Y!W
M3#\;Z%N_(FPU/(X#0M0V7=,Y5[TLGDL/JV&O<YDZG?F^]D[EE8SQ[8^I#L=_
M2M.S&L:IEM)RD8YK-9BW9HCIUW*XHI^C5#YJJBFF:IXHC%B7[IMN:W[<=LWO
M9+B6[V+==ESNVY^ZEA/++<YK8\I=9C*W$LM2>K4A+6OKRI-"$TTT?5]6,?NO
M1WIV0RVEZ?8TS)QR<IEK-%JB.E1;IBBF.AQ4Q"QZIFJJ:IXYEQEW7R
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M,44Q33P4Q&$.6N@_0
M                                &1CXX?UM'7;^W/+?B;"IY^;9\Q.S
M'P93]76L_/\ MRYZ)%0S@Z8                #0^]#R^(_U.?*KK_!%QLB
M;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?[->@G
MV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $
MY7HVOUTW1C_>)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                                            !B)\G_VE<A^WG;?Q
M_D'I$T7\CY3W-:^HI6+5YJ?!<&5-\@                -5ST;7ZEGHQ_O$
M_P"*_G5!]SP/XBMHO[!^C,DNW3/:-'A_52G):TN^              K%>EH_
M5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M   !(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M+@
M                   9&/CA_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_P"W
M+GHD5#.#I@                -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-
M9A<FC?8*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO
M7\L;4>YLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/]XG
M_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M                               &(GR?_:5R'[>=M_'^0>D31?R/E/<U
MKZBE8M7FI\%P94WR                 U7/1M?J6>C'^\3_ (K^=4'W/ _B
M*VB_L'Z,R2[=,]HT>']5*<EK2[X             "L5Z6C]5MKWRK.)?S-Y5
M;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@__ %I/
M0%\JSAK\\L:Q#O\ OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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M,.">7CU5WZ=:[%E*(Z,QC/A_T8)E&O;N@
M                                                 ,C'QP_K:.NW
M]N>6_$V%3S\VSYB=F/@RGZNM9^?]N7/1(J&<'3                 :'WH>
M7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M    "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M               G*]&U^NFZ,?[Q/^%#G5K3SP/X==HO[!^D\D[^F>WJ/#^I
MEJMH/EV@
M,1/D_P#M*Y#]O.V_C_(/2)HOY'RGN:U]12L6KS4^"X,J;Y
M   :KGHVOU+/1C_>)_Q7\ZH/N>!_$5M%_8/T9DEVZ9[1H\/ZJ4Y+6EWP
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MF[]RJY75/'5775-554]69F97Q$13&$<4/MNL_0
M                                                      &1CXX?
MUM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M-#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M         !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2
M?+?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;
MU'A_4RU6T'R[0
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M/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MQ1PQWM-HY><HCH1,SUH\EJ](-%W
M                                             ,C'QP_K:.NW]N>6
M_$V%3S\VSYB=F/@RGZNM9^?]N7/1(J&<'3                 :'WH>7Q'^
MISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M"E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M           G*]&U^NFZ,?[Q/^%#G5K3SP/X==HO[!^D\D[^F>WJ/#^IEJMH
M/EV@
M                               *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_
M >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\ 6D] 7RK.&OSR
MQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MCF:JNE1XLPT9T1RY0
M                                  &1CXX?UM'7;^W/+?B;"IY^;9\Q
M.S'P93]76L_/^W+GHD5#.#I@                -#[T/+XC_4Y\JNO\$7&R
M)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@                !2F],M_LUZ"
M?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M
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M57J%VJ.'Z6,G11/2X>5<ZL8=")X:]HE/#<J]#'BKT:,Y7@
M
M   &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M         -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,
M5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS
M-OP9\90S2?+?                 3E>C:_73=&/]XG_  H<ZM:>>!_#KM%_
M8/TGDG?TSV]1X?U,M5M!\NT
M                                                  !6*]+1^JVU
M[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M"1[P?_K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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MG^M'B+DR/=6@
M                             &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P9
M3]76L_/^W+GHD5#.#I@                -#[T/+XC_ %.?*KK_  1<;(F^
M^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O
M/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\                !.5
MZ-K]=-T8_P!XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M
M                   %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J
M1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G#7YY8UB'?]\R>U/P
M'F_8JG:R?MNWZ./%; Z 9>0                                #+<])
MV^N(Y_\ :-P+\#6FIKN9C_#_ *5[ISOXW=6IJGMVKP(\2%?UM2IP
M         #0^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#
M%8
M                    9&/CA_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_[<
MN>B14,X.F                 T/O0\OB/\ 4Y\JNO\ !%QLB;[X!\Y.B_ <
M?C687)HWV"OT?C0MSM#%8                 4IO3+?[->@GV\]0'X@XI2,
M][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $Y7HVOUTW1C_
M 'B?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M
M          5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F
M)6P                 D>\'_P"M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^
MV[?HX\5L#H!EY                                 ,MSTG;ZXCG_P!H
MW OP-::FNYF/\/\ I7NG._C=U:FJ>W:O CQ(5_6U*G
M-#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M
M          !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M                #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8
M*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>Y
MLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_PH<ZM
M:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M
M!6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M          "1[P?_ *TGH"^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.
M@&7D                                 RZ_2@L;>V/C <UW5U1\E0S/
M''!.2QL_E*4_KFRI<6Z]AZE;NTZD\]'NY'%7%/NU(23Q\GWH0[LTLT9JN9;>
MMW=P.FT43C5;SF=IJX^"9S-RO#J^5JIG@QCAPXXF%J:K&&=J\"/$5[FUJG
M                - 7T.+.>N.FKK)UKU_Y3\$\Y:'G/P9V__P '_2'0:]AZ
M_P"[W?4_"7]&/)]O;'M]:_<AV>K%=WP7+<C;'9[.<G#LFF7Z.5T^QWXJY/\
MH]DQ_P!)<6BS]:KC^M'B+D"/E6@
M                                            &1CXX?UM'7;^W/+?
MB;"IY^;9\Q.S'P93]76L_/\ MRYZ)%0S@Z8                #0^]#R^(_
MU.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M 4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M           $Y7HVOUTW1C_>)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M
M!\NT
M                               !6*]+1^JVU[Y5G$OYF\JMSN8G\]EW
MX#S7LN64K6/:D>CCQ)9IZ8E;                 "1[P?\ ZTGH"^59PU^>
M6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M        S+_2M\-5Q?BMWM]4K4ZLFQ].G#F9H222S0FMJ5"OM^O1HU8S>I/4
MFK8&>I",/4[M2$/NPBF3YCF8IO;C:;<1,39U?-T3U9F+5S&/"KB/!A:^KQAF
M_!IA6J;B*6                  O&^AF[;W:_B"Z+7JS1C4H]-.VXNA"E1A
M++Y&?G'#YVK4K]Z%Q--/ZXQT)).R:2$)9H]LL8_?1J]\,R&-.RFITQQ3J%JJ
M<9Z/:==$8<70N8SQ\7'T*]HD_9*?0^.O,(TE>
M                                                       9&/CA
M_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_P"W+GHD5#.#I@
M  -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M           !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90
MS2?+?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3
M/;U'A_4RU6T'R[0
M                                          %8KTM'ZK;7OE6<2_F;
MRJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_P#K
M2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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M3/#P81RL:QHU6&8JIZ='B3#1;1)+D
M                                               9&/CA_6T==O[<
M\M^)L*GGYMGS$[,?!E/U=:S\_P"W+GHD5#.#I@                -#[T/+
MXC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M   !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M              3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4R
MU6T'R[0
M                                  %8KTM'ZK;7OE6<2_F;RJW.YB?S
MV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_P#K2>@+Y5G#
M7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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MD9RCI3C'7CR6K0@Z7:
M                                    R,?'#^MHZ[?VYY;\385//S;/
MF)V8^#*?JZUGY_VY<]$BH9P=,                !H?>AY?$?ZG/E5U_@BX
MV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO
M03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X
M "<KT;7ZZ;HQ_O$_X4.=6M// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:
M
M                      K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K
M'M2/1QXDLT],2M@                !(]X/_P!:3T!?*LX:_/+&L0[_ +YD
M]J?@/-^Q5.UD_;=OT<>*V!T R\@                                %
M,WTR+1I,AP#T4<E1HTYI]2Y@Y1T:6O&%#RM.3D/2]?S\]&2,T?7,*=>/&$L9
MH20[D8TY>_ZL).V0SO?.IS:VIVCT?&<+^GY:]AP_["]71CTN#MGH\/#.'143
M6J?K=NKI3,=>/Z% Q*6MX                 !W1TX\NY#I_P"H3@OG;%23
MU<CPQS!QKRI9T*<T99KFOH&Y8;:I+2/9&'>DN_P5Y.:6/J32SQA'U(Q6[M?H
M%K:K934]F+^$6=1T_,9:9Z47[5=K'PN5C'@.2U7-NY3<CCIJB>M+:KPV8QFP
MXC%9_"7M#)8;.8VQS&(R-K-W[;(8S)VM*]L+VWG[(=^A=6M>2I)'L]66:#SH
M9C+WLIF*\KF:9HS%JNJBJF>.FJF9BJ)ZL3$Q*]XF)C&.)])POT
M
M      !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M            #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^
M-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7
MF5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_PH<ZM:>>!
M_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                                                        !6*]
M+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M      "1[P?_ *TGH"^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M                                 K5>E;\>S;IX4EYLD)._#B/J+X<Y
M"FF[9X>2ER5#;^*._P#>75O+'MFY.A+]])7E^^_U(1[*E/</F-ZM&G;\:<GC
M[?TC-V/2S:S/2G\&Z<>#T)I>KT\K*8]*J)\6/'9EZ91:X
M   #6Q\"?J1I=3_A7=).Y7%[Z[V30^/Z/!>Y25*TMQ>T,]PE<5>/+.ODJLL9
MHS7V?U7"8W+31FC&I-)D)9I_OHQ01<YO9"K8O?=KVGTT\G)YK-SG;7!A$T9R
M.SS%,>=HNUW+7!P8VYB.!>&0N]ERE%71B,)\+@\3A2Z,"NX
M
M    R,?'#^MHZ[?VYY;\385//S;/F)V8^#*?JZUGY_VY<]$BH9P=,
M         !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVA
MBL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^
M9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6M// _AUVB_L
M'Z3R3OZ9[>H\/ZF6JV@^7:
M                                                  K%>EH_5;:]
M\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !
M(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M                           $5OC>\71Y@\)OKLU&6WFNIL9P7F.3)*,D
MTLDT:G"F6PW,U.I+WJ=7OS4)]"A/"2$.]/W>[+&6:,)H9OYMNM]P-^NS&?QY
M,5ZG1E\?=E->4ZG'V?#'H<<X\3J9^CEY.Y']7'K</C,BQ/0LX
M       !=R]#UZLY,?L74_T2;#E>Y2V&TQ/49QACZUQ&G1_"V(EQ^A<L6]M2
MJ=M.O?9+$U=8N))*<99X4,;<3QA/++&-.-[G_P"PDW<IHN\C*48U6JJLAF:H
MCAY-?*OY69GH4TU1F*9F>#&Y3'!,\-=T:]A-=B>CY:/$GQE[-&2KX
M
M         #(Q\</ZVCKM_;GEOQ-A4\_-L^8G9CX,I^KK6?G_ &Y<]$BH9P=,
M                !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z
M/QH6YVABL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:CW-D?
MJ\RH>M^9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6M//
M_AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:
M                                                         K%>
MEH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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MT[.7M/S]NJUGK%VJW<HJC"JBNBJ::Z*HZ%5-43$QT)A>D3%4153PQ+[KK/T
M
M              !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0
MS@Z8                #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<
MFC?8*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L
M;4>YLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_P
MH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M
M    !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
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M.9[)9[!5YNCB\#^CBZRUBT=5<
M                                        !D8^.'];1UV_MSRWXFPJ
M>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8                #0^]#R^(_U.?*K
MK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3
M+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M      $Y7HVOUTW1C_>)_P *'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M
M                            5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U
M[+EE*UCVI'HX\26:>F)6P                 D>\'_ZTGH"^59PU^>6-8AW
M_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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MRB[;BY1.-,P[F6\^P
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M77,4Q%,355.$1$<40CT_BOZI?.4Y^]^/D3W1KP[@:#^!93[C;]2VI^1#<O\
M%#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/X
MK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY
M$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RG
MW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\
M%#9?_"LC]X6B?1X.4N3>3M.ZI:_)/(V]\A5\/LW%5+$UMXV[8-LJXNE>8O>I
M[RECJF>R%_/94[J>WIQJ2THRPGC3EC-V]V'9@K?#D,CD<SD(R5FU9BJB[CR*
M*:,<)HPQY,1CAT,4,O?6-B]CMCM?V+M[(Z3IFE6\QD]2F[&3RMC+1<FBYDXI
MFY%FBB*YIBJJ*9JQPY4X88RL>L,HE
M                                           %8KTM'ZK;7OE6<2_F
M;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\
MK2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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M&,)I9H1[81A]U$!,3$X3QKF?Z?@
M                                         R,?'#^MHZ[?VYY;\385
M//S;/F)V8^#*?JZUGY_VY<]$BH9P=,                !H?>AY?$?ZG/E5
MU_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WI
MEO\ 9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M        G*]&U^NFZ,?[Q/\ A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y
M=H    #/B\7[ZR#JC]M6J?!KI3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L
M+T;=@    +9GHU']2>K;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN1
M6>&#D-X
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MCA5T
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M\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M                                                         %8K
MTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
M       )'O!_^M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
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MJ9B:9<B=1^@
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MV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M
M  K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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M?@
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MZ_;6G_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
M                                                  *Q7I:/U6VO
M?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8
M2/>#_P#6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M_1PXS3%=,3-%6'T]NK&BN."::Z:HF(F,%E7;=5JY5;J\U3.#I1<;C
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M;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\
M        !.5Z-K]=-T8_WB?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+
MM     9\7B_?60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_"1L7[BS/Z0S:-A
M>C;L    !;,]&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<
MBL\,'(;P
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MQ;ICBPM7JJ;D=&>V*^A0M[6,OR:XS%/%5P3X,<77CQ%,A(<H@
M
M                                          #0^]#R^(_U.?*KK_!%
MQLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?[-
M>@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M  $Y7HVOUTW1C_>)_P *'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M 9\7B_?60=4?MJU3X-=*;>[N_P!2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV[
M     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_P"UWO%MH.N^]_K%L+[BU3V7(K/#
M!R&\
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M%43A+KY57R
M
M   T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M            %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE
M#-)\M\                !.5Z-K]=-T8_WB?\*'.K6GG@?PZ[1?V#])Y)W]
M,]O4>']3+5;0?+M     9\7B_?60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_
M  D;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_[7>\6V@Z
M[[W^L6PON+5/9<BL\,'(;P
M                                   %8KTM'ZK;7OE6<2_F;RJW.YB?
MSV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G
M#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M               "AOZ63X;,^N[7JGB3<5X'LP>XSX+B_J8ML=;PA)CMNM+6
M3&<8\G7=.A0FFEH;)B+277LC<U)Y*-*ZL<5)+":M>U)HR>\Q;?!&;R-_<_K=
MW_F<O%>9TZ:I\U:F>5F<O&,\=NJ>SVZ8B9FFN_,X4VXA;^KY7"8S5'%/!5X/
M0GQNLI1)&E#
M
M    :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M             "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,
M^,H9I/EO@                )RO1M?KINC'^\3_ (4.=6M// _AUVB_L'Z3
MR3OZ9[>H\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-
M<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBV
MT'7?>_UBV%]Q:I[+D5GA@Y#>
M                                      K%>EH_5;:]\JSB7\S>56YW
M,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_P!:3T!?
M*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M75HJ\S,Q'+MS1<B,*X6;F+%67O3:KZ'T8Z$O&;(;@
M
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M)ZMO;5Q#^*.0&O\ OK]M:?\ :[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M
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MF.&)B>*8GHQ*U7\7T_
M
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MVN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M                                           *Q7I:/U6VO?*LXE_,
MWE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\
M6D] 7RK.&OSRQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                          !GY^DX^#K5X=W/->(OTXZSV<3\BYVE-U*Z
M;AK6;R7'7).=NI*-OREC[:WIQDHZ;R-DJT*>5A&$L+#8*LM2$T]/)0DM)4^9
MGS@:=H-.M[I-KKW_ /=REJ>Y]VN>',9>B,9RU4SQW<O3&-KS]B)C")LXW+=U
M3)<BKMFU'E)GRT=*>GX$^+X*G,D$44
M
M                    !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;
M[!7Z/QH6YVABL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:C
MW-D?J\RH>M^9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6
MM// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W
M=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY
M:_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M                                                    K%>EH_5;
M:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M !(]X/\ ]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MH,&S#H
M                                                        -#[T
M/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M     !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M                3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_
M4RU6T'R[0    &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_P )&Q?N
M+,_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_WU^VM/^UWO%MH.N^]_K%L
M+[BU3V7(K/#!R&\
M                            !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S
M7LN64K6/:D>CCQ)9IZ8E;                 "1[P?_ *TGH"^59PU^>6-8
MAW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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M:[%SAFU<PC'"JBK"NBNF+2S>4KRESDU<-$\4]/\ IZ:+AFMU
M
M                                     &A]Z'E\1_J<^577^"+C9$WW
MP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F6_P!FO03[
M>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X                "<
MKT;7ZZ;HQ_O$_P"%#G5K3SP/X==HO[!^D\D[^F>WJ/#^IEJMH/EV@    ,^+
MQ?OK(.J/VU:I\&NE-O=W?ZEY#[77[)6]37,-_A(V+]Q9G](9M&PO1MV
MMF>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M
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M9NV*Y\Q=BF(Q\I7%-<32M/-Y2YE*^35PT3Q3T_Z>HBM9O=0
M
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MHU']2>K;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN16>&#D-X
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M?@/-^Q5.UD_;=OT<>*V!T R\@
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MFJNS,S=M1$S]<MTS<6QG<A<RL\NGRUGI]+P?)XD"#:)3@
M
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MK;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN16>&#D-X
M                                  "GYZ0)\<GC3Y,NF_"GS.V"W4?J
M[>]VU^Q64XW>S_F(U;]K<U^C]+08,GI$     $Y_H_?QR>2_DR[E\*?##&&]
M?]7;/NVCV*\CO[YA\Q&D_M;E?T?JBX&U]0<@                  *Q7I:/
MU6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8
M    2/>#_P#6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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MJIJB8F*HF8F)QB5#F)B<)X)A\ESOP
M
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MG_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
M                  *?GI GQR>-/DRZ;\*?,[8+=1^KM[W;7[%93C=[/^8C
M5OVMS7Z/TM!@R>D0     3G^C]_')Y+^3+N7PI\,,8;U_P!7;/NVCV*\CO[Y
MA\Q&D_M;E?T?JBX&U]0<@                  *Q7I:/U6VO?*LXE_,WE5N
M=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\ 6D]
M7RK.&OSRQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MT=..+^CPT73-;J
M                                                          -#
M[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M       !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+
M?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'
MA_4RU6T'R[0    &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_PD;%^
MXLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^VM/^UWO%MH.N^]_K
M%L+[BU3V7(K/#!R&\
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M,\C,VOMMBO"Y3&/!%?)FW5/F*ZHX5"OY:]EYPNTS'5Z$^&\3LCN
M
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M4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
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M1.,3''$CPOS7X87AX]1'KZMS!T9=.^UY7)=OKW:*'&6N:ON]QV]G^MO>H6>
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MK\\L:M'?]\R>U/P'F_8JG+D_;=OT<>*V!T R\@
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M8X8F."8='BX)?F?;\
M                                                        :'WH
M>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M     "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO
M@                )RO1M?KINC'^\3_ (4.=6M// _AUVB_L'Z3R3OZ9[>H
M\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8O
MW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UB
MV%]Q:I[+D5GA@Y#>
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M<]PX5YB]7=F,>A3RZIBBGI4TQ%,1$1$1$/JBW;M1R;=,4QU(P=S+>?8
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MJ(Y-=,Q/!Q<'4XNM@F8:\NZ
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M;2[.[39;MS9S/Y+/Y28\WEK]N_1Z:W55'T71KMUVYPKIFF>K&#JU6WP
M
M                               T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HO
MP''XUF%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O/4!^(.*
M4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\                !.5Z-K]=-T
M8_WB?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M     9\7B_?60=4?M
MJU3X-=*;>[N_U+R'VNOV2MZFN8;_  D;%^XLS^D,VC87HV[     6S/1J/ZD
M]6WMJXA_%'(#7_?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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MT5U3%,353$S,88S$8XS"VFP*A6
M
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M0C&G7MKB2G6HU(0C]R:6$7?M7;=ZW%VS537:JC&)IF)B8ZDQP2_.+C?D<C\
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M7_?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M
M
M
M                         &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76
ML_/^W+GHD5#.#I@                -#[T/+XC_ %.?*KK_  1<;(F^^ ?.
M3HOP''XUF%R:-]@K]'XT+<[0Q6
M         &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_P )&Q?N+,_I
M#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_WU^VM/^UWO%MH.N^]_K%L+[BU
M3V7(K/#!R&\
M
M
M                                                          !D
M8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M    #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M                                          !GQ>+]]9!U1^VK5/@U
MTIM[N[_4O(?:Z_9*WJ:YAO\ "1L7[BS/Z0S:-A>C;L    !;,]&H_J3U;>VK
MB'\4<@-?]]?MK3_M=[Q;:#KOO?ZQ;"^XM4]ER*SPP<AO
M
M
M
M                                8_'C 9C\.>*3U^WOX0_"?D.JSF7#
M^N?+>7\G_1[<LE@/P?W^V/=_!/X,]:]S_P#Q^1[GJ=U/SN"R_:VY/9:WR.1C
MH>4KPPP^R6J:^5_I<KE8]'''HK-SDXYNYZ.?%1PLO.J
MT6?0^<--0\/SJ'V&-Q+-)E.L;9\-+:PIQA-1FP/"G"-]/<1J]^,)Y;F&QRRP
ME[L.[Y*,>V/>]2)+G^YB*MZNDY3#AHV?MUX]/EYS.1AAU.Q_1ZBY=&C_ )>J
M?Z_C0MF-%57                                           9\7B_?
M60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_"1L7[BS/Z0S:-A>C;L    !;,]
M&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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M0
M
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MQ?OK(.J/VU:I\&NE-O=W?ZEY#[77[)6]37,-_A(V+]Q9G](9M&PO1MV
MMF>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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MFJM MX_\_D\,YDN3&'EJ[MCE3EXF9PB,U18JF8X*9C"9]TK5:U@
M
M
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M]2>K;VU<0_BCD!K_ +Z_;6G_ &N]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M^J11FKU-7!PV+,T4Y;+83CR*[5F+\4SR:KU?#,QF+V;A
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MI%CAH/,33/)JX)A_T?@
M
M                           "'+Q^.=;?@/PENL#-0N_(9?D?0[;@K VT
MM2%*MD[CFG-8_0,_:49H^I-ZWTC,Y6[J2_\ :H6T\(>K&#8+FM;,U[4[]M R
MW)QR^3S4YVN>.*8RE%5^B9\&]1:ICI550Z6H7.QY.N>C,8=?@\1DSIU5H
M               -:SP$]%CQWX0G0W@(T9J'X0XOS6]=R;RW;-#E#D;=N2X5
MH>7KW$_=N8;;Y2'9-"3LF^\EDE[))8(^=#J?=;?YM+FL<>1G:+/0_P#QLO9R
M^'!$<78L.GP<,S/#-X:?3R<G;CJ8]>9E+RP([@
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M.#9?<U^K%_W?7[%8>A7O37\.FM?MKG/T9HZ 5EI*      L1^C?_ !IN<_V
M5OA%TEAW?/\ D+*^Z_\ AUHI>^V?,MLW^U$?B&<7(6N" 0
M  !'EUJ^)ITR=$./N<=OFQS[CRM5LH76&X<TFK:Y#;[CR]*::QN]CKSU(8W2
M\+7G[L8W%_/+7J48S3VMO=1DC(O#9G8C7-J*XKRE'8\ACA5>KQBCJQ3T:ZNI
M3P1/FIIXVU7-XYGF^+G&9JC-[,Y2,AL33<Y-W5<W%5&5IY,^7IL1$=DS=Z(Q
M\I9B:*:L*;UVS%45*?76GXK?5-UGU<GKV;V*/&/#UY&-*EQ#H%]>66%O[.$T
MLTDF[9KMHY?>:\TU.2:>2ZC3QT*LD)Z5G1F;%[,[ Z#LU%-ZU1V?48_VUR(F
MJ)_J4\5'A>6PX)JE/3S>N9'N6YOE%G5=.RG=G;ZWPSJF=HHKO45]&<I9X;63
MCAF(FWRK_)F::[]R$9J]FX0                    "3SHN\67JJZ-:V-U[
M&[%/ROP]:STJ5?B7D._O+_'8^QD[LL:6C['-ZYS>BU9*7>\E2MXUL7"I/&I5
ML:TW9&%C[3;O]!VDBJ]71VOJ,_[6W$1,S_7IX*:^K,X5="*H:;\X3F.[D^<!
M;O:KF\I&B;>UQ,QJ>1HHHN5UST<Y8\K9SD3.'*JKY&8Y,131F;=.*X!T6^)A
MTQ];N,MK+0=F_HCRE3M)J^8X<W>O9XW=;:-O3[UY=Z_W*TUAN>%H]D9O7./G
MJ5*5+NS75&UGFA3:Z[3;$ZYLO7-6;H[)D,>"]1C-$]**NC15U*N"9\S-7&@9
MYPO,_P!\?-SSE>8VHR?;^Q<UX6M5R<5W,I5RI\I3?QB*\I>G@CL=^*::JL8L
MW+U,<I(0M!JP
M
M                    H\^F&=6%K+C^EWHDP&2FGO:MYE>I/DNQHUX2RVUK
M;T,OQWQ/0N):?>FJS7M6ZVFO4I5(R0IPH6]3NS]^2:22?F ;"US=UO>1FJ,+
M<4TZ?EZICCF9HOYJ8Z6$1EHB8QQY5<8QA,30M9O>8L1Z*?$CQU&!)@H
M             #:/Z+^-YN'.CWI3XDJ4?6];C'IPX1T&YI1A2[\+O4>--9P-
MY-5C1J5J4]>I=6$\U2>$\_?GC&;O3=O;'SL[Q-8C:#;_ %S7HG&G.ZOG+\3P
M\5W,7*XPQPG#"J,(PC".#"%[V*>19HHZ5,1]!Z66<Y0
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MTW.?[ *WPBZ2P[OG_(65]U_\.M%+WVSYEMF_VHC\0SBY"UP0"
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M\=%RW7%-5%4=&*HB7WG$I@
M
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M<Q<F;E^[PQ$X57:JN1%7#3;Y%'%3"S,S>G,7JKL]&>#J1T/H/%S(K@
M           >B^D#B*?G_JOZ:.#I;?UU)RYSSQ+QU=THTX5:<N.V_>\%@\I7
MN))I9I/6EICKVK5K1FA&66E)-&/J0BM';[7HV6V&UG:69Y,Y#2\UF(GB\M:L
MUUTQ'5FJ(B.K,.6S1V2]3;\]5$=>6TT\ZR]P
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M&*,Q.
M
M        _E7KT+6A6NKJM2MK:VI5*]Q<5ZDE&A0H49(U*U:M6J1EITJ5*G+&
M::::,(2PAVQ]1]4TU5U111$S7,X1$<,S,\41'1F1GB>DA^-GB>J?-9#H1Z5-
MJI97IYTC8J%SS9R;@,A"OA^;]YUZ[M[K%ZIK=S;PEI9'C+0<W;1KSW<)ZMMG
M<S1HW%O#UK8VMS>2Q<T+FXW]B,O1O.VXL31M9F;,QD\O73A7D[-R)BJ[<B>&
MG,7Z)Y,4X159LS517Y>[71;MS4\]%V>U[,_6XGAGISY$?1E4:;YJ,
M           GR]&AX.FYG\6_@S*7%E+?8/@W5N2^<<_2F[>RE+K^JW.GZK>P
MFA_JS6'(F]86M#_\QD[/]+5SGC;2QL[N'U.Q15R<SJ=_+Y.B>GR[L7;L?Z5B
MS>CPU1TNWR\Y3/0IB9\;Q9AJ9H2UU@
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M.6:6>66:6:$TLT(32S2QA&6:6,.V$TL8=L(PC"/J18 0?S$TSR:N"8?]'X
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M:V*W?92+.6C"K,9BO"K,YR_$83?S-W")KKGAY-,13:M4SR+5%%$12\S*VS"
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MEFJW=K]R+6:W@
M
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M<<,38IKB*KMVF>&+]RFF:9B)MV[=4<J;=SFIW,Q$V[6--GZ,^#Y"M W'4L
M                !>D]#CZ>)Z6(ZQNK#)V';3OLCH_3QI64[D(=V?%VT>2>
M3[#RD>V:/?ES&H5.R'9"'=[8]O;#NQG=\%VLBJ_L_L+9KX::+V?O4^BGM?+5
M?ZF:C_QPU_1;?!7>GJ1'BSXR\"C95T
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M73+5,1&;B(FJ[G<I1'!&:B,:\Q8IC#-1C=MQVSRJ<S;<:^(+P
M%+7TC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *RTE
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M9'):;E:,CIUFUE\E:C"BW;HIHHHCI4T4Q%-,=2(B'0F9JG&J<9? =I^
M               -:KP(NE^KTH>%MTMZ3E<?^#]QW_4:G.N]R3RS27<=@YDN
M9MTQMID:,\E.:WR6OZ5?XG%5Z<8=LE2PC+&,8PC&,$G.<VTC;G?9K>I6*^7I
M^5S':5GI<C*1V&J:9Z--=ZF[=IGHQ7BO#3[78<I13/FIC&?#X?$2]L!NX
M                                         SXO%^^L@ZH_;5JGP:Z4
MV]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/X
MHY :_P"^OVUI_P!KO>+;0==][_6+87W%JGLN16>&#D-X
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M4PT"[7-S6<E:IX,M<KJ\MJ-BBG_\>Y5,=MVZ8^L7)G,1]9KN]@LT,(H>0
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MP]GD9.Q'*OWZHI[/G,Q5$1<S.8JIB.5<KPB(CS-NW31:MQ3;HIB/-JM,N
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M:[F8_P /^E>Z<[^-W5J:I[=J\"/$A7];4J<
M
M                       ]T>&CTHWO6WUU]-'393LJ]Y@=^Y+P]QR#-0[\
MDUEQ9J<*NX<GWL*\)8R6]>GHV"OY+:,\999[N>E3[>]/+".,]\>W-O=ONRUG
M;":HIS65R=<6,>CF;N%K+1AT8[-71-6'%3%4\42[&5L]GS%-KH3/#X''/T&Q
MQ0H4+6A1M;6C2MK:VI4Z%O;T*<E&A0H49(4Z-&C1IPEITJ5*G+"6666$(2PA
MV0]1Y]JJJJZIKKF9KF<9F>&9F>.9GHS*]']7R
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MBS.\#4J;=[5<W3'!7>B)Y&6LU3'*[5RO*JHM8X3<KJNYB::)N]CHCH7DVP
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M:TU-=S,?X?\ 2O=.=_&[JU-4]NU>!'B0K^MJ5.
M
M                          7F?1!>BB>G1Y]Z^]NQ522%QW^G;AFM=T(2
MRU*-.?#[;RWLEE+7AWZDD:TN#Q5K=T80D[U/)6_>C&%266-'G\[QHFK2]UN0
MKC@_Y_-Q$]'R]K*VYPZG9KE5,\/#9KPXIFO:-8\UF)]#'BSXWT5XQ&LKP
M                                         #/B\7[ZR#JC]M6J?!KI
M3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L+T;=@    +9GHU']2>K;VU<0_
MBCD!K_OK]M:?]KO>+;0==][_ %BV%]Q:I[+D5GA@Y#>
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MCM+I=B*=7M6Z>',Y*B,*,[A3PU7LE3Y6]5,535E,*JJJ:,I$56_&NR!P
M                        !EN>D[?7$<_^T;@7X&M-37<S'^'_ $KW3G?Q
MNZM35/;M7@1XD*_K:E3@
M
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M-JGBIC__ &?#EZD62Y0
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MB:H[/DIJG'&O)7*XHIQFJJK+UY>Y75RZZHB3I8[3D
M        !EN>D[?7$<_^T;@7X&M-37<S'^'_ $KW3G?QNZM35/;M7@1XD*_K
M:E3@
M                                                  %S;T37PY:^
M\<F[CXC')F%__P"2XHJ9CC'I[M[^VDFIYODS,XOUKR!O=K"K/+/ZTT74\I#%
M6M2%.I1N+[,W,9)Y*^-FA&/+GU;W*=-T;+[H]&N?\_GHHS.>FF?,9>BK&Q9G
M#HWKM/9:HQB::+5&,33>A6](RW*KG,U>9C@CP>C/A>/U%^]%JN$
M                                    !GQ>+]]9!U1^VK5/@UTIM[N[
M_4O(?:Z_9*WJ:YAO\)&Q?N+,_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U
M_P!]?MK3_M=[Q;:#KOO?ZQ;"^XM4]ER*SPP<AO
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MUQ'/_M&X%^!K34UW,Q_A_P!*]TYW\;NK4U3V[5X$>)"OZVI4X
M
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M&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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M_5R8\I:U*WAVY1.'%VQRJ,W3-4XUW+F8BF.3:3H,6(V@
M          &6YZ3M]<1S_P"T;@7X&M-37<S'^'_2O=.=_&[JU-4]NU>!'B0K
M^MJ5.
M                                                  ?ZEEFGFEDD
MEFGGGFA+))+",TTTTT>R6666';&:::,>R$(?=?DS$1C/$-.+T=+PE*W0'T\5
M^>.;=9EQ_5CU&X3'7N>QN3LH4\SP]Q5/4I936N+YO+QFN,?L68JRT<MLM/NT
M)Y+V%M85:<9\9"K4AFYVV_>G>EM9&R^S=[E["Z1<JBBJF?*9O,\--S,\'!5;
MHC&UEYX8FCEW:9PO<F+ITW)]KV^R7(^O5?0CI>3_ $+(+4)4P
M                                   &?%XOWUD'5'[:M4^#72FWN[O]
M2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_
M 'U^VM/^UWO%MH.N^]_K%L+[BU3V7(K/#!R&\
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M .E=MU>5SNHVY^P3,>:L9"K&F:<>37G(KJFF>U[%Q8A8=13
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MP-::FNYF/\/^E>Z<[^-W5J:I[=J\"/$A7];4J<
M
M                       N/>C0^"]<\N[;K/B)]3^I5:?$VBY>7*=,^AY^
MQEEH\F[WAKN:6CRQE+.ZEC-6T?0LI;QCAY8R0ER>;HPK][UM8QDO(^N>-SB*
M- R%[=+L7?B==S5ODZC>HJX<O9KCARM,QQ7K],_79Q^MV9Y.'+NXVZUI>1Y<
MQF;L>4CS,=.>GX$=#JM =%:N(
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M%%-.;JKG,VJ>#DTQ:SE.8IHMT\%%F;7!3$Q"458K3$
M       !EN>D[?7$<_\ M&X%^!K34UW,Q_A_TKW3G?QNZM35/;M7@1XD*_K:
ME3@
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MJIF9F9F9G%=$1%,81P1#[+KOT
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M975-A=K]4V*UNGDZOI.H9C)WHC'#LF6NUV:YIQ^EFJB9IGHTS$QP2YVZBV@
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MBU5-54<,Q1FZ,I%$3P4]FN3$Q-4Q5<T:V//P
M  RW/2=OKB.?_:-P+\#6FIKN9C_#_I7NG._C=U:FJ>W:O CQ(5_6U*G
M
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M>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M                         (3/':Z7).<^CR[Y6P6,EN]]Z;<A6WRUK4J<
M)KZXXZR4MKC^2L;)/&7LA:6-C1M,W6C--+V4\--"7MFF[LV3MU6NSI6T<9"[
M5AE,['8YZ79(QFW/@S.-$=6M(GWM/?/5NVW]V]B=2O31LSM=:C)51,^4ISUO
ME5Y"Y,>>KKF[E*<(G&K-QCA$8Q1N;1O2$      O.> QS9-RET)8C2\A>>N,
MYP5O6T<=59*U6%2\FUV_J4-WU>ZGE_UI+*E;;16QUOV_]C&QEAZDK5K>OID9
M#:NK,T1A:S5JFYU.5'E*H\'RL53Z)YMN^:;NZ=B^<M?VARMOD:;M+IN6S\3$
M84=GHBK)YBF.G7-67HOW.KF(GHIJ&,T>8     "EKZ1I\=SBWY*^D?"WS@V7
MW-?JQ?\ =]?L5AZ%>]-?PZ:U^VN<_1FCH!66DH     "Q'Z-_P#&FYS_ & 5
MOA%TEAW?/^0LK[K_ .'6BE[[9\RVS?[41^(9Q<A:X(!      'Y[N[MK"UN;
MZ]KTK6SLK>M=W=U7GEI4+:VMZ<U:O7K5)XPEITJ-*2,TTT8]D(0[7[33575%
M%,8U3.$1TYERV+%[,WZ,MEZ:J\Q<KBFFFF,9JJJG"FF(CAF9F8B(Z,LS_JFY
MEN>H7J-YKYJN*E6>ER/R/M&QXF2O)-3JVFMW&2K4=6QLTD_;/+^"M;H6EM"$
MWWW92]7U6[6@Z;3H^C973(X[-FFF>K5AY:?#JQGPWL"W+;O[.ZO=-L[N\M13
M%>DZ3E[%V8G&*K]-N)S-R)C@^N9BJY<X.#RW!P.@U69.     2O>#3TL4>IO
MK3TVOL..]?<><)V\.7]RIU[;RV/R%WK]_9T=*UVYFJ0C;3_A;;KFVKU;>I">
M%S865U)W>R$T9;!WDZ].A[,W8LU89S-3V&CAX8BJ)Y=4='@HB8B>A552TB[X
M#OIN;G>;SJ%K2KO8]JMHJNY>4FFK"NBF_15.;OTX>6CL>5IN44UTS'8[UZQ5
MCCA$WYFICS#@                            *%7C3=+=/IMZU-MS&OXZ
MG8\>\\6T_+VJ26M/R=E89?,WMQ;[_@J<):=*A1J6>W4:][)0I0\G;V.2MI(?
M<[(;8;M-=G6MF;=N]5CG,I/8:\>.8B/K=7AT84XSPS535+TV][TWT5[W.;SD
M<AJEV;NU.S-<:7F9JG&NNU:HIJR5Z>&9F*\K-%J:ZIY5=ZQ>JGIS$@R"WH
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MNG._C=U:FJ>W:O CQ(5_6U*G
M
M      +@'@H^C:;7S[6U/JE\0'7,[HG!G_\ +-CX[Z?[V6ZP6\\PT/*T[RSR
MW(<D?(9;2.-+VA)+&G92PH9G-4:OE)9[*UA2JWF@?.-YX&1V6IO[$[J[UK-;
M3>6MW\]&%=G*3AA--CCIO9B)XZ_+6K,QA,7*\:;=9R.F3<PNYB,+?0CHSX/2
MCZ,M K6M:UW3-=P6HZC@L1J^JZOB,=K^MZWK^.M,/@L!@L/:4K#%8;#8JPI6
M]CC<7C;&WDHT*%&22E2I20EEA"$(016YS.9O4<W=S^?NW+^>OW*J[ERNJ:ZZ
MZZYFJJNNJJ9JJJJJF9JJF9F9G&5Q1$4QA'!$/MNL_0
M                               &?%XOWUD'5'[:M4^#72FWN[O]2\A]
MKK]DK>IKF&_PD;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^
MVM/^UWO%MH.N^]_K%L+[BU3V7(K/#!R&\
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MD[G*T39/(TV,(G&F<[FZ;>9S5<<.&,6^U;%7!$Q78JB9GH3HL6(V0
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M5MW+]=J(C@B;<TQP0D%6@U:                         9;GI.WUQ'/\
M[1N!?@:TU-=S,?X?]*]TYW\;NK4U3V[5X$>)"OZVI4X
M
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MO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8
M"V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
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MTU_#IK7[:YS]&:.@%9:2@     +$?HW_ ,:;G/\ 8!6^$726'=\_Y"RONO\
MX=:*7OMGS+;-_M1'XAG%R%K@@$      5XO2->2IL!TO\-\7V]S&A=<C\QSY
M^[I2SQEC>X'CS5\GZ\MJDG;]_0ESFWXRM'_\3TI&8=S62[-KN9SU48TV<MR8
MZE5RJ,)]+15'ARE7[TSLA&J;Y=H-LKM'*LZ3H$6:9F/,7L]F;?(JB>A,V<KF
M*.K%52FPV03_      #D6H:KFMZVW5])UNU]>[%N.Q835<#9=Z,OKO-;#DK;
M$8NU[T)9HR^N+Z[IR=O9'L[?N.',YBUE<O<S5Z<+-NBJNJ>E33$S,]:%)U[6
MM/V:T/.[1:O7V/2M/RE[,WJ_.VK%NJ[<J_T:*:I\)IP\3<=X;B'B[CGBK798
M2X+C?1M5T;$QA3EI1JV&JX.QPEM<5))(0AY>YIV4*E2/W9IYHQC&,8QBT@U#
M.7-1S][/WOLMZ[77/@UU35/6Q>.G;C:O4-N]M-6VVU6?_P"EJ^I9G.7>''"O
M,WJ[U5,3/0IFODT]*(B(X'8+IK6                             <(Y,
MT'!<K<<[[QAM%+R^M\B:;LVD9VE"66>:;$[3AKS"9"-.6?[WRLEK>S1DCZG9
M-"$?4[':R.;NY#.VL]8G"]9N4UT^#3,51]&%Q['[4:GL3M;IFV6C5<G5])U#
M+YRS/%]=RUVB]1CAT)JHB)Z<8PS&]XT_,\>[KN&@['1A;;#H^T[!I^>MY>]W
M:&9UK+7>%RE&7ORR3]E*^LIY8=L(1]3U80;P97,6LYEK>;LSC9NVZ:Z?0U1%
M4?0E[&-F]>T_:K9W(;3Z35R]*U+)6,U9JX/+6LQ:INVYX,8X:*XG@F8<6<ZM
M     +B_HX?)M3/=.'.?%%Q<PKU>..6\;M5G3FJ]ZM98?DO6*%K;VDM+OQ\E
M9QS&@W]>2/=AWJM:KZL>SLEURWS9&+6M974(C"+V7FF>K-NK''P<+E,>!$("
M^^U;'T:9O:V;VWM4<FC5M"N9:J8C@KNZ?F)JJJQPX:^Q9VS1/#P4T4<$<<V+
M6&T3P                        #+<])V^N(Y_]HW OP-::FNYF/\ #_I7
MNG._C=U:FJ>W:O CQ(5_6U*G
M
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MO:R]'(M1A'T9\&7KQ8+F
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MIMN.+E1G[]O+WX]Z59BKJ\G#@B<8T#VHKRW
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MK::>5=T_:*K+8X3,TT9W*7KE4XQ&$4S7DK=,S,QY::(C&97%VN* H
M                 !EN>D[?7$<_^T;@7X&M-37<S'^'_2O=.=_&[JU-4]NU
M>!'B0K^MJ5.
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MHBF.!6\OD<OEN&B,:^G/#/\ 1X25Y@QW
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M7NG._C=U:FJ>W:O CQ(5_6U*G
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M$XTTW+D]BHF>/L5BGDV;6/1[';IB>BJMJQ9L1A:IBGQ>OQO4RR'*
M                                                 SXO%^^L@ZH_
M;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4G
MJV]M7$/XHY :_P"^OVUI_P!KO>+;0==][_6+87W%JGLN16>&#D-X
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MGO\ \I3^8?\ _#_^J_\ MIW$_P![_J_^8^QA_P#V1_\ )[_\I3^8?_\ #_\
MJO\ [:=Q/][_ *O_ )C[&'_]D?\ R>__ "E/YA__ ,/_ .J_^VG<3_>_ZO\
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MOKSZD^R!>)7^N_H:]\KGS_IG/W^]SOYMVE][Y+_N)W&S7GK?7GU)]D"\2O\
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MI\.7:IIIIC"F(B.HY:Z#Z
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M\AR>&ULC9N<K'C[+J.HTX8=3L4SCCP\KJ<-A!B!%B
M            K]^D;V-K4Z,>)<E/2[;VTZGM5L;>MWZD/)VN0XJYAKWE+R<)
MX4I_+5<90CWII8S2]SLEC"$9NW+FYFJJ-I<Q1]+.1KGPXNV</%E*/WIC,WJ>
M<'KN4IG_ )>O8W,UU1A'#51J6E4TSCAC&$7*XPB<)QX8G",*7[95Z#@    '
MM+PY/CY](G[?^-/SEL5M;9_JGJ/N2Y]3+7KG9_PS;=_LOJ'XO6T<FF;R7@
M
M
M                                                           ,
M_#QC\=<8OQ*.I^VN8TXU*N<T#(R^2FC-+ZWR_$7'^6M(1C&66,*D+6]D[\.S
MLA/VPA&,(=L=NMV]<5[%9&JGBY-R.M>N1/T8>I'F!9JUG.:'L;>LX\B,MG:.
M'@\M:U3/6JO"Y5$X=.,)X.)&4O=N(     MF>C4?U)ZMO;5Q#^*.0&O^^OVU
MI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M-%X!][76_P#T1_G/:S\XYO[I5Y)^]GSFOCWM1_B&8]6?1Q]!GFB\ ^]KK?\
MZ(_SGM9^<<W]TJ\D_>SYS7Q[VH_Q#,>K/HX^@SS1> ?>UUO_ -$?YSVL_..;
M^Z5>2?O9\YKX][4?XAF/5O0G$_"O$G!&NWNH\,\<ZAQCJ^1S5SL=_@=*P=E@
M,5=YZ\L<;C+K+W%G84J5&ID+C'X>UHSU8P[T:=O)+V]DL%'U#4]0U6]&8U*]
M<OWZ:8IBJNJ:IBF)F8C&>AC,SATYEBS;C>'MUO+U:WKN\#5L_K.LVLO38HO9
MN]7?N4V::[ERFU377,S%%-=VY7%/%%5=4\<R[/=%9H
M            " ;TC3XD?%ORJ-(^"3G!EO<U^L]_W!7[+82@=Z:_B+UK]BLY
M^D]'4M&RST*@    /:7AR?'SZ1/V_P#&GYRV*VML_P!4]1]R7/J9:]<[/^&;
M;O\ 9?4/Q>MHY-,WDO
M
M
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M)Y4S7&FUVXQPPPCL=V<)F)QJX(G&J8M7,"(30
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M]YMGR67GN\K0U3CKCK7)[7^EO)6[WMK<WMK@,/&\GDM,=86=C9UKO(Y&X_\
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MGB:*S3AY00
M
M
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ME;69RF;IJGI?9;=BGACZ;@F.*;G[6IY\0
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MV3'H<6/'"JZ1RNVIPXN1./T/':5*'A<X
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M3Y[#C7]&I3R_
M
M
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M9HY>;R61MZA1.$S-$:??M9N]5&'_ /S6K],S/!%-4SP<<:#[4)Y9
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MIJJI\I-%44S%-<S$Q''E<]8S<S3;QBN.A/\ XE+JP*[@
M             "BEX\?)DN_^(1M^ HUZ=>UXBX\X[XVH3T9H34_*U<7<<BY&
MGWI8QEFKVV3Y K4*G^F6>E&2/JRMJ=U.1[4V0MWIC"K,7KESZ/8XZ\6XF/!>
ME3O9VQ\[+\UC(:I<IFF_KNJY[/S$\>$7*<C1/@56\C173TXJBJ."4-#)"0$
M   !/1Z/!ID^?ZV]QVFI3CZTT/@7;[^G7[)XRRY;/;5I&O6=O'N5Z4(1KXR^
MOIX1FEJR_P E&'=A-&6>7%&^',]BV8MV(\U=S=$>%3175/T8IZ7&C*[ZQM!3
MIG-UT_1:)^OZGM/E:)C@^Q6<MG+]=7#$\5RBS'!-,^6X\(FF;KC65YWP
M
M
M                                                         %>O
MTC/CV;.]*?$7(UM;3U[GC[FRWQ%W4DI0F]9X+>M1V"G>756KV=ZG2FSFMXRC
MV?<FGK2]OW(,O[FLYV+7\QDZIPIO969CJU45TX1Z6JJ?"2H]Z;VJC3-]NN[)
MWJXILZKL[5=IB9\W>R>:L333$=&>PYC,5]2*9Z<J9[9)Z!     ')-.VG+:-
MMVJ[M@:L*&=T_8\'M.%KS0C&6CEM?R=KEL=5FA",(QA3O+22,>R,/N.',V+>
M:R]S*WN&U<HJIJ\"J)B?H2I.OZ+D=I-"SNSNIT\K3<_E+V6NQT[5^W5:N1X=
M-4PTZ>,M]PO*G'&@<G:W/W]?Y%TK5MYP<W?A4C'$[9@['/8[O3PED[T\+2_D
MA'[V7U?]$/N-'L]E+N0SM[(WOLUF[515X-%4TS]&'CCVPV8U#8K:W5-C=7C#
M5=)U',Y.]&&'UW+7J[-S@X>#E43APSP=&7-W56X
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M%<VW;7:#E]CNT[/9NQ;JX,:;V<MSD[$QCP8Q>S%$QCCP]">*='5IF\EH
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M)M6-0SUVG'C[+7E\OEZII_J]AS,1/#CRIB,,)QM&,%(8P
M
M
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M0B*[M41$<$1A$1$<"\<C7->4MU5<?)PZW!XR4MA-VP
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MJ?\ 0S.;OT3Q>6IGP9E]8[:'
M
M
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ME?G/T<F)FJK)UTQ;U"W&'%33;BWFZY\[E,(X^&\^U9>;0
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M1'!$1$1P1#LETEH@
M
M
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M9N-IVUUFQV/:S:ZNWG*N5&%=&0HIF-/MSTHKHKN9O@XZ<U135PT81">R:D1
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M7C<KM7+<533%RJNNBJW5RKE454Q35=-SU>9B;=W[)3&./3CR5FIIJJ@
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M3$\GM&UF:<8X.551$\$X3?I:F/,,
M
M
M                                AC\=/IPJ<X=$N;WG"V4;G;NGC.4.
M4K/R,O>N:^G>MY\+R%90C&G/"6SM<)=T\Q7]62/9AY?OONRS9*W5ZU&E[3TY
M6[.&7SE/8IZ7+\U;GP9JCD1Z-(+WMC>U1NXYQ67V;U"YR-"VKRTZ=7CYF,UR
MHNY&OCCRU5ZFK*T<?#FIX.C%%=M.]*      "<GP,NMJATY=1%?@[>\K"RXH
MZBKS$X.A=7=2:%EJW*]M-4M-+R\T\]3R=E8[1"[GP][/+)]_6JV-6K/)1M9I
MH8NWI[,3K.C1JF4IQU#)Q-6$<=5J>&N.K-.'+IZD5Q$8U(WN^2<W6YO9W4T[
MQ]FK'9-M]D[=V]--,>7S.FU859NUA$8UUY?DQFK43/!13F:**:KEZ(F[VU?>
M<L                          !'-XHG6=9]%?2SM6XXF]H2<K[W"XT#A[
M'QJ4HW$FU96SK>N]KFMYIHU9L=HV)\I?SS]R>E/>2VMM4C+ZYEF7EL+LU5M-
MKUO+7(GN?:^N7I_J1/!1X-<^5Z>'*JCS+;+F9<WS,<X;?3DM SUNJ=B-,Y.=
MU2O">3.6M5QR<MRN+LF<N\FS$8Q5%J;UZG'L,PSV:]>O=5ZUS<UJMQ<W%6I7
MN+BO4GK5Z]>M/&I5K5JM2,U2K5JU)HS3331C&:,>V/JMOHB*8BFF,*8>J"U:
MMV;=-FS3319HIBFFFF(B*8B,(B(C@B(C@B(X(A_)^OL    !*1X.O3C'J,ZZ
MN+:&3L(7NF<15*O-6Y0K49:UI/;Z/=6535K"XIU99K:YIY3?+W%TJM"?MA5M
M/+Q[LT)9H+%WC:UW&V5OS1.&9S'UFCI^7B>5/3C"W%4Q/0G!IAS^=[7R3<VO
M6KN3N]CV@UZ(TG*83A5%6<IKC,UTS'EJ9MY*C,54UQYF[V/AB9B5_P :D/+R
M       I:^D:?'<XM^2OI'PM\X-E]S7ZL7_=]?L5AZ%>]-?PZ:U^VN<_1FCH
M!66DH     "Q'Z-_\:;G/]@%;X1=)8=WS_D+*^Z_^'6BE[[9\RVS?[41^(9Q
M<A:X(!           $-?/?@!>$_U&<B93E3>NEC%8/<\_=W%_LMSQANW(/%F
M%V+(75;US<Y+):EHNSX34J65N[F>K5N;NULK:ZO*U:>I<5*L_=FEV$V7YT^_
M/9'2:-$TS6Z[NG6J8IMQF;-C,UVZ8C"*:;MZW7=FF(PBFFJNJFB(B*(IC&)Z
M5S3LI=JY=5&%74F8\1(ATU=*'3ET=\=4>*.F3A_3>'-$DNXY&ZQ&J6-66[S>
M5FH4K6;-;1L&1KW^R;;G9K2A3HQOLI>7=W&C3DI^4[DDLL,3;8[<[7;P-6G7
M-L]0S&H:G-/)BN[5&%%.,SR+=NF*;=JC&9GD6Z*:<9F<,9F79M6;5FGD6J8I
MI_\ '7>A%J.1P?DW0,#RQQMR#Q9M,+F.L<E:/MF@;'"SJPH7D<#N6!O]=R\+
M2M-)4EHW,<?D:GDYHRS0EF[(]D52T;5<UH6L936\EAV[D\S:OV\8QCEVJZ;E
M&,=&.53&,=)\UTQ73-$\4QAUV3IU?>"IXB721S#L'&M]TR\R<NZO3SE[9Z%R
MOPSQMMO)6D;_ (/UU5DPF3MKS2\9GYM=S.3LY99ZF'R7K;)6]3O2^3GDA+5G
MG1V!YQFZ7;S9^UK%K6=/R&=FU$W\KF\Q:R]ZQ7A'+IF+U5'9**9X(NV^5;JC
M"<8G&(M&]D<S9KFF::ICH3$3,3UO$6X_1B_"6Y_Z,:'+O5EU1:E?<7;]R_IN
M-XRXYXISU*6WW; :%3SUEM6S;%O6-[:E77+[9,UA,73LL97C3O[>E8UJEU2I
MQK498:&\\[?MLMO#JR&PNQ5^G.Z7I^8JS&8S-$XV:[_(FU;MV:N*Y3;HKN37
M<C&BJ:Z8HJGDU2K&EY.Y8Y5Z[&%5481'1PZJW T.5@
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MM,V9R79,Q$3P=OY^*+M5-41P53:RE&6FF<9FFJ_>HPIGE<JPBQ BP
M
M
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MPQPBN_<JN333CQ44<KD41]+1333'!#L-TUJ
M
M
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M3R]>&,3V?,4U9BJF<*J>U;%7#3=X;;;7Q!B
M
M
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M(X8GCIKHJC&FY:N4S%=J[1-5NY;JIKHJFF8EV2Z2T0
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M^7L[LS<FYG9HJQHNZG<HPY$X8Q/:-FJ;7'$TW[V9MUQC;C"PPP^BL
M 4M?2-/CN<6_)7TCX6^<&R^YK]6+_N^OV*P]"O>FOX=-:_;7.?HS1T K+24
M    !8C]&_\ C3<Y_L K?"+I+#N^?\A97W7_ ,.M%+WVSYEMF_VHC\0SBY"U
MP0"       ,W'TMGA_9M+\1S1N5[RTN9]0YIZ>=.GP&7FHS2V4VP\=YO8=7V
MK7J-:,LLM6]Q&/K8B]K0A&/<IY:CZOJ]D)?N8CK^3U'=%F=#MU1V_IVK7>73
MCP]COT6[EJY,="*JHNT1TYM5+9UBB:<S%?TM5,?0_P#$*M#=E20'T,3B<IGL
MKC,'A,?>Y?,YK(66)Q&*QUM5O,AD\ID;FG9V&/L+.WDJ5[J]O;NM)3I4Y)9I
MYYYH2PA&,8.&_?LY6Q7F<S73;R]NB:JJJIB*:::8QJJJF>"(B(F9F>"(X7[$
M3,X1QMJ'I>XOO^$>F?IVX7RL]*KD^(>"^).+\E4MZM2O0J7^@:!K^J7D]&O5
MKW56M2GN,3-&6>:K4FFAV1C--'U8^=3;76K6TFV6K;16(F+.?U/-9FG&,)Y-
M^_<NQC$1$1.%7%A'@0O>U1-NU31/'33$=:%5KTQN\W.3IAZ.\?8RU_T>W//.
MZ7FT32PNO6T-SL>/9Z.B2UII)H64*\V$R.Q^3A4EC5C+"?R<82PJ]N[W>^[>
MG3MIM!=NX=UJ=+LQ;XL>PU7\;V'1PY=.7QPX.+'AY*DZURNQ41]+RIZ^'!X[
M/S2IK= :SG@ 7FY7W@]]$%;>Y:\N;DX_W&SL87,+J%2.FX[EOD+'\<S2PO)I
MZOD)^/;;%QI1A'R4:49?)0A3[D(04\Z>WIUK?_M+3IF':TYJU-6&'V:K*V*L
MQQ<&/9YN8]''''AQ7?IW*[2M\KCPGK8SA]!,2U^=UT3U27O)V-Z9>HO(\)4J
M]?F;'\$\NWO$="UIS5KFMR=:\?[#7T&E;TI+>[GJUZFU4[2$DL*56,TT80A)
M-]R-S[$V]%O;9Z19VDF(V=KU/*QFIG@B,M-^W%^9G&,([%RL>&/!AQW>7%JJ
M;?F^3.'@X<#%?REUDK[)9&]S5Q?7F8O+Z[NLM=Y2M<7&2NLE<7%2K?7&1KW<
MT]U7OJ]U//-6GJ1C4FJ1C&:,8QB]%=FBS:LT6\O%-.7IIB*8IB(IBF(PIBF(
MX(IB,(B(X,.)9$XX\/&U9O1WLORYF?"&Z3;KF&.<JY2ABM[QND7>RU;BIF;O
MB?%\C[78<:SSRWDDEU2PUKJ]O1ML/";MDGPM"SGHQC0GI10=\[.QH.7W]Z[1
ML_V*+,UV:KT6XCD1FJLO:JS'%P37-R9JN]&+U5R*O+14NW39KG)T<OCX</ Q
MX/Z.HFP:XN\                    ZVY=Y=XZX(XZVGE?E?:<=IVAZ=CI\
MEF\WDIYH24Y(32TK:RLK:E+/=9/+Y.ZGDM[.SMY*EQ=7%22E2DFGFA"/=T[3
MLYJN<MZ?I]NJYF[E6%-,?1F9XHB(X9F>"(QF9P7=L)L)M9O+VLR6Q&Q&2NY_
M:;/W8MV;-N.&9XZJZZIPIMVK=,37=NUS3;MVZ:JZZHIB94'_ !(/$+WOKUY<
MFR]27(ZQPKI=S>6G$O'-Q6HQJ8ZSKRT:%YM6SQM)IK:]W'8X6\M2MV35:6/H
M1EM*$\\)*E>XVRV+V/RFR>G]CCDW-3NQ$W;D=&>A13CPQ13T.*:I\M,1C$1Z
M=.:1S5MFN;)L+&0IFUG-X>H445:GGZ8G"NJ,9HRV7Y7EJ,K8Y4Q3C%-5^OE7
M[E-,U46K4<B\FV8     #L3B3BW<>;N3=&XDX^QD^7W+D+9<9J^ LH=Z%+UY
MDKB6E&[O*LDL_K7&8ZAW[FZKQAW*%M2J5)NR66,73U#/Y;2\C=U#.5<G+6:)
MJJGJ1T(Z<SQ1'1F8A:FW6VF@;NMCM2VZVIO18V?TK)W,Q?KX,>1;IQY-$3,<
MJY<JPMVZ(X:[E5-$<,PTC>FG@/3NF#@KC7@C19(QU_CO6[;$>OZE*G1N\]F:
M]2KD=DV;(4Z7\G+D=EV"\N;ZO++]Y)4KQEDA"2$L(:7ZWJV9UW5;^JYK[->K
MQPZ%,<5-,=2FF(ICP'D>WO[SM?WR[RM8WE[2S_\ U-5S=5WD1,S39M1$6\OE
MZ)GA['E[%%NS1,\,TT1-6-4S+O-2F-@
M
M
M                                     %?SQY.AJ?FWANRZH^/L1&ZY
M,X'Q-Q0W6TL+:2>]VKAZ:YJ7^0KU)I98UJ]SQQ?5ZV2I2]L)9<?<Y":/>GEI
M2LN;J-J8TS4IT+.589'-U>4F9X*+V&$>%<C"F?ZT4=5*-WLWG(T[NMO[FYC:
MJ_R-C]IK]-64JKJF*,MJG)BBB(QG"FG/T4T9>J<)F;]O*Q&%,URI?-E7H/
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M_P#C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_ &HC\0SBY"UP0"
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MNQ7"SDP>AS
M
M
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M4SO.T*FWE]2IX(JS%,Q,9?/TQ'!AF::*HO<G"*,S1=B**+=5GE14+];L@
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M5VK?B<9IHN1C5.5S/)B9JR]VJ9QBJ;-R];CLD^^5I-80
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M.KN4[OM*Y>5TJU/*C&S%7US.5T3AR;V<KB+DXTTU46:;%FO&JS-54DRRFHH
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MC/9W-Q$9N]=NQ3Q<NNJK#'CPQF<'Y%,1Q1$/O.J_0
M        $9O7IXI'3]T-8B[P>3O:7)/.-S91JX'AW6<G;2Y&TJ5K>6M99'?\
MM)+=TM'P5:6K)/)&M2K7]U3GA-;6M62$]2G>^R>PFK[4W(NVX[!I<3Y:]5$X
M3TXMQP<NKP)BF/IJHG")W!YLG,OWI<Y'/6]2R=NK2-W%%S"]JN8MU=CJB*IB
MNWDK4\F<Y>B8F)Y-5-FW,87KU%4TTU4D.K#K$YTZSN1JO(W-FTSY.I;>N;?5
M=1Q<M:PTK1<3<U9:DV)U3!35Z\EI)4\G3A<75:>O?WL:4DUQ7JQDEC+L[L_L
MYI6S62[3TRWR8G":ZYX:ZYCHUU='J1&%-.,\F(Q>BW<?N#W:\WS9*G9/=WDH
MLT5\FK,YJYA7F\Y=IC#LN9O81-4QC5R+=,46;7*JBU;HBJK'RXKK,X
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MHS,ON.)30
M
M
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M^5MY'(6K=C)6:*:+=NW3%%%%%,84T444Q%---,1$4TTQ$1$81&#\3Z=@
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MB>3.8O3]=S%<8\JN8HB>Q6K44^WUKM<@
M
M
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MW/Y^[<OYZ_<JN7+ERJJNY<N5U3577775,U5UUU3-5554S555,S,S,OVOEUP
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M9S-4<JJU3:G#8N1Q
M
M
M                             *^7C$^%%3ZAL7FNI_IXP="CSGKV)JWG
M(.CXNS[L_,F$Q-KWI<ABJ%K)VUN2\18V_DZ4G<FGS-O));PCZXI4):N7MW.W
M\Z/<IT+6*IG2JZL+=<S]AJF>*<?]G,\?G)QGBF<)3>8-SW:]U6=R^YK>KF:J
MMVV;OQ1D<Y<JX-*O7:O,7*JIX-/NUU<JJ<8C*7)JNX=BKNS13,JTJM"K5H5Z
M52C7HU)Z5:C5DFIU:56G-&2I2JTYX0GIU*<\(PFEC"$81AV1;)Q,3&,<,2]
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MS>-Q^ZJJB[L!LOH^G9VWAR<Q38INYJ,.+_F[_9<S/AW9Z?&\OJXS*
M   _[++---"66$9IIHPEEEEA&,TTT8]D(0A#U8QC$?DS%,8SP1"WGX-WA+U>
M+9,#U9=3^KPI\E5Z=EF.&.,\W;S0K\<V]22>M0WK;\;7EA"GO=W3J4Y\9959
M>]A*?\M6EAD)Y)+#7C>1O C/\O9_0[G_ "48Q>NT_P"T_J43ZW'TU4>;XH\I
MC-<$//\ N?)1MI5FMQ^YO.X[(4S7:U;4+-7!GZHF(JR>5N1QY*F8F,Q>IG#.
M3];MSVK355FK*#"J(D
M
M
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MBNBJ(JIKHJIF::J:J9B::HF8F)B8G!^1^N<
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ME!A5$2
M
M
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M:+E7#;S6J1'!CF,)QM92>&:,I$_7(F*\SC5R;5F<5BY'
M
M
M
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MFWYIHSN5G@BJJ;<3]>L<J8BC,VN5:JQBFJ;=WE6Z?$JYVQ0
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M*\WFZZ[N:NUU5UUUU357775,S5555,S-554S,U53,S,S,S.+]+Y<(
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MM?9G+W)JR>F6)FG*9:)QB*IC@G,9CDS,59F]C7.-5-N+5J8MT^Y5K-;@
M
M
M
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M+U++W**OIN3>F<O<HCJ53<HJF.#AMTSCP835-(KFG-<CH54S]#A:7:'-=
M  #JKG;^Q#F3]E7(?YHY=W]*_*F6]T6_JX7KNU^<;0/AO(_C5IF(-XGL@
M       <]XTXNY&YDW#%\?\ %6D[+R!NF:GFEQVMZIB;O,92O3I]D;BZJ4+2
MG4]:X^SDF[]Q<UHT[>WIPC/4GDDA&,.KG<_D]-RU6;S]VBSEJ>.JN8B/ X>.
M9Z$1PSQ1"V=K]L]D]@- O;4[;:CD]+V>R\?7,QF;M-JW$SYFF)JF.577/!1;
MIY5==6%-%-54Q"T'T+^C^8O$QPW)'6[E*.;R$L;;(67 VH92I^!K2:$LM66A
MR)NF.JTZV7KRSS=E3'X>>G:RS4X1FO[FG/-1EP7M5O<N7.5DMF*9IHX8F_7'
M#/VNB>+J55XS_4IF,4-'.3[Z-G,]VQLES<[-67RL\JBO6<U;CLM70QR.4N1,
M6HPX:;^:BJY,53AEK-5--<V9-5U36-&UW#ZAI>O874]5U^RI8W!:YKF,L\-A
M,/84>WR5GC<7CZ-O9V=O)&:,>[3DEAVQC'[L8L)9C,7\U>JS&9KJN9BN<:JJ
MIF:IGIS,\,H>];US6=I-6S&O;0YO,9[6\U<FY>OW[E=V]=KGCJN7*YJKKJGI
MU3/!$1Q0Y X5+
M
M
M                                     >0.JWH3Z9^LW 1Q/-W'UG?Y
MVVLYK/ \C:]&A@N2-8IQGC4DEP^TTK:O4K6=.K--/"ROJ5[CIIYHS36\TWJK
MBT#:K6]FKW9-+O3%J9QJMU>6MU>#3CQ_UJ9IJZK/.Y'G*[X>;[JG;V[K5;EK
M3*[G+O9"_C>R&8G#">RY::HB*YC".S6:K5^(C"F[$<"JQU?^ QU,<)7&6VGI
M]JQZCN-K>G6O9,=BK>ABN6\/;21[TUK=Z;&O/0VZI1EGEDIU,+5KW=W-+--Z
MPH0[)6>MG=Z^B:I%-C5_^2SL\&,SC:F>G%?TG@5Q$1Y^4UVX;OFFY_>+:L:+
MO2I_REM=7,43<N557-,NU3]-3F\(JRL3A,U4YNFBU;B8CMJ[.,H,<KB<I@LG
M?X7.8W(8;,8N[KV&3Q.5L[C'9/'7UM4FI7-G?V%W3HW5G=V]66,L].I)+/)-
M",(PA%E.W<MW:(NVJHJMU1C$Q,3$Q/%,3'!,)),EGLEJ>3M:AIMZUF,A>HBN
MW=MUTW+=RBJ,::Z*Z9FFJFJ.&*J9F)CAB7SWT[0                 #V#T
MO=!O5+U@Y2WMN%.+<SD]<FN8VV0Y&SU.IKG&N&C2J>2NHWNWY&E+87ES9Q]6
MI9V$+S(1A"/=MYENZ[M7H.SEN:M3OTTWL,8MT^6N3TL*(X8B>G5A3U6!=\W.
M9W+;A<E5>WB:UE[.K11RJ,A9F+^H7<8QIY&5MS-=%-7TMV]V*QCYJ["TMT9>
M OT^\'SXO=.HZ^M.HGD:UGM;VAK]S97&.XAUZ^HQ\I&G)KE>KZ[WSN5/O8SY
MB$+&O)V=['230[6"-I=Z^KZI%66T:)R>3G&.5$XWJH]%Q6_]#RT>?0N<X+OF
MN]+>/3>V>W2VZ]E-DZXJHF_373<U2_1/!C-^(Y.2QCAPRN-ZB>+-U1P)XK"P
ML<78V>,QEG:8[&XZTM[#'X^PMZ-G8V%C9T9+>TL[.TMY*="UM+6A3EDITY)9
M9)))82RPA"$(,4UUU7*IKKF:JZIQF9X9F9XYF>C,HSLSF<SG<S<SF<N5W<W=
MKJKKKKJFJNNNJ9JJKKJJF:JJJJIF:JIF9F9F9G%^M\N
M!2U](T^.YQ;\E?2/A;YP;+[FOU8O^[Z_8K#T*]Z:_ATUK]M<Y^C-'0"LM)0
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M[';IFO")KFJKA>@%(8N
M
M
M                                               >3NI7H>Z7.KC&
MSVO.?$FN[/F)+3UICMWL:=77N0</3DA-ZVEQVYX.I8YR-I:U8^4EL[BK7L)Y
MH?RE">6,98W!HFU&N[/5\K2LQ7;MXXS1/EK<]/&BK&G&>G$15TIAG#=!SC]\
M^XO-Q>W;:[F\GD)KY5S)US%_(W9GS7+REZ*[/*JCRLW:*:+T1YBY3.$Q79ZE
M?1SMXP]3(Y_I2Y=QNXXR$]:O;<>\M2R:_L]"AY2'D;/';QA;2IKF>NYI)_NW
M=AA:<L)/5J31F[(9BT3?+E;D1:U_+U6Z^C<M>6I\&:*IY5,>!57/42N;H.^Q
M[.9^BUIF^W0;V0SF$15GM,F;^7F<.&JYD[M47[-.,?[*]FZIQX*(B$#7.G27
MU*=-&0FQ_.G"^]\=2PKPMJ.9RV'GN]3O[B;MA"CB=UP\^2U#,U/O?5A:7U:,
M/]/W65]*V@T36Z.7I69M7N#'")PKCP:)PKCPZ829[M=^6Z+?!E8S6[;:'3-6
MGD\J;5J[%.9HIZ=W*78MYJU'VVS0\[JPRL             ^Q@=>S^U9:RP&
MKX/,;)G<E5A0QV%P.-O<QEK^O&$8PHV6-Q]&XO+JK&$/]6G)-%QW;UJQ;F]?
MJIHM4\=54Q$1X,SP0Z&IZKIFB9&YJFLYFQE-,LT\JY>O7*+5JB.G7<KFFBF.
MK,Q"6WIQ\#[KCYUGL,GMFGX_I]TVY[M6KFN7:];';+-0A-)"K)8\=8ZG>;=3
MR$L)^V6EE*.)HS]D?Y:$8=D<?:SO0V6TJ)HR]R<YF8^EL\-/AW)PHPZM,USU
M&C&]KOCG-OW:TW<GH>?N[4Z_1P19TN(N9?E<.$UY^Y-.5FC@X:LO7F:HX/K<
MK"G2YX%71UP/-C-@Y,L\EU(;Y9>3KSWG(5O0L>/K:^IU9:DM7&<:8^M7Q]U;
M]R7NS4<U=YJG-&,9H0E[982X@UW>IM'JW*LY&:<EE)Z%OAN8=6Y/#'@T11**
M[?/WRG?YO,B]I>Q]RSLCLS<QB*,C5->>JHF,,+FH5Q%=-6,XQ7E+64JC@C&>
M&9F;Q6)Q6!QEAA<'C,?AL/BK2A88S$XJSML=C,=8VU.6E;6=A86=.C:V=I;T
MI82R4Z<DLDDL(0A"$&-;ERY=KF[=JFJY5.,S,S,S,\<S,\,RC[SV>SNIYR[J
M&I7KN8S]ZN:[EV[75<N7*ZIQJKKKJF:JJJIX9JJF9F>&9?0?#J@
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MJGD6;>/%;M4T6XZ%,.U'064
M
M
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MC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *RTE
M6(_1O_C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_:B/Q#.+D+7! (
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MFI3&P
M
M
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MU3/17RN5VQF[][E<KS6/9+E6/*^FQX^B[!=-:P
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M35551PX\G&(F/9"VV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
9                             '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GRI BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2223 Avenida de la Playa<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-1170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GRI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,281<span></span>
</td>
<td class="nump">$ 5,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">649<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,930<span></span>
</td>
<td class="nump">5,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,042<span></span>
</td>
<td class="nump">5,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,361<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,779<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,837<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, 0.0001 par value; 250,000,000 shares authorized as of March&#160;31, 2025 and December&#160;31, 2024; 525,358 and 525,485 shares issued and outstanding as of March&#160;31, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">43,991<span></span>
</td>
<td class="nump">43,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(42,786)<span></span>
</td>
<td class="num">(39,740)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">4,032<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 4,042<span></span>
</td>
<td class="nump">$ 5,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">525,358<span></span>
</td>
<td class="nump">525,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">525,358<span></span>
</td>
<td class="nump">525,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,640<span></span>
</td>
<td class="nump">$ 933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="nump">962<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,051<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,051)<span></span>
</td>
<td class="num">(1,895)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,046)<span></span>
</td>
<td class="num">$ (1,887)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in usd per share)</a></td>
<td class="num">$ (5.80)<span></span>
</td>
<td class="num">$ (101.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in usd per share)</a></td>
<td class="num">$ (5.80)<span></span>
</td>
<td class="num">$ (101.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">525,447<span></span>
</td>
<td class="nump">18,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">525,447<span></span>
</td>
<td class="nump">18,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional&#160; Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,792<span></span>
</td>
<td class="num">$ (31,533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment', window );">Fractional share adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and prefunded warrants in financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and prefunded warrants in financing</a></td>
<td class="nump">4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise', window );">Prefunded warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,887)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 2,798<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">36,218<span></span>
</td>
<td class="num">(33,420)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">525,485<span></span>
</td>
<td class="nump">525,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 4,032<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">43,772<span></span>
</td>
<td class="num">(39,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment', window );">Fractional share adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment', window );">Fractional share adjustment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,046)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="nump">525,358<span></span>
</td>
<td class="nump">525,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 1,205<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 43,991<span></span>
</td>
<td class="num">$ (42,786)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Fractional Share Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrant Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Fractional Share Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,046)<span></span>
</td>
<td class="num">$ (1,887)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Change in operating lease right-of-use assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">331<span></span>
</td>
<td class="num">(744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">562<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(1,736)<span></span>
</td>
<td class="num">(2,203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PaymentForFractionalSharesReverseStockSplit', window );">Payment for fractional shares in connection with reverse stock split</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred stock issuance costs</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(1,014)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash (used in) provided by financing activities</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">4,486<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(1,747)<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">4,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities', window );">Recognition of right-of-use assets and lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid', window );">Deferred stock issuance costs in accounts payable and accrued expenses</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember', window );">Through Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing transactions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs And Financing Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PaymentForFractionalSharesReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Fractional Shares, Reverse Stock Split</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PaymentForFractionalSharesReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition Of Right Of Use Assets And Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recapitalization</span></div>On January 29, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split). On February 21, 2025, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen (the February 2025 Reverse Stock Split and together with the January 2024 Reverse Stock Split and the June 2024 Reverse Stock Split, the Reverse Stock Splits). Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text">LIQUIDITY<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $42,786 in accumulated deficit through March&#160;31, 2025. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of March&#160;31, 2025, the Company had cash of approximately $3,281. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, Common Stock, pre-funded warrants and common warrants in a public offering (the February 2024 Offering) for net proceeds of $4,389, after deducting offering expenses of $1,110. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0&#160;million shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement. As of March&#160;31, 2025, the Company has sold 325,618 shares of Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3,605 of gross proceeds and net proceeds of $3,467, after deducting commissions to the sales agent and other ATM Offering related expenses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell Common Stock, pre-funded warrants and common warrants, in a public offering (the June 2024 Offering), for net proceeds of $3,172, after deducting offering expenses of $1,057.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2024, the Company entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of certain of its issued and outstanding common warrants to purchase shares of its Common Stock, offering these Holders the opportunity to exercise all of their common warrants for cash at a reduced exercise price. In addition, these Holders received new unregistered common warrants. The net proceeds to the Company from the exercise of the common warrants were $609 after deducting placement agent fees and offering expenses of $154.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through the third quarter of 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#8217;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements. These unaudited interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the U.S. Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2024 balance sheet was derived from the Company&#8217;s audited consolidated financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim consolidated financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2025, and the consolidated results of operations and consolidated stockholders&#8217; deficit for the three months ended March&#160;31, 2025 and 2024 and consolidated cash flows for the three months ended March&#160;31, 2025 and 2024. Consolidated results of operations for the three months ended March&#160;31, 2025, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2024, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March&#160;14, 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the consolidated balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At March&#160;31, 2025, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the consolidated balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its consolidated statements of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the consolidated statement of operations for the three months ended March&#160;31, 2025. As of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the warrant liability was immaterial.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. For the three-month period ended March&#160;31, 2024, basic net loss per common share includes the weighted average of the February 2024 Pre-Funded Warrants (as defined below). Diluted net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period, plus the dilutive effect of common stock equivalents outstanding during each period, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As the Company had a net loss in each of the three months ended March&#160;31, 2025 and 2024, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended March&#160;31, 2025. ASUs not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on these unaudited interim consolidated financial statements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-07). This amended guidance applies to all public entities and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the provisions of ASU 2023-07 and has included the required disclosures in this Quarterly Report on Form 10-Q. See Note 8 for additional disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $1 in each of the three-month periods ended March&#160;31, 2025 and 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the February 2024 Offering, (i) 1,495 shares (the February 2024 Shares) of Common Stock, (ii) 21,131 pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock and (iv) 22,631 Series B-2 common warrants (the Series B-2 Common Warrants and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q (the Quarterly Report) as the &#8220;February 2024 Warrants.&#8221; The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $243.10 (less $0.0221 for each February 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain ownership limitations, the February 2024 Warrants were exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for one share of Common Stock at a price per share of $0.0221 and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 for a five-year period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 for an 18-month period after February 6, 2024, the date of issuance. The February 2024 Warrants were classified as equity and the allocated fair value of $4,279 is included in additional paid-in capital. As of March&#160;31, 2025, all of the February 2024 Pre-Funded Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Company&#8217;s previously outstanding Series A-1 Warrants was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants. As of March&#160;31, 2025, all of the Series A-1 Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company has sold 325,618 shares of Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3,605 of gross proceeds and net proceeds of $3,467, after deducting commissions to the sales agent and other ATM Offering related expenses. On May 5, 2025, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1,671, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3,605 that were sold under the ATM Offering through March&#160;31, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company issued and sold, in the June 2024 Offering, (i) 3,529 shares (the June 2024 Shares) of Common Stock, (ii) 125,047 pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of 125,047 shares of Common Stock, (iii) 128,577 Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of 128,577 shares of Common Stock, and (iv) 128,577 Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants), exercisable for an aggregate of 128,577 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Quarterly Report as the &#8220;June 2024 Warrants.&#8221; The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $31.11 (less $0.0017 for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants were exercisable for one share of Common Stock at a price per share of $0.0017, were exercisable immediately and have been exercised in full as of March&#160;31, 2025. Each Series C-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 for a five-year period beginning after September 6, 2024. Each Series C-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 for an 18-month period beginning after September 6, 2024. The June 2024 Warrants were classified as equity and the allocated fair value of $2,908 is included in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an engagement agreement with Wainwright, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,001</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Common Stock (the June 2024 PA Warrants). The June 2024 PA Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$38.89</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, will expire on June 26, 2029 and are exercisable beginning after September 6, 2024. The June 2024 PA Warrants were classified as equity and the fair value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$229 is included in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2024 Repricing Letter Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2024, the Company entered into the Repricing Letter Agreements with certain Holders of its issued and outstanding Series B Common Warrants to purchase an aggregate of 44,842 shares of its Common Stock, offering these Holders the opportunity to exercise all of their Series B Common Warrants for cash at a reduced exercise price equal to $17.00 per share. In addition, these Holders received new unregistered Series D-1 common warrants (the Series D-1 Common Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock and new unregistered Series D-2 common warrants (the Series D-2 Common Warrants and, together with the Series D-1 Common Warrants, the Series D Common Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $17.00 per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. This transaction is referred to as the &#8220;Warrant Repricing Transaction.&#8221;</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rsuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $25,000 and non-accountable expenses of $10,000. The Company has also issued to Wainwright or its designees the October 2024 PA Warrants to purchase up to an aggregate of 3,140 shares of Common Stock (the October 2024 PA Warrant). The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $21.25 per share.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to the Company from the exercise of the Series B Common Warrants were $202 after deducting placement agent fees and offering expenses of $560. The issuance under the Repricing Letter Agreements represented $1,526 in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company had the following warrants outstanding to purchase Common Stock: </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$243.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$464,100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,577</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$31.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,839</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$17.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$43,548.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$94,970.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$243.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,002</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$38.8875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,577</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$31.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$17.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$21.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;R 2018 Plan generally have a contractual life of up to 10 years. As of March&#160;31, 2025, awards granted under the A&amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of 21,270 shares of the Company's Common Stock were outstanding and 21,275 shares of the Company&#8217;s Common Stock were reserved for issuance under the A&amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;R 2018 Plan may be increased pursuant to the A&amp;R 2018 Plan&#8217;s &#8220;evergreen&#8221; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#8217;s Common Stock outstanding on the final day of the immediately preceding calendar year.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three months ended March&#160;31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the three months ended March&#160;31, 2025:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average remaining contractual term&#160;(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,376.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,128</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.81</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,196&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.81</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.81</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, all of the outstanding and exercisable stock options were out of the money and therefore had no intrinsic value. As of March&#160;31, 2025, the unrecognized compensation cost related to unvested stock options expected to vest was $214. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 1.57 years. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 21,128 stock options to its employees and non-employee directors during the three months ended March&#160;31, 2025. The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No equity-based awards were granted during the three-month period ended March&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text">SEGMENT REPORTING<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one reportable segment: biotechnology research. The biotechnology research segment consists of the research and development of products for the treatment of inflammatory disease. The Company&#8217;s CODM is W. Marc Hertz, Ph.D., Chief Executive Officer and Director.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the biotechnology research segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the biotechnology research segment based on research and development expenses and general and administrative expenses as part of the overall review of the Company&#8217;s consolidated net loss and consolidated cash flows as compared to prior quarters and the Company&#8217;s operating budget.</span></div>The Company has incurred significant losses since its inception and anticipates incurring continued losses in the future. As such, the CODM uses cash forecast models in deciding how to allocate resources based on the Company&#8217;s available cash resources, as well as its forecasted expenditures.  This information, in conjunction with the assessment of the probability of the success of the Company&#8217;s research and development activities, is used to plan the timing and size of future capital raises.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation and Release Agreement</span></div>In connection with the resignation of David Baker, the Company&#8217;s Former Chief Executive Officer, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker received continuation of his then current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, the Company entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which the Company agreed to sell, in a public offering (the April 2025 Offering), (i) 202,000 shares (the April 2025 Shares) of Common Stock, (ii) 1,186,888 pre-funded warrants (the April 2025 Pre-Funded Warrants) exercisable for an aggregate of 1,186,888 shares of Common Stock, (iii) 1,388,888 Series E-1 common stock warrants (the Series E-1 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, (iv) 1,388,888 Series E-2 common stock warrants (the Series E-2 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, and (v) 1,388,888 Series E-3 common stock warrants (the Series E-3 Common Warrants, and collectively with the Series E-1 Warrants and the Series E-2 Warrants, the Series E Common Warrants) to purchase up to 1,388,888 shares of Common Stock, for gross proceeds of $5,000, before deducting offering expenses. The April 2025 Offering closed on April 2, 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities were offered in combinations of (a) one April 2025 Share or one April 2025 Pre-Funded Warrant, together with (b) one Series E-1 Common Warrant, one Series E-2 Common Warrant and one Series E-3 Common Warrant, for a combined purchase price of $3.60 (less $0.0001 for each April 2025 Pre-Funded Warrant). The April 2025 Pre-Funded Warrants have an exercise price of $0.0001 per share, become exercisable immediately upon issuance and expire when exercised in full. Each Series E Common Warrant has an exercise price of $3.20 per share and became exercisable immediately upon issuance. The Series E-1 Common Warrants expire April 2, 2030. The Series E-2 Common Warrants expire on October 2, 2026. The Series E-3 Common Warrants expire on January 2, 2026. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the April 2025 Offering pursuant to an engagement agreement between the Company and Wainwright dated as of March 7, 2025. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the offering, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the offering,  reimbursement for accountable expenses of $25,000,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reimbursement of up to $100,000 for legal fees and expenses and other out-of-pocket expenses and up to $15,950 for the clearing expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company also issued to Wainwright, or its designees, warrants to purchase up to an aggregate of 97,222 shares of Common Stock (the April 2025 PA Warrants). The April 2025 PA Warrants became exercisable immediately upon issuance, expire on April 1, 2030, and have an exercise price of $4.50 per share.</span></div>As discussed in Note 6, &#8220;Stockholders&#8217; Equity&#8221; to these unaudited interim consolidated financial statements, on May 5, 2025, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1,671, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3,605 that were sold under the ATM Offering through March 31, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3. Since March 31, 2025, the Company has sold shares of Common Stock with an aggregate gross sales price of $399. As of the date of the filing of this Quarterly Report considering the net proceeds from the April 2025 Offering and the net proceeds from the Sales Agreement for sales occurring since March 31, 2025, the Company&#8217;s stockholders&#8217; equity is greater than $2.5&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,046)<span></span>
</td>
<td class="num">$ (1,887)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the U.S. Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2024 balance sheet was derived from the Company&#8217;s audited consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the consolidated balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At March&#160;31, 2025, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the consolidated balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its consolidated statements of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the consolidated statement of operations for the three months ended March&#160;31, 2025. As of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the warrant liability was immaterial.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Stock Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. For the three-month period ended March&#160;31, 2024, basic net loss per common share includes the weighted average of the February 2024 Pre-Funded Warrants (as defined below). Diluted net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period, plus the dilutive effect of common stock equivalents outstanding during each period, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span>. As the Company had a net loss in each of the three months ended March&#160;31, 2025 and 2024, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended March&#160;31, 2025. ASUs not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on these unaudited interim consolidated financial statements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-07). This amended guidance applies to all public entities and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the provisions of ASU 2023-07 and has included the required disclosures in this Quarterly Report on Form 10-Q. See Note 8 for additional disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding to Purchase Common Stock</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the Company had the following warrants outstanding to purchase Common Stock: </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$243.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$464,100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,577</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$31.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,839</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$17.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$43,548.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$94,970.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$243.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,002</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$38.8875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,577</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$31.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$17.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$21.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three months ended March&#160;31, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.262%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Activity of Stock Options Granted</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the three months ended March&#160;31, 2025:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average remaining contractual term&#160;(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,376.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,128</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.81</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,196&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.81</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.81</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th"><div>Feb. 21, 2025</div></th>
<th class="th"><div>Jun. 17, 2024</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.0588<span></span>
</td>
<td class="nump">0.0769<span></span>
</td>
<td class="nump">0.1429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2024</div></th>
<th class="th"><div>Oct. 21, 2024</div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (42,786)<span></span>
</td>
<td class="num">$ (39,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
<td class="nump">$ 5,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember', window );">Series B Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense', window );">Placement agent fees and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAgentCompensationPercentage', window );">Sale of stock, agent compensation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Agent Fees and Offering Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAgentCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Compensation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAgentCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value Of Shares Offered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockMaximumValueOfSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">380,676<span></span>
</td>
<td class="nump">46,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">21,270<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">359,406<span></span>
</td>
<td class="nump">46,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 630<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent', window );">General and administrative</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,368<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued General And Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 05, 2025</div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Dec. 20, 2024</div></th>
<th class="th"><div>Oct. 21, 2024</div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>May 15, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settleable in cash, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds', window );">Cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds', window );">Management fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses', window );">Reimbursement of accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses', window );">Reimbursement of non-accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds', window );">Cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds', window );">Management fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses', window );">Reimbursement of accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAgentCompensationPercentage', window );">Sale of stock, agent compensation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="nump">$ 1,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Public Offering | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember', window );">Series B Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense', window );">Proceeds from warrant exercise, net of offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantOrRightOfferingCost', window );">Class of warrant or right, offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember', window );">Series B-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember', window );">Series B-1 Common Warrants | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember', window );">Series B-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember', window );">Series B-2 Common Warrants | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember', window );">Series A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember', window );">Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember', window );">Series C-1 Common Warrants | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember', window );">Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember', window );">Series C-2 Common Warrants | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedAndSeriesCWarrantsMember', window );">Pre-Funded And Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settleable in cash, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember', window );">June 2024 PA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settleable in cash, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember', window );">Series D Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember', window );">Series D-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember', window );">Series D-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_October2024PAWarrantsMember', window );">October 2024 PA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClassOfWarrantOrRightOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Offering Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClassOfWarrantOrRightOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Warrant Exercises, Net Of Offering Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAgentCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Compensation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAgentCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value Of Shares Offered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockMaximumValueOfSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Securities Issued Per Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Reimbursement Of Accountable Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockReimbursementOfAccountableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Reimbursement Of Non-Accountable Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedAndSeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedAndSeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_October2024PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_October2024PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member', window );">Warrants Expiring In August 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 243.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member', window );">Warrants Expiring In February 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 464,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMarch2026Member', window );">Warrants Expiring In March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">128,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 31.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2026Member', window );">Warrants Expiring In April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">44,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member', window );">Warrants Expiring In May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 43,548.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member', window );">Warrants Expiring In July 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member', window );">Warrants Expiring In April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 94,970.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member', window );">Warrants Expiring In February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 243.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member', window );">Warrants Expiring In June 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">9,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 38.8875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInSeptember2029Member', window );">Warrants Expiring In September 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">128,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 31.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029OneMember', window );">Warrants Expiring In October 2029, One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">44,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029TwoMember', window );">Warrants Expiring In October 2029, Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">3,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 21.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInSeptember2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInSeptember2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options exercisable, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">21,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity based award granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period</a></td>
<td class="text">1 year 6 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">21,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future awards (in shares)</a></td>
<td class="nump">21,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum', window );">Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan | Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">21,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance (in shares)</a></td>
<td class="nump">21,270<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Ending balance (in shares)</a></td>
<td class="nump">21,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">21,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning balance (in usd per share)</a></td>
<td class="nump">$ 4,376.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">11.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/cancelled (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending balance (in usd per share)</a></td>
<td class="nump">40.80<span></span>
</td>
<td class="nump">$ 4,376.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending balance (in usd per share)</a></td>
<td class="nump">28.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in usd per share)</a></td>
<td class="nump">$ 40.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-average remaining contractual term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (years)</a></td>
<td class="text">9 years 9 months 21 days<span></span>
</td>
<td class="text">9 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (years)</a></td>
<td class="text">9 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (years)</a></td>
<td class="text">9 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">110.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date (in usd per share)</a></td>
<td class="nump">$ 9.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Former Chief Executive Officer<br></strong></div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_COBRABenefitsPaymentPeriod', window );">COBRA benefits, payment period</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PercentageOfTargetBonus', window );">Percentage of target bonus</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_COBRABenefitsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>COBRA Benefits, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_COBRABenefitsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PercentageOfTargetBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Target Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PercentageOfTargetBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 05, 2025</div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Dec. 20, 2024</div></th>
<th class="th"><div>Oct. 21, 2024</div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>May 15, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds', window );">Cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds', window );">Management fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses', window );">Reimbursement of accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds', window );">Cash fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds', window );">Management fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses', window );">Reimbursement of accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockClearingExpenses', window );">Clearing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; equity (greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses', window );">Legal fees and expenses and other out of pocket expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series E Common Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | April 2025 PA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Public Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Public Offering | Series E-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Public Offering | Series E-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Public Offering | Series E-3 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="nump">$ 1,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockClearingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Clearing Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockClearingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Legal Fees And expenses And Other Out Of Pocket Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value Of Shares Offered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockMaximumValueOfSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Securities Issued Per Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Reimbursement Of Accountable Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockReimbursementOfAccountableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesECommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesECommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_April2025PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_April2025PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE3CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE3CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,]$KUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ,]$KUJD1#*,\P   "L"   1
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M9;S:<B'+.RGNWR?7'WY78=<9N[/_R[CDWXPO@DT-O^ZB^0102P,$%     @
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M3@H\W/[O#;#"Q([A[8N_ 5!+ P04    " #/1*]:&E>K"_$%  "/(   &
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MS &P?RZEWJ^8/U#\'X3!?U!+ P04    " #/1*]:^"%&#.H$   \$P  &
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U877.C-A3]*QIV9[L[8\=(?">.
M9Q)G.NU#V\QFMWV600Z: /)*(D[ZZRMA!S 2)&WSD%C O5?G7J%SKECN&7\0
M.2$2/)5%)2Z=7,K=^6(ATIR46)RQ':G4DRWC)9;JDM\OQ(X3G#5.9;% KALN
M2DPK9[5L[MWRU9+5LJ 5N>5 U&6)^?,U*=C^TH'.RXVO]#Z7^L9BM=SA>W)'
MY/?=+5=7BS9*1DM2"<HJP,GVTKF"YVN$M$-C\2<E>]$; YW*AK$'??%K=NFX
M&A$I2"IU"*Q^'LF:%(6.I'#\. 9UVCFU8W_\$OWG)GF5S 8+LF;%7S23^:43
M.R C6UP7\BO;_T*."04Z7LH*T?P'^Z.MZX"T%I*51V>%H*35X1<_'0O1<X#^
MB ,Z.J"W.GA'!Z])]("L2>L&2[Q:<K8'7%NK:'K0U*;Q5MG02B_CG>3J*55^
M<K5FE6 %S; D&;C&!:Y2 NYT. 'FX/O=#?C\\0OX"&@%ON6L%KC*Q'(AU<S:
M?Y$>9[D^S()&9OD-\S/@P1E +@HL[NMI]QN2MN[^J?M"Y=LFC=JD41//&TNZ
MYIQ4$F A5)[GMGP. 7Q[ +VWSL4.I^3249M'$/Y(G-6G#S!T+VS9O5.PDUR]
M-E=O*OIJC44.U*J!5 _(CYH^XD(E;UW%0ZBP":4)X''EH1@N%X_];$RCP$5Q
M:W2"TF]1^I,H;SG989H!\J3X21#1(&8R)UQM@OYBV5 ?0@<]0*&?#$";-D$<
MV3$'+>9@$O,W)G'Q!GB!,;67>.X GVD4A#"P PQ;@.$K155LS^5S4TR]\CO%
MOW(&*B)M.$,3YP"D:>';$48MPF@2X1\*'Y:TN@<%45P,N";=.=O.:W4Q7M'(
MP '=X8);;)!K1QNW:.,W+/@XK-@LC^NC 2[3*(B\Q XL:8$E;^*S@N(-+:BD
MQ$YJR7N2VCL%.TD8NIULN9-K<96FK%8L!G;X&6\*8M4DUWP'O'!(9Q:K.!FA
M!MB35?@:/EZ3CM"L^* -7SS$9UJ%"1S!URD@G!0=8^?U7IW9"Z=9,2/S_1UR
MF<7&']$'V,D8G-:Q4[;MP;6B] P$*(J&%&&Q@J$7CB#MI Q.:]ED:2M6S:?*
M:].I(6S3)AI['SHM@V\1L]?*:JH4BKUHB,^T@I$[MJ,Z,8/3:K9F94FE5K!#
M=Y"R2A>95*E""S[_SB0!R1<K[,G =JH"UB[U_P<Z3;[321A-,OR=9.E#SHJ,
M</%3H^7RV4KQ<%)P_RW'OU>TTZP[O873@JN77!WUA$Y^!MPSUW6A(GP.5 M;
MDPN  G>F[ND_('+,==]8RYQQ^K>B7BP VP)U]$CS Z:7 TCS^J@S!2DWA)\\
M\B] @(*9%\2-C1[[<? 2FPJA*;UI36LII!KH7?Y?YIFI([#8D>8,6SQ;%])L
M% R>G3(Y+7G72<!)W5Y=91G5YVM%!KHAGZMS7XIW5)&#%61B,KV7)(;$VLRB
M"-G!HJX)0*\V 759%\W951W=:4JMI(I,A9_[*(K# 4R;G9=$_DA14=<,H.EF
MX$"NHK>'/WV($8PNCCO9"MK2'" W&$(VK7S7&RML[WP\W1T8:M"\RL)"0E;H
MR#@A6AIABY6E$U[T/FWH[TIJF]W32BAIW2HW]RQ2J?/#IYK#A62[YFO'ADG)
MRF:8$ZP@:P/U?,N44!PO] >4]H/9ZA]02P,$%     @ ST2O6AOBI"^; @
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M2AHLKZY9X04(R@;@_%I*<]^Q-;:_4O-_4$L#!!0    ( ,]$KUI.F@!1R@,
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M3NJ@@FQP4ZD'?OB-' W%6B_GE32_Z-#&)I&#\D8J7A^3@:"FK+WBEV-']!)
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M^0=3C;IGF;:HAV)I2Z$<K,@&)+W9')A$6R>W#XKO3*GYQ!44KN:VA/\61.@
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M*3R(+ZA77_]"\>J1>Y=Y6UX-(%)WH49C1J;0FMP?%!;42RP-]YU\MP6-^J_
M3!^Q=P&?CQB9BMCD\""AH%Y#:??R8<<?HHXW5#DS*6WF1M$BV!9GS2DTSQ$.
M$@CI)=#E>WF_\QBA+3'$'LGUU8WEA79S_6A[GQ(80FMR>]!)J)=.NHA/V*I4
MB!QU9]IAI6ZD.DP\-PS5E[;#;."A8*36E7UTL"C/C<5$Q#Z1@8PLA*-S'8C,
MEKNCV-T-I^OJK/&)<D[SZG)%L-@_20/Q?$$I?[N1QY?U@?CT'U!+ P04
M" #/1*]:/N/OO\D%  "T&   &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;*U96V_;-A3^*X17#"TP5Q(MVTKF&$B<%=M#UZ!IMV=:HBVNDJB2E-W\^QU2
MBF1+%),"?HDN/CSZSO4[9%9'+K[)E%*%?N19(6\FJ5+EM>?).*4YD>]Y20OX
M9<=%3A0\BKTG2T%)8A;EF8=]?^'EA!63]<J\>Q#K%:]4Q@KZ()"L\IR(ISN:
M\>/-))@\O_C,]JG2+[SUJB1[^DC5U_)!P)/7:DE83@O)>($$W=U,;H/K#8[T
M B/Q#Z-'>7*/M"E;SK_IA[^2FXFO$=&,QDJK(' YT W-,JT)<'QOE$[:;^J%
MI_?/VC\8X\&8+9%TP[-_6:+2FTDT00G=D2I3G_GQ3]H8--?Z8IY)\Q<=:]DE
MGJ"XDHKGS6) D+.BOI(?C2-.%H >^P+<+,#]!>'(@EFS8&8,K9$9L^Z)(NN5
MX$<DM#1HTS?&-V8U6,,*'<9')>!7!NO4>L,+R3.6$$43]*C@ C%2$O$=VA"9
MH@\09XFFZ.OC/7K[YAUZ@UB!OJ2\DJ1(Y,I3@$%K\N+F>W?U]_#(]V;H(R]4
M*M$?14*3\_4>8&\-P,\&W&&GPH]$O$>SX#>$?3RWX-F\?GGH@#-K_3DS^F8C
M^CZ55!#%BGV=H$PQ*J]M;JK5A'8UNGBO94EB>C.!ZI14'.AD_>LOP<+_W6;C
MA92=61RV%H<N[>N_H==D7%ISH5ZY,"MU0SFLIS,_7*R\PREZBU001<M6Z@S6
MO(4U=P;B-OD/JJ=.9L6AX\2\B%E&4='@U6]CG>*5A-2'K.:O#=W\DJ&[D+(S
M'RU:'RV<H;NGH#1FQ#14^@.H05*;P;66^4F @EX(71)GT)8MM*43VJ/B\;>I
M;M )BGFNH;T(<SD @;'? SJ4F8TD6M0BC9Q(-RDI]E0GT(XP@0XDJZANGT<B
M!"D@UQC9LHRI)QOD: "G#W@H,<5VP%<MX*M7 NXR/J/@:20TYTWY;@HE@8B4
M5%FK^FH8['X^6$1".^K [YC*=U:T#7<-$@$7M7X>J]I&^X7*]E+:SGUQPMJ!
M,X8/@I:$)<_54'N JY0*&!J$@*[GB%^C^RPZ5_VF;!&:+\9BB#O<V(G[-HYY
MI5MR29[(-K.6<:/BK$9G_02S"$V7X1B^CKT#)U5J?**BG5^M^&86S^ ^OJ'0
M-%B.5&[0<6W@)MM/O8H]27HKU-""8N!*F]"8)SOZ#9S,M=Z\1*U6O'.;UV:#
MW+2(0:N?C6#NZ#!8.#O,!U80&!)>G@ ")Z_^="^YD+9SJSNF#=Q4^T">])B$
M8$^(=H*8[17)D$P)?$U'#R:GHMEU'9E*898Z4 '))S5'(UE"_EF=-.3:Z2#W
MAC+^2!0[/@[<A/QL#W P[.<H=,.D@<JDK"# %"R2(ZW10K=!GY+M0J,ET_%R
M\ (QZY)YV]3,.U0*?F"P24+;)[2S9*85_Y!X+04_% K#:&&'CSM^QD[.,QN!
MMPF-A>Y,[\"$^LYDD+9,4Y2YH=\K!F.2'LUM-C2?Z36!<-FSPB*&<332 W#'
MK-C-K)LQJ(@HM*5[5A0Z#)!<T-,83ZP66+C3QU'?  L-1WXT8D!'L=A-L4X#
MJ!X3G- MY(NC?@99I$+_:F3DQQW[8O?F^;$JR\P<0$#_29B,89]6"3--%[R8
M&H-LE6#MT?BB.^Q+:3OW3,?[V,W[GV'[NB^8Z<'@#<N@7L_ KQD*\)#O^QW.
M(A+,1X87W(T$V#T2W+NZL6X3I#<=&IO(*T8R/!P(\+!A#(6N1O9^N!L9L'L+
M_245O-JGJ!T=K/ N.BY<2MNYQ=VX@)>7&9*P<^SX::LOI.W<ZFZHP"\,%8+'
ME"82)B2>=ZD+M1CS/(>J;'*Z.&E0"O;_LIZG[%D;#0Z^!H4X%)G/_?Z(Y)V<
M_^94[,VQN$2FF.J3U/9M??1^%UQOS EU[_UM<'UK#J*]3DU]GO^1"* ^"1UF
M!RK]]TLH(U$?D=</BI?FE'G+E>*YN4TI2:C0 O#[CG/U_* _T/ZC8OT_4$L#
M!!0    ( ,]$KUH&.VHOGP0  /@)   8    >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&ULK5;9;ALW%/V5BPD0V*@BR?(2-[$%R%NJQALLIP5:](&:X6B(<,@I
MR9&B?'W/)279112C:/LBD1S>Y9R[\61AW6=?21GH2ZV-/\VJ$)IWO9[/*UD+
MW[6--/A26E>+@*V;]7SCI"BB4*U[@W[_J%<+9;+A23R[=\,3VP:MC+QWY-NZ
M%FYY)K5=G&9[V?K@0<VJP >]X4DC9G(BPZ?FWF'7VV@I5"V-5]:0D^5I-MI[
M=W; ]^.%7Y1<^&=K8B13:S_S9ER<9GUV2&J9!]8@\#>7YU)K5@0W_ESIS#8F
M6?#Y>JW]*F('EJGP\MSJ7U41JM/L.*-"EJ+5X<$N?I(K/(>L+[?:QU]:K.[V
M,\I;'VR]$H8'M3+I7WQ9\?!/! 8K@4'T.QF*7EZ(((8GSB[(\6UHXT6$&J7A
MG#(<E$EP^*H@%X9W#Q]&M^/?1H_CNUL:W5[0Q>7D_&%\'_=W5W3V:3*^O9Q,
M3GH!UEBFEZ\TGR7-@^]HWJ<;:T+EZ=(4LOB[? ]>;EP=K%T]&[RH\$:X+NWO
M=6C0'QR^H&]_ WT_ZMO_'G0W$T9]%9P='3JWQENM"I&2Q11T[Z27)J0#6]*5
M,L+D2FB:X% B,X.GWT=3'QQRZX]M#"4'#K8[P/7VSC<BEZ=9P[;<7&;#UZ_V
MCOKO7X!WL(%W\)+V_Q39_T<S?7@8TYFR'1J;O$L[O+6.0B7!=MT(L]SMQ)(J
M2!FZ%O2SU5H@%*,.+83'86Y=8QW(CC<NI!8+X22O;\02>=#_$3<KE5>D?-2+
M\$F.%41EPX'K1B?P55 .'"H7^HT/:#<T5;:I! H[EVW@<\J34U1:%!Y,(NR%
M\KF=2Z?,K(-BGZ.)-7'-"8+[M72<$>HK#F'4V+G@+L.^.-$HR5Z)0$&X&1HL
M0JQLZUFK!&PXY;V%/.-;J%!1L?1.SEJ=$-=U:R0ZGV^0F[BMT7393K P56J!
M-AJL6W:H5%-G@2%Z)=I@5Z*P8UTAG>_2XQ/IKU\=#_;>OO<TLP#-Q%F:2LA"
M:X&.XY;1DG3,\Q/FYY@L!4R P$=>/H,#\^Q<W3B;2" --CQ'I $QL6)\6Y:1
M4"J=K;%%]-8:MOO)WA!4%FT>*(<1KE+9X<B^Z1\-T!$XOJA1QWA,I:8*O+#1
ML&PD[>%L+IP2)M"M""W?^JBT!L!'VE&W'Q]W*<=82/Y#U52R=ROD"$2Y2MJ(
MF<N>57M\1BINJ-<MRZR9B*@XA0MDF0A(46I:75N#P9=D/ SMC.^O=K=C_@8N
MH1!"B0YE26C/&9#KMH"IR,)Q?S\%GP4;IV1@0QJ&^!_N'O;[/\0$MZTI?'<C
MU4E18H9KBU'9:DEI9C)P#E"*8E24B"9DN=2);3&S1OFPX7H "L +DN);IHM_
MR?2VA.ZD>JF99B[WP(S)=87'EP!G[V3IT:A!_G7;H.XNW3+PHR98C]U%"A;M
M3*XO=[DQZ7B)7:LQTU7#5.1P/L7J9H)0/<@<)1"XXN-<V-:G>\^F,?K#++XY
M/,AO34B#>7.Z>=:,TC1_NI[>1!AY,V6X DJ(]KMO#S-RZ9V1-L$V<;9/;<!+
M(2ZK6+M\ =]+:\-ZPP8VC[WA7U!+ P04    " #/1*]:0MJH1ST(  !B%0
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M>S(]V6$K-SY[7>7!N9/I]4[RT5FK_,8UQQ;_Q/;99'H,[U#^O%.9*F?0,P+
M(7"ZX+B'OK:"WCG\<D/YXVS)NYP$_Y'1^\]?(1+1A4]FVU"<!^MMI0W9"+5+
M:=#!Z/: ;_U($L\;9S04SL42L8:'D:)%DR/612$,=:""'>DH>QSY1.9_HD&$
MU21?PT@L-W"']^BP%#=&&\1R+K5#CF^RO)?&UNO0*SEA :K9LD75 >]. M9L
M@7PT0'X>3,%QV$->KSV&1I9]6=H"*OJX,S5/(&O--45RZZ532I2A,RCJ#/=4
M8+$<X ?R,^F78@Z*X7] W! ^>=*D[Q8+1SF%B-5M)#0\KTW.18&"BWD>92.0
M:<-Z*6ODTAVP3*C;"L2%DB7N>Z>DH_UHP?V,?Q8*X0?2;I RI,V[@<@M:X^U
MM8R5[M371E-RY=IGA?4-%F$[1#,@ RDIC6D@^SL*Z&\!?;^T39&3JXB,$B1A
MS9^-"6R/$9^1,FCUW>4=:ZS@!^ & FE.!;I^/Q9XY 'X#%+AMC!YO^ F0:4K
M55E7"RA+_%+LCW;_!8T*K&N51P>@^R&_]@]3K"^[]@7%NMPEPW\P#UJT2=VE
M,:$"WE^=BV-M!T"];,A.T+BQ0BDCJ>W*4&TW,V"/!N(,TN/B4ULX<>4$*,;:
MQ+ GC X.!Z\R7F:ATKIVK@H-SDM*#\6UY\HY];4NN6F0I:'?!\MQ\Q'+R'R:
M7W1]%WS+.1MSVO?0FQ"SE%]0?>TNI)WTF%FJH!S7J)S/49RQ,BB*\((L6Y_A
M>14SJ=!RIHNNV=.2KH;H82HSU #M_MBZL!,%+V''HYG[F$H$)\9#6-YP[^B>
M8S[$_&78<^Y]LPG2P)K* &:ES)F*<)V0[R/7N9%%TP;#+VF1K6(6K*1SQ"K
M<!INSK0%I0["0,8[U:[&TYTDM#^["ID2MB/M+34/Y0B1:GD;'3>@Q'4-KK76
MTAXQEE$K4A.Y[MAG\-_,.K!M1F'R;ZKP#IP+A:$/37].$R35;4)KT!PB1X\R
MBC:'!L*ZY"%U6W.>+0&Z_2R#IT([#[ Q;VI*C\@K!QOE?T<;SA@B%5(>BL[
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M'M)+K<GTVB<VVSN6_(J*!)(_UC]H$4WA=+S2>)_J,E EHN]\C7;+%8TM7+I
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M)6UI8"YSS/_U#XE-1RDY4)HF9P'ON+X"%E]"$B7],WBL2Y%Y//8*WH(_\[5
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M-'1:MT?,KE:9M55@5:4&YD,@Z#')-R%C4(MW94$K<U #IV;=G1L0Z7U5M]E
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M9X>H?62M>.J24GM3Y-=4PKK1ZS8HZ[@_(?F>L'4#OS*S1,XW9O*"*@J9*8A
M=52<>/[TANTACFVAX8PV65OC34FGV,0 (EP807*/4FS1EKKGD'^C=%2CK,XQ
M"[$^\BNSE]#+R9DV*CA .:!%F@;%O-H ")VK3 0,P@\W+'\6TYD1 4$X[YB]
MFR,CJ C-.*#L9KF':D&,C^E=0W/O:;H-/)STF0!\EIX!TV7(N5Q7OF.^(AQY
MY9,Q3D[H?< C?TQD&%84]U./VO'1'@T/Z%X[[(,LB?"?%SH1*% $->? -N^V
MR-1%5R^HU.7N>B70A*10AJ8"_QY$7LLV4;(&;?@YH#TSX>#/2O4/.&R$O(U/
M<*W&4Z,.^EAPG&%EK0)3KGZ%BD= E,X8 _'DIV;@0&-,V-NAQ5S!G<IV()R9
M/:#3<+Q;%M-&A*VD'UZ#])"WC;=\'+Q1K&.C0R,M^'&=GQL.\,;OA"KO^GO#
M_E1;SD6/DHV'$!&[\LLWW;"MQNR&6Y\ZJ=5W<WI #3#Z^"8N'&J$#0+<3<0D
MEV&-CW?8,4FFO!T+E><,M< _A?QMU'*>=,(7DW57"U[REP5V'B/3UC[]C43\
M[F(\ID\K#&QE_.'O$C+;15LWN!K!8=*D"A[#R 7#GNPC#W#_:J!B-0(X:0KZ
MR??]G^FZVRT=O04D>K'#%N_C48*:'.T,#_;[1PD=]?>']+XQ%JTU3@ZQ'<?]
M_7VZ:M3)5J7?_@)/IA)ID U2#D&>;SGS2)-'V-2, = DZA]&4.,P;N7Y<&VE
MB(_V&54.^P=QH/B,2FJF2TZVM(D8%]AWRGQF3D(>-67Y>/R0'24W4Z:=5EI*
M9(-<>AH>(B5216*"XPQ"A\"HB1MO&E#KN7&-N=1EIR:?5&VW6]7E0W#'IEI/
M'+- 9;]*XA%7!XKK>0%JDWBR 0\>$P2,?I2CHM#&J7\"AS7"Q?V]@W8V[6+%
M;#/U-E6'4&Z2SQ=@9^[.:M-.JM\LQJ#"12XP =REN,=P0_8R=[GRF$^A,YE[
M5]6V@0& =L&HNNXI 9 [S:>9O;I6M.TGX!98K&$9K%N5U[/"4X=BX"B"0UYL
MY(^2_;-&8H0;3QQ'_:,1O4:!M=%DR,"8X@-">_THHK>*[T[<)-FHB)=>TZVR
M7W:G+ H9*_F&%+9'_=$>MM]MF-[8NS+9>^<5RFPTI$_;ARE?,FT*/([@KH]@
MFT-;XCCJ;[MT#SI?20K,S?Y;$#?\NG3A@\EJ=?6Y:1R^LJR/AV]5D(:QV5(N
MIR"-^@=[O7#-:5^<KOPWEXEV3A?^<2X%)D,^@/VIUJY]80&KCW#G_P)02P,$
M%     @ ST2O6KV9//W9 P  G @  !D   !X;"]W;W)K<VAE971S+W-H965T
M,30N>&ULE59M<]LV#/XK./6NM]UEEE^2-DMMWR6.U_9#&I^3K1]V^T!3L,0+
M1:HD9<?]]0,H67$V)]V^)!0!/'CP0L#CK74/OD ,\%AJXR=)$4)UD:9>%E@*
MW[,5&I*LK2M%H$^7I[YR*+)H5.ITV.^_2TNA3#(=Q[N%FXYM';0RN'#@Z[(4
M;G>%VFXGR2#97RQ57@2^2*?C2N1XA^'W:N'H*^U0,E6B\<H:<+B>))>#BZM3
MUH\*?RC<^H,S<"0K:Q_XXW,V2?I,"#7*P B"_FUPAEHS$-'XUF(FG4LV/#SO
MT7^+L5,L*^%Q9O57E85BDIPGD.%:U#HL[?83MO&<,9ZTVL>_L&UTA[\F(&L?
M;-D:$X-2F>:_>&SS<&!PWG_!8-@:#"/OQE%D>2V"F(Z=W8)C;4+C0PPU6A,Y
M9;@H=\&15)%=F-[-/][,O]S#<KZX7=Y__O)QG :"96$J6XBK!F+X L0(;JP)
MA8>YR3![;I\2G8[3<,_I:O@JX(UP/1@-3F#8'YZ]@C?J8AQ%O-%+,6).;11@
MB95U09D<_KQ<^>"H(_XZ%FZ#=GH<C5_)A:^$Q$E"S\"CVV R??MF\*[_X16N
MIQW7T]?0_UL]_B<$W%;H1 S<-ZGP(!QR\Y)I!L*#M&5E3938-0@#=$17.>41
MQ(H>,VP+)0NRKP1!D:WRTB$=E&DF S\Q1;@;H;18:02Z!MP(73>RU0Y"@2 +
MA6NP':$,I8H/O!0/Z."GV>WUS<\G0+9[R2\D8<W<V;HZ(7]1DO%50;D-%H36
M5C(I*H>MG43/6L)[])[5R%GD:"3VX)Y(S"A:87904.04-=EQ8T36;8(N8*5L
M0%D8JVV^8V043A:-_7'9WI:223/+-ZGDF#L%83(BOZ%)6$5%DE?.9K4D74X7
M*P<:K6$OI>1J0=,R6+?CE"/-GV<AO'US/AR\_^"!\\;Y_]H#>CX2/J$+WT]@
M4?2N>R<PBUF?/Z*L>0C"[7JM)*6;"5TK1Q/2N@972&EK$TM36:VDPBZ,'T3-
M'<5J7I3(+14*Z[G'J$_4BKJ,2A+%S?1G4*]RHXB(8.M_^VT#Y<":6A*5@U)V
M&?L!+Y[9&<05\D(9\)%6'*.S($=#O:GC660T<15/BIBU)STB(ES8)\9NV$*3
M@PVOH?;VGQ7BKJ#(,FK4# RM6VU]X_*91 I?P)IVI=^_2TILQFU.KY$B_E:3
M9W2-Y3$_3V]K56<YAMZQJ90>;(P271[W(KNC&C3+H[OM5N]ELW&>U)N]3>V6
M*^-!XYI,^[WW9PFX9A<V'\%6<?^L;*!M%H\%_7Q QPHD7UNJ7_O!#KH?)-._
M 5!+ P04    " #/1*]:W6M/@/$"  "%!@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6RE55UOVC 4_2M7F;2GBH0 6]4!$E"V\0"M"ML>ICV8Y":Q
M&MNI[4#Y][MV(&52BU3M!?QQS[GG7MLGP[W2CZ9 M/ L2FE&06%M=1.&)BE0
M,--1%4K:R906S-)4YZ&I-++4@T09QE'T*12,RV \]&OW>CQ4M2VYQ'L-IA:"
MZ<,42[4?!=W@M/# \\*ZA7 \K%B.:[0_JGM-L[!E2;E :;B2H#$;!9/NS;3O
MXGW 3XY[<S8&5\E6J4<W6:2C('*"L,3$.@9&?SN<85DZ(I+Q=.0,VI0.>#X^
ML7_UM5,M6V9PILI?/+7%*+@.(,6,U:5]4/OO>*QGX/@251K_"_LF=A 'D-3&
M*G$$DP+!9?//GH]]. -<1V\ XB,@]KJ;1%[E+;-L/-1J#]I%$YL;^%(]FL1Q
MZ0YE;37M<L+9\>QNN5QLEO/59@V3U2W,[E:;Q>K;?#5;S-?#T%(*%Q@F1[II
M0Q>_0=>#I9*V,#"7*:;_XD.2UNJ+3_JF\47")=,=Z'6O(([BP06^7EMOS_/U
MWJI7"<$MW2IK@,D49B27RQQEPM' +3=)J4RM$7Y/ML9JNC1_7NM"DZ3_>A+W
MD&Y,Q1(<!?12#.H=!N./'[J?HB\72NBW)?0OL;__R/Z##N:B*M7!]0LFN49L
M.K<ID#HG*B8/4# #M(@:4^#2*L 72$+==3TT=*MM 9P&*LMX@MJ +9B%2JL=
M3Q'(7<#@#C63"?J#2?S!U,R_797!%B5FCH!+@B)0,"6@#<I,[Z*-.\N^/?C(
MDU G@6P)$E8;!$IXW&\0V(C(E4K);)A1L@,+<HTTY8[ZZAUY,U62U]&M @9)
MP>AV.;#OA2JO/,L.C;MV#DC-L&2>@$\UMP=@>Z930T_\0"63:25D8)I93#NP
MQHKI)J'KT /MD!^]G,MK=RL\LP:!.O<&:$A,+6WC$NUJZ[&3QEI>PAN#IJ>8
M<VF@Q(R@4>?S( #=F%XSL:KR1K-5EFS+#POZ3J!V ;2?*65/$Y>@_?*,_P)0
M2P,$%     @ ST2O6IZ!H@QN!0  7P\  !D   !X;"]W;W)K<VAE971S+W-H
M965T,38N>&ULK5=;;]LV%/XKA)8-":#8LAPG3I88<#H7W8"N6=W+P[ '6CJV
MB%*B2E)Q\N]W#BG)\BU(@;[(EGC.Q^_<R=NUTM],!F#94RX+<Q=DUI8W_;Y)
M,LBYZ:D2"EQ9*IUSBZ]ZU3>E!IXZI5SVXRBZ[.=<%,'DUGU[T)-;55DI"GC0
MS%1YSO7S/4BUO@L&0?/AHUAEEC[T)[<E7\$<[.?R0>-;OT5)10Z%$:I@&I9W
MP71P<W]!\D[@BX"UZ?QG9,E"J6_T\F=Z%T1$""0DEA X_CS"&Y"2@)#&]QHS
M:+<DQ>[_!OVMLQUM67 #;Y3\*E*;W07C@*6PY)6T']7Z'=3VC @O4=*X)UM[
MV?@Z8$EEK,IK9620B\+_\J?:#QV%<71$(:X58L?;;^18_L$MG]QJM6::I!&-
M_CA3G3:2$P4%96XUK@K4LY/YY_OY[)_/L[\_L=D7?,YO^Q9A:;&?U!#W'B(^
M C%D[U5A,\-F10KIMGX?Z;2<XH;3??PBX'NN>VPX"%D<Q:,7\(:MC4.'-SQF
M8[4P\+V"PK+9(SX-^W>Z,%9C1OQWR%R/=G$8C:KDQI0\@;L R\" ?H1@\MLO
M@\OH]Q>X7K1<+UY"?UT\?A""?2C8M-1"LMJG(;,9L#<J+WGQS- CH"%EHK"*
M<68@J;2P @PK*YUDF/*,KS1 3@X\)4T/1DCLH1&9-B)G(>F9BJ,T JXSD61;
M^SFPE-:P.&6(^^*N9;60(F%JN00MBM7>/A_J!40_%6?T+8RBB)F,8PSVI.?N
M\QG"T:XY5O_<JN0;Z:+R(!R,+\/Q>,PP@.?+BM*6K;G6G')CST*4>>MEOM8R
M9PR>0"?"\(4$AIV1<;1AA7:MN 7:=;-%S? 0$T=E.!X[N3F:AW*S\P%+O* A
MP1U>':D:;L,)'=H&K"KI=8-^G,7C01+QJTC$/X<$+U)V>IC'\%4\AKL\/";V
M1M?\'T$^8UNU/@T[+FS$G?2.91NH[L+/,9@R9J65P0K3*L%B<#(G(TKID"T
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M*!*/HZR1%D7RP-G,$&X[&R]:6_.N#^AA+AA8U2(.<@DD09R,1P/1[SUF$?3
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MNX[O-F67\%T4!1ULTQ#?F:#]/5RI_3P>,Z@AF[("ZYW7%7, I!&0LC3<UVF
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MO=C@U0?:.>!^K93=*"[!<)GF;U!+ P04    " #/1*]:\NUUQY "  ",!0
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M>)TEZX5D117'[IE4X:YZW*C\#5P7J/<KQN3S0O] F^@G_P-02P,$%     @
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MD"BBZ[)DZGD$A=P,O)ZW#<SY*C<V0..H8BNX!7-?)0IWM&/)> E"<RF(@N7
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M"*0)P/V%$/IE8CI=^V-+_P)02P,$%     @ ST2O6ND#ZZ*^%@  E(8! !D
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M'_YGNX-$\_*SY1\U-@)[QV7VELOL/9?9FRZS=UUNOLJY7V\$]H;*[!V5OT5
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M1F>CFC!1Q^A*CD]#S)..>WL]_G8R&KK3"1E?7\ZF5^[P]N+ZBIP0%TO&7T9
MV)RXDGD/)\HOGXQ9C$4DJ#Z&Z:,: SF<@*1A)(XP\<Z=D,.#(W) PH3<!FPI
M:.*+OBF1K]K5]')NHXR;_0JW)KEDB0P$F28^^-OY)NHLQ-H;L2-[+^ EY:>D
MV3@FMF6W*_B,_S^]M8=.L_"^J?&:KWD?4 ZYJ3/ZA"^')$/.:;( -3[>F.L3
M](^,:1I*&H5_P3\FPY@M,?K7=X0D%Q)B\;O*WVS_5O7^ZH8X%RGU8&#@%2"
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M*5F8G*Z!>L#U /7_DC&YO] 3Y#N\H_\ 4$L#!!0    ( ,]$KUI/OY0X$@,
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M@-ZI _J; ?U3!PPV P:G#AAN!@Q/_:%'FP&C4V>XW RXW!\P>&' U6; U?Z
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M*/__8;$H/G]23?!ID?VVNGDW_P=02P,$%     @ ST2O6@$ZWGLV P  U!,
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MKX9Y P:6!S+]V5KCNXU7R.MU@.WI:Q6"S12O1&RF^%H#XE\W8"2)?[>Q/,#
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M1*@<P @ C(X&B$Y*[$#& &3\%R%K"V$_H)!8H&*U=ZM/ <C3HT$F2\P=R#,
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MN1E>F?X6L[:4R!ZV_\V<GMG":;%F+#%]!;\1N-L]%-D]T'G['5!+ P04
M" #/1*]:0+O#+8<!  "\%P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSS=C+;L(P$(7A5T%Y )R9X5H!JV[85KQ !.8B<E/LJO#VC6 !!W71#?)9
M1;:5R;_Z%'GQY<LBGIHZ'$]M&%RJL@[+[!AC^^%<V!Y]581AT_JZ/]DW757$
M?MD=7%MLS\7!.\WSB>N>9V2KQ?/,P>;:^O],;/;[T]9_-MOORM?QC\'NI^G.
MX>A]S :;HCOXN,S<I7QL!W=[R+"?G W6NV76K7>2N=1!"D&:/L@@R-('C2!H
ME#YH#$'C]$$3")JD#YI"T#1]T R"9NF#YA T3Q\D.<J8$R2]8$V@M2#70N"U
M(-A"(+8@V4)@MB#:0J"V(-M"X+8@W$(@MR#=0F"W(-Y"H+>BWDJ@MZ+>2J"W
MOOQL$^BMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z&VHMQ'H
M;:BW$>AMJ+<1Z&TOER4$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFWO
MU#O$:^G#H^>^QMO(=U(=^W?]X_.WY7T3<1[=<'9P6;_Z!5!+ P04    " #/
M1*]:_WEJDI\!   =&   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-F<UN@S 0
MA%\%<8V"8[M-?Y3DTO;:YM 7<&$)*( MVTF3MZ\A/U*K%"5*I<X%"[P[,WBE
M[P"3]ZTA%VWJJG'3N/#>/#+FTH)JY1)MJ D[N;:U\N'6+IA1Z5(MB(G1:,Q2
MW7AJ_-"W&O%L\DRY6E4^>MF$QZ[4S32V5+DX>MH5ME[36!E3E:GR89^MF^R'
MRW#OD(3.KL85I7&#4!"SDP[MSN\&^[ZW-5E;9A3-E?6OJ@Y5;%,QY[<5N:1?
MXD1&G>=E2IE.5W5H29RQI#)7$/FZ2G:B@WYG'TZ8=E=^M7\GTV<8*N=6&Q<F
M9NERN\-(VNZA"4)D?=G_BD?'('WU^U$[[8RR,[W#\7YJN^SFX5BW7'_&WV=\
MU+\PAP#)(4%RW(#DN 7),0;)<0>2XQXDQP-(#CY""8)"5(Z"5(["5(X"58Y"
M58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5HE"
M5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OF?9/W0>OG7'ZS;-:E5V1S\6?=7
M8/8%4$L! A0#%     @ ST2O6D;'34B5    S0   !               ( !
M     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #/1*]:I$0RC/,    K
M @  $0              @ '#    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M    " #/1*]:F5R<(Q &  "<)P  $P              @ 'E 0  >&PO=&AE
M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,]$KUH:5ZL+\04  (\@   8
M          " @28(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #/1*]:^"%&#.H$   \$P  &               @(%-#@  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ST2O6AOBI"^; @  7@<
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M965T-RYX;6Q02P$"% ,4    " #/1*]:0MJH1ST(  !B%0  &
M    @(&=*@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
MST2O6A^.%,'+#0  LB8  !@              ("!$#,  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ,]$KUHIDPC@F (  ,0%   9
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M970Q-"YX;6Q02P$"% ,4    " #/1*]:W6M/@/$"  "%!@  &0
M    @('?70  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M ,]$KUJ>@:(,;@4  %\/   9              " @0=A  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ ST2O6OB^6@Y" @  F 4  !D
M             ("!K&8  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " #/1*]:$ZV'ZT0"  "*!@  &0              @($E:0  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,]$KUH#G?X)CPP
M %(C   9              " @:!K  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ ST2O6N1GL^76 @  ZP4  !D              ("!
M9G@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #/1*]:
MGV!(3G("  !8!0  &0              @(%S>P  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ,]$KUKR[77'D (  (P%   9
M      " @1Q^  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ ST2O6BZ.<&P3 P  A08  !D              ("!XX   'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #/1*]:#3,&B+D$   C"P
M&0              @($MA   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( ,]$KUKI+T09;0(  !,&   9              " @1V)  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ST2O6FUHV*>]
M!@  Q#P  !D              ("!P8L  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " #/1*]:)P>!KU4#  #="P  &0
M@(&UD@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,]$
MKUHC,I3' P,  ,(+   9              " @4&6  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ ST2O6H?XLY5P @  M@4  !D
M         ("!>YD  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " #/1*]:V'310J "  #D!@  &0              @($BG   >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,]$KUKI ^NBOA8  )2&
M 0 9              " @?F>  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ ST2O6HT.R2PB!0  &"(  !D              ("![K4
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #/1*]:P3S(
M69H$   %%   &0              @(%'NP  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( ,]$KUJ_GBF5+P,  )$+   9
M  " @1C   !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
MST2O6ES5")-M!   [14  !D              ("!?L,  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " #/1*]:3[^4.!(#  !5!P  &0
M            @($BR   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( ,]$KUK'WEUS)P(  )H$   9              " @6O+  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ST2O6GA7JLU, @
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M96QS+RYR96QS4$L! A0#%     @ ST2O6OHK2)BP P  5!H   \
M     ( !R>,  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,]$KUI N\,M
MAP$  +P7   :              "  :;G  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( ,]$KUK_>6J2GP$  !T8   3
M  "  67I  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     O "\ P P  #7K
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>105</ContextCount>
  <ElementCount>179</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SEGMENTREPORTING</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITYDetails</Role>
      <ShortName>LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LIQUIDITY</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/SEGMENTREPORTING</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ck0001824293-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ck0001824293-20250331.htm">ck0001824293-20250331.htm</File>
    <File>ck0001824293-20250331.xsd</File>
    <File>ck0001824293-20250331_cal.xml</File>
    <File>ck0001824293-20250331_def.xml</File>
    <File>ck0001824293-20250331_lab.xml</File>
    <File>ck0001824293-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ck0001824293-20250331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="321">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ck0001824293-20250331.htm": {
   "nsprefix": "ck0001824293",
   "nsuri": "http://www.vallon-pharma.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "ck0001824293-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "ck0001824293-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ck0001824293-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001824293-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001824293-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001824293-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 154,
   "keyCustom": 25,
   "axisStandard": 11,
   "axisCustom": 0,
   "memberStandard": 12,
   "memberCustom": 35,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 3
   },
   "contextCount": 105,
   "entityCount": 1,
   "segmentCount": 48,
   "elementCount": 396,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 321,
    "http://xbrl.sec.gov/dei/2024": 31,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.vallon-pharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "longName": "9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.vallon-pharma.com/role/LIQUIDITY",
     "longName": "9952157 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952158 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT",
     "longName": "9952159 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES",
     "longName": "9952160 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952161 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION",
     "longName": "9952162 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.vallon-pharma.com/role/SEGMENTREPORTING",
     "longName": "9952163 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS",
     "longName": "9952165 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9955512 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables",
     "longName": "9955513 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables",
     "longName": "9955514 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9955515 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9955516 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
     "longName": "9955517 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
     "longName": "9955518 - Disclosure - LIQUIDITY (Details)",
     "shortName": "LIQUIDITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-37",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
     "longName": "9955519 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
     "longName": "9955520 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails",
     "longName": "9955521 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
     "longName": "9955522 - Disclosure - ACCRUED EXPENSES (Details)",
     "shortName": "ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9955523 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-53",
      "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-53",
      "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails",
     "longName": "9955524 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9955525 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails",
     "longName": "9955526 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails",
     "longName": "9955527 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails",
     "longName": "9955528 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-90",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-90",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails",
     "longName": "9955529 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9955530 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-92",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9955531 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-69",
      "name": "ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-101",
      "name": "ck0001824293:SaleOfStockClearingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r39",
      "r42",
      "r564"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r408"
     ]
    },
    "ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Accrued General And Administrative Expenses, Current",
        "documentation": "Accrued General And Administrative Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ck0001824293_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Accrued Research And Development Costs, Current",
        "documentation": "Accrued Research And Development Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r92",
      "r292"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional\u00a0 Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r517",
      "r518",
      "r519",
      "r520",
      "r565",
      "r585"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r200"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant issuance",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r18",
      "r66"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r429",
      "r439",
      "r449",
      "r481"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r432",
      "r442",
      "r452",
      "r484"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r443",
      "r453",
      "r477",
      "r485",
      "r489",
      "r497"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r234"
     ]
    },
    "ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "AmendedAndRestated2018EquityIncentivePlanMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A&amp;R 2918 Plan",
        "label": "Amended and Restated 2018 Equity Incentive Plan [Member]",
        "documentation": "Amended and Restated 2018 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ck0001824293_April2025PAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "April2025PAWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2025 PA Warrants",
        "label": "April 2025 PA Warrants [Member]",
        "documentation": "April 2025 PA Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r75",
      "r94",
      "r108",
      "r133",
      "r140",
      "r144",
      "r147",
      "r154",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r246",
      "r248",
      "r264",
      "r288",
      "r338",
      "r391",
      "r392",
      "r408",
      "r420",
      "r534",
      "r535",
      "r574"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r98",
      "r108",
      "r154",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r246",
      "r248",
      "r264",
      "r408",
      "r534",
      "r535",
      "r574"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Accounting",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ck0001824293_COBRABenefitsPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "COBRABenefitsPaymentPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COBRA benefits, payment period",
        "label": "COBRA Benefits, Payment Period",
        "documentation": "COBRA Benefits, Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r90",
      "r383"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r54",
      "r106"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r54"
     ]
    },
    "ck0001824293_ChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "ChangeInFairValueOfWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant liability",
        "label": "Change In Fair Value Of Warrant Liability",
        "documentation": "Change In Fair Value Of Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r135",
      "r179",
      "r180",
      "r181",
      "r183",
      "r186",
      "r191",
      "r193",
      "r308",
      "r309",
      "r310",
      "r311",
      "r398",
      "r508",
      "r515"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in usd per share)",
        "verboseLabel": "Exercise Price per Share (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares called by each warrant",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants granted (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "ck0001824293_ClassOfWarrantOrRightOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "ClassOfWarrantOrRightOfferingCost",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, offering cost",
        "label": "Class of Warrant or Right, Offering Cost",
        "documentation": "Class of Warrant or Right, Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "verboseLabel": "Number of Shares (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "ClassOfWarrantsOrRightAgentFeesAndOfferingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement agent fees and offering expenses",
        "label": "Class Of Warrants Or Right, Agent Fees and Offering Expense",
        "documentation": "Class Of Warrants Or Right, Agent Fees and Offering Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 9)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r71",
      "r289",
      "r325"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r161",
      "r162",
      "r379",
      "r529",
      "r531"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for future awards (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common\u00a0Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r517",
      "r518",
      "r520",
      "r565",
      "r584",
      "r585"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r326"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r46",
      "r326",
      "r344",
      "r585",
      "r586"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, 0.0001 par value; 250,000,000 shares authorized as of March\u00a031, 2025 and December\u00a031, 2024; 525,358 and 525,485 shares issued and outstanding as of March\u00a031, 2025 and December\u00a031, 2024, respectively",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r326"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r384"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock issuance costs in accounts payable and accrued expenses",
        "label": "Debt Issuance Costs And Financing Costs Incurred But Not Yet Paid",
        "documentation": "Debt Issuance Costs And Financing Costs Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Stock Issuance Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r202",
      "r230",
      "r231",
      "r233",
      "r400"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity of Stock Options Granted",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r26"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r123",
      "r125",
      "r127",
      "r128",
      "r129",
      "r132",
      "r242",
      "r245",
      "r258",
      "r259",
      "r286",
      "r296",
      "r385"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r125",
      "r127",
      "r128",
      "r129",
      "r132",
      "r242",
      "r245",
      "r258",
      "r259",
      "r286",
      "r296",
      "r385"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r131"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll and related",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation, weighted average amortization period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r85",
      "r101",
      "r102",
      "r103",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r122",
      "r134",
      "r155",
      "r156",
      "r157",
      "r195",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r274",
      "r278",
      "r295",
      "r301",
      "r302",
      "r303",
      "r314",
      "r366"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r429",
      "r439",
      "r449",
      "r481"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r426",
      "r436",
      "r446",
      "r478"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r443",
      "r453",
      "r485"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r443",
      "r453",
      "r485"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r443",
      "r453",
      "r485"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r443",
      "r453",
      "r485"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r443",
      "r453",
      "r485"
     ]
    },
    "ck0001824293_FormerChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "FormerChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Chief Executive Officer",
        "label": "Former Chief Executive Officer [Member]",
        "documentation": "Former Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r348"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r261",
      "r262",
      "r263",
      "r298",
      "r300",
      "r351",
      "r382",
      "r403",
      "r583"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r261",
      "r262",
      "r263",
      "r298",
      "r300",
      "r351",
      "r382",
      "r403",
      "r583"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r513"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r443",
      "r453",
      "r477",
      "r485",
      "r489",
      "r497"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r425",
      "r501"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r425",
      "r501"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r425",
      "r501"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r511",
      "r523"
     ]
    },
    "ck0001824293_June2024PAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "June2024PAWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2024 PA Warrants",
        "label": "June 2024 PA Warrants [Member]",
        "documentation": "June 2024 PA Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r108",
      "r154",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r247",
      "r248",
      "r249",
      "r264",
      "r324",
      "r386",
      "r420",
      "r534",
      "r574",
      "r575"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r72",
      "r291",
      "r408",
      "r516",
      "r528",
      "r572"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r89",
      "r108",
      "r154",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r247",
      "r248",
      "r249",
      "r264",
      "r408",
      "r534",
      "r574",
      "r575"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r168",
      "r235",
      "r397",
      "r532",
      "r533"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r168",
      "r235",
      "r397",
      "r532",
      "r533"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r197",
      "r235",
      "r260",
      "r284",
      "r297",
      "r299",
      "r306",
      "r316",
      "r317",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r380",
      "r381",
      "r396",
      "r398",
      "r399",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r536",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r84"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r56",
      "r73",
      "r87",
      "r99",
      "r100",
      "r103",
      "r108",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r126",
      "r154",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r242",
      "r245",
      "r259",
      "r264",
      "r294",
      "r346",
      "r364",
      "r365",
      "r418",
      "r534"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r443",
      "r453",
      "r477",
      "r485"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r395",
      "r522"
     ]
    },
    "ck0001824293_October2024PAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "October2024PAWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2024 PA Warrants",
        "label": "October 2024 PA Warrants [Member]",
        "documentation": "October 2024 PA Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r387",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r431",
      "r441",
      "r451",
      "r483"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r434",
      "r444",
      "r454",
      "r486"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r434",
      "r444",
      "r454",
      "r486"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PaymentForFractionalSharesReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "PaymentForFractionalSharesReverseStockSplit",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment for fractional shares in connection with reverse stock split",
        "label": "Payment For Fractional Shares, Reverse Stock Split",
        "documentation": "Payment For Fractional Shares, Reverse Stock Split"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of deferred stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ck0001824293_PercentageOfTargetBonus": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "PercentageOfTargetBonus",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of target bonus",
        "label": "Percentage Of Target Bonus",
        "documentation": "Percentage Of Target Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "ck0001824293_PreFundedAndSeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "PreFundedAndSeriesCWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded And Series C Warrants",
        "label": "Pre-Funded And Series C Warrants [Member]",
        "documentation": "Pre-Funded And Series C Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Proceeds from issuance of common stock in financing transactions",
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant exercise",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "ProceedsFromWarrantExercisesNetOfOfferingExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant exercise, net of offering cost",
        "label": "Proceeds From Warrant Exercises, Net Of Offering Expense",
        "documentation": "Proceeds From Warrant Exercises, Net Of Offering Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r277"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r79",
      "r82",
      "r83"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r91",
      "r293"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r277",
      "r287",
      "r293",
      "r408"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r277"
     ]
    },
    "ck0001824293_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Offering",
        "label": "Public Offering [Member]",
        "documentation": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r196",
      "r197",
      "r225",
      "r226",
      "r227",
      "r235",
      "r260",
      "r282",
      "r283",
      "r284",
      "r297",
      "r299",
      "r306",
      "r316",
      "r317",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r380",
      "r381",
      "r396",
      "r398",
      "r399",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r412",
      "r530",
      "r536",
      "r569",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r196",
      "r197",
      "r225",
      "r226",
      "r227",
      "r235",
      "r260",
      "r282",
      "r283",
      "r284",
      "r297",
      "r299",
      "r306",
      "r316",
      "r317",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r380",
      "r381",
      "r396",
      "r398",
      "r399",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r412",
      "r530",
      "r536",
      "r569",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ]
    },
    "ck0001824293_RecognitionOfRightOfUseAssetsAndLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "RecognitionOfRightOfUseAssetsAndLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of right-of-use assets and lease liabilities",
        "label": "Recognition Of Right Of Use Assets And Lease Liabilities",
        "documentation": "Recognition Of Right Of Use Assets And Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r426",
      "r436",
      "r446",
      "r478"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r382",
      "r391",
      "r582"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r427",
      "r437",
      "r447",
      "r479"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r428",
      "r438",
      "r448",
      "r480"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r435",
      "r445",
      "r455",
      "r487"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r66",
      "r290",
      "r304",
      "r305",
      "r312",
      "r327",
      "r408"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r122",
      "r155",
      "r156",
      "r157",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r250",
      "r252",
      "r253",
      "r255",
      "r257",
      "r272",
      "r274",
      "r301",
      "r303",
      "r314",
      "r585"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "ck0001824293_SaleOfStockAgentCompensationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SaleOfStockAgentCompensationPercentage",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, agent compensation, percentage",
        "label": "Sale Of Stock, Agent Compensation, Percentage",
        "documentation": "Sale Of Stock, Agent Compensation, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SaleOfStockAggregateCashFeePercentageOfGrossProceeds",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash fee",
        "label": "Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds",
        "documentation": "Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockClearingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SaleOfStockClearingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clearing expenses",
        "label": "Sale Of Stock, Clearing Expenses",
        "documentation": "Sale Of Stock, Clearing Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sale of stock",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal fees and expenses and other out of pocket expenses",
        "label": "Sale Of Stock, Legal Fees And expenses And Other Out Of Pocket Expenses",
        "documentation": "Sale Of Stock, Legal Fees And expenses And Other Out Of Pocket Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SaleOfStockManagementFeePercentageOfGrossProceeds",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fee",
        "label": "Sale Of Stock, Management Fee, Percentage Of Gross Proceeds",
        "documentation": "Sale Of Stock, Management Fee, Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockMaximumValueOfSharesOffered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SaleOfStockMaximumValueOfSharesOffered",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, maximum value of shares offered",
        "label": "Sale Of Stock, Maximum Value Of Shares Offered",
        "documentation": "Sale Of Stock, Maximum Value Of Shares Offered"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SaleOfStockNumberOfSecuritiesIssuedPerTransaction",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities issued (in shares)",
        "label": "Sale Of Stock, Number Of Securities Issued Per Transaction",
        "documentation": "Sale Of Stock, Number Of Securities Issued Per Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockReimbursementOfAccountableExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SaleOfStockReimbursementOfAccountableExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of accountable expenses",
        "label": "Sale Of Stock, Reimbursement Of Accountable Expenses",
        "documentation": "Sale Of Stock, Reimbursement Of Accountable Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SaleOfStockReimbursementOfNonAccountableExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of non-accountable expenses",
        "label": "Sale Of Stock, Reimbursement Of Non-Accountable Expenses",
        "documentation": "Sale Of Stock, Reimbursement Of Non-Accountable Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r277"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r62",
      "r64",
      "r65",
      "r66",
      "r95",
      "r96",
      "r97",
      "r135",
      "r179",
      "r180",
      "r181",
      "r183",
      "r186",
      "r191",
      "r193",
      "r308",
      "r309",
      "r310",
      "r311",
      "r398",
      "r508",
      "r515"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Outstanding to Purchase Common Stock",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SEGMENTREPORTING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT REPORTING",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r133",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395"
     ]
    },
    "ck0001824293_SeriesA1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesA1WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 Warrants",
        "label": "Series A-1 Warrants [Member]",
        "documentation": "Series A-1 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesB1CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesB1CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-1 Common Warrants",
        "label": "Series B-1 Common Warrants [Member]",
        "documentation": "Series B-1 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesB2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesB2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-2 Common Warrants",
        "label": "Series B-2 Common Warrants [Member]",
        "documentation": "Series B-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesBCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesBCommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Common Warrants",
        "label": "Series B Common Warrants [Member]",
        "documentation": "Series B Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesC1CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesC1CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-1 Common Warrants",
        "label": "Series C-1 Common Warrants [Member]",
        "documentation": "Series C-1 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesC2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesC2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-2 Common Warrants",
        "label": "Series C-2 Common Warrants [Member]",
        "documentation": "Series C-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesD1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesD1WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-1 Warrants",
        "label": "Series D-1 Warrants [Member]",
        "documentation": "Series D-1 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesD2WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesD2WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-2 Warrants",
        "label": "Series D-2 Warrants [Member]",
        "documentation": "Series D-2 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesDWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Warrants",
        "label": "Series D Warrants [Member]",
        "documentation": "Series D Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesE1CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesE1CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E-1 Common Warrants",
        "label": "Series E-1 Common Warrants [Member]",
        "documentation": "Series E-1 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesE2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesE2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E-2 Common Warrants",
        "label": "Series E-2 Common Warrants [Member]",
        "documentation": "Series E-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesE3CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesE3CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E-3 Common Warrants",
        "label": "Series E-3 Common Warrants [Member]",
        "documentation": "Series E-3 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesECommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "SeriesECommonWarrantMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E Common Warrant",
        "label": "Series E Common Warrant [Member]",
        "documentation": "Series E Common Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity based award granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r201",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term\u00a0(years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable, Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, Beginning balance (in shares)",
        "periodEndLabel": "Outstanding, Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, Beginning balance (in usd per share)",
        "periodEndLabel": "Outstanding, Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited/cancelled (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of option on grant date (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards, contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r46",
      "r49",
      "r50",
      "r85",
      "r101",
      "r102",
      "r103",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r122",
      "r134",
      "r155",
      "r156",
      "r157",
      "r195",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r272",
      "r274",
      "r278",
      "r295",
      "r301",
      "r302",
      "r303",
      "r314",
      "r366"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r134",
      "r274",
      "r285",
      "r307",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r326",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r347",
      "r348",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r413"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r134",
      "r153",
      "r274",
      "r285",
      "r307",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r326",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r347",
      "r348",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r413"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r430",
      "r440",
      "r450",
      "r482"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuanceCostsOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "StockIssuanceCostsOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses",
        "label": "Stock Issuance Costs, Offering Expenses",
        "documentation": "Stock Issuance Costs, Offering Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesFractionalShareAdjustment",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fractional share adjustment (in shares)",
        "label": "Stock Issued During Period, Shares, Fractional Share Adjustment",
        "documentation": "Stock Issued During Period, Shares, Fractional Share Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and prefunded warrants in financing (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r45",
      "r46",
      "r66",
      "r308",
      "r366",
      "r376"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r45",
      "r46",
      "r66",
      "r211"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercise",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prefunded warrant exercise (in shares)",
        "label": "Stock Issued During Period, Shares, Warrant Exercise",
        "documentation": "Stock Issued During Period, Shares, Warrant Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "StockIssuedDuringPeriodValueFractionalShareAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fractional share adjustment",
        "label": "Stock Issued During Period, Value, Fractional Share Adjustment",
        "documentation": "Stock Issued During Period, Value, Fractional Share Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and prefunded warrants in financing",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r45",
      "r46",
      "r66",
      "r314",
      "r366",
      "r376",
      "r419"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r49",
      "r50",
      "r58",
      "r328",
      "r344",
      "r367",
      "r368",
      "r408",
      "r420",
      "r516",
      "r528",
      "r572",
      "r585"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity (greater than)",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r33",
      "r85",
      "r86",
      "r102",
      "r109",
      "r110",
      "r111",
      "r113",
      "r118",
      "r120",
      "r155",
      "r156",
      "r157",
      "r195",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r245",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r265",
      "r266",
      "r270",
      "r273",
      "r278",
      "r302",
      "r303",
      "r313",
      "r328",
      "r344",
      "r367",
      "r368",
      "r377",
      "r419",
      "r516",
      "r528",
      "r572",
      "r585"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r107",
      "r178",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r195",
      "r256",
      "r369",
      "r370",
      "r378"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r280"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r280"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r280"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r280"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r280"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r281"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIQUIDITY",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash financing activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "ck0001824293_ThroughFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "ThroughFinancingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Through Financing",
        "label": "Through Financing [Member]",
        "documentation": "Through Financing"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r527",
      "r573"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r77",
      "r78",
      "r80",
      "r81"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r414",
      "r415",
      "r416",
      "r417"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, outstanding term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r569",
      "r570"
     ]
    },
    "ck0001824293_WarrantsExpiringInApril2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInApril2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In April 2026",
        "label": "Warrants Expiring In April 2026 [Member]",
        "documentation": "Warrants Expiring In April 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInApril2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInApril2028Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In April 2028",
        "label": "Warrants Expiring In April 2028 [Member]",
        "documentation": "Warrants Expiring In April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInAugust2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInAugust2025Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In August 2025",
        "label": "Warrants Expiring In August 2025 [Member]",
        "documentation": "Warrants Expiring In August 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInFebruary2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInFebruary2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In February 2026",
        "label": "Warrants Expiring In February 2026 [Member]",
        "documentation": "Warrants Expiring In February 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInFebruary2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInFebruary2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In February 2029",
        "label": "Warrants Expiring In February 2029 [Member]",
        "documentation": "Warrants Expiring In February 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJuly2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInJuly2027Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In July 2027",
        "label": "Warrants Expiring In July 2027 [Member]",
        "documentation": "Warrants Expiring In July 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJune2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInJune2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In June 2029",
        "label": "Warrants Expiring In June 2029 [Member]",
        "documentation": "Warrants Expiring In June 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInMarch2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInMarch2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In March 2026",
        "label": "Warrants Expiring In March 2026 [Member]",
        "documentation": "Warrants Expiring In March 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInMay2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInMay2027Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In May 2027",
        "label": "Warrants Expiring In May 2027 [Member]",
        "documentation": "Warrants Expiring In May 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInOctober2029OneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInOctober2029OneMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In October 2029, One",
        "label": "Warrants Expiring In October 2029, One [Member]",
        "documentation": "Warrants Expiring In October 2029, One"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInOctober2029TwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInOctober2029TwoMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In October 2029, Two",
        "label": "Warrants Expiring In October 2029, Two [Member]",
        "documentation": "Warrants Expiring In October 2029, Two"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInSeptember2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250331",
     "localname": "WarrantsExpiringInSeptember2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In September 2029",
        "label": "Warrants Expiring In September 2029 [Member]",
        "documentation": "Warrants Expiring In September 2029"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants not settleable in cash, fair value disclosure",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r567",
      "r571"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r283",
      "r380",
      "r381",
      "r404",
      "r576",
      "r578",
      "r581"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r129"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r129"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001824293-25-000073-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001824293-25-000073-xbrl.zip
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MGC=T\[>EYU]E^K0X&HT^T6^#O?QT6[#/I8?]?>LF/$D0J9]<6S$=Q)GB A7
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MV]L%8>]UEEC6+QIT81TB\"HD=H^^PNC(W#4_5XL>TI!5\W,%\-=;R\_G-!_
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M#V?5W<ZX4-AUS-XH_PC K;8;VR<7K?DVZ\\$["9-?"\R%_U G4TYE1ZM-.)
MS%C"6]YDTNX=DQ/[A]EN,9PX ,MCV.SW,U@>56#$*D3%Z[['==_CW2)JW97H
MV'9]CWMUW^.Z[W'=]WCS;M?T/699T@X6-SPDC,&Z7!X@4]8#KFF)_%ZZ'T=E
M^[\]Q]5G;_PXXU^F]J=Q,6\.X'383LNC47O8%_,V6N[VVIU!,3V-AVU)'!;6
M9[E_LGL"/ T']9ZR[&FT?NWD$& GL,PKU;-W79-I(=;_F!]]Q606>ZS%>W)\
M8KMFF:*4XPV5@#2;&LT\7:K0US5'M:W76*!F&S!D'5J_=X6[$4;2\M#ZE8C
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M[/8=W _X$,;,;]H40 F0_M[N!M*=[)3*K4Z4?:YOKA([^%(#\MIQ/*)=>#;
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M07@B)F&^$GZ*I8WZ#*P-,%)04 )V>3]3*_!NX2&\V0Z<);HYS2+L?7B5C4+
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MD@03ODS<] 9MGXM2?SCD=G;IN#0!."R;'G6K0)L_6"0]V'XE")+Y!(%KGT*
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MX**"R1'JPH&/9K^@E=/T?0D-'&?5Q4"-38/&["^6]Q[)<. !?DR\$%BZ"G/
M G46Z*[MZ:%*W"\?F1;N&!%8=K(6H!3!PR*!QO"I!!#PO-10@7NTR8J?ZGW/
M#$E'^*"W21L++Q<\.C'%WE>N:]!\&M/R;1.>=O56CD9.:R&:K?XNX5Y+-T$Z
M>DOQ479/U(PE"C99C$M?"6JPDB$_.S$2_UB:RI 2$?&3CT/+T<^2B=3!, 6O
M\OX"02PI""[QVX*E*,32M6R8-ESPJ1)G341[+_ LY@AE3J,YGI'TN3DV0$,
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M7U[@E@^ ;@H?](]"WH$C2VF&US=7,;91,,N*,L\-'3X+?] W7=.^C-?FHPW
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MJ?CXW^!Z\:$E"Q^NX$5TDJXLRRUP<N3N\".[G%1M@B8V]>+H%''$6 H?NL_
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MY@M%!IK 5%J@*M? LS"LQ=(L/HZ@36?.1IL=H0HP^6,J=4I%]0/KPE<4(%%
MT/!&J2"1IX7YL+>AA;D_3#O904AO/R]CQ[_]YP/6%%Y3^ 8*[Q=#X=&HUTS_
M2;36?XAM)5'^H#&F 0#I\S;D7WH-6B5%^95%]=DP96VNF[KCVG3,0(XVN5'&
M6#EPQ5DC93S'[L)_V!B+HZVD_Q:]B4\3-\-]X0;GI6^5R%QZR935MF?4(I=<
M=CU:KF)L:='SV!H<4= L#R-U5-77UE"!8#I!6TG<D\SI8A&KM/^\U)H[:N[8
M'W?LRU7NBA77R.NS"DM^_3<G"N;U.8E7>WY"3#0/*1A+&G["?L/N='5;F"GP
M'S9RC=_S:CS)A4V'Q;0!-M257ZFN3"/V+P?9O9X%_^+;L5[X#:.-FW5T>"D?
M4(SS/W1+P]0;^!?U54V5\,.P[_PA;[H327;"E^$0.#H(D+]BQI=P%D2E:6)T
M=99*P:%%QP720]')R6P/?#4&Q_!R= D ]/!L%&8],RXGU8IR/3.NGAFWG-B[
M*87W2*2Z)$N79)N*:2-TAFX@_>BH25_F;11QRW.26?*&LR0RXP+0ET7+.;0
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MS"SB1$61+<R34ZIAYHU%NI:H4C%,?("-=8H1,4@0_=#-8@22B5 (75@0D%-
M%0P8P3]8/Z6CA<%=?P8@5]^K8N#$(-7G$FE'&=:VH'BU)',G')U&F)GA6WQF
M$=QS)TDYYB)9D^R;_9X6CC)G332#_JJ!J'$G .5P]TS<:&[!61#8601K<;0L
M#@<S.!ZQ(]CF'UGHRNXC(.Y2=PRZ8XHR4KL2:F!"OD/U$^P>YD^6X?C2*R9;
M;_BX=C\/1ID%3J@"2E0T)>()CL\PAYW/_!3N8^Q@U:?6(OXNQFDI;*U[/5&O
MI]X< 3#^N[Z6<G2HE92Z050UUO(T#:*J9,TH5\J.6ZR++_YW,VT-B-?4)U$P
M.0N]<Z(IP/U1]'A0<>N5*%*]1<7M_.KSY\MOJ+O=6&=?/@"[^(+JV\67\\N+
MF^V4N%ZI$M=[>26N_* XX)?H_]DX%EQ):B>D8%.Z(-I-\JON#J6T$$J<2)B%
M^J2/D-@ONX !^T1OI^QKB#(BBB)2X,L/%^[D$&3.$<LHQ WA9<F%10S44[]G
MS"Z54[507 +JO*Z38>>S6#W7,;&XB'$48:=()XG"EG4)<I#''<@:&\R;1W@Z
MH!FCP4\*%&D<!8U"$TCX$("1.O"\V,AQZMQSOS-7!"BK+K0\JR NW[ 908F/
MU[!RD-QRO'Y-0C81E$LZU5#,28D@X8%$HS'C@P,H;KU'2TBC5"+\"((G*,)+
M%.3"-P38SW&+ARO>.\=:=0 H0Y^!BA18';;1=JT]'-SX3K^[W[*^9G&2H9X
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MO<Y+!<RC'$FX ,\UW\;2,V(ENUJ:/+*,BI7P+4HBR0=:W!4(RMW688GE8"_
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M+['.(R\WR^Z=W9SO6P.[W^RU&]83:P(;5N#[  -Q/2*5M.^-<2MT.3NGY-I
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M\!+%]Z(0@JH#[17K$, F.1$*@^@IY#$_F/S$*7"##Y6S<#R%O$JL7XT=#3-
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M8V#JS@?U_V%_#XB#)@F$!Y[)3+??L8Z2!3=##R;ZU6&N34RY^K_%MEQ)3)<
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MP?3\EX7#9W/_)7"A* 63\!IBGI!/N"<;?:2NM[ZI^2T)AU4-^1^!\.^(_%C
M35^&XHGDOOV:3*P'U/)J**9-,'L>%3GW6.FF]BW80)HMQ&);77?,_WF,2SZQ
M3BG*+H^?<CB$*;FGNT/A^VK>2.-V0M"8,/^#8R;H _UGH :1KB@2*1$F98F/
MV5(P7"P'Q!'^%DK?PVHN/ZVR-=+7S[<QKO6K6[/YL-VUZ:XP<7)8-,8OP;?K
M#B*234!^#!$44-.U3>+C/!>/T@^)$S#<A3\;Z=9$?JY1MT0R(7(+X*SCF'>
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M^%Z>H(PT+J$]N0;':.L26M3,95&D=9DLT@WN"J7R=*9$DC+9MI,BCCRIGK@
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M>2"^S/"I?%&-"3=OT9O!]>=!O[QL1U^[HT[07"<(N Z>T+8RQA)G(Q#M(Z-
M%34\MD6,18 J\N0)&^ )WFR@Z&6<V5K@BRBT)1OF,+UM3J^50'7FK))*;%@(
MJ"(+EEI53W!@>\4-VI+ZSBA!'>4IZD0< T:D58P$%C/Q7-ODM8R&^>^7"@\,
MUOTS81UAM\  A',]N+&X/C1V;,>BEQV]]P3W003$:20N441E'9>66\-9[6/A
M$8B:FE]D_#]6>P7E#&I*]K&JZ;:J/DJI$:+OG?MN.NF_\9^[8]^;@DO:Q9B!
MXCEG')&1XRJIM40D$"P%M)J8K:SV)P$= @7J2;R%-_\"QK@^2,=^V._V/XVF
MJ%!)F@++A#+<W*33@5@/@4@A*.?:2Q9291XL1G((!*@@X\>:Y]MJ_J0?A^!'
M\!9N_GNRP..^&/1Z[P;#W_TP=6@6WH&6B-1H(I4K1)5 ,D1!,RCA@ZY,B34A
M[IXKE9W--E72PE%R[VS[>.6',#J;C$NLNUP@=!1Z2."R(UE(W-<L]\12QPCS
M&HVD&)D1N3T#XA&>W7.C564NMS*VTT0+)\SC57>2I#PZ/.1B8*$XUY38S!/1
M!@WKX"5NM NBL5O&'!9',@^5$5M*O87SYBC]O\EHW$1Y+P=+;**&O.6.*I7S
M%WVUYNKK G !H^X8/L+P2S?".0R[@W0!<?#I1F5_][T)=#RC%(7"24I>$9ET
M),$)@1LQ14$)%8TVU6W7=M=TV!Q]48QXS'BQ*>/O7[C<O(@GH]$$TMO)$/?C
M&ZPWV_2[H8\WBV[^?B>0CA0<8O"<>"40.O."!)$H22;K%&6,$5:^YJF YS")
MN&M%/>:8;)-CS4NP''D4UDN#_J9U OT/'X$$K@S)#A0$2876NB;%GH;SXS*L
MHIH>$TQ5,=^6O1:G\'OSHU'':>.4#Y8HK3,:%Q)?@V@RR0: :V#&2]Z&2?<L
MLL/D58O:><PAW1*'&N+?@<S!VFQ$($9'3R3WB01K&$E2@%#X,\?$;BCT$-@/
MR: M=/.80*9]2^H??CCT_?'Q5QC&[@@Z03'+O$<O5VC 8QD<08N/$J:IUXHK
M)>:=@1KVTQR*PV3.;I3RF$5VVVWH%,8HG\$UO!^,1AUKP6>C*!*Y7.+9J(CS
MN/ZLC3>:.JU<[1/K 8##),?VLGZL>-=JH#(P#IX7VSU87*K4B"UP3D+"/[D*
MB+ V#U8/5%8)MT5T@C./$8U'F] -CH)8IAA1!B(:EMD8%G84;OOWG^?8_A[_
MVD[*I!]=O>L-?A^UDB!Y^^&MIT,N7D9[R8^>JL T4H1[A^Z&T8PX9O"=,$E)
M?"48C>I[2WXTU@AO<.=2R>,K[@.:OQ(XX3I0ZBAX0^O'FU](\N,Z^GPF^7$=
M,;Z8Y,=)&'53UP^_??0].,O-QM0D\41THG5R"IT@1_%T*\:(3(EHGW/0N >D
M4#M<O!3,"TEZ7$O!\URI(N@V[I_NX)SZ:_SR$FW2T4VT97JYOPK"EK(?GT>W
MIU3(.NJ<)TD[NM@/:Y3-VFD=24H*?6+/(@GXAJ!916VBPD4;JZ?4[XDMSV5+
M[HLLZZB@(DD>>,"75\/!Y-/5NV[?]R,:\-/LGEP\6N\-40JW41G*D:O0EZ)*
M6.TA"3^?0+EB &+Q\_:0^U)9/8NB"Q5DVT+>"_JVQ2P_'PZ^=-$&?_WM5S1G
M3OIG>/#Z,:(\0AE\0>G#Z"B,QB6PW]$F:>V,),&@VXO^M"-617P/F < G7$A
MM:WJ]5&^B/RI;>S5EA73#I7NA4F$RU%E3TD&,$3F",3;B):842X'!R%7S[[=
M<TBJ;8T]&95:1]PMF!@/TA]*[@)N<3UX /%RL*YTO/4N0O0$:$XH'9Z(C\H1
MX73)^)&2B]JUBVVLX^"9N'?EMY#A]18^#R%VFPR=#N[4 J3Q)'/<O?&5TL3Y
M$D:FEE(($7?YVN5#]Y^_>P+M7Z.#2NIHPYTJ8>[7\VE<'28UN"@#P3>&$1DA
M$QM#,1!!15X2X:O'WA<C^8,N-534PI[RSG>'S5WTG;S.\O1><=21)@B#/B1Q
M494+Q6 (TCF09%/D.GK/4^V:A"<!_4&CB@JKF)$Y W>[Z/?E_O.B="8ZRRB/
MH]$(QD?7@^&X^S\-[8^_EC< .MHY!8+C9JFB0P]6!1(8H$Q &\,$LR;5+H-<
M%^,?G&M7K163-I=?Q-^N8)KV?">6DI4/P$EB3! I<B2^*1DU@3+%//6RMCV_
M.KH_J->6*EM(Y'R,]'P(GWTWO84,PR&DZ<MQU$]GXRL8-B]/J6<+P7,OB6>F
MQ/ D)8Z6#=QQ$80 &G7MK+S-D+Z$?)HZNG^68M45UX+%_QCU48R#";ZXY_Y;
M<]L(27%N@T-$UI>D5$LLV$RB91P0HLJVMH?X+*@?B$3;J&,GY<@(<#B!]+[K
M0[?7[-B=Y Q#[BK<GTM7'IJ ^%)[(:EF8)P-4#TY915</Q9KME%*"S;]$Z)H
MS,$9U&^=D)S/.7&2J6$E!B)(<(D1RWR,/,>L?>WP^LK@?B *U5!/"T;YZ@'@
M3O:"R0B OBLZL))Y0[RWD0C!:*#*F*1J)U2NCN[@0^<M*:J%K6D)TMOK[ 6"
M00>49D<Y$=)%(B4XXC6^:IG[TB@9#V%;N_'*^B@/]:*XEF):,*<1*O(XC=ZA
M:$JY1>DH?9;O)9(C0,NRY9+PP(%(JW&3IE02IJT5-(H@;>U(P;.@7LQ>5$VS
M@S;5TE:*$IKXY=UY-QC.E9F.+J#T?X>;4H3/> QWM!9XUE)&0);7*G)#0F:2
M6*V,,C9X-K\!K9BWM :(@Z7-3K32@G,VA3J:YGO-F/YF,!J/.H$QK8.@! 1(
M(CDSQ"7M2+!2495S%+*V'_\4GH,E3W5E[-7BZ3AA(J>*D\!HJ2YCC(1R-QU-
M\"H&GU7U=BVKHSMX$K6DJ!;\L@*S_+^4D7WQO<+\"T )=.,84OG!43\]_,:]
MW[RI1GWL@\;>I!3;'7^-3;OY"[0NCW,&%*K5++/&N;5.EI$DZ#Q8M#)1"%1Z
MCB)GM4-,NUWA=V^\OV!"M'#T;K7:CDT"<K;XL@J-[Z[6G+CH@"C! IX263A5
MVYW<"O"/3<ZUU-7"Z;T=>&8C#3IDHGC0)=@2B$-Q$<8%&A]9XM>U'="*7-ND
MM/#SYYMJ1=^;E>F>],OXJR;7X.Z8!NW N424-QR5RE&I@'+)-#;=%S7WM=_!
M%:%]]V];&RJH>/7^P-V[UYWN+,_EJ(R0IP^BX<7NXCZ(D*DA!KP@,B=!@DJ&
M2)]XRHY%+^Q&GOBZ2/9 DS;TNL@';U4I;85SWD(8/_#Z$.BMX=Y\ ^V92<D,
M>#T9GP[&_X1QZ:G8B49%*;@DA@M7+E@R^@NE):Q,CEM<5=:;E:1M".B >;4+
M%2TU-NLWV7A_\E^_GKP]N?SGV]+*O+=53XU'GU6KA<;3("MUS+B 7FG1<>Z'
MXV_W"A[OCC,PSE/)*7$\H5,>(UI!&8VY4ELOO;4RNMI5P<]AVMK0B5>0)J7:
M<\F31J^_/?C)33Z)$F XE21F2HD,OF35V4P@J$BUUM[SZDTW-@&ZJ]X<59GS
MR!!J744OOZ$'2PPW:2-+ZU5&I N1!*HDP2W<R6 HU?7']KVXAA[M\V#EOA_K
MZ&,_'1Q60?A'WX]-U+E^*X=-=+$GUEBC-2MM<2"XFX9QMAAJB-X%G52I+#@0
MMFS<]Z-MLJRA@M8NU2>AUXUG.</PKC.%MIREK!.1'!0ZA0 DY,C0<1 B<1&L
M]V$C%VO1TUYDSX^U5+/P6GQ;N59LT_  V-'X\@H^^.%O,)Y#)V((C*M(N/'(
M=HKGI[/9H..8%361T2 WB]0L?>1AJKZ.A"N^\*/AN'-1[H.:3<TSKZEG@OBD
M.9I)B1(O?4 0WM#L<Y1FI40'_-1[FS[^[6[#?_# PS<B-Y=OQ9NV6Q!3KJT"
M8QVK<!5UUW^KGS?YMA#^O/JVD%P;;^L4#DM!@,*M*.6$^Y'@Z%!;!GA\&!%=
ML#JO9JCM6X%+K+#Z^EM'8)7U]@\HP7=(1U]@Z&\!.>EU\JDT$&.E0P\P!&1P
MC4'@*J/!_Z]4W_^,!A<^?'='[%9J&-2481M# GM^-+KM ' V;"Y9&L9*[;CW
M0I ,%FTZ;@U!.RX07!\H2$D91FO?%R\#<_A';5U]M)%\L C8U+)<!5I+@9HG
M8.TG0E-)@:O08@OIMS&D_ F(F3H=J0-" 2QNF?B'YQJ(XUFX9)+E]?.<=DV,
M9X(QN^?%.D)O*PKS$;U$&+V^J;B8M9F9GGQ216U .!(%1Z=1>32)8LHD<:NC
M=<KX..>OK3H#9OE#=^^85]/0PO$NE<3;@F$Q/U7[*,;)]:0Y*M^BV&-WW#&6
MNYQ9F:MM!5K"" [-ITB\P/]884JF?/6[V.=0[9XAK=X\5E9#&Q;H31[@7/;?
MT?@-TOD;0KZ9%>JH-,J&8B;+8B:[8B%;3_!%H3GD+*.I;HVN NS Z%)?&>U>
M I6Y+-W45!:7L;,1NE\@G?7OR:7CE)-.!DJR+ZT5&92J9N.(*L/?:3;2Z.KY
MG>L /# &M:><BC'%Q3/2;K/!9M'M:>>>42=(H9#QF7!TRHDTPN,6&1@Z>.C-
M16>,#5O.8EWZ[ .A1YL2;VTV]!V5/_BOW>O)=;/]X;=NIH(5S) Z*J4L+)IM
M)I;NU$H;8AV:7&C<>1JD5&&^Z\VJY%CI^0=)D/J2;VVX\[VK]4]X6-[OSGH.
MPUB263]!)[J(6QQ%0UR48D"%YI:GT1-C1&")1D$W=796>OZ!DZ26Y-L8T'SO
M8G921#8C\<U4SI,'QZ$J'2X94WC^I=*A"=!GPS,0_<- )7 34JQMY:Z#[T!8
MU+IJVIC1?(?U?-B-@ 1OL':"H%+;2 E7"BVHB+NAU8@KL1A*K7FP*K='F0=8
M#I<>FXN\XK3EU9N:L$@3+I43%4O_W$@=\9DK/!RM9%Q9D+1VD?0+[#73*CGJ
M*J&%:<KW <X->AYUT$67FDN*NU>Y=,3E$K2G(U%>!3Q=78!8N]7>4W@.F!M;
MB;[BK.4'EM/#F/1H=AE1C*AW *48:LX?ZX#%A9=<41%,*7PJ"7[&< *>X>D7
MA>!*;&2^K@WE0+BR0WTLB,#1MBK17A]]//EX]N[\XOCC\>GET>7)V>G1Z=N/
MOW[X<'3QS[-W'T]^.3UY=_+F"'_VYLW9KZ>7)Z>_G)^]/WES<OQQ=MD^R&^[
MO0E*_!3&I6,XGKO3?;6<OA5*W'8'LE;MW)[$6JDH[Z@_[J;R[.X7^ AQ,FQJ
M=8^_EJ8>D,HN65RWR=C?U/G.KBIF]M;=BR:"XDW/48?Z))*A%^=H0CL,K/:)
M,>U4[=3^6MCK%?EMB>@F1<4&E83PFN!;88GT-RVH+ E42!&D3-G5OGJKNX)=
ME07NA;O+RP=WKOR74E>XY<)??UO\ 3<)&(IE4)R1[$L8D<9R%1H<R<)()A4U
MKOJDX!:7L_]<N=V3='YZWPLA2QM3*1<B*R4?LVRP%?"UE(OW'+;]).2]&#*L
M1-(M-;D/Q@4O&/JRAFBJ&)$Y6^(-U80)G6TH(Z;G&^%\ITQ[)L/ONR7:.@IL
M@6#'Z+L-OL%-/]VSST4ZTQ0V2[--*AI<9@1<M4)@(C!TK!$O:)VDJ-VZ=BF8
M/0S3JJJW01M";R$=;!H$F55'9!DH2YGH3#V1,@02C 5"G<&5AR!BJCW*X0&
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M>#3@MD.\2X&DZ .-($5**[7-W;<"E]A:]?6WCL JZ^T?4&(1D(Z^P-#? >+
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MZ#K@IS:=GRX@0O<+I+,'.R?U@3*#Z'3B^(8$HTF0EI6<+C3S.-="UIY)L1;
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M@&M6%K[5R 'QC2W7J2EY@[#@^&0^EJTFHBF-P,-PAJY6<U'66XJR8#D$9<<
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M%:!%E)!&F:IQ\7RB*N/^?-+7B6/I!.NQLGZTT4T9L)XQQ#(Q.*JJL_X> X$
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M1BR4G%RIQ=O=0J%0Q\L<6E_U2]TF349#;#FDXP70DV'BE8BS]X8,'.TY:F)
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M.* 5MY9Q'$(GZE&=(>,"Y8?*@/W-'13SUPQGJP@RJ$@$$$UK5A3:-N!*H!+
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M[BW>J*U@G_WLOJN.6.2UF>N?O^OK V=_->G43_>[\H1+#J3F;6\=^[=YD/N
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MD]/Z0OXZ.&IS;$/]2%5#H):Z?H8OF7B^6S_D:E2]3W+PE?&E,PV!SQH'DGA
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MLW+AN0>#6_</,TK&T8%=\ ];G)CVD"[0*8=C%BP[!7)JMT-6W+O6'5HBP'V
M19=^(=0*!G\*\8!^4HZ*&F)I9:PK;[HVZ;"O"#'0\EI#9AQ@Z0"<1!0[JOI
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M^V.6+]5DP1ADK_:Y$I_I ,7-M^X#ITD#PAM[MGG;?V7+)N^*V;+-X:GIEL;
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M/X9[BE[:TAJIOVUKUAII"!GJ4B0#O(G#8T,C]ZR+@2_*BR]]\#&>IV;X<ON
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MTWS8,EO5 LDLZ9(@MTJ\<>+H<O,Y!5UZ9':G9:  @'^[V_9E[23DJDL98Z9
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M4BQE1Y4V)\5)EP8>C__X9R_4?VT#D!HK$?O(C@IRR-JJ>3. (%DBFBK?U I
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MBT^92(>%\IV%5#3"JGO]O1Q]" ,H#U9@[A"!"O:9-K/U[[!X;P.'<C., +<
M1NKGZNPYK.:TOO^3"OH?\"^SO<;V]:703%:6CW!Q1O'JX0_S7+<.XIYO*Y!>
M9]WMF<%6>SD:?13V?0S4H4-?L)QKW*\[8GMRZ/_#MCKGA*1SU9MP9+/,L-R
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M5*H'S%U>7QJ=$I( X *<&WD91>"X@$D$GFO-E(;[;,]3!$^,KZAJ_9!722J
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M)@PW*Z,6;].#F[K&[^'+GDJ<<AXP1X<SRT.>CX^DY=]IY9V0-O,>G.R<"4%
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M52ZS)C0"Z='F'L1*_D,*K0U6*305M""A'MT]ZR-K.^=G&VZMGTC;5Y=T"39
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MP.OE&>0G\@\<07N 'M'.C,*I^OI?_&)%[&<8NB2;CKJPRROCMII*R,ZQH11
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M.M"%':)1.MKJWDB)*5EX>+'(.MU6$F]$DDVA&Z6M@'$\*>B 3L'6^QB)BZW
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M>M_V*NJ/_NF/?^O[R>RBIA_0<LMVX;%RKZC/^2M]QC;D3"DB6[G5OCDD[2X
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M.F9$)$X%6T>]VCS;/8A%BM"2FO9N)PYNDA?7Z>H".]U.18(,((DV[(9):/-
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MVI$/@R221OXAUO\77E;Y5ZF[D+B)8"U>G[=?R:J\AHQI^M9W^><&1G&]Z/)
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M/TPZ._?8DJ)KNX83:VA"'8>@T$&+49=V&S&X#K_$U09ES:)ZJXZH2G:O@G<
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M.B^V/Z@@*V7F.(Q,'%<@_RFM?<<>X9WK5&HF8'[14H@F=.!AV-S2E*.QWV+
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M!'#OOBZ*W(#"9)>;0_9- NL(./+8FZ-^O(47"(D&H(HF4;RNNGH7<2B$1^)
MF9[?U&Z$7[^#-<:RU\)7M+O6+R?!O#6D /<&#2!NF&WF</#\_&F.-D9K[IP
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M]UG]#H<O"9-=)L-7TPCC<L=J.3%9Q@FW78'"L?MNTM!7;ORZZ=PF&%XI'UU
MI,-U!">(''SVE=54M(3#BD"^FL2MQ:LZ^9SG?%/-'6Q_-#:XBG-$9_FE1*:1
M'5NQ5ME!;PL<G:TOQ0SU@*>;M7*Y*T-59@1-M5&#4973,L:;X;W5ZEJ';]H/
M<7+I6G+I2389?_[L1_HLS(>_6XSHJ1;='[M/W*J_ E /K>Q4<2&[W9CI791-
M@6PX PPM=I2<V<8:%H.N@C;A+- $,65UM_=M[V]?<'NI?XVWYJ&N8)@Y)D20
MPUUH\J@;KBB'WY1.A.*--TWZ6#:)ASW^L_>W"-E#.[:#O<[&/QDTFP:L3IKK
MU+@P-\': ;6A 6I/X3(6)D'.._O0"A>3@JX*%R^+/0U/HI8'/G9+_:OL)3Y*
MW"/OD'U.__CC,C@2-/Y>NHB-@U[1(5Y56.3LU!P OOR!.95AP80@5-3>ME;W
M.HXO;.?E%H@%&@]-G_-(OGS;4![EE> 596R>:D[3ID:M_JFQKK'4UFEE.-/W
M-<JT5*4:(76Q[JA1CFSWY?2<H?'7 W:+4&D)$%S3O]]<&2Y31':M9.%6RQKE
MT;[$E)4"-$X>_28%^V6#"P>YX^GIZ75K+;;A[ZZ@_UTD([JPK/_5H3DQ'AV)
M02O>KD6B&3TQ@LU)&R&D"K\FXPPL.&%>C7/.XY5T"4N7OO"GWX<(46!':P7G
M FQ/D$ES,#@[:URT8Y(N$!XCBIJTC*]\J*FM;&<CP.^Z5OL.UM$4C^+ ;YA\
M=V->E9ET@PF@>]*C4JMAZ9HHLL-[_UL,):L3OR%WGFT3RY,?4PL%NF)_Q,R3
MQ*/3@J1$3Q(#FBI&O#SI(')YD,&:Y\0N.<+)(B?*M^=*ZG$O4[OFX/@V#]6;
MU-C)XEC%^'&/CJ4))7V@\(5.'63PQS+69Y=\DV-S8Y)LI=Q3EN(E_"X*3+8L
M#(9E*%O\O&E4L_"/L?DGTYJO/M4X3H5#Q5^V+0+VG?R-P;UKHMD="P0?=Z\:
MQ[55086@ZL,KHKBP@*K/Y!Q'MR+(9=*M*C3+[W] 2 GIO2%201TTN,H4^K.=
M/<G/GTU.3A?*1PGEAS^,ZILN*225=+M2O'0]V>H*4V20G0LY)*4,)U_6")$K
M:Y1[@4-B\S^;J;2T] W7[<BMT<;EUJS'"RT/.EE3H9.]PLXOUECC,(?3_\7>
M>P"UE6R+HIKH; _&@<Q@#!@P8"PR F:P#6."&! BAP&9;, @0"#2C(V-3;0)
M H008X($$@(3! @1QF"$"4(D$200.>=L@N#A.57__?O/N?_-K7IS;M7_KTO:
M5=J[U6OUZM4K[>[5_-[D<8>=S80-2Z")!3*=4"'-@$=1B/QN1"\Y0X^#;6_)
M$D>/W9#*BF5Y_8IRYGTO"^F-T57WB=@WPMK/_80@STVCH%%(XQGQSI46->.$
MK-=LV0K3.KI LU9VC.;;U 3C*[.DWJC[=C&XDUG;&P?Q=Z\SD8Q=]^E3OJO[
MPY\TDM;^CNMH%Y#!7,E6\564U'RU%S/1$D?1S1JQ,J.Q;%V*<PW-V#XRQF<*
M68R"I0$E K,Z3GM3T&$#/.1D =3]P!'I[*T0U(270A+>HEY1O2ZJIR<JZ%NF
M&1G=#YG#(2\HS(Y4A]JN#VM'*"W5CK##OXS9OJ#A$><#A1+\.J8+7XX3@-9(
M3QQ:G.YZJYT9M7%#\AC@_3 $^8\A_/L#)U_R@ )J_C@215IE1RL;X4DA"H4Z
MC<@P;"5II+;)+S!51C3/J"+T#5JIX:*M0]?[7E1>V9ZGNF#&/'VT,M'59,2A
M<]?1807EC/%7ORT[/I%9OJ-V#-!S]L*F]!J9?/.0;_6QC^"T8;AIU?X(UJ%E
M*1%&-Y%1S%G)M6.R5*J##RZ86V((SF[)T%BE :',TGCAS/M;?_;](JR%]>UD
M&[6>2#L,_[6!I>H]H.Y4O*AV_G$2 Y'<_HC8KLN**S='9YU#WJ6Y,VSJK*?>
M^NI9$Z!8 W]C)8V]#HZM6"HEJ]/RVD9E(9I ",X13]R_H>8:+/[\!U9609>*
ME!N0:DM6)UK+9?66,4<['"EJ$!]F]304Q$>'@,R[C8P#F4K=#Y2AYO?G>,9;
MNN3?="'.LA=VR@;=U!'PM_'MFQ</=']B"/4'<>*M6(N#-LQ"4THNWK.42M*C
M87I:E3T6H)3"VV19^DUT?&6H+9I5!_9EQ@L$%J:7^W;V@@*A7.3:*V+^>Z,G
M]]K3-,%PMGZG6W#@HBINQ=9):;_8IJ<,HA8DJVSD7\)YF8&#6V.-E1T(DLXO
M8V[W A]4$PK/62];_-.<Y^%.2'=9Q \DGG'P&#H->R=$(D!J._Q.B0W;TI7M
M$;]@4]Z0HMHM*E&J@5O+.)O+ME.W&J^&I3@9K&2I+[+-4*I!+=ZN7B[*:AW=
M;25B\--UOJ+*)MB$:'FLAMLS$0%79QE4]Z;IK&H%9F@WUM>Q;<>N_\,L+M8&
MIX?./;=SP^U<?TZ)+']1E8Q7J=U&B(-#,[379QO.O[=A(N13>Z]^&0/[R.*N
MD&H]^(GT2)<_IB10UZ_QRTH?E#?:I,Q@GS-)S6KM%IR)E-ZNZK=F!A4X-&:#
M+ES3ZN9?DV#&"96PLVL;P<G@"N8^?$KN.A%&&.=@IP6=1T%5;D&;KG<U864A
MQ) 13)__EF,[)[=CP*=Z; PCB2[$G&C/'-DJ>V53>R6FT8<GT2Y^OW[F_17L
MU\*_1&3M.Q/?A[I"!D")O9%CW"#& )0ZD(&]U1H2.:>\E?6I7=EW[D,_<XTL
M@;_M4D4FE\5M(A:;JJP0I/*ZM@%-8AK^/ HA@+]XBRKBH]-#DUWH8$;S=D:&
M-3P9E<R<Q(=H"&/U6KT1\ER[] T4638X:)HW^OIC_P)ZKS)8>9B2'@-+]M X
M;Q7_^[^2X:C9O.7M#_!C0(7/-Y\$>B'V'2V?(GOJ>K,.?1;ZF%I4R]]$;LKN
MLU+_-R=0/;6/LL:CK6^B/&:Q[H8WDQJ!)[Z)?IFU"TJX%.V1*_)15S1P#\C#
MQ_BN-[:[9RV%U"5J<G5O,C,PPX]KM2T8U>(P6TK1O 7I6-N]:F*&@MA,[-76
MNE:W+%G'E'6W/ZXXJ)!*VKG6?]6#%O9(IN^%3Q![%X^TM194*$=00L_EV1%N
M$3(V,FH9%U2!(*&KMCF*Y#0L'UH=X8%1\'>>[_4/+_$MLTLL@6Z)YT^=.(\?
MY73-__A?]^K?K( !ITPW&T[[S9H>&E*?5$F/Y]'G;3DBQ0H2NB)@0_:Y5VY)
MBU>SFH;[\!;7U(>_-7LNV"[#':I-I?-+QI4;LF][:E@48KH#S]E@=8O!KDRK
M%@,DKU'+R43C(V@HWJVO\JCU)HS(#\^S&P=K/TSOQ!IU/&B'-RE9&GWH]:>S
MG&%IKEP*@<E23(#6++Q,QT@"\Q=:<-Z[>>!@3K7"ZP*&MC[THU[Q)2V)BIW!
MY?:?/^HA]_O'7T;U]B>I6!=%/G+#RQF\J: FD4D/:\EG7[^87#JJ2F')R?03
MD[.E_4%DM4DE2Q'/5PN]6C_1[A#4)$7>(43KA=-'ZY>V1J8?DTSYC9:+%*S1
M.<0,(R:?'DP6\50JS;/^-,$#)\_.1!0DM/B_RE8CWJ[X3*@+WX DD(1$Z C?
M^DRH:M+S8X#X>I::GZJ$'LG:K;Z&OF!A$;#&OMHG2=1"DE5(9A.T#7)PNX1&
MVN;(PYN:TBWEIHAGOR.^\O"U(8/Y98\!]E4],5X9TQ"1%_7F]P.DIR9I&P.,
M-/_(&Z"Q;7L@N'RPTM *.S__2>\*Q UH#P]J!O$8Z=D"C1=/+$V@<7HYU,%'
M,?F;U[UCGY'[PM#QI]Y)2G.#1+CXN"]&4(%2PHP]6BT9+-(ZNXMKB#;VVAE0
MWP?J_R K)_&Y_C<ON8+'@'A5]:,_9,-NS-_6K(_\:.T8> QH(EVIVV%D>&=R
M"Q(_ &-?D]\#?OW\AZ^.C)7*#)5ZC<^XH'C0'K@XL=MEC2?SS+VE[+LHL4L6
MXCLW/+'&(.#MM5J3FL)L8G%IB.IKOXS3H^X"S5/!O;&:J7BBATHL;H3#8KLL
MC2MMZAH(^KC6K3A_MX2ZVWATF29<5G7)J4)T8Z?3JG6 SW5%_Q&U=WJ !\@[
M)YZLOZ\ ':9728,GJK[)?5SI/P!CQ4W7SWFJ?7A@3T'C8@ADQU/GITD/BDKT
M19J O(V)J<.L7SYC;9?X1WE36^*E=2[>\K#\Z8I_R:UQU[284G5#QT-P-(W?
MYF>T?4*61EU]Y2!%I,?#\Z'9Y3W;,"&/UML;^SLKL7:JA96\!;-2;@'[QX"I
MV] 35WZ,$J2=1C2FC#7%>-&>;%2T 0ZF#A=6O%?Z!JJ]HSLF2S7D8<> >?LJ
MR]3.!979)5[%F:)',K0,O(AQR,?B0ERH0W/S2ZO *_]"$LB.3&:-S^NC/[%F
MB=HRC8@]KU?ORO63%(/;'=A9QX#8TKY)LWH+I+D'78O3W)(B@9YX.#FD_%B_
M6)JNM&G+@KQP''$=!&=DQ6<S!HX!FYM7PWU<@^5&L-%FF1A[@S7L><\4_&XE
MI6]X9&; M'JDLF/\'6L&=J0[W59;;&A*47M0G8&1+L5FQ$BJ.6,&G DWTJD1
M%!SL$?:WSQSPQ6KDA8L$F:WG_:?X_+VYQX"B"B/F4O!FRC3V;B,K0GM8WEON
M;LBY=+J6=JMR6.HY4$==LB$_OD77:J==J8?NL5SY3/!!>=6&DIYZ#:S,9G['
MX(;K#:TK,/U]8]CL;Q0;U?5J;S=863]5LF=Z>6<G,QH=MV.!)E0] /$VI5>I
M^I>_5WNPE][H+*ED@#<S*'MHD;)ACC=[^&=TT$3BH534G]%!192')$KK79S6
M3^_Q$%[>J/7:/*BQ.53)DO?JAW%%$"^OD)]B5WIDZ<:_D(3GJ[2D?(O%L[FY
M3Q3^Z$>C5UQUFHY25S"KDP@+7.$RJ_;TNIAC?U_A7Q#B_Y4BKS77]4G!;F.%
M7?3IU;9.(13_@27O8(<WVA>)H%F[;_CLOJ"B;4"E*>4U**!%]];M_%I8-.JN
MKAW6)TYVM\X;QJ\@OHA558M1.O]\N6?)_E,60MDWN8"34RQ4AYZ,EC5JN;JX
MQ1AP$R4-8<%"U&HVR2-$Q([FNA3RTZ9B+S;[-^&+Q!\"+(J__PNX_KN5$^"[
M^,GPKF61?(W ZAFZ^*5S":[SB]??#-YJ[.2D#!P@KIE%[5U@6!8JU;7M(M3.
MFIEDT%K99NXFN@N<^%O,^N47)B,1?>#8(EH&FGA!5=T<TM3\@",CL_# P;E8
M7L/5[:R9 F=Z5A0>8#N8B[#53Y]:.7$^2FQ+037X-ZE];F?O9KR<Q*%]._D-
M-Y\K/@_R&2Z^U>ZD%.#-V_TGNE+)W<> !0O\E6U8^M@P_1CPIJ\FII\ >US
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ML59[0469CO@"OS@H; AI=":3;"V:G+='O.S^F%SV4].*_"*J]&U<D].=0:*
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M#)G;MN3?YROF]E4LC1(T53QP2++3-+Z)R+_&^:-*CGJ@21Q1Z5S9Z(-<G=<
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M&9+G JC00('=LI_S+TGYPI(JDT3A98).5..@0%)&E<^VU>S=Y$&OE@1G\<7
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MAGX,[GU1V_A('&Q]M-O6ZA6J]"BQ<$A)3!12ROHXLS(%K"SOESK7[P.QU[X
MO*K?_;RE],"T< G</Y_ID@MM96YEW5/ E(,<[=OM<[;YQKO0!2^Q&-AYVFZ\
M#K"%6CS^^U* D_>[N0/P>_PL:7H5X>X:6$3F7)?6<S@L,QDRV&\+<6*?UN_;
M=OIVS05^K3S#*X0*C,^LG"_.OF?^P'1+8@GFNKVLXUF)$*O8-[:KDS5KM:);
M$Y^UVW38X)8I8S0U]V*IIZY"UIVDS_VL;LB-;B4#1]3@V5?L[!KK'-2F:WV8
M;F#/NH5^JPC#_ELV;):A88.HA)L0[5FDPT^[3ARB30E1I+,UL#ULB(],<@D\
M'7=CQ\$#6\0F"H4)R4-$OM;]\F#95E0OHXZ4R0XU]W=G5LAF>.+$GU)K(IP]
M"45/QDM*W1YW@T!7NO6_]J/'6GGS_O'/ _#O]U.^VK)A#8_:L8>L;0=J:VM+
M]/I[>OKC#6,SB9DQ23UO?7UU4\J9)0YUUN.WDPQ/E'#WB4] 4XA9S!GA]9]J
M5IE_=6+XW[BAYOJ/*+$C4?.3%_).G=6V(\1QJK[(K6,K^?UU;-5'P^B.B:G$
MGP5Q=_/$+&RLM*[+&BBI[3R?RBK;/W#&RS'Y:#8IZPCSF2@;6+U(R,&Y=]T(
MO4&'EA)O+;7>]IR2/4%E/YC]@IO@IE!8+*\2X[SQ@N15H^)4Y"ZJ;EJ.R[]6
M(R)J'5$<7W-YWO?WB+OYS>%W_!QX?VBR,W2S=!L,;7BN6G<@[6*0KQ%2MPNO
MB]HCI8G=9B[0XE(]=7O:;,I[*W)]]>[@3U=QKFU6LI$:'8N9'E@*ND-/T6<T
MH]PY8]_P&JS-%O]4,3T!&GQ_F%!3;7DAKJZH3BC6-"J<?\UEL?GIS%^D]Q?9
MUV-W^W]DBE:2(&,#!MXK*\< LXT3>VM(%HF>$3R\^=BQNEPG#^@^Z!!/_5S_
M,4,O=S^96559+'9H^O%"Y*AC9<4Q@,Q9]_Y]L7YWO_E=_013*^U&>=,IL=K_
M!*;E,:!'<F(^"/M&;3'9^_&XK42S74O\6P1B)!K9#AU]9_U8&U+F2SUM]WAP
MZ69I]'!BX3%@XCR%TK'["TMV2 !_%LCOT:@1:$N0U&&B>UYQ<MGJW8AEXN/
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M'*L/?76TRW4\9*SOW#D&'(@? Y)'C\P:(M,CCP&7C@&$8\ RWD^'\Z<)G'[
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M![)\;G(.2+_^:_AR8 .7YPC.8G2J-]1 I[+KLM5+$D--C\32M]VZ6[K<T J
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MLKS%M/D!VZ5PXVNOWSQV,WT8D'IQ^,SMI0QA=ZOG*W]E4;.=81J_)[;!0/P
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M!DWL-//GT4%Z %WP"IVO#5>DJ+@DI*^Y%-25D"@E6ZG&-I:MFCTM+9@YW#
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M!-F=.@D!C2J]5]L9HU5<TXIRDP'G\ME@#3C9#Z/!ZNRIC(!<9R7:.8VM5?5
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M(6DQ(8*,M&!ML\P1#LX[@N8P:H;GZ ./=4S\@'F5+T&CP/:PS1)ID1- #K]
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M%A#B6]PS>I5KF487KT=W.-5_SL#4#RN9R2PY9M97 DWP5P9.<..<<)5$= L
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MUW-"OOM:GG[<$.1&Q:\,V8. EFUM;5S=K[66NJWBE^UB(DK(2X>/TF&VS0&
MTCF,4P1_&2((%8["U%+*6-@&)(J>LIA/Q7^=__3Q02IO3F(__.ZN;]X5F>U
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M?50HLX+6.YG$EW'.#?*+=/M$TG*/\5HOXWWD(O]E2/A](RD,?O,':_\9^F+
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M'J*BEG\Y=F#Q9*5'"N[X<Q*=/O#;T :<&;PU 1==0TX$Q 7KS5%_*K%3,U=
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M([++8O=4U( -28KE/FY+UEM*-I?\I6E\CF>-]UKI_K#)L?O^9--=>:[!QJK
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M<373J-3 1=626YUJ_*>?C^!C?SE8T9K4Y(1]P!UF>KZS+_GT$C_]*?3SD?*
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MW)!_W!7%EM'W6W$C6N>3_H)66_9!U$1P7Z$!O:]:6X01B6(?I<!-(Q_ F&4
MNZ$/F,M\1'&001PM3IK:2+H[.AA)R8)<3Y\!N=B#=PH!WT$[!'3\1"W6JSC5
MUCBI6<?&T7%J?)P:H28[_\JI<+IR.@RNT'*NYV>PCH=NF]&:KKL=AFNZ]U-X
MI.;W:T&Z0$!@"D?Z(P635M0K>KM%N6A-(0S,:N&'S6I)7O<7RY1%H0<) @CY
M&8 >34"2QB'P*?-QZB>(N+%*/X@1>+;O^%CIB/)L(4=M/*Q"0ZUV;(QIPTK>
M BO4-'D+N.)"!?K*J8$[OS;_-7H)KTBPH<*G,6BS5BI)DGY<6B3[FI[LGU8=
M[1H4?!3__W&)\'*U+%\7?I9E;H8R$,4>!#!@7 N$* )!2I,L='T2(*6N,-*0
M+>N#?0^0555=N&K@+F6#C^JLE-,-5ABDIB5Z2BY%I'+/L@H19X>).3VA3+PA
MC2$/=U;=H<R.8RVBOH!6>L_$M(?S*\R0^&,L^V& #^,1(S,L4!-S">J-YD&,
MTZB;4W3Q;(AQTHZRC<SF1.PN-KX\/XD@L<JM0^][EJ^_Q*67.$<.KKN,7S$,
M4J9_W76RXKPW7><(.KGD.ON@^K=U7WYEN;B(:+H8*5P/]+QJV[(3$ \NLAK0
M5\HW 7UTCTO41)+5Y$F?6B59&J!)2Y+ZUIM-C@:(Z4K1T&.:?8:JN$,5[*F<
MNJ+3.G01^CYD$3^)41I$ *:9"W#L$4#]((PA#;,L2E4\K2%@ED6PB:\4 O95
M'7$OG,T>O/-'[D[4OU;L6CW(P8C$,45>#&B4^@ R" $.8 :P3T@8!1Z&E"U>
MCN8US,;'8\#2W'S'GI;KJALS1JM*Q.VPCT8>=#WD @(I%6U?4Y &*08N8BS,
M(/&1AQKVM2,#9F9>_U"$H7A7_;G9Y9N<7V^*$VK'0QOIK"6Q!GS0_=M@KR0)
M DUU-AH"-6\?(@FB3[H&R;PSX6:X332\_?ZR%'<)=^O/G)(JZY!S,FWR6=W0
M3=.0GR])F#( XPB!!">^&%,4QUD483<)E;.CI4!;/GQVF< M$LX=%X 6#3',
M*=6XDI1CZK JL,LJ-<4@P:4IJ=1R[-*XL37.-KT;VBD?F=XUK!+A2M>N<BO/
M?\VJ1''OM:K:"IHV?5^7@NOORV(14Q\G*$@!H=RJAS"D "/*?V(>]3(4NIZ?
M*1GTYR#9MN;/M<EP?A70)=7#.+\D[2@37% THG09H&Y#C1%GRH Z"V=>ZVF,
MW!/3:?0%/2$^<RORB9.QS7.17)32B&!Q!9K0*!;MU0. 6! "+TV]@,8H\S.H
M(LRC$"]W_WGEK#=KT*"A)MSC?)03<J/<40RH'=YR7NVO.:^</7QS(B]-JB'1
M'X<WJPJ0)O]8%<B_J*<26MM!M' 56J;KI8D9/@L:N0ES?0*B-/8!]+DRP A"
M$#,OC=/8PXROIJ 1Q@#.Y#9='03JRJ&97WI\D], )KFAZ1E5':HKV(?CTLS.
M09,EU)#XCX*;5?IEB3\6?NGW]&3_@7\0G] SJ^=T++R(12$-$,@()%S280#2
M&$8@3,(@"D,$LTQ)T@^7MRS7 I@CH"G.5#G#"SGIU:=03585B%,6S'X:#(GA
MT>*S"ET_8<<B=N8I/8'ZC%;L/JM"G@_YDK VJW'AT9 %&8: 41P B#P&DI@?
MIV[D(PR3.(F)DH]\#I!E(1-@A8/8W'B]"- .-U"::A-Q[[ MZ/XWJK-:S[%/
M3AI-,$5-+EM^-/<.%=1]SK'!(:(CE)D:Z7D.S+P#-D>(/1EW.?:\>FONVW7)
M;>POZ/L=Y1;V,EN2*FSZ:5N%<[V$X2R, A!F&04P#B. 8Q0#S'!(71JZT).Z
M4AB%9%F::]@.!^X<0G=J\/+-O(?Y-2R]1KF@)K[:#%!J_RU%G%8[\.&59VL/
M+D5@MUVXW N:,V/Y@G2YVI;+;^PSXSYR%>OI6KE>EF21YX,TRA"  4I! D,,
M:)C2-$RAGX:NTOS7$8"6A;@+WMG#OYIB"X_R4.X\-LD9-<&>R!3U :B2E)H:
M9CH&;M[!I)+$GPP9E7U/3Q%\8J7DA-)%0+,L\ST70$PC &'$#W2/92" GDOY
MB<ZRC*D,JI,'K:0<U(?,W8S-<%;3"PHLE=,0=ABEIBM$Q:3B$&5SBD.= 894
MB +@696).D..U8K&"I.=_9O-NN# \LJ,>62$<95&[]=?<K0NZJKF143#V*<N
M V$48P 9(X [_BGPLCCSD)]25\YIT()NV081(O22;PACM'#$GCI%-U"@'020
M8*MR9, LLR:%"PY0<5I<'/YS!QLK001Y)IB/+$C OE2X09XM S$(A45L&S:[
M*= ,TRQ@?@H(RL3<0\9]'I1E(":0X!3Q7T*BHGS449CMFG]OV_S%EG$C.5Q[
M'F99-W:,SNR>SI/9[9]Y9X)/9Y"^/31QROA(2N+U2[Y<\7U(FJ18+V4)3.,4
MQ&'(#2(:>@ AD@&7I0'WMR(6!=1 8O81V)FR"P[R92L41*YL8B3#^)B1PUK(
M'GO4-,\(9\PF81^SR$@"]@16&4R^EOB83"5>GR%X8M+U\:IO(>'Z#*62R=;G
MWIZ6E%'E"OLT9C%T(Q"Y, 0P1"% F'@@2;P@@A&$OBO5#;MO\?D2,C32IP^X
M(&=GZ=*FIL>DR=).Q+"0!WVP]$62,(:RG7N?T8S)<!5;=?80 ^C+5S'Q:;,6
M8]RJ[PBFGI^%L0M@3!/1%92(.UL(? _[E"&?)4&D%(,9@F;[\K8"Z>QA:HG9
M,+\D@RNFN* FB,H,4 ^8R!!F*D R"&O>@(@,V2<!$*F7-#LX/K^L-J^,?6;Y
MMR5A57+'.\2]F.[,O>M5M:'\I_OLD9'-TWKY/XS6_27%$-7BXZY9C.MG/J*Q
M#S#&,8 H)0 E20PB@@,<!"GT7"4U8!@_VSE< CV !7[. WJMVR#M6R)="6N3
M(\W_*A*#;]#+LD0K@6O;:4.NA<TL.RFGH"ZX/XKQX6IKWMG>&O6VEG88:*H-
MIF'LYFV;:8>U)VTV+8'1[]_U$RN_;JCR!-PSK]M.LNEV\ZI!*X[NZ:%X6'D9
M(E9- ?70:6%<[0A9DUJ6':\Y>].R,T3UM2T[]ZBZ4.WG5K][O5M3I2%9?>]:
M%J>^V>97XB:"PU]^6](M6LF+5R_MX[(UE6PUP9*@V.P@K"'RM 2L=\'9I&N(
MG*YH#3ZGFP<^V!4)^Q&+,?:!&WC<F?"S""0BPP/'V"6![[E^+-7.3 Z<[:!"
MG1#=UTU)JIF2#@.'1=4\6Q2C#!,YHI$IKME@2C9=_/)-I=1(/4T<M]!82NB.
MNSIOHU$A52/Z)2L>\HU2GUF)5>Q]K0UPISUN6O"5ORAP8-12$UH%LK6.'YGU
M9SN-%(CM'DXJK^E%RGXNV'UV6Y3+9U2R8I&A,'.QZX$LA3Z "&<@B<,0$)\%
M 0O=V$-*:3^'RUL^BS@PD2NW Z<6:3KBA%R@2)\^-3$])FV>X23]U!D*PAPM
M/FL,I9^PXQ#(F:<T(ACT[U\V(FZBT!ZZ^X[M6,5N<)(8M]N-[Z@WACX@52)>
MH4FE8I#B+(%&6T'W$:,7FN@N-%\\H@?]@R!$W]\U+UW[HXE[5_?=Z_Z1)JY=
MQ4#N7\2#7?/M;EWF2WY,DFHDV")BR*,D#0!*LQ3 P'4!"D/N:R&$PS2-,(Z4
M#C!KF%J6Z0:\P[ZSG"P+X=5>.<L6 ^>;0$'QXM?:GLD=M6]B)_1O9PZU3F>@
M"'YU>F]Q!.I73H/\U6&CG1T!]=!#@Q?8MIELZO+;&I[S7IS;9O?)I;MU@)HU
MV)0NZU&.#VA)[];-367';U\D'B89Q D(4<@U>YS& ,5I!A#, D20QT(_4:K"
M'@5IW>QJ$7!>. 9@N79(C8-B[?4X[^0TK%F.J)IH.V8(X*+ZM %_=1!*,UB!
M+4VMJ1KL<8#S5F%+,^"D#EO^3<V,5O0J+!;1Q>R:D'R+5JHE- ,KV/N(6Z!5
M\*P%:Z4:1H(\4XF@ Y#FS0L=)_DD353B%8V93_LS4.0\?&/YJZ)O?WX%RT>.
MBNNK0O>XHV^&9#5Q[,!T6J#VO/]Q"O7F09U?=KZQ4*.D'4R'&G]:(X3V]%3>
M?%T_/:R+-3<X[]:?M\_/]<)%N?Z"5Q\V^?7+"J_^EC<5/+)Q-M6%;5N%3T\Y
M>T(E<VZ^"J-<6$(/_'GA$U:6MH@#<VVV?=ZND!A$^8ZM6;8LG6R3.]<K;C[Q
MKUM\VR)'ON#?_<LF+^MV'H(R="P"U86W0GQ/>1\D@H VMT#1#+T$]\<KV=3"
MD+KLU(M5*D.;+Z"IRXB#J*?V(KK)(Y^?T6KU;ELLUZPH%BP@:8Q=%Z0A<@$,
M$@_@*'-!$@3030-*7.*K98L<K#]/>D@%TFEAJB:#'#)D6)\8(%--8ZA1J)'<
MT4O'A&R.P_5F3M_H)>8T7Z/_,<W0$B'"R"L:9Z#U!1C]N!_LL!^WNT^V=9,T
MB9(H I! ",0 2H!82$"(LLS%-,.!KS370A,/V^;&S<WCS[?OG=O_?KC]]/GV
MLV+H29.WDO$H^QQ3M X:A)P&H[V?SX_X#E*=\<V&DZ$-L<941$L3BWG#7--8
M=1+[FKB<NNMSL_G,5HQP,U)]R'3?NS/$&-":GX@-X';LLG*\H9?N<6]B*LEJ
M*D&76B6+?H@D+:.]=\'9[/(A<KJF]^!S&B4/"'.G+?^X+,K*[5*N)#J[@&6)
M:N Z O"5JL-^GNIQ43)"L)H\=6EMZAO,YK9)T:57[W!VU?F*'L8(.ZA\&'UX
MYN2>C[NDZ2Q+<!IZ%$24>[[0]6*0^# !!%&2I3B!<3I/%L_'64NL)V2*3"BQ
M-K!?<O;\O+N@IG=FVH#Y$G).>';IS)N/ERF7-L= 8[DTIRNK*=HB+Q=_96*Z
M%Z/7WUB.GE@3:X\3R@A$!,2Q2[C>C$.01)%HXAD'C(0^S&*I>5QG(5A6@RU,
MIP$JI\C.\V-8+QFA4DW-'!-H,/0_2LV0 N O=X2?_]]>\,^O.XL<CY+5BN7X
M@^HNP^T_R]?KWW):F+MO5%ARMIO&'ZO9S>_%CQ_0,M_?=#4=D^H#KO9HS5\I
MJC!YW&>QQ%_=:T0;K#5\7ZC!,2W_2 7.;!Z3!O%='TKG=3VOJG? =SW_Z#[;
M#T.Y0:N5:-G;]IQL'BP6-,")%[@(N"F% $9\=U+103=-HS@B68 B7ZF%U41\
M;!L2;2/4)_$?+E!BT& U8+!0G# XE>]RKM&,W%2,;PK$A+YJ0/)OMA[]>]5,
M/*NF$^P0=&H,A:>TVX+V#8-#4 RQRY!+-!6;6?TA0ZP[=H9,+:M]QWMT!7-3
MCSI?A)BP.,H\$+K,$[/((Y"&00!"/XG=F,7$9VI5 ^<@V3;6FEM&5O=S4ZQM
M/L\?% 2N"T-^&$ 4\6,!!2 EJ0]0 %F<^"B"J:<RR,H,?]3G5GT1KSC($I?D
ME+@1VA4-S=/+YRNG@6KTMGF8,'/WR6?@S'UC/$QNSYWPR LF)U/>?B>K+67T
M T=<F)O;LNG =XOR]7+]5+3C;&NO8@&3F!*8N2"D+ -0Y))A#\8@(&X4^7[(
ML!=,'U^IB)5M==D=YUCLS1-M,]#,5DCJD;D9K*AS^D=E.BV"]3RO#HJ5N]L@
MN9]U/=I;P-!,34V^61V\J8K3&YC.J<E&N1&>NHMKNM*H^"K^$2&8;V@E.NL]
MLJ+,ER+50/SA>DT/?]%Y<L$HAJ&;!0 3Z@*N5PE((,$@"$D4DA![F9<M7JH6
MJ)]+E)>2[O04G%1D_1@S>4]0#($2"6]$_,#VT!U4.I@]+==BIX2LUR 4W>Q)
M>^)S<Q7C) *9ST( N44+,#?M08@H\:,T<[/,;?;D=DW?Y(ZT>)G9#\9_?Y&=
MD QWS,5;Q6 '!W153SOKP+MR]J@X]2."[4>_[+YA,-!A@E&FPAR3<)DWR&&"
M;2<A#B.+6IF0%C77(PC'U(4X!0@E_&Q"O@]2EC"0X(AZ;A F62)EZJN!G2N6
MVSO4*C(Z_BN2NF>RQQ[%V^1ASMB9D-:RR.B$- U6V9B0=OYC,CTA+>J[4)L\
M(2V:\_I,CU+%"6G';VL&4HJ"E6U09M=)(@YI',:)#]PX3FM+'E&?F_,!<2&+
MLPSZ2@.V>Z%85HX-- =5L!4'V/:S13)(,958Q:!#!6X7V[325&.0)%/Q@%X8
M\_KW0V2>^.N##ZMGU'S@6&_6K&T,\'[+OFS>+XM_;M%JF2W;62)?T/>FL+I0
M*';16=NR>#8H[=M/T"T3/2B/T1+.&D?,:3%3;[RIQ=AA49^#IVI:P!H[E1)F
MIO!$*W-&"^!L*313V-'-I9FTSL0Y<:)G5=WBKK%N(?%8DD8)2$C*;8.008#\
M) ,,Q01ZC*8L4QJC>A:29074PJV[IS7M)#5'L)TP2<Y2,$*ZFIX8'8M6HV$P
MD4Z:6-,CS$[@7&88V3ERSXX5._N"GB2_9R\Y(\O:&74SUXM<R'THB$2K2 H!
M]D,NRZ'KQPF77Y<J)7UT%[<LKUU0;1J#FK@><$).0G7I4Q/*+A1S M>'NR$9
M.UAZ5K'J(^I8DGJ?T:S8(U\9W:[8?3;Q>JX>I449B[G_C$ 4HQC -,& 'Z4,
MT-3S$NHG+D*Q4O6>4?3FS#QH<'R]VE^.WSY\%DF21/2/JHZ@D1E><VR8G):X
MW#8HA@H,[X!ZS9X51IFJWS.+W+RU?%88>U+79P>*GFIN(J.-P<U59P"C@ )"
M7 ] XKL@H5X&<,S"V U=+T!*$<N#U6>ZQE'3=(?TRRDJ;:JT;E\L.!&]!!B2
M_\.U9Q7?7K*.I:__(?5>>JWBY]):=7+\A)ZY91(CFB4^!2ZC@<AV]KEE C&(
M0R\A+$%A&B'99GI] "R+4 O2:6$Z JA\.[U>G@S+E E*%7UW-2*5.NH-4:+5
M4J]WP=EZZ@V1TVVJ-_B<YHU:-9&8OWO]?5DL_) FV&<QB .< ,B2 *303T"4
M0(JBR,M27TJN>E>W;;#7$ZSY8XJ79P<<D+PTTZ5+T0+>D>3\*B"9O"/KH\#4
MW=C!VO/>B?61=7(7UOO0A(2>IF[@D16,+R#RA]ZS;VRU>1%!RIM-L;MX6V0$
MNI#@#* X)@ B%(G M O\$&5QC)(@RESEQ!YI\)8EL$6@2JNC>Q0TTE;D.3HL
ML/;YI"C139W/CE4<":>#A5.A,5[Z8X)S&HD_5CBHEP!DBI-Z"4'*C%!*#))?
M??X$(67*>Q.%U%>QU,.L&!F4=5O/W6/%W?JA2L(^:DW2_OTA7Q*V2!&+8I)Z
M@"51"* ?B^)\$G,//\Y<C+.,>_U&^YT91=_V%68#JR[BWQ94I+7755R*15PS
M[ZID6/7-[I6BWR;10:V0G7:XHZD:P%!1=>6<-$]JGW(JTF9LNF9E2^9JT&86
M^;?5S,W*QB@W?K.#Q01'H[IMORL*?G2^WXH$VQILA63Q0:3T5=/<ZA*[W;#D
M!4GCS(O"&*",<:\CB . /%\,H,#,#2,6!&FR6%>-CD:*J@Q@(Z6YTEIS=7&2
M3R[;0:X/%P?MQT8KUPV;8+^"BV*1I7J'095M5"/DU!CMU'B-U)73X7?U*V>/
MV'P\UG!F[/-:S[.QQ7,]3V<:EY3<'DU0\_M TWC2ZQ!-7%)S/&>^X29X^2J&
M7)7<!Q-U;I4']HGQ0X.1E#&: 19A[L' @(#4#P,01PPE*//B($Y5?)DA8)8]
MCQ9T%9AB+=PK9\TD-904P[*89L** R$D&8 ,QB EC *<DH2F-&&>&ZJTX#'&
M,/4N//,P3,ZO,L4&M8.OA7I538 K*T;<[AGQ:8 1ZD-@)2@T-05V"-2\8V E
MB#Z9 ROSCIXJ[/3\62"8Q82)%HM>@ &,1<9I3&) @H@E 4DS%C(50>ZL;5EN
MZ^Y9JST\-6GM,D%..#5)4Y/%CQ+T* M=#^:&9*R[\JPBU4/2L03U/3+S=(A#
MWUFD5@T&WQ(7NHQ%*4A9QD]5%X< QS017:\@A3 D+""J+4%FPEU%(C2;AW0P
MN7)NZQ')&/%'"+,?936TPX;"J_/OF?FXJF)8M=[VMQ-.-;L%EQYTH8CUVPJ@
MFMT*8R,S-,%/")F^9[@4?K50B=7%(K<;/RS7_'^YKJQ^<;<FXJZ1OMN6GS;E
MWUCY@)9T0=W0"SQ^VOA12 %,8Y%B2!# KH\]C_\K"J7<7Q/(6':/W[.,"9A.
M446>E@V"#A$(B8L;U,[+?.G,R]3KT6ID;Q0"JC-P7.T8$ @Y+49UDD*5NK!#
MJOE=BY;#\7(X8@['S!&HS<AGC:#J#/S6BZK:X[M>7'4BHY0"J[JPYH^L3N1*
M;VAUZIJ:S2DWS\^;=176?4#Y??ZY%#=9U=B0MJYDX2),4N*'@/DQ A!F$4@C
M)+I^><1+H]AWF5*(50*FY:.DQJ ^2*[X<9$[WZI!*5-]$1ENROD1AGFDIOP;
M]GRNV</ABZ$*-0;-1)E=6UV#O0?E*3;585 "XKQ]!.59<-(M4.'5R6UT;K^_
M\.^E*4.[>WZI[GU(';)Y59YSJ[6X905QW/E%^+([M$2[EV/$M#OG2/)R6&O,
MPD8U':+,0<.CZR>SQ$3K'$F(E^J=H\:0@>8YB@OIF2K]6;BWM5^W0!3'@1_&
M@ 9$],G.,FZ?1#Z W-QD6>R2A"GEM Y"LZQ]IE4HR/%+S@PQQ@4UY7' @&ZV
M_.U(BQ)EJT.*0$/VQC"L62T-*;*/;0RYEZ;V!-%/=ZR[2Z1NB!+.$^!E+@0P
MP!Y(H!<!+PE91'WF<]6@UPYD(F:6E4:+9S4A;7)R]-1&(5-W4?*VY1)[HWB?
M,N^V3.@>8HB%QAN'3,7K0CU##+'S?+L04P#4W<$O.>5@JN[)%4PQ;U;6V^M[
MU[)FW .K)N/*NVJ]=(Y[8E-)5%,P7W)4W:=W[V=E*5;RIH;(TG*6>A><S1<:
M(J?KZ@P^-\MPW5M$OAX^NP@(3N.XBL&ZW,=!40*PAV(0!EF2I0C[1*U?Z&2,
M+(OP?OAK71;AD-W@5\9Q<7ZKD;$Z:[=G&R1CN7,R5S'2JSUO5V!Y\M;%1NZ>
MY]EEAN[VX/.6Q^Z>9]_$P;L#"T](EGA@_&M>E^B)B0;-^1,KWVW6VV)!?.QC
MY'L T3 %D/DI2-S8!2%+O"ST:1!%5#D9X@PPRPIO#U5(8%G!=;  K'&Q?HY?
MP^K+-!?4-%.' ?>BNWK%@'>&&:"1.6" $7J9 1H,T;OR'Z%0Z4K_W%KS7]F/
M4-5[)3_VCI[U=__"A"6Y?OK(N&/6ICJ_MOU.HB@+&4MBP)B7B!'B!"28N<#-
M<)#Y..$*SE<Q[8;!659C.^#.2D#OYOQ?.42E>XPD]^0L,G,\45-J>W94@*]V
M@[1?+8S1EB/2D'TT FQ6XT>.\&/+1O(MC6B)J':I C%?-RO^RF.Y5I@RT_^V
M9;&M"W0Z4)U'5F[SM?*8F#.T2\10)I.M&$71I%@M@C)(E%X,I7_)^:(H@R0=
MQ%&&GYR<OE;7(->UR0OFNCC*1!%.%G%/@'*?(,4L "FE211X./4CI9$,9^#,
MFJ;61#Z6=<6]]FCY<RR3C&5,9X1BA.(@%ZUM+%!#M9)\UD>6^82S RB72C+K
M(W4@L:SW<?7S\/:?Y>OU;SDMKNG?/ZR5T\7.O&[[#N&?6Y&C5%V?%)TV%J+)
MQ693KC<J]PKG.#!^+!H@7DW\).BVD+@U0J;627ENS=F.RA&BNF?EV*/:A^7+
MEG_[NWKT=HRSET4NBC (DP@!2((0I#Y+0.CR9;PX2B.U 2IGX-@_+"NH^T80
MRN=B+W>DS\6I-"N?BS6Y.X@6)@.,4&7N6.R%,O>Q.$1JS[$X^/B4[FDL7[+B
MO=].L-B-"$0)#7P"@B2- $RA"Y(D\;AQFR),@X0%4.K*3P*6[4RE"JCS'OCM
M!9).3/<,FQ1BVM.)5Q/9'KJGS$P_PP"=%F.3&:'90DSA0]!L"S9(F5K;K_ZE
M+M#6:Y"F_K9=PZ^HV_!WZV+)G_R2TX?-:DGXX@_YAES3S4O)Z(<5>I*UYD<7
MLJR+&OA.FT738E%E'@M4&-T*K[O!2-[&'^?0N+5OE#EJNDJ1+\ZO AU#UK\T
MV5I^P/CJLWD$TH1V?0/YES1'K1"NRL6P.D:[,Q_YSRM6)1BNZ?7S)B^7_U/]
M_FRSJT46,^C'* ,XBB& T.-N!<8^$,48/D$T2WW<MG/]HC"LQ1!^4K)SV.#U
MB[I^Z6#K4)F)I';W1,Z9F97%N@,J=FSMHGCE[)"L-%47S2OGJ%O>U6&[/(-3
M:PSSS]3 &U-HS3LKQS S3\;LF%Y?LP!FBPOVSZTHJ/G&__5QN69W)7LN%G&*
M:$(A QE+,N[W$0)2&',U2C +49QE,59*]3P'R+;3MP/K5'"=7P5DIP*M6F5R
MCE5RVLT$ Q0=/RW:U4LY1@@S59EQ#LR\A18CQ)[438P];[@W\8_YIB@684IH
M3&$$<) E *(8B>&I$?!2ZE/BH33P B/=B2MPED7X7+O=)P';4,/=FFUR@FR.
M&6KB/-)T]\=!=IAKNWM I>W&NS6PM]%Z]X!PZ>:[AV]I'M)#[<^K/QZ-W* +
M#_J9[_D,N%Z* ,2>"Q*,*$B\, H\Q,(0ZWA!ZIC,X^\<3D_22E#08++DP6^'
M9V^ES69W>I%!HT*;::;,#74$YC5$M!ET8J+HKZ0>P15#>2E?B%3CYN^S;$FX
MM&OD8XPN9-DJJ> [.P2<%@.=Q(QQIHP';8WR0TVIC+/"0JZ&-+U:T=KQU6>+
MUDH3VHW6RK]TF?[F]]NR*%'5D7NHQ>WC9K7*-KEX<1%Z,&(^#@')A$^392E
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MB877=VMN/#(Q[6?!_"#V*(Y F,1<W_FI!Q),,L""*/)]0@AB<%$*?2UG;_?
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M)=CS3N'28<O)="ZM172/?FXZLZ*LKYD;"?RT6>^:P7]BY0(E099Z. 891AF
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M<V.$8A\"$L4!@'[5&<@+  Z2F&0DQBY6[Z2FA()E\3M 0-B2:(^"PQH<-&[
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M2Q0]P.E#ESNW.!U"Z@MY08K3V7%!S!L8Q*S.^4N/9E; ^/<QK%E]"XR-;]8
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M-'IUPHV^!]=FH@AI6HDM2VV''&5UR2_)DM<_]G[.US^\LN&S;0A0*4Y-W%[
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MS7W][[M/WH??O]W<7G_[!IR:<HJ4G@Z/DQ^FN@TMI;L[:I;K<X;%LC6XY)3
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MH!X>-6_&#JHN ;,LC/(T]4-$>1"JAMW2$P^*%/F,!)$:M1+Z&)H<<$QDJOR
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MT)8;0,4_\N;/F^4I6U\EQ4^K4A7HSPJ6Q$$<92A(>(!BPA-$L @1+TB<ACS
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MDLYY/7RJ:=];A#R/*2Y0AJ-">CR90"3$ 4HBSGU<^$4@M'I"#)-RK/J*L'=
M6:_/+Q0P/46W P-,RTT1 *OUL'"6=+J'T*0*/2SPL39KO $//EZMOO$%I](Q
M_\*Q"F)!HHZ=+SO62>51X*5T6EO*7DNZ/]ZF*?=P '*TR##],Y,6%%WLE<@H
MK-B]XF3QQ%Z!]@.)_0^>TZ5]U*4&_N?_^8?-3^1_B/1H_\\__#]02P,$%
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M</*_QU^73G52FCFN#(FF2(K%A(*(AD,P)95,!R2/+8*7^]9>#QX=WWTV$NO
MX*A6[V"&84FW,M%(YQ)D&PTHG@1$JSFDX!)*&VSB:B<X7%]M/0!T?-.YM>@&
M5GE]0S]Y_V4ZN;B;P\(+.N^!>5E=H%(@))-!:*V$BLK&(G92^^T5UU-]Q]>;
M.XEP8/5_Q'0V(^AR$3^-%R<XBBI'6:0%\FQ"31+QQ#^YP6@,G6B*?)V\VR%P
M>\7UU-_QO>9.(AQ8_9]FH>8I??Q^&J<G(RZQL,PY<$OD4B@LP06M05?^&;,V
M)[>3[F\LMY[B.[ZHW%YXG6SZPS_2ES#YC,N;>"6MTD@^;!%*@9+,@1,4\!@"
ML0F&<:*SR<:_ONIZ&.CX!G)G4781#KP^FU5QG;_-5DB3#L[F(Z.+B3X&$$YZ
M4):<UEBL <8$":6*I.QF#QY;?3UH='__V$"T74#D:$*?1N(8?\,W81%6;(VX
M8CIE1ZYMU F4"QF<RP[J/9JQ%/B@;G$]??_JZ^5/=7\1V4"T74"D/O#/7H<%
M?I[.OH]TH#-/> 26(CG!$A/X$@M]&Q1ZFT*P+8S'C477 T3W=Y#;"[(+''P\
M#2<GK\[FXPG.YR-1C[S,+03M)8G",@A*>X@8#9>2*[MC+MT]BZZ'@^YO&[<7
M9!<X.#S%V6<Z\GZ>37]??'D]/?T:)@3GDI.W.4+DA?QDFQA$BPR8$H$")\>E
MVBW9]I'%U\-%]]>,NPNV#WS\<946>)XS.E*1D;>L> V8.<E%9O A*R I9:&5
MX(:W>+RZN_)ZR.CX_K&)2+N Q<<O>')R >JL;?"8D?QD.O<4*XSX4 DT3YP7
M9<D/:@&(ZVNN!X6.[R-W%&,7("#"3VO>US3]_>,7DMO\^&Q1"\#JA<LHB518
MT:[Z00Q4T@5<*!*B<2KKH#AW+8Z0QVA8#R0=WUHV%G,?H"')S<+)T23C'_^*
MWT?%\FA+(7^9!0TJ2P3OE87"4'CG8G!JMRNM>Y==#QH=WVON+LRAGS'/(^BW
MXWD*)W_#,+NH11$A2>^L!V:9(QZ* *<"!Q%]SM&27=2[G28/K;P>)CJ^YVPB
MTD[*>ZZ8>$L_F8]8R=IIX2#K2(=CDIJ0G1TP,G+1$_V2[?;0_<#"ZX&BXQO.
M%@+M"A/G+O,Y$\E['9Q4$!W3M;B5PNV<JF122#[[(N)N]U</+KU>'6#'UYIM
MA#HP,@Z(@[SDXB1\'@4T048;0201B'#E('@I0?(L0V#HN=GMGOO&<NLAH.-[
MS.V%UTSK__27.\+[A7ZP8T>'R7QZ,LZU;<>K<%+[45"8A8OY3>HW[?+PT(>V
M[/RP%N$[=H,XF\/G$+Z.ENF15?O'Y>UX0HN-R0I,SV\E+J'%T!1'GB.X(D/-
MD8H00A!D#YAW4095 GMD1Y4PCTL$K!8]WU9XLIA?_.1J?VU"U[8FXV*-@_F<
MQ'K)I3&HO T(!AF"4L2E=Q1XY^R44,SHD!Y+NMV&RYL4#--K8F](N# R#<0]
MX/ERD_J5;WW%!".3F)D!ETP$9>B/P*V#F$PVR(,R^3%_='O,W")D6.CLHME[
M0;*+F#O RNLP_W(PR?6OP_\\&Y.A)V;F!XO783;[/IY\_O=P<H:CK(WPA;OZ
M/D1_:(<00XQ@0U$4E]5C^[$KCVVPLQ9A/6!I)P!,]ZV-#B#V?H9?PS@?_O$5
M)W,D]HX77\@9O"Z\418F<<45!?A6DM"J+U\O!177.NHBBA>/E9UM [ UR!JF
MD\[^X-5:$QV ZR;QP:7D,6BH6P"4U102B,C :F$+B0VS>"R>VOF,&Z;7SOX
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M \_J4>.%C%(B2Z9UDO=VE/96K=T&-T_"L[D2^ZF"N<OL04K3LTD=H/Y]^=:
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M*[*+6;SW\]J9NZ?);63&WL^F%!TLOK\_J4B8Y/IB\;6>U)?8T]*PE!4'3$R
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M]12IC8S6^5B6JT>NG))E14)QUH)R@4.0=?IXL)$%+:WSK;V'FQ2TG_KS;KK
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MKTS-R77@(@E:9AU#S+7JI/4@F0>)&?AB:7"<3/>AM)[0M]-1=?7&9S.6)(R
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MQKA?C[(?*\5_(_#<+IMMK\D7?>EZD.CT&B^^K^X;5U?0SW#;^OC"SW?-NH$
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M<Y\ ? D;M)&KSZS6);,(#&O&O)<9(G)-7_$D==!:Y([?W';>CB_A):Z+[3@
MW'Z\M[M'15-2,2R(#$S) /1_!JYZ$%X&S4BU5O".7_3ZW8DO^ )U']#Y07;5
MTX\XCTK,9LO04_S,%*K:.LN#0T5VB%FF:D]OZ7K;;+MQ/&R#WA>\!Y\1:#^
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M@,^YJ$Z"U("NJ_=LY]B4.8QXHMW?8N)EBY 9/O4"8XI#QS3M"0U<U<7"%G6
M6\74$"[C1@/0U^43MLCH]5K4Y[<6Y=N02FPWL$.?KR8G#(LBARDPHH;E3":N
M.PD=4BVKRZ8\]0-JZ"M#6*U-=Q1 K(N[W/'/+LVO1!MFFFSMV9KCT*E)?-LV
MK*EXJ)QPL! R*0_3$[Z8""SDF?8@CVD>$S;G.:O3* ):,[^QCNS9302'6$Y(
M3$?<EHIX/.8X^?:4?]9MV\68(^@R/,9S:D>%"3AGX;C%?\8#KID'V;4&68Y#
MW3!P#-?S.%P3OHP,3&X:L:=V$"+B.Z$SQH-J1X6)/F_M0>,!U\R#)K4&A:9G
M.H%MB0OCQ!+2L_EGV?(,/)UZ))Q.G( .RW?:1H598KVU!XT'7!</FCUE42RH
M7LPJUO@>GH83.C$"9/%<SO>9$2+^T3=#,[2GH4!K8+VG:4C8Y?E9<Q\U, .?
MKK@5Q[8W^\4!0XQ.;,-$EHB5(340P\2P;&9;;N"'@=RF:,>YB?V P)<KJ"K<
M# =1!^:W#HNGC)HAG^$A-7W#H0$V?$:(,0U-9T)-3+ G=9^!#/?0YQ@&DE6E
M>P!RP(1_0W^BU7JU53RP$:4(FUQG6\0H@HW %1?8>#8-/-\2ES0HH/QH4&#2
MAU"6JL!/@W)L)=Y]W3<]N\Q$9H"H,6'B(B/7(49 76;@B>?9H>_Q.7+FQLVO
MO<Z=G.]BDS/WX V#7 ?7.=@TV]Z44-["DG_)\S4E7Y*#3;2'J4^QBWW'"#''
MRK&8QP'SL$$1F4P)"8E+E/?E]= /OL5AO$>T=#@HI4<#UZO-WP^>"'HP$?*9
M:]D&QH%8_(6N@2A?"R+;='D*3\7+[F^QDW2@DU9=66I<3"D-NKK5?O)0O,ZB
M(J+Y!8IC2CZ][%9WVU_,'X)@2D.73?EG0&00!/-OOTF908B)I_SS/S4=U?VC
M(U76:I?\C$YY)A(U\-F#,'^1)GG$&=N^RH-I]$S)_"C.(]&C9%%B,!N'AN,A
M5UQMS@R&?![Y7=LEH?+C1GT4U&KQK_P[K)@@7>J*=9G&?IYMLHT%S0ZMM'P7
M3>P0&SR]$(WDIE@?6:Y(-\RI&3B6RX9U)/961:NUQ3B'>T-.](I[Y;6/W)HR
MO7VP0L>AE$X,2L1C(2Q 1H 0,IAK(N)- VOJ*>_$;]!%RKF\=^%<2F'7P'UJ
MLX3M\\&;>T3W/]RG!M8#039&A/#IX7D<.>)3GL^*2T:=B17RV>-XINISB8,4
ME7*\Z;MRO/,3IN'G=+9<9G2)"GJ!\L=K2@\O$OB<I7F^R%),*<D?&)Y8S I<
M48823R0Q'L<][!I\VGDXM$PRG;"Q7U1I;:3<SW\7[O>VS&CH@M]0@C87.+=:
MZ1)*ISQ',$SD\%63>'49!6AB\*P!>\QAH5=]5ZV__\FI(N5\P;MVOC-PHJ'G
MW=)H%:ZY=&'HG,TP3M=)>0VO>'DAR2FW<.(3-K5-@UE,W)!)0R,DEF>8V!$G
M;@(?,S36Z[K5D"L>F^_:Y123H:&[?>7A/.;S*=^^/2]LXG^=%X]\\;3F-B_X
M+]%B;RY/:DW?YB'=]@+;<"ARC%#<#Q1.'']B,M?BJZ>QOM=3)SE'?!_;&! T
M:>B5%S%%XJC8WI[ (I9KA]2P?<<4.X^.$02,_Y-R2UT>U<U@8*=?\Z!R?O4^
M]B[. K2&CK/M2B@?7-GM_)7G#BEY,%G E42NX4SX,MT)"#,"[/-('3*&O"!P
ML3FP8UUJ?#EW>A^[#N>&7X-2R2Z?O.9(BLHA2L1:>],56]KZ@+G6$\=!!O/X
M'T[H4/'>52">OR*F2 I8]7;)T6613J7DG.Q];26H94(#URJ5?DQC3D9^]6L=
M%2]?$AROQ=[Q0CSDP<DJBBP*UV6F>9_>I E.DX)KP24N=X]&/?#UM6M[T]"@
M%N&V$FMB^%-,C6#"\TZ+34S)GK4^)5\EFLLYZ?O8?@#D%/YNS%)V3O$_E^GS
MOR@F&_&;-Z6C%;?K]7F'8Z7K+L4\<LY#H1N_Q.35'>M'Z'E'YF#E1UZ.R8=Z
MV(RR*H?8^]]@.)HE#@Q4AP*_)4^1$'K/S?X4BT^,"C5/I8*THG5RL9OF4H@
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MQ=XQ>%"P8Y[*8\@@L*';F'>*;_1-R.EW<Q/XKF-2VG:1)B2_S/A?5'F.(A7
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M%T<UYQ8PH'<*]JJ-/DM:$07&32O:M:QH=+IT%L<UL43-=;G-@C7@JN7FW$Y
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M6<:: ZT#D;5EXX7"A85"7&A2LN>AC!*V]#^E1UF, YTVM@6>?'O@63DB-UR
MP5X<8T6%[-- *MD:Z_/<;#[%%KL!("B*E5SY5+E&!4A+0V&([% *$M)CF](9
M3<Y3K0;)"65%_9PAI530L!T42)EHBU%2!'0@-OG B$!P+>P&A*OR1/Z)U90;
M6WDI*0V5::)&90 -PJ,P34JQBQ1^+KEE=-P6&3&KX#C#]0/S;0S^-0 KB*2+
M\R'X?)+=*A0/M@?%RQ#>F*F6D+PYQVT,:$R"H0@L3KE1";=DS@UBW/:1%KQ<
M!Q,@(;0%'P@ILK$MZ:N6M6E%F",XN8Q8$)WK0ZEFW!<;2G.=(IP-M2"^KW1
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MT.M(%F.H;MC.N_MB8G+OEI 9$G2IMY?L/'@;__-?'H[L+Q[_ 5!+ 0(4 Q0
M   ( ,]$KUJQST>B?+$  ![$!P 9              "  0    !C:S P,#$X
M,C0R.3,M,C R-3 S,S$N:'1M4$L! A0#%     @ ST2O6L8P"'K4#   7X4
M !D              ( !L[$  &-K,# P,3@R-#(Y,RTR,#(U,#,S,2YX<V10
M2P$"% ,4    " #/1*]:VB5"AF8-  #D;@  '0              @ &^O@
M8VLP,# Q.#(T,CDS+3(P,C4P,S,Q7V-A;"YX;6Q02P$"% ,4    " #/1*]:
M*0W :?,T  #U-@( '0              @ %?S   8VLP,# Q.#(T,CDS+3(P
M,C4P,S,Q7V1E9BYX;6Q02P$"% ,4    " #/1*]:6#\$3Q-* @#Q8 , '
M            @ &- 0$ 8VLP,# Q.#(T,CDS+3(P,C4P,S,Q7V<Q+FIP9U!+
M 0(4 Q0    ( ,]$KUH;I#/7>Z   %.Q!@ =              "  =I+ P!C
M:S P,#$X,C0R.3,M,C R-3 S,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,]$KUJ5
M7Y1WKV   'V'!  =              "  9#L P!C:S P,#$X,C0R.3,M,C R
M-3 S,S%?<')E+GAM;%!+ 0(4 Q0    ( ,]$KUHA]]A79P@  ,TJ   9
M          "  7I-! !E>#,Q,5]C96\S,#)C97)T,S,Q,C4N:'1M4$L! A0#
M%     @ ST2O6JP*L(99"   L"H  !D              ( !&%8$ &5X,S$R
M7V-F;S,P,F-E<G0S,S$R-2YH=&U02P$"% ,4    " #/1*]:OB?A3<(%   B
M&0  '@              @ &H7@0 97@S,C%?8V5O<V5C=&EO;CDP-F-E<G0S
M,S$N:'1M4$L! A0#%     @ ST2O6HX,BQJV!0  ^!@  !X
M ( !IF0$ &5X,S(R7V-F;W-E8W1I;VXY,#9C97)T,S,Q+FAT;5!+!08
."P + "H#  "8:@0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>ck0001824293-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001824293="http://www.vallon-pharma.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001824293-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2025-05-14</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2025-02-21</startDate>
            <endDate>2025-02-21</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-20</startDate>
            <endDate>2024-05-20</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-21</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-20</startDate>
            <endDate>2024-12-20</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-26</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesBCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-21</startDate>
            <endDate>2024-10-21</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-05</startDate>
            <endDate>2025-05-05</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedAndSeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesBCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD2WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-10-21</startDate>
            <endDate>2024-10-21</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:October2024PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInAugust2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMarch2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInSeptember2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE1CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE3CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:April2025PAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-05-15</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-15</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>ck0001824293:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0001824293</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-30">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-28" decimals="4" id="f-173" unitRef="number">0.1429</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-29" decimals="4" id="f-174" unitRef="number">0.0769</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-30" decimals="4" id="f-175" unitRef="number">0.0588</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">GRI BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">2223 Avenida de la Playa</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">#208</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">400-1170</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.0001per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">GRI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-24">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-25">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-26" unitRef="shares">2141473</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">3281000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">5028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">649000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">587000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">3930000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">5615000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">109000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">120000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">4042000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">5739000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">1361000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">897000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">1368000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">691000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">50000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">48000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">2779000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">1636000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">58000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">71000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">2837000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">1707000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-56" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-57" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-58"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-59"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="0" id="f-60" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="0" id="f-61" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-62" unitRef="shares">525358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="0" id="f-63" unitRef="shares">525358</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="0" id="f-64" unitRef="shares">525485</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="0" id="f-65" unitRef="shares">525485</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">43991000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">43772000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">-42786000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">-39740000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">1205000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">4032000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">4042000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">5739000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-76" unitRef="usd">1640000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">933000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-78" unitRef="usd">1411000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">962000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-80" unitRef="usd">3051000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">1895000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-82" unitRef="usd">-3051000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">-1895000</us-gaap:OperatingIncomeLoss>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-1" decimals="-3" id="f-84" unitRef="usd">0</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">2000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-86" unitRef="usd">5000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">6000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-88" unitRef="usd">-3046000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">-1887000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-90"
      unitRef="usdPerShare">-5.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-91"
      unitRef="usdPerShare">-5.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-92"
      unitRef="usdPerShare">-101.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-93"
      unitRef="usdPerShare">-101.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-94" unitRef="shares">525447</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-95" unitRef="shares">525447</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-96" unitRef="shares">18665</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-97" unitRef="shares">18665</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="0" id="f-98" unitRef="shares">525485</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-99" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">43772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-101" unitRef="usd">-39740000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-102" unitRef="usd">4032000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-9" decimals="-3" id="f-103" unitRef="usd">220000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-104" unitRef="usd">220000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment
      contextRef="c-10"
      decimals="INF"
      id="f-105"
      unitRef="shares">127</ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment>
    <ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment contextRef="c-9" decimals="-3" id="f-106" unitRef="usd">1000</ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment>
    <ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">1000</ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-108" unitRef="usd">-3046000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-109" unitRef="usd">-3046000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-110"
      unitRef="shares">525358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-111" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-112" unitRef="usd">43991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-113" unitRef="usd">-42786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-114" unitRef="usd">1205000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-115"
      unitRef="shares">2909</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-116" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-117" unitRef="usd">31792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-118" unitRef="usd">-31533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-119" unitRef="usd">259000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-3" id="f-120" unitRef="usd">37000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">37000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment
      contextRef="c-20"
      decimals="INF"
      id="f-122"
      unitRef="shares">1</ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-20"
      decimals="INF"
      id="f-123"
      unitRef="shares">1495</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-19" decimals="-3" id="f-124" unitRef="usd">4389000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">4389000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c-20"
      decimals="INF"
      id="f-126"
      unitRef="shares">10047</ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-127" unitRef="usd">-1887000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-128" unitRef="usd">-1887000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-129"
      unitRef="shares">14450</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-130" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-131" unitRef="usd">36218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-132" unitRef="usd">-33420000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-133" unitRef="usd">2798000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">-3046000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-135" unitRef="usd">-1887000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">1000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-137" unitRef="usd">1000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">220000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-139" unitRef="usd">37000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-5" decimals="-3" id="f-141" unitRef="usd">-2000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">11000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-5" decimals="-3" id="f-143" unitRef="usd">14000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">-196000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-145" unitRef="usd">-564000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">331000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-147" unitRef="usd">-744000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">562000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-5" decimals="-3" id="f-149" unitRef="usd">-172000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">-11000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-151" unitRef="usd">-14000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">-1736000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-153" unitRef="usd">-2203000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-26" decimals="-3" id="f-154" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-27" decimals="-3" id="f-155" unitRef="usd">5500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001824293:PaymentForFractionalSharesReverseStockSplit contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">1000</ck0001824293:PaymentForFractionalSharesReverseStockSplit>
    <ck0001824293:PaymentForFractionalSharesReverseStockSplit contextRef="c-5" decimals="-3" id="f-157" unitRef="usd">0</ck0001824293:PaymentForFractionalSharesReverseStockSplit>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">10000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-5" decimals="-3" id="f-159" unitRef="usd">1014000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">-11000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-161" unitRef="usd">4486000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">-1747000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-163" unitRef="usd">2283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-164" unitRef="usd">5028000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-3" id="f-165" unitRef="usd">1808000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-166" unitRef="usd">3281000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-25" decimals="-3" id="f-167" unitRef="usd">4091000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ck0001824293:RecognitionOfRightOfUseAssetsAndLeaseLiabilities contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">0</ck0001824293:RecognitionOfRightOfUseAssetsAndLeaseLiabilities>
    <ck0001824293:RecognitionOfRightOfUseAssetsAndLeaseLiabilities contextRef="c-5" decimals="-3" id="f-169" unitRef="usd">152000</ck0001824293:RecognitionOfRightOfUseAssetsAndLeaseLiabilities>
    <ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">247000</ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid>
    <ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid contextRef="c-5" decimals="-3" id="f-171" unitRef="usd">97000</ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-172">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. The Company&#x2019;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#x2019;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#x2019;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recapitalization&lt;/span&gt;&lt;/div&gt;On January 29, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split). On February 21, 2025, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen (the February 2025 Reverse Stock Split and together with the January 2024 Reverse Stock Split and the June 2024 Reverse Stock Split, the Reverse Stock Splits). Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits.</us-gaap:NatureOfOperations>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c-1" id="f-176">LIQUIDITY&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $42,786 in accumulated deficit through March&#160;31, 2025. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of March&#160;31, 2025, the Company had cash of approximately $3,281. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2024, the Company entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, Common Stock, pre-funded warrants and common warrants in a public offering (the February 2024 Offering) for net proceeds of $4,389, after deducting offering expenses of $1,110. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp;amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0&#160;million shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement. As of March&#160;31, 2025, the Company has sold 325,618 shares of Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3,605 of gross proceeds and net proceeds of $3,467, after deducting commissions to the sales agent and other ATM Offering related expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell Common Stock, pre-funded warrants and common warrants, in a public offering (the June 2024 Offering), for net proceeds of $3,172, after deducting offering expenses of $1,057.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 21, 2024, the Company entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of certain of its issued and outstanding common warrants to purchase shares of its Common Stock, offering these Holders the opportunity to exercise all of their common warrants for cash at a reduced exercise price. In addition, these Holders received new unregistered common warrants. The net proceeds to the Company from the exercise of the common warrants were $609 after deducting placement agent fees and offering expenses of $154.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through the third quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#x2019;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements. These unaudited interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-177" unitRef="usd">-42786000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-178" unitRef="usd">3281000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-31" decimals="-3" id="f-179" unitRef="usd">4389000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-31" decimals="-3" id="f-180" unitRef="usd">1110000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-32" decimals="-5" id="f-181" unitRef="usd">10000000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <ck0001824293:SaleOfStockAgentCompensationPercentage contextRef="c-32" decimals="3" id="f-182" unitRef="number">0.030</ck0001824293:SaleOfStockAgentCompensationPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-33"
      decimals="INF"
      id="f-183"
      unitRef="shares">325618</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-34"
      decimals="2"
      id="f-184"
      unitRef="usdPerShare">11.07</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-35" decimals="-3" id="f-185" unitRef="usd">3605000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-33" decimals="-3" id="f-186" unitRef="usd">3467000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-36" decimals="-3" id="f-187" unitRef="usd">3172000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-36" decimals="-3" id="f-188" unitRef="usd">1057000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-37" decimals="-3" id="f-189" unitRef="usd">609000</us-gaap:ProceedsFromWarrantExercises>
    <ck0001824293:ClassOfWarrantsOrRightAgentFeesAndOfferingExpense contextRef="c-37" decimals="-3" id="f-190" unitRef="usd">154000</ck0001824293:ClassOfWarrantsOrRightAgentFeesAndOfferingExpense>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-191">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the U.S. Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2024 balance sheet was derived from the Company&#x2019;s audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the unaudited interim consolidated financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2025, and the consolidated results of operations and consolidated stockholders&#x2019; deficit for the three months ended March&#160;31, 2025 and 2024 and consolidated cash flows for the three months ended March&#160;31, 2025 and 2024. Consolidated results of operations for the three months ended March&#160;31, 2025, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2024, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March&#160;14, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the consolidated balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At March&#160;31, 2025, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the consolidated balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its consolidated statements of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the consolidated statement of operations for the three months ended March&#160;31, 2025. As of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the warrant liability was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Stock Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. For the three-month period ended March&#160;31, 2024, basic net loss per common share includes the weighted average of the February 2024 Pre-Funded Warrants (as defined below). Diluted net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period, plus the dilutive effect of common stock equivalents outstanding during each period, in accordance with ASC 260,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As the Company had a net loss in each of the three months ended March&#160;31, 2025 and 2024, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended March&#160;31, 2025. ASUs not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on these unaudited interim consolidated financial statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2023-07). This amended guidance applies to all public entities and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the provisions of ASU 2023-07 and has included the required disclosures in this Quarterly Report on Form 10-Q. See Note 8 for additional disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-192">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the U.S. Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2024 balance sheet was derived from the Company&#x2019;s audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-193">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-194">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-195">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the consolidated balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At March&#160;31, 2025, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the consolidated balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its consolidated statements of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the consolidated statement of operations for the three months ended March&#160;31, 2025. As of March&#160;31, 2025 and December&#160;31, 2024, the fair value of the warrant liability was immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c-1" id="f-196">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Stock Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-197">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. For the three-month period ended March&#160;31, 2024, basic net loss per common share includes the weighted average of the February 2024 Pre-Funded Warrants (as defined below). Diluted net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period, plus the dilutive effect of common stock equivalents outstanding during each period, in accordance with ASC 260,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;. As the Company had a net loss in each of the three months ended March&#160;31, 2025 and 2024, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-198">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-38" decimals="0" id="f-199" unitRef="shares">21270</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-39" decimals="0" id="f-200" unitRef="shares">142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-40" decimals="0" id="f-201" unitRef="shares">359406</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-41" decimals="0" id="f-202" unitRef="shares">46621</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-203" unitRef="shares">380676</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="0" id="f-204" unitRef="shares">46763</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-205">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended March&#160;31, 2025. ASUs not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on these unaudited interim consolidated financial statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2023-07). This amended guidance applies to all public entities and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the provisions of ASU 2023-07 and has included the required disclosures in this Quarterly Report on Form 10-Q. See Note 8 for additional disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-206">PROPERTY AND EQUIPMENT&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $1 in each of the three-month periods ended March&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-207">&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-42" decimals="-3" id="f-208" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-43" decimals="-3" id="f-209" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-44" decimals="-3" id="f-210" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-45" decimals="-3" id="f-211" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-212" unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-213" unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-214" unitRef="usd">31000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-215" unitRef="usd">30000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-216" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-217" unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-218" unitRef="usd">1000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-219" unitRef="usd">1000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-220">ACCRUED EXPENSES&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-221">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-3" decimals="-3" id="f-222" unitRef="usd">630000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-4" decimals="-3" id="f-223" unitRef="usd">342000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-3" decimals="-3" id="f-224" unitRef="usd">233000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-4" decimals="-3" id="f-225" unitRef="usd">12000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-226" unitRef="usd">505000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-227" unitRef="usd">337000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-228" unitRef="usd">1368000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-229" unitRef="usd">691000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-230">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;February 2024 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the February 2024 Offering, (i) 1,495 shares (the February 2024 Shares) of Common Stock, (ii) 21,131 pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock and (iv) 22,631 Series B-2 common warrants (the Series B-2 Common Warrants and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q (the Quarterly Report) as the &#x201c;February 2024 Warrants.&#x201d; The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $243.10 (less $0.0221 for each February 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain ownership limitations, the February 2024 Warrants were exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for one share of Common Stock at a price per share of $0.0221 and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 for a five-year period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 for an 18-month period after February 6, 2024, the date of issuance. The February 2024 Warrants were classified as equity and the allocated fair value of $4,279 is included in additional paid-in capital. As of March&#160;31, 2025, all of the February 2024 Pre-Funded Warrants have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Company&#x2019;s previously outstanding Series A-1 Warrants was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants. As of March&#160;31, 2025, all of the Series A-1 Warrants have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;May 2024 At The Market Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the Company has sold 325,618 shares of Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3,605 of gross proceeds and net proceeds of $3,467, after deducting commissions to the sales agent and other ATM Offering related expenses. On May 5, 2025, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1,671, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3,605 that were sold under the ATM Offering through March&#160;31, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;June 2024 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company issued and sold, in the June 2024 Offering, (i) 3,529 shares (the June 2024 Shares) of Common Stock, (ii) 125,047 pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of 125,047 shares of Common Stock, (iii) 128,577 Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of 128,577 shares of Common Stock, and (iv) 128,577 Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants), exercisable for an aggregate of 128,577 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Quarterly Report as the &#x201c;June 2024 Warrants.&#x201d; The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $31.11 (less $0.0017 for each June 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2024 Pre-Funded Warrants were exercisable for one share of Common Stock at a price per share of $0.0017, were exercisable immediately and have been exercised in full as of March&#160;31, 2025. Each Series C-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 for a five-year period beginning after September 6, 2024. Each Series C-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 for an 18-month period beginning after September 6, 2024. The June 2024 Warrants were classified as equity and the allocated fair value of $2,908 is included in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to an engagement agreement with Wainwright, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,001&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of Common Stock (the June 2024 PA Warrants). The June 2024 PA Warrants have an exercise price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$38.89&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share, will expire on June 26, 2029 and are exercisable beginning after September 6, 2024. The June 2024 PA Warrants were classified as equity and the fair value of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$229 is included in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;October 2024 Repricing Letter Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 21, 2024, the Company entered into the Repricing Letter Agreements with certain Holders of its issued and outstanding Series B Common Warrants to purchase an aggregate of 44,842 shares of its Common Stock, offering these Holders the opportunity to exercise all of their Series B Common Warrants for cash at a reduced exercise price equal to $17.00 per share. In addition, these Holders received new unregistered Series D-1 common warrants (the Series D-1 Common Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock and new unregistered Series D-2 common warrants (the Series D-2 Common Warrants and, together with the Series D-1 Common Warrants, the Series D Common Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $17.00 per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. This transaction is referred to as the &#x201c;Warrant Repricing Transaction.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rsuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $25,000 and non-accountable expenses of $10,000. The Company has also issued to Wainwright or its designees the October 2024 PA Warrants to purchase up to an aggregate of 3,140 shares of Common Stock (the October 2024 PA Warrant). The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $21.25 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds to the Company from the exercise of the Series B Common Warrants were $202 after deducting placement agent fees and offering expenses of $560. The issuance under the Repricing Letter Agreements represented $1,526 in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the Company had the following warrants outstanding to purchase Common Stock: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$464,100.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$43,548.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$94,970.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$38.8875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$21.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-31"
      decimals="INF"
      id="f-231"
      unitRef="shares">1495</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-46"
      decimals="INF"
      id="f-232"
      unitRef="shares">21131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-46"
      decimals="INF"
      id="f-233"
      unitRef="shares">21131</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-47"
      decimals="INF"
      id="f-234"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-47"
      decimals="INF"
      id="f-235"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-48"
      decimals="INF"
      id="f-236"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-48"
      decimals="INF"
      id="f-237"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-31" decimals="-3" id="f-238" unitRef="usd">4389000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-31" decimals="-3" id="f-239" unitRef="usd">1110000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-49"
      decimals="INF"
      id="f-240"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-46"
      decimals="INF"
      id="f-241"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-47"
      decimals="INF"
      id="f-242"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-48"
      decimals="INF"
      id="f-243"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-49"
      decimals="INF"
      id="f-244"
      unitRef="usdPerShare">243.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-50"
      decimals="INF"
      id="f-245"
      unitRef="usdPerShare">0.0221</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-50"
      decimals="INF"
      id="f-246"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-50"
      decimals="INF"
      id="f-247"
      unitRef="usdPerShare">0.0221</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-51"
      decimals="INF"
      id="f-248"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-51"
      decimals="INF"
      id="f-249"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-51" id="f-250">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-52"
      decimals="INF"
      id="f-251"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-52"
      decimals="INF"
      id="f-252"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-52" id="f-253">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-53" decimals="-3" id="f-254" unitRef="usd">4279000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-54"
      decimals="INF"
      id="f-255"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-32" decimals="-5" id="f-256" unitRef="usd">10000000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <ck0001824293:SaleOfStockAgentCompensationPercentage contextRef="c-32" decimals="3" id="f-257" unitRef="number">0.030</ck0001824293:SaleOfStockAgentCompensationPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-33"
      decimals="INF"
      id="f-258"
      unitRef="shares">325618</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-34"
      decimals="2"
      id="f-259"
      unitRef="usdPerShare">11.07</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-33" decimals="-3" id="f-260" unitRef="usd">3605000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-33" decimals="-3" id="f-261" unitRef="usd">3467000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-55" decimals="-3" id="f-262" unitRef="usd">1671000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-33" decimals="-3" id="f-263" unitRef="usd">3605000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-36"
      decimals="INF"
      id="f-264"
      unitRef="shares">3529</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-56"
      decimals="INF"
      id="f-265"
      unitRef="shares">125047</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-56"
      decimals="INF"
      id="f-266"
      unitRef="shares">125047</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-57"
      decimals="INF"
      id="f-267"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-57"
      decimals="INF"
      id="f-268"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-58"
      decimals="INF"
      id="f-269"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-58"
      decimals="INF"
      id="f-270"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-36" decimals="-3" id="f-271" unitRef="usd">3172000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-36" decimals="-3" id="f-272" unitRef="usd">1057000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-59"
      decimals="INF"
      id="f-273"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-56"
      decimals="INF"
      id="f-274"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-57"
      decimals="INF"
      id="f-275"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-58"
      decimals="INF"
      id="f-276"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-59"
      decimals="INF"
      id="f-277"
      unitRef="usdPerShare">31.11</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-60"
      decimals="INF"
      id="f-278"
      unitRef="usdPerShare">0.0017</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-60"
      decimals="INF"
      id="f-279"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-60"
      decimals="INF"
      id="f-280"
      unitRef="usdPerShare">0.0017</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-61"
      decimals="INF"
      id="f-281"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-61"
      decimals="INF"
      id="f-282"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-61" id="f-283">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-62"
      decimals="INF"
      id="f-284"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-62"
      decimals="INF"
      id="f-285"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-62" id="f-286">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-63" decimals="-3" id="f-287" unitRef="usd">2908000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-64"
      decimals="INF"
      id="f-288"
      unitRef="shares">9001</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-64"
      decimals="INF"
      id="f-289"
      unitRef="usdPerShare">38.89</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-64" decimals="-3" id="f-290" unitRef="usd">229000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-65"
      decimals="INF"
      id="f-291"
      unitRef="shares">44842</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-65"
      decimals="INF"
      id="f-292"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-66"
      decimals="INF"
      id="f-293"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-67"
      decimals="INF"
      id="f-294"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-68"
      decimals="INF"
      id="f-295"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds
      contextRef="c-69"
      decimals="INF"
      id="f-296"
      unitRef="number">0.070</ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds
      contextRef="c-69"
      decimals="INF"
      id="f-297"
      unitRef="number">0.010</ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockReimbursementOfAccountableExpenses contextRef="c-69" decimals="-3" id="f-298" unitRef="usd">25000</ck0001824293:SaleOfStockReimbursementOfAccountableExpenses>
    <ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses contextRef="c-69" decimals="-3" id="f-299" unitRef="usd">10000</ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-70"
      decimals="INF"
      id="f-300"
      unitRef="shares">3140</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-70"
      decimals="INF"
      id="f-301"
      unitRef="usdPerShare">21.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:ProceedsFromWarrantExercisesNetOfOfferingExpense contextRef="c-37" decimals="-3" id="f-302" unitRef="usd">202000</ck0001824293:ProceedsFromWarrantExercisesNetOfOfferingExpense>
    <ck0001824293:ClassOfWarrantOrRightOfferingCost contextRef="c-37" decimals="-3" id="f-303" unitRef="usd">560000</ck0001824293:ClassOfWarrantOrRightOfferingCost>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-69" decimals="-3" id="f-304" unitRef="usd">1526000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-305">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the Company had the following warrants outstanding to purchase Common Stock: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$464,100.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$43,548.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$94,970.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$38.8875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$21.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-71"
      decimals="INF"
      id="f-306"
      unitRef="shares">210</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-71"
      decimals="INF"
      id="f-307"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-72"
      decimals="INF"
      id="f-308"
      unitRef="shares">9</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-72"
      decimals="INF"
      id="f-309"
      unitRef="usdPerShare">464100</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-73"
      decimals="INF"
      id="f-310"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-73"
      decimals="INF"
      id="f-311"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-74"
      decimals="INF"
      id="f-312"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-74"
      decimals="INF"
      id="f-313"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-75"
      decimals="INF"
      id="f-314"
      unitRef="shares">16</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-75"
      decimals="INF"
      id="f-315"
      unitRef="usdPerShare">43548.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-76"
      decimals="INF"
      id="f-316"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-76"
      decimals="INF"
      id="f-317"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-77"
      decimals="INF"
      id="f-318"
      unitRef="shares">3</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-77"
      decimals="INF"
      id="f-319"
      unitRef="usdPerShare">94970.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-78"
      decimals="INF"
      id="f-320"
      unitRef="shares">210</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-78"
      decimals="INF"
      id="f-321"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-79"
      decimals="INF"
      id="f-322"
      unitRef="shares">9002</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-79"
      decimals="INF"
      id="f-323"
      unitRef="usdPerShare">38.8875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-80"
      decimals="INF"
      id="f-324"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-80"
      decimals="INF"
      id="f-325"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-81"
      decimals="INF"
      id="f-326"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-81"
      decimals="INF"
      id="f-327"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-82"
      decimals="INF"
      id="f-328"
      unitRef="shares">3140</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-82"
      decimals="INF"
      id="f-329"
      unitRef="usdPerShare">21.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-330">STOCK-BASED COMPENSATION&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated 2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan (the A&amp;amp;R 2018 Plan). The A&amp;amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;amp;R 2018 Plan generally have a contractual life of up to 10 years. As of March&#160;31, 2025, awards granted under the A&amp;amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of 21,270 shares of the Company's Common Stock were outstanding and 21,275 shares of the Company&#x2019;s Common Stock were reserved for issuance under the A&amp;amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;amp;R 2018 Plan may be increased pursuant to the A&amp;amp;R 2018 Plan&#x2019;s &#x201c;evergreen&#x201d; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#x2019;s Common Stock outstanding on the final day of the immediately preceding calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to equity-based awards issued under the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three months ended March&#160;31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,376.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, all of the outstanding and exercisable stock options were out of the money and therefore had no intrinsic value. As of March&#160;31, 2025, the unrecognized compensation cost related to unvested stock options expected to vest was $214. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 1.57 years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 21,128 stock options to its employees and non-employee directors during the three months ended March&#160;31, 2025. The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No equity-based awards were granted during the three-month period ended March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-83" id="f-331">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-84"
      decimals="INF"
      id="f-332"
      unitRef="shares">21270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-84"
      decimals="INF"
      id="f-333"
      unitRef="shares">21275</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum contextRef="c-84" decimals="2" id="f-334" unitRef="number">0.04</ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-335">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to equity-based awards issued under the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three months ended March&#160;31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.262%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-85" decimals="-3" id="f-336" unitRef="usd">25000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-86" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-87" decimals="-3" id="f-338" unitRef="usd">195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-88" decimals="-3" id="f-339" unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">220000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-341" unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-342">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,376.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.81&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-343" unitRef="shares">142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-344"
      unitRef="usdPerShare">4376.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-89" id="f-345">P9Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-346" unitRef="shares">21128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-347"
      unitRef="usdPerShare">11.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-348" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-349"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-350" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-351"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-352" unitRef="shares">21270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-353"
      unitRef="usdPerShare">40.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-354">P9Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-355" unitRef="shares">21196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-356"
      unitRef="usdPerShare">28.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-357">P9Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-3" decimals="INF" id="f-358" unitRef="shares">21270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-359"
      unitRef="usdPerShare">40.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-360">P9Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-361" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-3" id="f-362" unitRef="usd">214000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-90" id="f-363">P1Y6M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-364" unitRef="shares">21128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-365">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-90" decimals="4" id="f-366" unitRef="number">1.1094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-90" id="f-367">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-90" decimals="4" id="f-368" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-90" decimals="4" id="f-369" unitRef="number">0.0445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="c-91"
      decimals="2"
      id="f-370"
      unitRef="usdPerShare">9.43</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-5" decimals="INF" id="f-371" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-372">SEGMENT REPORTING&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one reportable segment: biotechnology research. The biotechnology research segment consists of the research and development of products for the treatment of inflammatory disease. The Company&#x2019;s CODM is W. Marc Hertz, Ph.D., Chief Executive Officer and Director.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the biotechnology research segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the biotechnology research segment based on research and development expenses and general and administrative expenses as part of the overall review of the Company&#x2019;s consolidated net loss and consolidated cash flows as compared to prior quarters and the Company&#x2019;s operating budget.&lt;/span&gt;&lt;/div&gt;The Company has incurred significant losses since its inception and anticipates incurring continued losses in the future. As such, the CODM uses cash forecast models in deciding how to allocate resources based on the Company&#x2019;s available cash resources, as well as its forecasted expenditures.  This information, in conjunction with the assessment of the probability of the success of the Company&#x2019;s research and development activities, is used to plan the timing and size of future capital raises.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-373"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-374">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation and Release Agreement&lt;/span&gt;&lt;/div&gt;In connection with the resignation of David Baker, the Company&#x2019;s Former Chief Executive Officer, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker received continuation of his then current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#x2019;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ck0001824293:COBRABenefitsPaymentPeriod contextRef="c-92" id="f-375">P18M</ck0001824293:COBRABenefitsPaymentPeriod>
    <ck0001824293:PercentageOfTargetBonus
      contextRef="c-92"
      decimals="INF"
      id="f-376"
      unitRef="number">1.50</ck0001824293:PercentageOfTargetBonus>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-377">SUBSEQUENT EVENTS&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2025, the Company entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which the Company agreed to sell, in a public offering (the April 2025 Offering), (i) 202,000 shares (the April 2025 Shares) of Common Stock, (ii) 1,186,888 pre-funded warrants (the April 2025 Pre-Funded Warrants) exercisable for an aggregate of 1,186,888 shares of Common Stock, (iii) 1,388,888 Series E-1 common stock warrants (the Series E-1 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, (iv) 1,388,888 Series E-2 common stock warrants (the Series E-2 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, and (v) 1,388,888 Series E-3 common stock warrants (the Series E-3 Common Warrants, and collectively with the Series E-1 Warrants and the Series E-2 Warrants, the Series E Common Warrants) to purchase up to 1,388,888 shares of Common Stock, for gross proceeds of $5,000, before deducting offering expenses. The April 2025 Offering closed on April 2, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The securities were offered in combinations of (a) one April 2025 Share or one April 2025 Pre-Funded Warrant, together with (b) one Series E-1 Common Warrant, one Series E-2 Common Warrant and one Series E-3 Common Warrant, for a combined purchase price of $3.60 (less $0.0001 for each April 2025 Pre-Funded Warrant). The April 2025 Pre-Funded Warrants have an exercise price of $0.0001 per share, become exercisable immediately upon issuance and expire when exercised in full. Each Series E Common Warrant has an exercise price of $3.20 per share and became exercisable immediately upon issuance. The Series E-1 Common Warrants expire April 2, 2030. The Series E-2 Common Warrants expire on October 2, 2026. The Series E-3 Common Warrants expire on January 2, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wainwright acted as the exclusive placement agent for the April 2025 Offering pursuant to an engagement agreement between the Company and Wainwright dated as of March 7, 2025. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the offering, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the offering,  reimbursement for accountable expenses of $25,000,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; reimbursement of up to $100,000 for legal fees and expenses and other out-of-pocket expenses and up to $15,950 for the clearing expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company also issued to Wainwright, or its designees, warrants to purchase up to an aggregate of 97,222 shares of Common Stock (the April 2025 PA Warrants). The April 2025 PA Warrants became exercisable immediately upon issuance, expire on April 1, 2030, and have an exercise price of $4.50 per share.&lt;/span&gt;&lt;/div&gt;As discussed in Note 6, &#x201c;Stockholders&#x2019; Equity&#x201d; to these unaudited interim consolidated financial statements, on May 5, 2025, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1,671, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3,605 that were sold under the ATM Offering through March 31, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3. Since March 31, 2025, the Company has sold shares of Common Stock with an aggregate gross sales price of $399. As of the date of the filing of this Quarterly Report considering the net proceeds from the April 2025 Offering and the net proceeds from the Sales Agreement for sales occurring since March 31, 2025, the Company&#x2019;s stockholders&#x2019; equity is greater than $2.5&#160;million.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-93"
      decimals="INF"
      id="f-378"
      unitRef="shares">202000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-94"
      decimals="INF"
      id="f-379"
      unitRef="shares">1186888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-94"
      decimals="INF"
      id="f-380"
      unitRef="shares">1186888</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-95"
      decimals="INF"
      id="f-381"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-95"
      decimals="INF"
      id="f-382"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-96"
      decimals="INF"
      id="f-383"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-96"
      decimals="INF"
      id="f-384"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-97"
      decimals="INF"
      id="f-385"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-97"
      decimals="INF"
      id="f-386"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-93" decimals="-3" id="f-387" unitRef="usd">5000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-98"
      decimals="INF"
      id="f-388"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-94"
      decimals="INF"
      id="f-389"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-95"
      decimals="INF"
      id="f-390"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-96"
      decimals="INF"
      id="f-391"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-97"
      decimals="INF"
      id="f-392"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-98"
      decimals="INF"
      id="f-393"
      unitRef="usdPerShare">3.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-99"
      decimals="INF"
      id="f-394"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-99"
      decimals="INF"
      id="f-395"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-100"
      decimals="INF"
      id="f-396"
      unitRef="usdPerShare">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds
      contextRef="c-101"
      decimals="INF"
      id="f-397"
      unitRef="number">0.070</ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds
      contextRef="c-101"
      decimals="INF"
      id="f-398"
      unitRef="number">0.010</ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockReimbursementOfAccountableExpenses contextRef="c-101" decimals="-3" id="f-399" unitRef="usd">25000</ck0001824293:SaleOfStockReimbursementOfAccountableExpenses>
    <ck0001824293:SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses contextRef="c-102" decimals="-3" id="f-400" unitRef="usd">100000</ck0001824293:SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses>
    <ck0001824293:SaleOfStockClearingExpenses contextRef="c-101" decimals="-3" id="f-401" unitRef="usd">15950000</ck0001824293:SaleOfStockClearingExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-103"
      decimals="INF"
      id="f-402"
      unitRef="shares">97222</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-103"
      decimals="2"
      id="f-403"
      unitRef="usdPerShare">4.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-55" decimals="-3" id="f-404" unitRef="usd">1671000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-33" decimals="-3" id="f-405" unitRef="usd">3605000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-104" decimals="-3" id="f-406" unitRef="usd">399000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-105" decimals="-5" id="f-407" unitRef="usd">2500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-408">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-409">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-410">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-411">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
